Diet and Immune Function by Childs, Caroline E et al.
Diet and 
Immune Function
Elizabeth A. Miles, Philip Calder and Caroline E. Childs
www.mdpi.com/journal/nutrients
Edited by
Printed Edition of the Special Issue Published in Nutrients
nutrients
Diet and Immune Function






MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade
Philip Calder
University of Southampton 
UK
Special Issue Editors 










This is a reprint of articles from the Special Issue published online in the open access journal Nutrients
(ISSN 2072-6643) from 2018 to 2019 (available at: https://www.mdpi.com/journal/nutrients/
special issues/diet-immune)
For citation purposes, cite each article independently as indicated on the article page online and as
indicated below:




c© 2020 by the authors. Articles in this book are Open Access and distributed under the Creative
Commons Attribution (CC BY) license, which allows users to download, copy and build upon
published articles, as long as the author and publisher are properly credited, which ensures maximum
dissemination and a wider impact of our publications.
The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons
license CC BY-NC-ND.
Contents
About the Special Issue Editors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
Diet and Immune Function
Reprinted from: Nutrients 2019, 11, 1933, doi:10.3390/nu11081933 . . . . . . . . . . . . . . . . . . 1
Bethan Dalton, Iain C. Campbell, Raymond Chung, Gerome Breen, Ulrike Schmidt and
Hubertus Himmerich
Inflammatory Markers in Anorexia Nervosa: An Exploratory Study
Reprinted from: Nutrients 2018, 10, 1573, doi:10.3390/nu10111573 . . . . . . . . . . . . . . . . . . 10
Paulina Torres-Castro, Mar Abril-Gil, Marı́a J. Rodrı́guez-Lagunas, Margarida Castell,
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Abstract: A well-functioning immune system is critical for survival. The immune system must be
constantly alert, monitoring for signs of invasion or danger. Cells of the immune system must be able
to distinguish self from non-self and furthermore discriminate between non-self molecules which are
harmful (e.g., those from pathogens) and innocuous non-self molecules (e.g., from food). This Special
Issue of Nutrients explores the relationship between diet and nutrients and immune function. In this
preface, we outline the key functions of the immune system, and how it interacts with nutrients
across the life course, highlighting the work included within this Special Issue. This includes the
role of macronutrients, micronutrients, and the gut microbiome in mediating immunological effects.
Nutritional modulation of the immune system has applications within the clinical setting, but can
also have a role in healthy populations, acting to reduce or delay the onset of immune-mediated
chronic diseases. Ongoing research in this field will ultimately lead to a better understanding of
the role of diet and nutrients in immune function and will facilitate the use of bespoke nutrition to
improve human health.
Keywords: nutrition; immunity; macronutrients; micronutrients; microbiome; life course; probiotic;
prebiotic; inflammation
1. Overview of the Immune System
Broadly, cells of the immune system may be divided into those of the innate and those of the
adaptive immune response. The innate response is the first response to an invading pathogen. Cells of
the innate immune response include phagocytes (e.g., macrophages and monocytes), neutrophils,
dendritic cells, mast cells, eosinophils, and others. The innate response is rapid, but not specialised
and is generally less effective than the adaptive immune response.
The adaptive immune response has the ability to specifically recognise a pathogen and ‘remember’
it if exposed to it again. T cells are critical in antigen recognition and the co-ordination of the immune
response. T cells are present in an array of subtypes that coordinate different types of immune responses.
Broadly, they are divided into the cytotoxic T cells (bearing the CD8 receptor), which are involved
in direct killing of infected damaged cells and tumour cells, and the T helper cells. T helper (Th)
cells bear the CD4 receptor and are important in coordinating the responses of other immune cells.
There are a number of subtypes of Th cells, defined by the cytokines they produce. Initial studies
identified two subsets, the Th1 cells, which produced interferon gamma (IFN-γ) and interleukin (IL)-2
and were important in antiviral and cellular immune responses, and the Th2 subset producing IL-4,
IL-5, and IL-13 and involved in humoral (antibody) and anti-parasitic responses (but also in allergic
responses) [1]. It is now apparent that there are a number of other Th subtypes, which do not fall
into these categories. This includes Th17 cells, which produce IL-17A, IL-17F, and IL-22 and are
important in fighting extracellular pathogens (bacteria and fungi) [2]. There are also T regulatory cells
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(Treg), which are CD4-bearing T cells vital in maintaining immune tolerance to allow the immune
system to ignore non-harmful non-self (such as food, pollen, and environmental antigens such as
latex). Thus, the role of T cells is coordinating an appropriate immune response following immune
stimulation or challenge.
The other lymphocytes of the adaptive immune system are the B cells, which are responsible for
antibody or immunoglobulin (Ig) production. Like T cells, B cells respond specifically to an antigen.
They can differentiate into short-lived plasma cells, which produce Igs in the short term, or can become
long-lived plasma cells. Igs are pathogen-specific molecules, which help the immune system to recognise
and destroy pathogens. The B cells can differentiate into plasma cells, which produce one of five classes of
Ig (IgM, IgD, IgG, IgA, and IgE). Each class of Ig has a specialised role [3]. IgM is the first Ig expressed
during development, is often found as a multimeric molecule (e.g., pentameric), and can bind an antigen
to identify it for destruction by immune cells. IgD is found in low concentrations in the plasma and the
specialist role of IgD is not yet clear. IgG is the predominant Ig class and can persist for long periods.
It has important roles in antigen labelling, resulting in more effective removal. IgA can be found in the
serum (mostly as a monomer) and at mucosal surfaces (normally as a dimer). At the mucosal surface,
IgA protects against bacteria and or viruses, preventing infection. IgA also has an important role in
neutralising food antigens and helping to maintain immune tolerance to food antigens (preventing the
development of food allergy) [4]. IgE has a role in clearance of extracellular parasites (e.g., helminths) but
when produced inappropriately to innocuous environmental and food antigens, has an important role in
IgE-mediated allergy. B cells go through a process called class switching to set the class of Ig that the
plasma cells derived from them will produce. B cell class switching is controlled by the cytokines present,
particularly IL-4, IL-6, and IFN-γ secreted from Th cells [5].
T and B cells can specialise to become memory cells, which persist permanently or for very long
periods and are able to recognise the antigen if encountered again and elicit a rapid, pathogen-specific
immune response.
The effective deployment of the immune system against pathogens or harmful signals and the
swift resolution of the immune response is required for survival. The fighting of infection is only
one piece of the puzzle. A fulminating immune response is costly in terms of energy expended and
results in damage to the host tissues; thus, rapid and complete resolution of an immune response is
also key. Cytokines play a role in resolution of immune responses. IL-10, which is produced by a range
of immune cells including Tregs, has anti-inflammatory actions including suppressing inflammatory
cytokine production [6].
The instigation of an immune response and the activities of the immune cells results in inflammation
(seen as redness, swelling, and the feeling of heat and pain), which are signs of the damage to the
tissue going on whilst the immune system does its work. This is an expected outcome of an effective
immune response. Increasingly there is concern that modern lifestyle changes have resulted in the
promotion of ongoing, low-grade, whole-body (systemic) inflammation caused by immune and other
cells (e.g., adipocytes, the cells that store lipids in fat tissue) [7]. Such exposures may include diet
quality and quantity [8].
2. The Role of Nutrition in Immune Function
Adequate and appropriate nutrition is required for all cells to function optimally and this includes
the cells in the immune system. An “activated” immune system further increases the demand for
energy during periods of infection, with greater basal energy expenditure during fever for example.
Thus, optimal nutrition for the best immunological outcomes would be nutrition, which supports the
functions of immune cells allowing them to initiate effective responses against pathogens but also
to resolve the response rapidly when necessary and to avoid any underlying chronic inflammation.
The immune system’s demands for energy and nutrients can be met from exogenous sources i.e., the diet,
or if dietary sources are inadequate, from endogenous sources such as body stores. Some micronutrients
and dietary components have very specific roles in the development and maintenance of an effective
2
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immune system throughout the life course or in reducing chronic inflammation. For example, the amino
acid arginine is essential for the generation of nitric oxide by macrophages, and the micronutrients
vitamin A and zinc regulate cell division and so are essential for a successful proliferative response
within the immune system.
Undernutrition is well understood to impair immune function, whether as a result of food
shortages or famines in developing countries, or as a result of malnutrition arising from periods
of hospitalisation in developed countries. The extent of impairment that results will depend upon
the severity of the deficiency, whether there are nutrient interactions to consider, the presence of
infection, and the age of the subject [9]. A single nutrient can also exert multiple diverse immunological
effects, such as in the case of vitamin E, where it has a role as both antioxidant, inhibitor of protein
kinase C activity, and potentially interacting with enzymes and transport proteins [10]. For some
micronutrients, excessive intake can also be associated with impaired immune responses. For example,
supplementation with iron can increase morbidity and mortality of those in malaria endemic regions.
As well as nutrition having the potential to effectively treat immune deficiencies related to poor
intake, there is a great deal of research interest in whether specific nutrient interventions can further
enhance immune function in sub-clinical situations, and so prevent the onset of infections or chronic
inflammatory diseases.
3. Gut-Associated Lymphoid Tissue
The majority of immune cells within the human body are found within the gut-associated
lymphoid tissue (GALT), reflecting the importance of this immune tissue in maintaining host health.
In ingesting food, we expose ourselves to near constant and massive antigenic stimulation, and our
immune system must be able to provide strong and protective immunity against invasive pathogens,
while tolerating food proteins and commensal bacteria. In order to achieve this, the GALT contains a
variety of sensing and effector immune functions. Dendritic cells and M cells sample the gut content,
while plasma B cells within the lamina propria produce IgA, providing protection against pathogenic
organisms. Specialised immune regions known as Peyer’s patches, rich in immune cells, allow for
communication between immune cells resident within the GALT, propagation of signals to the wider
systemic immune system, and the recruitment or efflux of immune cells [11].
Within the gut lumen itself, the human gut microbiome will provide antigens and signals with the
potential to interact with resident and systemic immune cells. The composition of the gut microbiome
changes over the life course, in response to dietary components, and to environmental factors such
as antibiotic exposure. Dietary interventions targeted at the gut microbiome include probiotics
and prebiotics. Probiotics are defined as “live microorganisms, which, when consumed in adequate
amounts, confer a health benefit of the host” [12] while prebiotics, “a substrate that is selectively utilized
by host microorganisms conferring a health benefit” [13], tend to be non-digestible oligosaccharides
such as fructo-oligosaccharides and galacto-oligosaccharides. Provision of plant-based diets may
enhance the diversity of nutrients that reach the gut microbiome, with the indigestibility of plant cell
walls enabling peptides and lipids, which may otherwise have been absorbed in the upper digestive
tract to reach the microbiome [14]. There may be circumstances in which immune cells of the GALT
come into direct contact with nutrients or gut microbiota, such as in the case of reduced epithelial
integrity, or ‘leaky gut’ observed in both acute and chronic gut inflammation [15]. Such changes in gut
permeability may be influenced by micronutrient status such as that of vitamin D [16].
A number of nutrients and dietary interventions have demonstrated the capacity to improve
measures of gut health or to reduce gut inflammation. Protein hydrolysates have been demonstrated to
enhance barrier function and IgA production in animal models, and as a result may have applications
for incorporation within hypo-allergenic infant formula and clinical nutrition for those with conditions
such as inflammatory bowel disease [17]. Animal models of gut inflammation have identified that
providing probiotic bacteria can reduce inflammation, with reductions in proinflammatory Th1 and
Th17 cytokines such as IL-17 and IFN-γ, and enhanced production of inflammation resolving cytokine
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IL-10 [18]. Prebiotics can also enhance barrier function, in addition to their role as substrates for
bacterial metabolism [19]. Santiago-Lopez et al. have investigated the effect of fermented milk on a
murine model of inflammatory bowel disease [18] and demonstrated a reduction in serum IL-17 and
IFN-γ following fermented milk consumption when compared with the control group.
4. Immune Function Over the Life course
The developing foetus and neonates have an immature immune system, with poor antibody
production and a low proliferative response to challenge. In utero, the foetus can gain passive protection
from its mother via antibodies, which cross the placenta. This is the basis by which infants in the
UK are provided with early protection against whooping cough, with mothers offered vaccination in
their third trimester, in order to provide passive immunity to their infants until they reach the age of
infant vaccinations. While immature, the foetal immune system can produce antibodies, and allergens
can reach the developing foetus, and allergen-specific IgE can be detected in cord blood samples [20].
Another signature of the immaturity of the immune system in early life is the susceptibility of neonates
to infections, and the associated higher burden of morbidity and mortality.
The development of the immune system in early life will be influenced by both feeding practices and
environmental exposures. Breastfeeding provides further passive immunity to the infant, for example
via transfer of antibodies and cytokines. Breast milk components can also stimulate maturation of
the gut-associated lymphoid tissue, with breast milk known to be rich in bifidogenic oligosaccharides
and to contain its own unique microbiota. Human milk oligosaccharides (HMOs) are synthesised
from lactose in the mammary gland, and the specific HMO profile will vary between individuals and
across contexts and changes over the time course of lactation [21]. These HMOs have been found to
confer health benefits to infants by inhibiting the adhesion of microorganisms to the intestinal mucosa,
enhancing the production of short-chain fatty acids by bacteria within the microbiome, and inhibiting
inflammation [22]. Other immune active components of breast milk are also likely to be involved in
immune system maturation, with studies identifying that the growth factors epidermal growth factor,
fibroblast growth factor 21, and transforming growth factor-β2 can change lymphocyte phenotypes in
new-born rats when provided as supplements by oral gavage [23].
In infancy, diverse environmental factors will impact upon immune system development;
identified factors include pet ownership, antibiotic use, and the timing of introduction of foods [24].
The opportunity for introduction of prebiotic oligosaccharides during the introduction of foods has been
explored, with the suggestion that this could provide a unique opportunity to influence the developing
microbiome and thereby interact with the developing immune system [19]. These early years of life
are a critical period in the development of the immune system, particularly for T cell function, with the
thymus maturing and reaching its maximum size relative to body weight in infancy [25].
As we move through the life course towards later life, a decline in immune function is observed
among older adults. As was the case in infancy, older adults are more susceptible to infections, and have
more serious complications as a result than younger people. This declining immune function is known
as immunosenescence and reflects deterioration of both the acquired and innate immune systems [26].
Declining T cell function with age arises from thymic involution and decreased thymic output, resulting
in fewer naive T cells and more memory cells in the circulation [27]. Ageing is also associated with
increased inflammation in the absence of infection and has been found to predict hospitalisation
and death [28]. A number of micronutrient deficiencies have been identified as contributors to such
declining immunity, and so may provide opportunities for targeted interventions to restore immune
function [29].
5. Chronic Systemic Inflammation
Chronic systemic inflammation is a key underlying feature for a range of chronic
non-communicable disease conditions such as cardiovascular disease, stroke, and autoimmune
disorders such as rheumatoid arthritis. This chronic inflammation is positively correlated with aging
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and other co-morbidities (e.g., obesity, cardiovascular disease, insulin resistance). Interestingly, in a
study in healthy adults, increasing age was found to be a risk factor for chronic systemic inflammation,
independent of other risk factors such as body mass index, blood pressure, and blood lipid profiles [30].
The rising worldwide prevalence of obesity in children and adults is of grave concern. Obesity
and over nutrition are strongly associated with chronic inflammation, metabolic perturbation, and
higher risk for a number of chronic diseases including cardiovascular disease, stroke, type 2 diabetes
mellitus, and chronic liver disease. This metabolism-induced inflammation associated with obesity
is termed metaflammation, and the Western diet is a known risk factor [31,32]. The Western diet is
characterised by a diet high in sugar, trans and saturated fats, but low in complex carbohydrates, fibre,
micronutrients, and other bioactive molecules such as polyphenols and omega 3 polyunsaturated fatty
acids. The mechanisms by which the Western diet predispose individuals to metaflammation are still
under investigation. However, one mechanism which has been reported is the increased uptake of
lipopolysaccharide (LPS, a constituent of gram-negative bacterial cells walls), from microbes in the gut
because of increased gut leakiness. This LPS is sensed by cells of the innate immune system through
toll-like receptor 4 (TLR4). Activation of TLR4 by LPS will induce an inflammatory response by the
immune cells. Certain nutrients, notably long-chain omega 3 polyunsaturated fatty acids, can interfere
with TLR4 activation and, thus, can ameliorate this inflammatory signal. Rogero et al. describe the
relationship between obesity and inflammation and explores the immune pathway for this mechanism
and the anti-inflammatory roles of omega 3 fatty acids in this process [33].
Interestingly, in juxtaposition with the review by Rogero et al. on inflammation in obesity,
Dalton and colleagues report a study into systemic inflammation in individuals with the serious
psychological eating disorder, anorexia nervosa [34]. They show that in a severely undernourished
state, there are indications of systemic inflammation with an increased serum concentration of IL-6
when compared with healthy control participants. IL-6 is a classically inflammatory cytokine produced
by immune and other cells. Whether this inflammation is the result of the impact of undernutrition
or whether the clinical condition is the result of pre-existing inflammation is a matter that remains
to be determined. It has been shown that patients with clinical depression have increased systemic
inflammation suggesting that inflammation may have a bearing on mental health and wellbeing [35].
In contrast with the Western diet, the Mediterranean diet is rich in vegetables, fruit, nuts, legumes,
fish, and ‘healthy’ dietary fats. The Mediterranean diet is associated with a reduced risk of chronic
disease such as cardiovascular disease, cancer, and more recently Alzheimer’s disease [36]. A range of
bioactive compounds found in fruits and vegetables have been reported to offer one explanation for the
protective effect of diets rich in fruits and vegetables (e.g., Mediterranean diet) on the reduction of risk
for developing non-communicable diseases attributed to chronic inflammation (e.g., cardiovascular
disease). One family of molecules, which are known to have a role in regulation of inflammation
are the dietary polyphenols [37]. Yahfoufi et al. explain the mechanisms by which polyphenols
can be immunomodulatory and anti-inflammatory and explore the evidence for the role of dietary
polyphenols in reducing the risk of cardiovascular disease, some neurological diseases, and cancer [38].
6. Nutrition in the Clinical Setting
In clinical settings, acute inflammation may be a sudden, severe, and overwhelming process.
If not controlled, this severe systemic inflammation results in sepsis, culminating in multiple organ
failure and death. Sepsis is a major global cause of death killing approximately 6 million people per
year and is estimated to be the cause of 30% of neonatal deaths [39]. In this Special Issue of Nutrients,
the role of zinc in sepsis is discussed [40]. Zinc is known to be an important micronutrient for the
immune system. It has a role as a cofactor with both catalytic and structural roles in many proteins [41].
Even a mild deficiency in zinc has been associated with widespread defects in both the adaptive and
innate immune response [42]. During sepsis, zinc homeostasis is profoundly altered with zinc moving
from the serum into the liver. Alker and Haase consider this phenomenon and the implications for
therapeutic options to improve outcomes in patients presenting with sepsis [40].
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Selenium is a trace element that, like zinc, has critical functional, structural, and enzymatic roles,
in a range of proteins. Poor selenium status is associated with a higher risk for range of chronic diseases
including cancer and cardiovascular disease [43]. In addition to critical roles in many non-immune
tissues within the body, selenium is important for optimal immune function. Avery and Hoffman
explain the role of selenium in immunobiology and the mechanisms by which selenoproteins regulate
immunity. The evidence for the significance of selenium status in infectious diseases including human
immunodeficiency virus infection is reviewed [44].
Glutamine is a nonessential amino acid that provides an important energy source for many cell types
including those involved in immune responses. It also serves as a precursor for nucleotide synthesis,
particularly relevant for rapidly dividing cells such as the immune cells during an immune response.
During infection, the rate of glutamine consumption by immune cells is equivalent or greater than that
for glucose. Glutamine has roles in the functions of a number of immune cells including neutrophils,
macrophages, and lymphocytes [45]. In catabolic conditions (e.g., infection, inflammation, trauma),
glutamine is released into the circulation, an essential process controlled by metabolic organs such as the
liver, gut, and skeletal muscles. Despite this adaptation, a significant depletion of glutamine is seen in the
plasma and tissues in critical illness, which has provided a rationale for the use of in clinical nutrition
supplementation of critically ill patients. How glutamine homeostasis is maintained and when and how
to utilise glutamine in the clinical setting is explored in a review by Cruzat et al. [45].
The vitamin D receptor (VDR) is a nuclear receptor that can directly affect gene expression [46].
The presence of VDR in the majority of immune cells immediately suggests an important role
for this micronutrient in immune cell activities [47]. Furthermore, vitamin D-activating enzyme
1-α-hydroxylase (CYP27B1), which results in the active metabolite 1 α,25-dihydroxyvitamin D3
(1,25(OH)2D3), is expressed in many types of immune cells. Ligation of VDR by 1,25(OH)2D3 can elicit
the production of antimicrobial proteins and influence cytokine production by immune cells [47,48].
Sassi, Tamone, and d’Amelio have reviewed the evidence for the role of the nutrient vitamin D in the
innate and adaptive immune systems [16].
7. Conclusions
In this Special Issue of Nutrients, the collected works provide a breadth of reviews and research
indicating the key influence of nutrients and nutrition on immune responses in health and disease and
across the life course. Nutrients may impact directly or indirectly upon immune cells causing changes
in their function or may exert effects via changes in the gut microbiome. A better understanding
of the role of nutrients in immune function will facilitate the use of bespoke nutrition to improve
human health.
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Abstract: Inflammation has been suggested to play a pathophysiological role in anorexia nervosa
(AN). In this exploratory cross-sectional study, we measured serum concentrations of 40 inflammatory
markers (including cytokines, chemokines, and adhesion molecules) and brain-derived neurotrophic
factor (BDNF) in people with AN (n = 27) and healthy controls (HCs) (n = 13). Many of these
inflammatory markers had not been previously quantified in people with AN. Eating disorder
(ED) and general psychopathology symptoms were assessed. Body mass index (BMI) and body
composition data were obtained. Interleukin (IL)-6, IL-15, and vascular cell adhesion molecule
(VCAM)-1 concentrations were significantly elevated and concentrations of BDNF, tumor necrosis
factor (TNF)-β, and vascular endothelial growth factor (VEGF)-A were significantly lower in AN
participants compared to HCs. Age, BMI, and percentage body fat mass were identified as potential
confounding variables for several of these inflammatory markers. Of particular interest is that most of
the quantified markers were unchanged in people with AN, despite them being severely underweight
with evident body fat loss, and having clinically significant ED symptoms and severe depression and
anxiety symptoms. Future research should examine the replicability of our findings and consider the
effect of additional potential confounding variables, such as smoking and physical activity, on the
relationship between AN and inflammation.
Keywords: anorexia nervosa; inflammatory markers; inflammation; cytokines; chemokines;
adhesion molecules
1. Introduction
Anorexia nervosa (AN) is a serious psychiatric disorder characterised by low body weight due to
food restriction and weight-control behaviours, such as excessive exercise and self-induced vomiting,
together with an intense fear of weight gain and disturbed body perception [1]. Altered concentrations
of inflammatory markers, in particular cytokines, have been reported in people with AN [2,3].
Cytokines are cell signalling molecules produced by a range of cells (e.g., microglia, astrocytes) in the
brain and the periphery (e.g., by macrophages and T-lymphocytes) and are essential in coordinating
responses to infection [4]. In addition, changes in the circulating concentrations and production of
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cytokines have been associated with a range of disease states, including obesity [5] and diabetes [6],
as well as depression [7], schizophrenia [8], and eating disorders (EDs) [2,3].
Research in AN has primarily focused on pro-inflammatory cytokines, which promote and up-regulate
inflammatory reactions [4]. Recent meta-analyses have concluded that the pro-inflammatory cytokines
tumor necrosis factor (TNF)-α and interleukin (IL)-6, are elevated in people with AN, compared to
healthy individuals (for reviews see: [2,3]). However, few studies have quantified the concentrations
of cytokines in other categories, such as T-helper (TH)-1, TH2, and anti-inflammatory cytokines (e.g.,
IL-10), the latter of which play an immunomodulatory role by reducing inflammation [9]. An example
of one such cytokine yet to be measured in people with AN is TNF-β, which is produced by TH1
cells. TNF-β performs a variety of important roles in immune regulation [10,11], but has also been
implicated in the regulation of the commensal gut microbiota [12–14], which appears to be involved
in the pathology of AN [15–17]. Additionally, a number of cytokines implicated in other disorders,
such as depression and obesity, are yet to be measured in AN. One example is IL-17, a TH17 cytokine
that has been reported to predict treatment response in people with depression [18], and seems to
be involved in the pathophysiology of schizophrenia [19] and the molecular and cellular effects of
antipsychotics [20].
Chemokines are a subcategory of smaller cytokines known to induce chemotaxis, with some
also having a homeostatic function in relation to haematopoiesis, immune surveillance, and adaptive
immune system responses [21,22]. The chemokines RANTES, monocyte chemoattractant protein
(MCP)-1, and fractalkine have been measured in two studies in people with AN [23,24]. Similarly,
adhesion molecules, which mediate the binding of cells in the immune system [25], have been measured
in one study in a sample of people with AN [26]. Circulating concentrations of vascular cell adhesion
molecule (VCAM)-1 have been reported to be elevated in people with AN compared to healthy
participants, but intercellular adhesion molecule (ICAM)-1 did not differ between the groups.
Cytokines and chemokines impact several biological domains implicated in the pathophysiology
of AN, including the modulation of neurotransmitter systems, neuroendocrine functioning, and neural
plasticity [27–31]. For example, in the depression literature, it has been hypothesised that elevated
pro-inflammatory cytokine levels may lead to symptoms of depression, partly via their disruption of
growth factor production, e.g., brain-derived neurotropic factor (BDNF) [32] and vascular endothelial
growth factor (VEGF)-A [33], which has a subsequent effect on adult neurogenesis [28,34]. Disruption
to these biological processes can then lead to alterations in mental state, including affect, learning and
memory, and behaviour (e.g., depressive-like behaviours) [28,35].
A number of factors, including body mass index (BMI), age, medication, and smoking status,
have been reported to influence cytokine concentrations [36]. These may be potential confounding
factors in studies of the role of cytokines in AN, particularly given the low weight seen in AN,
the tendency for research in EDs to focus on adolescents and young adults [2], and research indicating
that people with EDs report higher rates of smoking than healthy controls [37]. Previous studies
have not assessed the potential impact of depression symptoms on cytokine concentrations in AN.
A pro-inflammatory profile has been identified in people with depression [38] and the comorbidity
between AN and unipolar depression is of significant clinical relevance, as approximately 40% of
people receiving treatment for AN also suffer from depression [39]. Therefore, it is unclear as to
whether the alterations observed in cytokine concentrations are due to the AN or symptoms of
comorbid disorders, such as depression.
Few studies have considered a broad range of cytokines and other markers involved in
inflammatory processes and their potential role in the biological profile of AN. Therefore, in this
exploratory cross-sectional study, we measured a variety of inflammatory markers in a sample of AN
participants and healthy controls (HCs) to determine whether these markers are altered in AN. Several
of these inflammatory markers have not been previously quantified in people with AN. A secondary
objective was to test for the effects of potential confounders on concentrations of the inflammatory
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markers, including age and BMI, and explore the effect of current symptom severity on markers of
inflammation in people with AN.
2. Materials and Methods
2.1. Participants and Study Design
Between 2010 and 2013, 55 participants with AN (outpatients n = 27; day-patients n = 10; inpatients
n = 18) and 30 HCs were recruited as part of the “Relationship between Overactivity, Stress and Anxiety
in Anorexia Nervosa” (ROSANA) study [40,41]. Female adults with a primary diagnosis of AN
(restricting or binge-eating/purging type) and a BMI < 17.5 kg/m2 were recruited within the first four
weeks of treatment for AN via Specialist Eating Disorder Services in and around London. HCs (n = 30)
were recruited via an e-mail circular to students and staff at King’s College London. Exclusion criteria
for HCs were a history of or current mental health disorder, including EDs, and the presence of physical
illness, which were assessed in the initial research session using a specially designed record form
and the research version of the Structured Clinical Interview for Diagnostic and Statistical Manual of
Mental Disorders (DSM)-IV Axis I Disorders [42], described below. All participants provided informed
consent before study participation. The study was conducted in accordance with the Declaration
of Helsinki and the study received ethical approval from the South East London Research Ethics
Committee (REC ref: 09/H0807/4).
2.2. Measures
2.2.1. Demographic Characteristics and Screening
A specially designed record form was used to collect demographic data and additional information
relating to the inclusion and exclusion criteria described above, e.g., the presence of medical conditions.
To determine smoking status, participants were asked if they smoked and if so, to report the number
of cigarettes smoked per day. For AN participants, illness duration (in this case, time since diagnosis)
was also recorded. All participants completed the research version of the Structured Clinical Interview
for DSM-IV Axis I Disorders [42], a validated structured interview, to confirm diagnosis in the AN
participants and identify a history of and/or current mental health problems in the HCs.
2.2.2. Anthropometry
Height and body weight were measured, and from these measurements, BMI (kg/m2) was
calculated. Body composition was also measured using a portable and non-invasive Inbody S10
machine (Inbody Co., Ltd., Seoul, Korea) which uses the Bioelectrical Impedance Analysis (BIA)
measurement method. Following the input of height and weight details, this machine provides data
on muscle and fat, bone mineral content, intracellular and extracellular water, protein, and minerals.
The calculations used to do this are based on the assumption that the body is a cylindrical-shaped
conductor. Resistance is low in lean tissue (as it contains the majority of intracellular and extracellular
fluid and is thus a good conductor of electrical current), and fat mass is high in resistance as it is does
not contain any water (and thus does not conduct electrical current). Based on the assumption that
impedance (resistance) is proportional to total body water, predictive equations then determine total
body water, total body fat, and lean tissue mass. Given that adipose tissue has been implicated in the
genesis of cytokines and produces certain pro-inflammatory cytokines (e.g., IL-6), we focused on the
association between inflammatory markers and body fat percentage and did not include other body
composition parameters in our analyses.
2.2.3. Eating Disorder Behaviours and General Psychopathology
ED symptoms were assessed using the Eating Disorder Examination-Questionnaire (EDE-Q) [43].
This questionnaire has 36-items assessing ED symptoms and behaviours over the previous 28 days.
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A global score can be calculated, and items can also be categorised and scored into the following four
subscales: restraint, eating concern, weight concern, and shape concern. Related psychopathology
was assessed using the Depression Anxiety Stress Scale 21-Version (DASS-21) [44]. This is a 21-item
questionnaire measuring symptoms of general psychopathology over the previous seven days. As well
as a total score, a score for the three subscales—depression, anxiety, and stress—can be calculated.
Additional measures related to physical activity were also collected and findings are reported
elsewhere [40,41].
2.2.4. Inflammatory Markers
Blood samples were collected, and serum was stored at −80 ◦C prior to use. Serum was thawed at
room temperature and the concentrations of 42 inflammatory markers were quantified simultaneously
using multiplex ELISA-based technology provided by the Meso Scale Discovery V-PLEX Human
Biomarker 40-Plex Kit and a customised human duplex kit assaying BDNF and interferon (IFN)-α,
following the manufacturer’s instructions (Meso Scale Diagnostics, LLC., Rockville, MD, USA). Cases
and controls were randomised across batches, and plates were scanned on the Mesoscale Scale
Discovery MESO Quickplex SQ 120 reader at the MRC SGDP Centre, Institute of Psychiatry, Psychology
& Neuroscience, King’s College London. The inflammatory markers measured in the 40-plex array
were: basic fibroblast growth factor (bFGF), C-reactive protein (CRP), Eotaxin, Eotaxin-3, Fms-like
tyrosine kinase (Flt)-1, granulocyte-macrophage colony-stimulating factor (GM-CSF), ICAM-1, IFN-γ,
IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A,
interferon γ-induced protein (IP)-10, MCP-1, MCP-4, macrophage inflammatory protein (MIP)-1α,
MIP-1β, placental growth factor (PlGF), serum amyloid A (SAA), thymus and activation-regulated
chemokine (TARC), tyrosine kinase (Tie)-2, TNF-α, TNF-β, VCAM-1, VEGF-A, VEGF-C, and VEGF-D.
The assay for macrophage-derived chemokine (MDC) was not included in the current panel due to
quality control issues.
2.3. Statistical Analysis
Thirty-two AN and 14 HC participants had available blood samples. One HC participant
was excluded from the analyses due to having a BMI below 18.5 kg/m2, i.e., in the underweight
range. Five AN participants were excluded from analyses due to reported autoimmune and/or
inflammatory diseases. Therefore, the current cross-sectional analyses are based on a sample consisting
of 27 participants with a diagnosis of AN and 13 HCs.
Standard curves were used to determine absolute quantities (pg/mL) of each inflammatory
marker. All statistical analyses were performed in Stata 15 [45].
2.3.1. Cross-Sectional Comparisons
For demographics and clinical characteristics, group comparisons were assessed using t-tests or
Mann-Whitney U-tests depending on the distribution of the data. Log-transformation of inflammatory
marker values was conducted due to the presence of outliers and non-normal distributions; however,
data remained non-normal for most of the measured molecules. Therefore, Mann-Whitney U-tests
were employed to compare concentrations of inflammatory markers between the AN and HC groups.
IFN-α was only detected in three samples (two HC and one AN); the results are therefore not presented.
2.3.2. Exploratory Regression Analyses
Absolute quantities of the inflammatory markers (pg/mL) were log-transformed to allow for
regression analyses. To identify marker-specific confounders, linear regressions were performed
for each log-transformed inflammatory marker (as the dependent variable) with each potential
confounding variable (age, BMI, percentage fat mass) separately in the whole sample. To test the
effect of illness severity on inflammatory marker concentrations, we performed linear regressions in
the AN participants, with the log-transformed inflammatory marker as the dependent variable and
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illness duration or ED symptoms, as measured by the EDE-Q, as the independent variable. To test
the effect of general psychopathology on inflammatory marker concentrations, linear regressions
in the AN participants, with the log-transformed inflammatory marker as the dependent variable
and the total DASS-21 score as the independent variable, were conducted. For both sets of analyses,
studentized residuals greater than ±3 standard deviations were deemed to be outliers and were
removed, and assumptions were tested and met.
The level of significance was set at p < 0.05, and as this was an exploratory study, levels of
significance were not adjusted for multiple testing.
3. Results
Demographic, anthropometric, and clinical characteristics of the AN participants and HCs are
presented in Table 1. All participants were female. Mean age did not significantly differ between the
AN and HC groups (U = 144, z = −1.36, p = 0.1735). Seven participants with AN reported being a
current smoker, with an average of 9.14 ± 5.90 cigarettes smoked per day. As expected, AN participants
had lower BMI (t (38) = 7.88, p < 0.001) and percentage body fat (U = −22, z = 3.63, p = 0.0003) scores,
and higher EDE-Q scores (global score: U = 85.5, z = −4.87, p < 0.001) than HCs. The EDE-Q global
score for the AN participants was greater than the commonly used clinical cut-off score of 4 e.g., [46,47].
AN participants also reported greater depression, anxiety, and stress than HCs on the DASS-21 (total
score: U = 92.5, z = −4.67, p <0.001). Proposed cut-off scores [44] suggest that the level of severity that
AN participants reported was severe for depression, anxiety, and stress.






(n = 27) p Value
Demographics
Age (years) (mean ± SD) 25.54 ± 4.52 31.48 ± 11.40 0.1735
Current smoker (n) 0 a 7
Anthropometrics
BMI (kg/m2) (mean ± SD) 20.88 ± 1.68 15.33 ± 2.25 <0.0010
Body fat (%) (mean ± SD) 17.08 ± 6.05 b 7.76 ± 6.07 0.0003
Clinical characteristics
Duration of diagnosis, years (mean ± SD) 11.64 ± 11.54 c
AN-R/AN-BP (n) 12/15
Current outpatient/inpatient (n) 16/11
EDE-Q Global (mean ± SD) 0.66 ± 0.70 4.20 ± 1.27 <0.0010
EDE-Q Restraint (mean ± SD) 0.62 ± 0.88 4.04 ± 1.77 <0.0010
EDE-Q Eating Concern (mean ± SD) 0.26 ± 0.48 3.82 ± 1.28 <0.0010
EDE-Q Weight Concern (mean ± SD) 0.74 ± 0.83 4.13 ± 1.59 <0.0010
EDE-Q Shape Concern (mean ± SD) 1.02 ± 0.85 4.82 ± 1.24 <0.0010
DASS-21 Total (mean ± SD) 13.85 ± 13.89 72.30 ± 33.32 <0.0010
DASS-21 Depression (mean ± SD) 3.54 ± 5.43 24.59 ± 13.73 <0.0010
DASS-21 Anxiety (mean ± SD) 3.08 ± 4.94 19.48 ± 11.84 0.0001
DASS-21 Stress (mean ± SD) 7.23 ± 5.20 28.22 ± 10.69 <0.0010
a n = 6 missing; b n = 1 missing; c n = 3 missing. Abbreviations: HCs—healthy controls; AN—anorexia nervosa;
SD—standard deviation; BMI—body mass index; AN-R—anorexia nervosa restricting type; AN-BP—anorexia
nervosa binge-eating/purging type; EDE-Q—Eating Disorder Examination—Questionnaire; DASS-21—Depression
Anxiety and Stress Scales-21 Version.
3.1. Inflammatory Markers
3.1.1. Cross-Sectional Comparison
The median concentrations (pg/mL) of the quantified inflammatory markers, along with the
interquartile range, and minimum and maximum values, for HCs and AN participants are shown in
Table 2. Median serum levels of TNF-β (U = 76, z = 2.87, p = 0.004) and VEGF-A (U = 102, z = 2.12,
p = 0.030) were lower in AN participants than in HCs. Median concentrations of IL-6 (U = 92, z = −2.41,
p = 0.016), IL-15 (U = 85, z = −2.61, p = 0.009), and VCAM-1 (U = 106, z = −2.01, p = 0.032) were found
to be higher in AN participants compared to HCs. No other inflammatory parameters were found to
differ between groups.
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3.1.2. Identification of Marker-Specific Confounding Variables
The full findings of the regressions assessing age, BMI, and percentage fat mass as potential
confounders of the serum concentrations of inflammatory markers across all participants are shown in
Table S1. Age significantly influenced the serum concentrations of Eotaxin-3 (F(1, 37) = 5.68, p = 0.0224),
IFN-γ (F(1, 33) = 7.91, p = 0.0082), MCP-1 (F(1, 38) = 8.87, p = 0.0050), MIP1-α (F(1, 38) = 4.48, p = 0.0408),
SAA (F(1, 38) = 6.99, p = 0.0119), and TNF-α (F(1, 38) = 5.07, p = 0.0302). BMI significantly predicted
concentrations of IL-4 (F(1, 34) = 4.73, p = 0.0367), IL-6 (F(1, 38) = 9.48, p = 0.0039), IL-10 (F(1, 37) = 6.67,
p = 0.0139), IL-12/IL-23p40 (F(1, 38) = 10.97, p = 0.0020), IL-15 (F(1, 38) = 9.54, p = 0.0037), TNF-β
(F(1, 35) = 7.45, p = 0.0098), and VEGF-C (F(1, 37) = 6.17, p = 0.0177). Percentage fat mass significantly
influenced IL-6 (F(1, 38) = 8.83, p = 0.0052), IL-12/IL-23p40 (F(1, 37) = 10.05, p = 0.0031), TNF-β
(F(1, 35) = 4.93, p = 0.0331), and VEGF-C (F(1, 38) = 5.00, p = 0.0315). Age, BMI, and percentage fat mass
were not found to be associated with concentrations of any of the remaining inflammatory markers.
3.1.3. Effect of Illness Severity
Full results from the regressions determining the effect of illness severity, in relation to illness
duration, ED symptoms, and general psychopathology, on serum concentrations of the inflammatory
markers in AN participants only are shown in Table S2. Illness duration of AN participants significantly
predicted serum concentrations of IL-4 (F(1, 18) = 15.82, p = 0.0009), IL-12/IL-23p40 (F(1, 21) = 6.70,
p = 0.0172), MCP-1 (F(1, 21) = 6.40, p = 0.0194), and VEGF-A (F(1, 22) = 5.55, p = 0.0278). Severity of ED
symptoms in AN participants, as measured by the EDE-Q, predicted serum concentrations of IP-10
(F(1, 23) = 12.60, p = 0.0017) and PlGF (F(1, 25) = 4.44, p = 0.0454). Level of general psychopathology
(symptoms of depression, anxiety, and stress, as measured by the DASS-21) significantly predicted
Eotaxin (F(1, 25) = 4.64, p = 0.0410), IL-7 (F(1, 25) = 4.60, p = 0.0419), IL-8 (F(1, 25) = 10.08, p = 0.0040),
IP-10 (F(1, 25) = 6.06, p = 0.0211), MCP-1 (F(1, 25) = 5.43, p = 0.0282), and TARC (F(1, 22) = 9.18,
p = 0.0062) concentrations. No other inflammatory markers were significantly associated with illness
duration or severity of ED and general psychopathology symptoms.
3.2. Brain-Derived Neurotrophic Factor
Median serum levels of BDNF were reduced in AN participants compared to HCs (U = 101,
z = 2.15, p = 0.0320). Concentrations of BDNF were significantly influenced by BMI (F(1, 38) = 13.86,
p = 0.0007) and percentage body fat mass (F(1, 38) = 7.08, p = 0.0114), but not by age, as shown in
Table S1. Illness duration, ED symptom severity, and general psychopathology symptoms were not
associated with serum concentrations of BDNF (see Table S2).
4. Discussion
4.1. Summary of Findings
We measured a range of markers involved in inflammatory processes, including cytokines,
chemokines, acute-phase reactants, and cell adhesion molecules, in people with AN and HCs. Median
concentrations of BDNF, IL-6, IL-15, TNF-β, VCAM-1, and VEGF-A were found to differ between
AN and HCs, with IL-6, IL-15, and VCAM-1 being elevated in AN, and BDNF, TNF-β, and VEGF-A
being reduced, compared to HCs. No other inflammatory markers differed between AN participants
and HCs. Our exploratory analyses also identified potential confounding variables of these markers,
including age, BMI, and percentage fat mass, which should be considered in future studies. Illness
severity, both with respect to ED and general psychopathology symptoms, predicted concentrations of
certain inflammatory markers that were not found to differ between AN participants and HCs. Of the
markers with significant cross-sectional differences, illness duration predicted serum concentrations
of VEGF-A.
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4.1.1. Inflammatory Markers
Given that the AN patients in this sample are seriously unwell, as evidenced by their low BMI,
the loss of fat mass, and the presence of clinically significant ED and severe depression and anxiety
symptoms, the finding that most inflammatory markers (n = 33) were unchanged may seem somewhat
surprising. However, it has been proposed that the functioning of the immune system is relatively
preserved in AN, despite malnutrition [48]. For example, extensive evidence suggests that patients
with AN tend to be free from infectious diseases, and rarely have colds and/or flu (at least until
very advanced stages of the disease) [48,49], which is in contrast to the heightened risk of infection
observed in those with typical malnutrition. A recent in vitro study of immune parameters in people
with AN reported that despite reductions in some immune cell populations, AN is also associated with
enhanced antioxidant potential and anti-inflammatory status, in comparison to HCs [50]. This may
contribute to the preservation of immune system functioning reported in AN. However, it needs
to be considered that data derived from in vitro methods may not reflect how cells would respond
in vivo. An additional contributing factor could be a relatively sustained/unaffected gut barrier
function in AN [51], in spite of the distinct alterations of the gut microbiome and low gut microbiome
diversity reported in AN patients [15]. A ‘leaky gut’ is associated with low-grade inflammation
(i.e., leaking of bacteria and/or their components from the gut into circulation is thought to elicit an
inflammatory response) [52,53]; therefore, sustained gut permeability will reduce the likelihood of an
inflammatory response.
To the best of our knowledge, this is the first time serum concentrations of IL-15, TNF-β,
and VEGF-A have been measured and were found to be altered in AN patients. Therefore, we have
discussed the potential significance of these findings in more detail.
IL-15, a T cell growth factor, has been suggested to be involved in the modulation of serotonergic
transmission [54,55], which may underlie the depressive symptoms and sleep disturbances that
are often present in people with AN, and fits with existing evidence of serotonergic alterations in
AN [56,57]. Elevations of IL-15 levels have also been reported in patients with schizophrenia [58],
which is interesting in light of the possible genetic overlaps between AN and schizophrenia that have
been identified in genome-wide association study (GWAS) data [59]. IL-15 has also been implicated
in cross-talk between fat and muscle and reported to have an anabolic role, i.e., decreasing fat and
increasing muscle mass [60]. It is unclear, therefore, why it is increased in the anorectic group given
that they show a severe loss of body fat. It may, for example, be raised as a way of trying to maintain
muscle mass in the ill state.
TNF-β (also known as lymphotoxin-α) has several roles in immune regulation [10] and is
involved in the regulation of cell survival, proliferation, differentiation, and apoptosis [11]. A TNF-β
polymorphism (+252G/A) has been proposed to increase the risk of developing schizophrenia [61].
TNF-β also has a role in maintaining lipid homeostasis, which is potentially important in AN. However,
what is perhaps of most interest is that it is involved in regulating intestinal microbiota [12–14],
especially as the gut microbiome has been implicated in the pathophysiology of AN e.g., [15].
VEGF-A induces angiogenesis, vasculogenesis, and endothelial cell growth, and also influences
vascular permeability, similar to VCAM-1 [62]. Altered levels of VEGF-A have also been found in
patients with depression [63] and schizophrenia [64]. Lastly, VEGF-A has been suggested to enhance
adult neurogenesis and hippocampus-dependent learning and memory [33], which may be important
in both responsivity to illness and in relation to therapy.
Taken together, changes in IL-15, TNF-β, and VEGF-A could potentially contribute to the
development of AN symptoms, such as low mood and disturbed sleep, as well as its clinical
consequences, such as impaired learning and memory. Furthermore, they provide a link between
the biological pathophysiology of AN with depression and schizophrenia, which are clinically- and
genetically-related psychiatric disorders. This association may be suggestive of inflammatory markers
being indicators of transdiagnostic symptoms, such as low mood, rather than specific psychiatric
diagnoses. Also, such a biological association between these disorders could have clinical and
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therapeutic relevance. For example, we could consider the question as to whether antipsychotics,
such as olanzapine, which is approved for the treatment of schizophrenia and alters cytokine
production [65], might help patients with AN [31,66]. This may also be of particular interest in
AN as olanzapine has been shown to alter the gut microbiome, which could additionally contribute to
weight gain [67–70].
The findings of increased IL-6 and VCAM-1 serum concentrations in our sample of people with
AN compared to HCs are of less novelty, but indicate the reliability of our findings, as these results
have also been reported previously.
As described, there are already a number of studies that have consistently identified an association
between AN and the pro-inflammatory cytokine IL-6 [2]. IL-6 is an inducer of the acute-phase response,
which has been shown to have suppressive effects on food intake [71] and inhibit adipogenesis [72].
Our results replicated the findings of increased concentrations of IL-6 in people with AN, as compared
to HCs.
Víctor et al. [26] previously reported increased VCAM-1 serum levels in patients with AN.
VCAM-1 is a cell adhesion molecule with a key role in leukocyte recruitment from blood into tissue
and is thus important for cellular immune response [73]. Because of its wide distribution in human
tissues and organs, VCAM-1 has been implicated in the development of a variety of pathophysiological
states in the brain and in the body periphery, including autoimmune diseases, cardiovascular disease,
and infections [74].
It is unclear why these particular inflammatory markers are altered in people with AN compared
to HCs. However, there are a number of potential factors which may contribute to these alterations,
including stress and neuroendocrine functioning, genetics, the gut microbiota, early life stress,
and negative health behaviours (e.g., disturbed sleep, altered diet, smoking) [75].
4.1.2. Brain-Derived Neurotrophic Factor
The reduced serum concentrations of BDNF in AN participants compared to HCs is consistent
with previous findings [76]. BDNF is a neurotrophin implicated in both central and peripheral
nervous system development. It is well-established that BDNF and cytokines cross-regulate each other.
Certain pro-inflammatory cytokines can suppress the expression of BDNF [34] and BDNF-dependent
synaptic plasticity [32]. It is thought that the detrimental effect of pro-inflammatory cytokines on
neuroplasticity may be mediated by BDNF [34]. Taking together the evidence in AN of elevated
pro-inflammatory cytokines [2,3], reduced concentrations of BDNF and VEGF-A [76], and reduced
hippocampal volumes [77,78], a key area for adult neurogenesis, it could be hypothesised that this
mechanism may be at play in AN, as proposed in the depression literature [34,79]. This hypothesis
would be consistent with the high prevalence (approximately 40%) of depression in patients with
AN [39].
4.1.3. Marker-Specific Confounding Variables
Our exploratory regression analyses found that BMI significantly predicted BDNF, IL-4, IL-6,
IL-10, IL-12/IL-23p40, IL-15, TNF-β, and VEGF-C concentrations. BDNF, IL-6, IL-12/IL-23p40, TNF-β,
and VEGF-C were also significantly predicted by percentage fat mass. Previous studies assessing IL-6
in AN have failed to control for BMI in cross-sectional analyses. Therefore, we cannot be certain that
the alterations we identified in concentrations of BDNF, IL-6, IL-15, and TNF-β are attributable to AN,
rather than simply BMI or percentage fat mass. We also identified age as a significant confounder
of Eotaxin-3, IFN-γ, MCP-1, MIP1-α, SAA, and TNF-α. Therefore, studies in larger samples with
adequate power should ensure that BMI, and other confounding variables, such as age and percentage
fat mass, are incorporated into analyses as covariates to further explore this relationship. Research is
also needed to consider the effect of additional potential confounding variables on the relationship
between AN and inflammation. Physical activity, for example, may be particularly pertinent in AN
patients, given that excessive exercise is often a key feature of the disorder.
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4.2. Strengths and Limitations
This study is the first to measure several inflammatory markers in patients with AN, including
IL-15 and TNF-β, identifying several alterations in inflammatory markers in AN that warrant future
research in larger samples. We also assessed illness severity, in terms of illness duration; ED
symptoms, including psychological and anthropometric measures; and associated psychopathology
(e.g., depression and anxiety), in our participants. Few previous studies have included such
variables [2], which in the current study have allowed us to explore the relationship between illness
severity and inflammatory markers. In addition, for the HCs, the median values of a number of the
assessed markers are similar to those observed in previous studies, suggesting that our HC group is a
valid comparison group.
Several limitations should be noted. The sample is small, which limits the power in this study and
due to the exploratory nature, we did not correct for multiple testing, thus increasing the likelihood of
receiving a significant result. Additionally, while the AN and HC groups did not differ in mean age,
it must be mentioned that the AN group had a larger age range (18–67 years) than the HCs (20–36 years).
The AN sample included both inpatients and outpatients; differences between these treatment settings
in the opportunity to engage in ED behaviours, such as calorie restriction, self-induced vomiting,
and excessive exercise, may effect cytokine concentrations e.g., [80,81]. As BIA measurements of body
composition are influenced by fluid and electrolyte status (for which there are known imbalances in
AN and these parameters are reported to be particularly affected in early refeeding), the accuracy
of BIA measurements of body composition may be limited, particularly in the AN group [82,83].
For practical reasons, it was not possible to ensure blood samples were drawn at a specific time of
day and as cytokine production and release is reported to occur in a circadian manner, it is possible
that some natural variations may have occurred [84]. As previously described, the inflammatory
markers measured in the current study can be affected by a number of pre-analytical factors [36],
including age, BMI, smoking, and medication. We did not have data on medication for all participants;
however, research has shown that antidepressant and antipsychotic medication can influence cytokine
concentrations and production [20,85]. As these medications are prescribed to AN patients to target
comorbid features of AN, such as depression and/or to induce weight gain [31], it would be important
to identify medication status and incorporate this into analyses as a potential covariate. However,
the limited power in this study precludes more complex analyses, such as incorporating several
confounding variables or considering the effect of nominal confounders, such as smoking status,
on inflammatory markers. Overall, future investigations of inflammatory markers in AN need to ensure
that such confounders are assessed and reported, and if possible, accounted for in statistical analyses.
5. Conclusions
This exploratory study measured a broad range of inflammatory markers, many of which had
not been previously assessed in AN. IL-15, VEGF-A, and TNF-β, for the first time, were shown to be
altered in people with AN in comparison to HCs. Previous findings regarding an elevation of IL-6 and
VCAM-1 and a reduction in BDNF in AN participants were replicated. We also considered age, BMI,
and percentage fat mass as potential confounding variables of concentrations of the inflammatory
markers. Our findings suggest that future research should include covariates in analyses of this
relationship to explore whether this may account for some of the group differences in inflammatory
markers observed in the current study. Finally, given that these inflammatory markers function as part
of a complex network, future studies in larger samples should consider developing a composite score
of cytokine concentrations.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/11/1573/
s1: Table S1: Findings from the linear regressions of potential confounders—age, BMI, percentage fat mass
(independent variable)—on log-transformed values of inflammatory markers (dependent variable) in the whole
sample; Table S2: Findings from the linear regressions of illness severity (independent variable) on log-transformed
values of inflammatory markers (dependent variable) in AN patients only.
20
Nutrients 2018, 10, 1573
Author Contributions: Conceptualization, G.B., U.S., and H.H.; Data curation, B.D.; Formal analysis, B.D.;
Funding acquisition, I.C.C., G.B., U.S., and H.H.; Investigation, B.D., I.C.C., R.C., and U.S.; Methodology, I.C.C.,
R.C., and U.S.; Project administration, U.S.; Supervision, I.C.C., G.B., U.S., and H.H.; Writing–original draft, B.D.;
Writing—review & editing, B.B., I.C.C., R.C., G.B., U.S., and H.H.
Funding: The ROSANA study was supported by an National Institute for Health Research (NIHR) Programme
Grant for Applied Research (RP-PG-0606-1043). The current study was funded by a studentship awarded to Bethan
Dalton by the Department of Psychological Medicine, King’s College London (KCL) and the Institute of Psychiatry,
Psychology and Neuroscience (IoPPN), KCL. Iain Campbell, Raymond Chung, Gerome Breen, and Ulrike Schmidt
receive salary support from the NIHR Mental Health Biomedical Research Centre at South London and Maudsley
NHS Foundation Trust and KCL. Ulrike Schmidt is supported by an NIHR Senior Investigator Award. The views
expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health
and Social Care. The APC was funded locally by monies supplied by Hubertus Himmerich.
Acknowledgments: We thank the participants of the ROSANA study and the research team who collected the
data between 2009 and 2013.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American
Psychiatric Publishing: Arlington, VA, USA, 2013.
2. Dalton, B.; Bartholdy, S.; Robinson, L.; Solmi, M.; Ibrahim, M.A.A.; Breen, G.; Schmidt, U.; Himmerich, H.
A meta-analysis of cytokine concentrations in eating disorders. J. Psychiatr. Res. 2018, 103, 252–264. [CrossRef]
[PubMed]
3. Solmi, M.; Veronese, N.; Favaro, A.; Santonastaso, P.; Manzato, E.; Sergi, G.; Correll, C.U.
Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies.
Psychoneuroendocrinology 2015, 51, 237–252. [CrossRef] [PubMed]
4. Dinarello, C.A. Proinflammatory cytokines. Chest 2000, 118, 503–508. [CrossRef] [PubMed]
5. Schmidt, F.M.; Weschenfelder, J.; Sander, C.; Minkwitz, J.; Thormann, J.; Chittka, T.; Mergl, R.; Kirkby, K.C.;
Fasshauer, M.; Stumvoll, M.; et al. Inflammatory cytokines in general and central obesity and modulating
effects of physical activity. PLoS ONE 2015, 10, e0121971. [CrossRef] [PubMed]
6. Xiao, J.; Li, J.; Cai, L.; Chakrabarti, S.; Li, X. Cytokines and diabetes research. J. Diabetes Res. 2014, 2014, 920613.
[CrossRef] [PubMed]
7. Lichtblau, N.; Schmidt, F.M.; Schumann, R.; Kirkby, K.C.; Himmerich, H. Cytokines as biomarkers in
depressive disorder: Current standing and prospects. Int. Rev. Psychiatry 2013, 25, 592–603. [CrossRef]
[PubMed]
8. Müller, N.; Weidinger, E.; Leitner, B.; Schwarz, M.J. The role of inflammation in schizophrenia. Front. Neurosci.
2015, 9, 372. [CrossRef] [PubMed]
9. Opal, S.M.; DePalo, V.A. Anti-inflammatory cytokines. Chest 2000, 117, 1162–1172. [CrossRef] [PubMed]
10. Ruddle, N.H. Lymphotoxin and TNF: How it all began-a tribute to the travelers. Cytokine Growth Factor Rev.
2014, 25, 83–89. [CrossRef] [PubMed]
11. Bauer, J.; Namineni, S.; Reisinger, F.; Zoller, J.; Yuan, D.; Heikenwalder, M. Lymphotoxin, NF-κB, and cancer:
The dark side of cytokines. Dig. Dis. 2012, 30, 453–468. [CrossRef] [PubMed]
12. McCarthy, D.D.; Summers-Deluca, L.; Vu, F.; Chiu, S.; Gao, Y.; Gommerman, J.L. The lymphotoxin pathway:
Beyond lymph node development. Immunol. Res. 2006, 35, 41–54. [CrossRef]
13. Upadhyay, V.; Fu, Y.X. Lymphotoxin signalling in immune homeostasis and the control of microorganisms.
Nat. Rev. Immunol. 2013, 13, 270–279. [CrossRef] [PubMed]
14. Kruglov, A.A.; Grivennikov, S.I.; Kuprash, D.V.; Winsauer, C.; Prepens, S.; Seleznik, G.M.; Eberl, G.;
Littman, D.R.; Heikenwalder, M.; Tumanov, A.V. Nonredundant function of soluble LTα3 produced by
innate lymphoid cells in intestinal homeostasis. Science 2013, 342, 1243–1246. [CrossRef] [PubMed]
15. Borgo, F.; Riva, A.; Benetti, A.; Casiraghi, M.C.; Bertelli, S.; Garbossa, S.; Anselmetti, S.; Scarone, S.;
Pontiroli, A.E.; Morace, G.; et al. Microbiota in anorexia nervosa: The triangle between bacterial species,
metabolites and psychological tests. PLoS ONE 2017, 12, e0179739. [CrossRef] [PubMed]
16. Herpertz-Dahlmann, B.; Seitz, J.; Baines, J. Food matters: How the microbiome and gut-brain interaction
might impact the development and course of anorexia nervosa. Eur. Child Adolesc. Psychiatry 2017,
26, 1031–1041. [CrossRef] [PubMed]
21
Nutrients 2018, 10, 1573
17. Lam, Y.Y.; Maguire, S.; Palacios, T.; Caterson, I.D. Are the gut bacteria telling us to eat or not to eat? Reviewing
the role of gut microbiota in the etiology, disease progression and treatment of eating disorders. Nutrients
2017, 9, E602. [CrossRef] [PubMed]
18. Jha, M.K.; Minhajuddin, A.; Gadad, B.S.; Greer, T.L.; Mayes, T.L.; Trivedi, M.H. Interleukin 17 selectively
predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant
medication selection. Brain Behav. Immun. 2017, 66, 103–110. [CrossRef] [PubMed]
19. Borovcanin, M.; Jovanovic, I.; Radosavljevic, G.; Djukic Dejanovic, S.; Bankovic, D.; Arsenijevic, N.;
Lukic, M.L. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and
schizophrenia in relapse. J. Psychiatr. Res. 2012, 46, 1421–1426. [CrossRef] [PubMed]
20. Himmerich, H.; Schonherr, J.; Fulda, S.; Sheldrick, A.J.; Bauer, K.; Sack, U. Impact of antipsychotics on
cytokine production in-vitro. J. Psychiatr. Res. 2011, 45, 1358–1365. [CrossRef] [PubMed]
21. Turner, M.D.; Nedjai, B.; Hurst, T.; Pennington, D.J. Cytokines and chemokines: At the crossroads of cell
signalling and inflammatory disease. Biochim. Biophys. Acta 2014, 1843, 2563–2582. [CrossRef] [PubMed]
22. Borish, L.C.; Steinke, J.W. 2. Cytokines and chemokines. J. Allergy Clin. Immunol. 2003, 111, S4604–S4675.
[CrossRef]
23. Pisetsky, D.S.; Trace, S.E.; Brownley, K.A.; Hamer, R.M.; Zucker, N.L.; Roux-Lombard, P.; Dayer, J.M.;
Bulik, C.M. The expression of cytokines and chemokines in the blood of patients with severe weight loss
from anorexia nervosa: An exploratory study. Cytokine 2014, 69, 110–115. [CrossRef] [PubMed]
24. Zhang, S.; Tang, H.; Gong, C.; Liu, J.; Chen, J. Assessment of serum CX3CL1/fractalkine level in Han Chinese
girls with anorexia nervosa and its correlation with nutritional status: A preliminary cross-sectional study.
J. Investig. Med. 2017, 65, 333–337. [CrossRef] [PubMed]
25. Murphy, K.; Travers, P.; Walport, M. Janeway’s Immunobiology, 7th ed.; Garland Science, Taylor & Francis
Group: Abingdon, UK, 2009.
26. Víctor, V.M.; Rovira-Llopis, S.; Saiz-Alarcon, V.; Sanguesa, M.C.; Rojo-Bofill, L.; Banuls, C.; de Pablo, C.;
Alvarez, A.; Rojo, L.; Rocha, M.; et al. Involvement of leucocyte/endothelial cell interactions in anorexia
nervosa. Eur. J. Clin. Investig. 2015, 45, 670–678. [CrossRef] [PubMed]
27. Jeon, S.W.; Kim, Y.K. Neuroinflammation and cytokine abnormality in major depression: Cause or
consequence in that illness? World J. Psychiatry 2016, 6, 283–293. [CrossRef] [PubMed]
28. Capuron, L.; Miller, A.H. Immune system to brain signaling: Neuropsychopharmacological implications.
Pharmacol. Ther. 2011, 130, 226–238. [CrossRef] [PubMed]
29. Stuart, M.J.; Singhal, G.; Baune, B.T. Systematic review of the neurobiological relevance of chemokines to
psychiatric disorders. Front. Cell. Neurosci. 2015, 9, 357. [CrossRef] [PubMed]
30. Kowalska, I.; Karczewska-Kupczewska, M.; Straczkowski, M. Adipocytokines, gut hormones and growth
factors in anorexia nervosa. Clin. Chim. Acta 2011, 412, 1702–1711. [CrossRef] [PubMed]
31. Himmerich, H.; Treasure, J. Psychopharmacological advances in eating disorders. Expert Rev. Clin. Pharmacol.
2018, 11, 95–108. [CrossRef] [PubMed]
32. Tong, L.; Prieto, G.A.; Kramár, E.A.; Smith, E.D.; Cribbs, D.H.; Lynch, G.; Cotman, C.W. BDNF-dependent
synaptic plasticity is suppressed by IL-1β via p38 MAPK. J. Neurosci. 2012, 32, 17714–17724. [CrossRef]
[PubMed]
33. Licht, T.; Keshet, E. Delineating multiple functions of VEGF-A. in the adult brain. Cell. Mol. Life Sci. 2013,
70, 1727–1737. [CrossRef] [PubMed]
34. Calabrese, F.; Rossetti, A.C.; Racagni, G.; Gass, P.; Riva, M.A.; Molteni, R. Brain-derived neurotrophic factor:
A bridge between inflammation and neuroplasticity. Front. Cell. Neurosci. 2014, 8, 430. [CrossRef] [PubMed]
35. Donzis, E.J.; Tronson, N.C. Modulation of learning and memory by cytokines: Signaling mechanisms and
long term consequences. Neurobiol. Learn. Mem. 2014, 115, 68–77. [CrossRef] [PubMed]
36. Dugué, B.; Leppanen, E.; Grasbeck, R. Preanalytical factors and the measurement of cytokines in human
subjects. Int. J. Clin. Lab. Res. 1996, 26, 99–105. [CrossRef] [PubMed]
37. Anzengruber, D.; Klump, K.L.; Thornton, L.; Brandt, H.; Crawford, S.; Fichter, M.M.; Halmi, K.A.; Johnson, C.;
Kaplan, A.S.; LaVia, M.; et al. Smoking in eating disorders. Eat. Behav. 2006, 7, 291–299. [CrossRef] [PubMed]
38. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctot, K.L. A meta-analysis of
cytokines in major depression. Biol. Psychiatry 2010, 67, 446–457. [CrossRef] [PubMed]
22
Nutrients 2018, 10, 1573
39. Ulfvebrand, S.; Birgegard, A.; Norring, C.; Hogdahl, L.; von Hausswolff-Juhlin, Y. Psychiatric comorbidity
in women and men with eating disorders results from a large clinical database. Psychiatry Res. 2015,
230, 294–299. [CrossRef] [PubMed]
40. Keyes, A.; Woerwag-Mehta, S.; Bartholdy, S.; Koskina, A.; Middleton, B.; Connan, F.; Webster, P.; Schmidt, U.;
Campbell, I.C. Physical activity and the drive to exercise in anorexia nervosa. Int. J. Eat. Disord. 2015,
48, 46–54. [CrossRef] [PubMed]
41. Schmidt, U.; Sharpe, H.; Bartholdy, S.; Bonin, E.M.; Davies, H.; Easter, A.; Goddard, E.; Hibbs, R.; House, J.;
Keyes, A.; et al. Treatment of anorexia nervosa: A multimethod investigation translating experimental
neuroscience into clinical practice. In Programme Grants for Applied Research; NIHR Journals Library:
Southampton, UK, 2017.
42. First, M.B.; Gibbon, M.; Spitzer, R.L.; Williams, J.B.W. User’s Guide for the Structured Clinical Interview for
DSM-IV Axis I Disorders—Research Version; Biometrics Research Department, New York State Psychiatric
Institute: New York, NY, USA, 1996.
43. Fairburn, C. Appendix: Eating Disorder Examination Questionnaire (EDE-Q. Version 6.0) In Cognitive Behaviour
Therapy and Eating Disorders; Guilford Press: New York, NY, USA, 2008.
44. Lovibond, S.; Lovibond, P. Manual for the Depression Anxiety Stress Scales, 2nd ed.; Psychology Foundation:
Sydney, Australia, 1995.
45. StataCorp. Stata Statistical Software: Release 15; StataCorp LLC: College Station, TX, USA, 2017.
46. Luce, K.H.; Crowther, J.H.; Pole, M. Eating Disorder Examination Questionnaire (EDE-Q): Norms for
undergraduate women. Int. J. Eat. Disord. 2008, 41, 273–276. [CrossRef] [PubMed]
47. Mond, J.M.; Hay, P.J.; Rodgers, B.; Owen, C. Eating Disorder Examination Questionnaire (EDE-Q): Norms
for young adult women. Behav. Res. Ther. 2006, 44, 53–62. [CrossRef] [PubMed]
48. Marcos, A. The immune system in eating disorders: An overview. Nutrition 1997, 13, 853–862. [CrossRef]
49. Slotwinska, S.M.; Slotwinski, R. Immune disorders in anorexia. Cent. Eur. J. Immunol. 2017, 42, 294–300.
[CrossRef] [PubMed]
50. Omodei, D.; Pucino, V.; Labruna, G.; Procaccini, C.; Galgani, M.; Perna, F.; Pirozzi, D.; De Caprio, C.;
Marone, G.; Fontana, L.; et al. Immune-metabolic profiling of anorexic patients reveals an anti-oxidant and
anti-inflammatory phenotype. Metabolism 2015, 64, 396–405. [CrossRef] [PubMed]
51. Mörkl, S.; Lackner, S.; Meinitzer, A.; Mangge, H.; Lehofer, M.; Halwachs, B.; Gorkiewicz, G.; Kashofer, K.;
Painold, A.; Holl, A.K.; et al. Gut microbiota, dietary intakes and intestinal permeability reflected by serum
zonulin in women. Eur. J. Nutr. 2018. [CrossRef] [PubMed]
52. Alam, R.; Abdolmaleky, H.M.; Zhou, J.R. Microbiome, inflammation, epigenetic alterations, and mental
diseases. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2017, 174, 651–660. [CrossRef] [PubMed]
53. Żak-Gołąb, A.; Kocelak, P.; Aptekorz, M.; Zientara, M.; Juszczyk, L.; Martirosian, G.; Chudek, J.;
Olszanecka-Glinianowicz, M. Gut microbiota, microinflammation, metabolic profile, and zonulin
concentration in obese and normal weight subjects. Int. J. Endocrinol. 2013, 2013, 674106. [CrossRef]
[PubMed]
54. Pan, W.; Wu, X.; He, Y.; Hsuchou, H.; Huang, E.Y.; Mishra, P.K.; Kastin, A.J. Brain interleukin-15 in
neuroinflammation and behavior. Neurosci. Biobehav. Rev. 2013, 37, 184–192. [CrossRef] [PubMed]
55. Wu, X.; Hsuchou, H.; Kastin, A.J.; He, Y.; Khan, R.S.; Stone, K.P.; Cash, M.S.; Pan, W. Interleukin-15 affects
serotonin system and exerts antidepressive effects through IL15Rα receptor. Psychoneuroendocrinology 2011,
36, 266–278. [CrossRef] [PubMed]
56. Gauthier, C.; Hassler, C.; Mattar, L.; Launay, J.M.; Callebert, J.; Steiger, H.; Melchior, J.C.; Falissard, B.;
Berthoz, S.; Mourier-Soleillant, V.; et al. Symptoms of depression and anxiety in anorexia nervosa: Links
with plasma tryptophan and serotonin metabolism. Psychoneuroendocrinology 2014, 39, 170–178. [CrossRef]
[PubMed]
57. Kaye, W.H.; Frank, G.K.; Bailer, U.F.; Henry, S.E.; Meltzer, C.C.; Price, J.C.; Mathis, C.A.; Wagner, A. Serotonin
alterations in anorexia and bulimia nervosa: New insights from imaging studies. Physiol. Behav. 2005,
85, 73–81. [CrossRef] [PubMed]
58. de Witte, L.; Tomasik, J.; Schwarz, E.; Guest, P.C.; Rahmoune, H.; Kahn, R.S.; Bahn, S. Cytokine alterations in
first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr. Res. 2014, 154, 23–29.
[CrossRef] [PubMed]
23
Nutrients 2018, 10, 1573
59. Bulik-Sullivan, B.; Finucane, H.K.; Anttila, V.; Gusev, A.; Day, F.R.; Loh, P.R.; Duncan, L.; Perry, J.R.;
Patterson, N.; Robinson, E.B.; et al. An atlas of genetic correlations across human diseases and traits.
Nat. Genet. 2015, 47, 1236–1241. [CrossRef] [PubMed]
60. Pedersen, B.K. Muscles and their myokines. J. Exp. Biol. 2011, 214, 337–346. [CrossRef] [PubMed]
61. Kadasah, S.; Arfin, M.; Rizvi, S.; Al-Asmari, M.; Al-Asmari, A. Tumor necrosis factor-α and -β genetic
polymorphisms as a risk factor in Saudi patients with schizophrenia. Neuropsychiatr. Dis. Treat. 2017,
13, 1081–1088. [CrossRef] [PubMed]
62. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004,
25, 581–611. [CrossRef] [PubMed]
63. Sharma, A.N.; da Costa e Silva, B.F.; Soares, J.C.; Carvalho, A.F.; Quevedo, J. Role of trophic factors GDNF,
IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies. J. Affect. Disord.
2016, 197, 9–20. [CrossRef] [PubMed]
64. Frydecka, D.; Krzystek-Korpacka, M.; Lubeiro, A.; Stramecki, F.; Stanczykiewicz, B.; Beszlej, J.A.;
Piotrowski, P.; Kotowicz, K.; Szewczuk-Boguslawska, M.; Pawlak-Adamska, E.; et al. Profiling inflammatory
signatures of schizophrenia: A cross-sectional and meta-analysis study. Brain Behav. Immun. 2018, 71, 28–36.
[CrossRef] [PubMed]
65. Kluge, M.; Schuld, A.; Schacht, A.; Himmerich, H.; Dalal, M.A.; Wehmeier, P.M.; Hinze-Selch, D.; Kraus, T.;
Dittmann, R.W.; Pollmacher, T. Effects of clozapine and olanzapine on cytokine systems are closely linked to
weight gain and drug-induced fever. Psychoneuroendocrinology 2009, 34, 118–128. [CrossRef] [PubMed]
66. Himmerich, H.; Au, K.; Dornik, J.; Bentley, J.; Schmidt, U.; Treasure, J. Olanzapine treatment for patients
with anorexia nervosa. Can. J. Psychiatry 2017, 62, 506–507. [CrossRef] [PubMed]
67. Davey, K.J.; Cotter, P.D.; O’Sullivan, O.; Crispie, F.; Dinan, T.G.; Cryan, J.F.; O’Mahony, S.M. Antipsychotics
and the gut microbiome: Olanzapine-induced metabolic dysfunction is attenuated by antibiotic
administration in the rat. Transl. Psychiatry 2013, 3, e309. [CrossRef] [PubMed]
68. Davey, K.J.; O’Mahony, S.M.; Schellekens, H.; O’Sullivan, O.; Bienenstock, J.; Cotter, P.D.; Dinan, T.G.;
Cryan, J.F. Gender-dependent consequences of chronic olanzapine in the rat: Effects on body weight,
inflammatory, metabolic and microbiota parameters. Psychopharmacology 2012, 221, 155–169. [CrossRef]
[PubMed]
69. Flowers, S.A.; Evans, S.J.; Ward, K.M.; McInnis, M.G.; Ellingrod, V.L. Interaction between atypical
antipsychotics and the gut microbiome in a bipolar disease cohort. Pharmacotherapy 2017, 37, 261–267.
[CrossRef] [PubMed]
70. Morgan, A.P.; Crowley, J.J.; Nonneman, R.J.; Quackenbush, C.R.; Miller, C.N.; Ryan, A.K.; Bogue, M.A.;
Paredes, S.H.; Yourstone, S.; Carroll, I.M.; et al. The antipsychotic Olanzapine interacts with the gut
microbiome to cause weight gain in mouse. PLoS ONE 2014, 9, e115225. [CrossRef] [PubMed]
71. Wong, S.; Pinkney, J. Role of cytokines in regulating feeding behaviour. Curr. Drug Targets 2004, 5, 251–263.
[CrossRef] [PubMed]
72. Ohsumi, J.; Sakakibara, S.; Yamaguchi, J.; Miyadai, K.; Yoshioka, S.; Fujiwara, T.; Horikoshi, H.; Serizawa, N.
Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte
differentiation in 3T3-L1 cells. Endocrinology 1994, 135, 2279–2282. [CrossRef] [PubMed]
73. Wittchen, E.S. Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front. Biosci.
2009, 14, 2522–2545. [CrossRef]
74. Allavena, R.; Noy, S.; Andrews, M.; Pullen, N. CNS elevation of vascular and not mucosal addressin cell
adhesion molecules in patients with multiple sclerosis. Am. J. Pathol. 2010, 176, 556–562. [CrossRef]
[PubMed]
75. Bauer, M.E.; Teixeira, A.L. Inflammation in psychiatric disorders: What comes first? Ann. N. Y. Acad. Sci. 2018.
[CrossRef] [PubMed]
76. Brandys, M.K.; Kas, M.J.H.; van Elburg, A.A.; Campbell, I.C.; Adan, R.A.H. A meta-analysis of circulating
BDNF concentrations in anorexia nervosa. World J. Biol. Psychiatry 2011, 12, 444–454. [CrossRef] [PubMed]
77. Burkert, N.T.; Koschutnig, K.; Ebner, F.; Freidl, W. Structural hippocampal alterations, perceived stress, and
coping deficiencies in patients with anorexia nervosa. Int. J. Eat. Disord. 2015, 48, 670–676. [CrossRef]
[PubMed]
24
Nutrients 2018, 10, 1573
78. Connan, F.; Murphy, F.; Connor, S.E.; Rich, P.; Murphy, T.; Bara-Carill, N.; Landau, S.; Krljes, S.; Ng, V.;
Williams, S.; et al. Hippocampal volume and cognitive function in anorexia nervosa. Psychiatry Res. 2006,
146, 117–125. [CrossRef] [PubMed]
79. Audet, M.-C.; Anisman, H. Interplay between pro-inflammatory cytokines and growth factors in depressive
illnesses. Front. Cell. Neurosci. 2013, 7, 68. [CrossRef] [PubMed]
80. Canavan, B.; Salem, R.O.; Schurgin, S.; Koutkia, P.; Lipinska, I.; Laposata, M.; Grinspoon, S. Effects of
physiological leptin administration on markers of inflammation, platelet activation, and platelet aggregation
during caloric deprivation. J. Clin. Endocrinol. Metab. 2005, 90, 5779–5785. [CrossRef] [PubMed]
81. Raschke, S.; Eckel, J. Adipo-myokines: Two sides of the same coin–mediators of inflammation and mediators
of exercise. Mediat. Inflamm. 2013, 2013, 320724. [CrossRef] [PubMed]
82. Kyle, U.G.; Bosaeus, I.; De Lorenzo, A.D.; Deurenberg, P.; Elia, M.; Manuel Gomez, J.; Lilienthal Heitmann, B.;
Kent-Smith, L.; Melchior, J.C.; Pirlich, M.; et al. Bioelectrical impedance analysis-part II: Utilization in clinical
practice. Clin. Nutr. 2004, 23, 1430–1453. [CrossRef] [PubMed]
83. Ackland, T.R.; Lohman, T.G.; Sundgot-Borgen, J.; Maughan, R.J.; Meyer, N.L.; Stewart, A.D.; Muller, W.
Current status of body composition assessment in sport: Review and position statement on behalf of the ad
hoc research working group on body composition health and performance, under the auspices of the I.O.C.
Medical Commission. Sports Med. 2012, 42, 227–249. [CrossRef] [PubMed]
84. Labrecque, N.; Cermakian, N. Circadian clocks in the immune system. J. Biol. Rhythms 2015, 30, 277–290.
[CrossRef] [PubMed]
85. Munzer, A.; Sack, U.; Mergl, R.; Schonherr, J.; Petersein, C.; Bartsch, S.; Kirkby, K.C.; Bauer, K.; Himmerich, H.
Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins 2013, 5, 2227–2240.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




TGF-β2, EGF, and FGF21 Growth Factors Present in
Breast Milk Promote Mesenteric Lymph Node
Lymphocytes Maturation in Suckling Rats
Paulina Torres-Castro 1,2, Mar Abril-Gil 1,2, María J. Rodríguez-Lagunas 1,2, Margarida Castell 1,2,
Francisco J. Pérez-Cano 1,2,* and Àngels Franch 1,2
1 Physiology Section, Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science,
University of Barcelona, 08028 Barcelona, Spain; mtorreca29@alumnes.ub.edu (P.T.-C.);
mariadelmar.abril@ub.edu (M.A.-G.); mjrodriguez@ub.edu (M.J.R.-L.); margaridacastell@ub.edu (M.C.);
angelsfranch@ub.edu (À.F.)
2 Nutrition and Food Safety Research Institute (INSA·UB), 08921 Santa Coloma de Gramenet, Spain
* Correspondence: franciscoperez@ub.edu; Tel.: +34-934-024-505
Received: 6 August 2018; Accepted: 24 August 2018; Published: 27 August 2018
Abstract: Breast milk, due to its large number of nutrients and bioactive factors, contributes to
optimal development and immune maturation in early life. In this study, we aimed to assess the
influence of some growth factors present in breast milk, such as transforming growth factor-β2
(TGF-β2), epidermal growth factor (EGF), and fibroblast growth factor 21 (FGF21), on the immune
response development. Newborn Wistar rats were supplemented daily with TGF-β2, EGF, or FGF21,
throughout the suckling period. At day 14 and 21 of life, lymphocytes from mesenteric lymph nodes
(MLNs) were isolated, immunophenotyped, and cultured to evaluate their ability to proliferate
and release cytokines. The main results demonstrated that supplementation with TGF-β2, EGF,
or FGF21 modified the lymphocyte composition in MLNs. At day 14, all supplementations were able
to induce a lower percentage of natural killer (NK) cells with the immature phenotype (CD8+), and
they reduced the CD8αα/CD8αβ ratio at day 21. Moreover, the cytokine pattern was modified by
the three treatments, with a down regulation of interleukin (IL)-13 secretion. These results showed
the contribution of these growth factors in the lymphocytes MLNs immune maturation during the
neonatal period.
Keywords: growth factors; breast milk; immunonutrition; cytokines; lymphocytes
1. Introduction
At time of birth, the intestine is immature, not only anatomically, but also metabolically and
immunologically [1–3]. Intestinal development is a key process in early life because it includes
important functions related to growth and survival. It is important to develop mechanisms to digest
and absorb nutrients in an efficient way [4]. Moreover, the intestine begins hosting the gut microbiota
and establishing appropriate host immune responses against pathogens [2]. The intestinal maturation
process can be conditioned through synergy of several factors, such as genetics, microbial colonization,
and nutrition [1–3].
Breast milk is the gold standard to feed the newborn because it includes a rich number of
components, which are essential for optimal growth and development [5]. It also contains a high
number of bioactive factors, which participate in the immune maturation process of infants [2,6].
Among these components, immunoglobulins (Igs), cytokines, and growth factors (GFs) have an
important role [7–9]. In this sense, the effects of several GFs present in maternal milk that promote
intestinal maturation have been described, although their impact on immune development is still
unclear [9].
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On the one hand, the transforming growth factor-β (TGF-β) family members have multifunctional
actions involved in maintaining intestinal homeostasis, regulating inflammation, and allergy
development [10–12]. TGF-βs act on different types of leukocytes, to control the initiation and
resolution of immune responses through the recruitment, activation, and survival of cells [12,13].
TGF-β2 is the predominant isoform present in human and rat breast milk; it reaches the neonatal
intestine where, at birth, endogenous production is low and increases towards weaning [3,10,12].
In infants, breast milk TGF-βs play an important role in developing immune response and promoting
oral tolerance development [12].
On the other hand, one of the most abundant GFs in breast milk is the epidermal growth factor
(EGF), the concentration of which is 500 times more than other GFs present in breast milk [14].
Its concentration is very high in colostrum and it decreases significantly during suckling, both in
human and rodent milk, suggesting that EGF plays a role in the promotion of early neonatal intestinal
growth [2,15]. In fact, EGF is a key intestinal regulator in protecting intestinal barrier integrity, essential
for the absorption of nutrients and the exclusion of pathogens, in both humans and animals [14,16,17].
EGF is a polyfacetic molecule, which acts by regulating different processes, such as cell growth,
survival, migration, apoptosis, proliferation, and differentiation. In early life, milk EGF seems to be
one of the crucial components involved in the prevention of necrotizing enterocolitis (NEC) [1,14].
EGF and TGF-β together with the immunosuppressive interleukin (IL)-10, also present in breast
milk, are involved in the functional development of the gastrointestinal mucosa, tolerance acquisition,
and inflammation downregulation in damaged intestinal cells [6,7].
In recent years, new components present in breast milk have been discovered. This is the case
of the fibroblast growth factor 21 (FGF21), which belongs to the hormone-like subgroup within the
FGF superfamily, and has been found in rodent and human milk [16]. The FGF21 present in milk,
seems to be involved in local actions in the neonatal intestine. It is a highly active pleiotropic factor,
involved in multiple aspects of metabolism through a variety of mechanisms, where it regulates both
the expression and activity of digestive enzymes, and the synthesis and release of several intestinal
hormone factors [16,18]. All these effects make FGF21 a good candidate to be studied, due to its
possible contribution to neonatal intestinal function.
Overall, because TGF-β2, EGF, and FGF21 are biologically active factors found in breast milk
and are suggested to be involved in neonatal intestine maturation; our hypothesis is that they could
also have an important role in the immune development process in early life. Therefore, the main
objective of the current study was to ascertain whether the effect of a daily supplementation with
these compounds could promote immune response development, during the suckling period in rats.
The effects of the supplementations on mesenteric lymph nodes (MLNs), an inductor site of the gut
associated lymphoid tissue (GALT), were studied specifically during and at the end of the suckling
period, in terms of lymphocyte phenotypic composition and on the immune functionality, such as their
lymphoproliferative and cytokine production abilities.
2. Materials and Methods
2.1. Animals
Pregnant Wistar rats (G15) were obtained from Janvier Labs (Le Genest-Saint-Isle, France), and
were individually housed in cages under controlled conditions of temperature and humidity in a
12:12 h light:dark cycle with access to food and water ad libitum. The pregnant rats were monitored
daily and allowed to deliver naturally. The day after birth was reported as day 1. The studies were
performed in accordance with institutional guidelines, for the care and use of laboratory animals, and
were approved by the Ethical Committee for Animal Experimentation (CEEA) at the University of
Barcelona (UB) and Catalonia Government (CEEA-UB Ref. 220/15, UB/DAAM 8521).
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2.2. Dietary Supplementation
The suckling pups were unified in litters of nine pups per mother and were randomized into
four groups, formed by three litters each (n = 27 pups/group). This sample size was required for each
group, as previous studies have demonstrated the remarkable role of variability among litters [19].
The Appraising Project Office’s program, from the Universidad Miguel Hernández de Elche (Alicante)
was used for such estimation, to detect statistically significant differences among groups, assuming
there was no dropout rate and a type I error of 0.05 (two-sided).
Besides the reference group (REF group), three supplemented groups based on nutritional
intervention were created: the transforming growth factor-β2 (TGF-β2), epidermal growth factor
(EGF), and the fibroblast growth factor 21 (FGF21). All animals were identified daily, weighed, and
supplemented by oral gavage with a volume of 10 mL/kg/day during the suckling period, from
day 1 to day 21 of age. The suckling pups were separated from their mothers 30 min before oral
administration, to allow gastric emptying. All daily handling was done at the same period of the day,
to avoid modifications in biological rhythms. All actions were performed as described in previous
studies in the group, References [19,20].
TGF-β2, EGF, and FGF21 groups were supplemented with recombinant human TGF-β2,
recombinant rat EGF, and recombinant human FGF21 (all from Peprotech®, Rocky Hill, NJ, USA).
The products were reconstituted according to the manufacturer’s recommendations.
The dose of TGF-β2 was 35 μg/kg/day, which was based on the amount of TGF-β2 found in the
last lactation rat milk (62 ng/mL), and the milk intake by pups within 4−14 days of age [3]. The dose
of EGF was 100 μg/kg/day, which had been demonstrated to be effective as a treatment in a rat model
of NEC [21]. Finally, the dose of FGF21 was 5 μg/kg/day, an amount that was established in relation
to TGF-β2, which has been found in a 1:10 ratio FGF21:TGF-β2 [10,16]. The REF group received a
matched volume of the vehicle used for the GFs administration (1% bovine serum albumin (BSA) in
phosphate buffer saline (PBS)).
2.3. Measurement of Growth and Development
Body weight was registered daily throughout the study. Two end points were established, at day
14 and at the end of the suckling period at day 21. At these times, prior to sacrifice, the pups were
anesthetized with intramuscular ketamine (90 mg/kg; Imalgene®, Merial, Barcelona, Spain) and
xylazine hydrochloride (10 mg/kg, Rompun®, Bayer, Barcelona, Spain); and body length (nose-anal)
was measured. These data allowed the calculation of morphologic variables, such as the body mass
index (BMI, g/cm2) and Lee index, for assessing obesity in rats ((g1/3/cm) × 1000).
2.4. Sample Collection and Processing
Once anesthetized, MLNs and small intestine (SI) were obtained through a ventral laparotomy.
The SI was weighed, measured, and divided into three equal length portions. Gut washes (GWs) were
obtained from the distal SI. Briefly, the intestine was flushed with cold PBS and cut into 5 mm pieces.
The tissue was incubated with PBS (10 min, 37 ◦C, shaking), centrifuged (538 g, 10 min, 4 ◦C), and later,
supernatant was collected and stored at −20 ◦C until Igs quantification.
2.5. Quantification of Intestinal IgA and IgM by ELISA
The IgA and IgM content were quantified in GWs from day 21 of study, by ELISA Quantitation
Set (Bethyl Laboratories, Inc., Montgomery, MD, USA), as previously described in Reference [19].
GWs were diluted at 1:20 (IgA) and 1:10 (IgM). Data were expressed as μg/g of tissue.
2.6. Lymphocyte Isolation from Mesenteric Lymph Nodes
The MLNs were placed in complete culture medium, containing Roswell Park Memorial Institute
(RPMI 1640, Sigma-Aldrich, St. Louis, MO, USA) 10% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis,
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MO, USA), 1% L-glutamine (Sigma-Aldrich, St. Louis, MO, USA), 1% penicillin streptomicin (PenStrep;
Sigma-Aldrich, St. Louis, MO, USA), and 0.05 mM 2-β-mercaptoethanol (Merck, Darmstadt, Germany).
MLNs lymphocytes were obtained in sterile conditions by passing the tissue through a cell strainer
(40 μm, BD Biosciences, San Diego, CA, USA). The cell suspensions were centrifuged (538 g, 10 min,
4 ◦C), and the pellet was resuspended with complete RPMI medium. The cell counts and viabilities
were determined using an automated cell counter, after staining the cells with trypan blue (CountessTM,
Invitrogen, Madrid, Spain), following usual laboratory procedures, as described in Reference [22].
The lymphocytes were immediately used to characterize their phenotype, and to determine their
ability to proliferate and secrete cytokines.
2.7. Mesenteric Lymph Node Cells Stimulation and Proliferation Assay
MLNs cell activation was performed in sterile conditions, using 96-well tissue culture plates
(TPP®, Trasadingen, Switzerland), which were pre-incubated with 200 μL/well of monoclonal
antibodies (mAbs) anti-CD3 (10 μg/mL, BD Biosciences, San Diego, CA, USA) and anti-CD28
(2 μg/mL, BD Biosciences, San Diego, CA, USA) (2 h, 37 ◦C, 5% CO2). Then, MLNs lymphocyte
suspensions (5 × 104 cells/mL) were added to each well. A total of eight wells were used for
each sample: four pre-incubated with the mitogenic mAbs (stimulated cells, SC) and four without
pre-incubation (non-stimulated cells, NSC). The plates were incubated for 48 h, at 37 ◦C and 5% CO2.
Four hours before the end time of the incubation, 5-bromo-2’-deoxyuridine (BrdU, 20 μL/well, Merck,
Darmstadt, Germany) was added to measure its incorporation as an indicator of DNA synthesis in a
colorimetric immunoassay.
The plates were centrifuged (210 g, 5 min) and supernatants were collected and stored at −80 ◦C,
until cytokine analysis. After fixation, the anti-BrdU mAbs and peroxidase conjugated anti-BrdU mAbs
and 3,3’,5,5’-tetramethylbenzidine (TMB) were added, following the manufacturer’s recommendations
of the BrdU Cell Proliferation Assay Kit (Merck, Darmstadt, Germany). The absorbance (Abs) was
measured at 450 nm (Multiskan MS, Labsystems, Helsinki, Finland). Data were expressed as a
proliferation rate as follows: Proliferation rate = (A/B), where, A = ((Abs-SC − Abs-NSC)/Abs-NSC)
supplemented group, and B = ((Abs-SC − Abs-NSC)/Abs-NSC) reference group.
2.8. Quantification of Cytokine Secretion by Mesenteric Lymph Node Lymphocytes
Supernatants collected after the cell stimulation process described above, were used for the
quantification of IL-2, IL-4, IL-10, IL-13, IL-17A, interferon (IFN)-γ, and tumor necrosis factor
(TNF)-α concentration using a ProcartaPlex® Multiplex Immunoassay, according to the manufacturer’s
instructions (eBioscience, San Diego, CA, USA) and as previously described in Reference [19].
Each analyte’s concentration was detected using the MAGPIX instrument (Luminex Corp., Austin,
TX, USA), in the facilities of the Scientific and Technological Centers of the University of Barcelona
(CCiT-UB), and the results were analyzed using xPONENT® 4.2 software (Luminex Corp., Austin,
TX, USA). The limits of detection were as follows: 2.10–8600 pg/mL for IL-2; 0.85–3500 pg/mL
for IL-4; 14–55,700 pg/mL for IL-10; 3.17–13,000 pg/mL for IL-13; 2.61–2675 pg/mL for IL-17A;
4.35−17,800 pg/mL for IFN-γ; and 3.08−12,600 pg/mL for TNF-α.
2.9. Immunofluorescence Staining and Flow Cytometry Analysis
Lymphocytes from MLNs (5 × 104 cells) were immunophenotyped by multiple
immunofluorescence staining technique. Mouse anti-rat mAbs conjugated to fluorescein isothiocyanate
(FITC), phycoerythrin (PE), peridinin-chlorophyll-a protein (PerCP), allophycocyanin (APC) or
APC-cyanine(Cy)7 were used, as in previous studies [19]. For cell subset differentiation, five different
mAbs panels were used; Panel 1: TCRαβ/NKR-P1A/CD8α; Panel 2: CD8α/CD8β/TCRγδ; Panel
3: αE integrin/CD62L/CD8α/CD4; Panel 4: CD45RA/TLR4/CD8α/CD4/CD25; and Panel 5:
CD25/CD4/Foxp3. With the first panel, NK cells (NKR-P1A+ TCRαβ−), natural killer T (NKT)
cells (NKR-P1A+ TCRαβ+), and TCRαβ+ cells (TCRαβ+ NKR-P1A−) could be differentiated, which
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in combination with the TCRγδ+ cells (obtained from Panel 2) constituted the total of T cells.
B cells (CD45RA+) were identified with Panel 4. The mAbs used in this study are detailed in the
Supplementary Materials (Table S1).
Briefly, cells were incubated with a mixture of 10 μL of saturating concentrations of each mouse
anti-rat mAbs in PBS pH 7.2, containing 2% FBS and 0.1% sodium azide (Merck, Darmstadt, Germany),
at 4 ◦C in darkness for 20 min. For T reg evaluation, an intracellular staining was performed. For that,
cells previously labeled with anti-CD4-PE and anti-CD25-FITC mAbs, were fixed/permeabilized
using a specific buffer kit (eBioscience, San Diego, CA, USA). Then, intracellular staining with
anti-Foxp3-APC mAb was carried out, under the same conditions as extracellular staining. After
washing, all stained cells were fixed with 0.5% paraformaldehyde (Panreac, Barcelona, Spain) and
stored at 4 ◦C in darkness, until analysis by flow cytometry. For each sample, a positive control
staining using each isotype matched mAbs and a negative control without staining were included.
Analyses were performed in a Gallios™ Cytometer (Beckman Coulter, Miami, FL, USA) in the
CCiT-UB. Data were assessed by FlowJo® version 10 software (Tree Star Inc., Ashland, Covington,
KY, USA). Results were expressed as percentages of positive cells in the lymphocyte population,
selected according to their forward- and side-scatter characteristics (FSC/SSC) using previous studies
protocols [19], or in a selected population. The gating strategy was specific for each panel used, but
overall, markers (e.g., CD8α in Panel 1, αE integrin, and CD62L in Panel 3) were evaluated in specific
gate subsets (e.g., NK, NKT, or T cells in Panel 1, and CD8 or CD4 cells in Panel 3).
2.10. Statistical Analysis
Statistical analyses were performed using the IBM Social Sciences Software Program (SPSS,
version 22.0, Chicago, IL, USA). Levene’s and Shapiro−Wilk tests were applied to assess variance
equality and normal distribution, respectively. When the results demonstrated equality of variance
and normal distribution, a one-way analysis of variance (ANOVA) test was performed. Nonparametric
tests were carried out when normal distribution and equality of variance did not exist. Specifically,
Kruskal–Wallis and Mann–Whitney U tests were used to assess significance for independent samples.
Significant differences were established at p < 0.05. Data in the text, tables, and figures are expressed
as the mean ± standard error of the mean (S.E.M).
3. Results
3.1. Animal Growth
Body growth was assessed in the three groups receiving supplementation (TGF-β2, EGF, and
FGF21), and compared with those receiving the vehicle (REF). Body weight increased during suckling
period in the REF group (p < 0.05) and the supplementations did not affect this growth pattern
(Supplementary Materials, Figure S1). With respect to morphometric variables and SI growth, there
were no differences among the studied groups at any age considered (Table 1).
Table 1. Morphometric variables and small intestinal growth.
BMI Lee Index SI Relative Weight SI Relative Length
(g/cm2) (( 3
√
g/cm) × 1000) (%) (%)
Day 14
REF 0.365 ± 0.009 332.9 ± 3.473 3.51 ± 0.05 118.29 ± 5.49
TGF-β2 0.373 ± 0.010 336.9 ± 3.844 3.59 ± 0.14 114.34 ± 4.28
EGF 0.340 ± 0.007 327.0 ± 2.845 3.48 ± 0.06 122.64 ± 2.91
FGF21 0.371 ± 0.009 337.4 ± 4.044 3.18 ± 0.06 105.59 ± 5.31
Day 21
REF 0.404 ± 0.010 Ψ 319.5 ± 2.551 Ψ 4.15 ± 0.24 Ψ 89.57 ± 3.12 Ψ
TGF-β2 0.404 ± 0.009 Ψ 320.8 ± 3.225 Ψ 4.25 ± 0.09 Ψ 85.65 ± 2.20 Ψ
EGF 0.404 ± 0.007 Ψ 322.9 ± 2.574 4.38 ± 0.07 Ψ 88.34 ± 2.20 Ψ
FGF21 0.420 ± 0.011 Ψ 329.0 ± 4.053 4.78 ± 0.17 Ψ 89.97 ± 4.01 Ψ
BMI: body mass index. SI: small intestine. TGF-β2: transforming growth factor-β2. EGF: epidermal growth factor.
FGF21: fibroblast growth factor 21. Results are expressed as mean ± standard error of the mean (S.E.M) (n = 9).
Ψ p < 0.05 vs. day 14 at same group.
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All groups increased BMI, SI relative weight, and SI relative length with age (p < 0.05, day 21 vs.
day 14). Regarding the Lee index, only the animals from the REF group and those supplemented with
TGF-β2, showed significant differences associated with age (p < 0.05), but the supplementation with
EGF and FGF21 did not display such a significant age difference.
3.2. IgA and IgM Concentration in Gut Wash
Intestinal secretory IgA and IgM were determined at day 21 of life. At that age, the pups’ intestinal
levels were not entirely influenced by maternal breast milk, as happens earlier in life when breast milk
(very rich in IgA) is the only source of food. Nevertheless, none of the interventions (TGF-β2, EGF,
and FGF21 supplemented groups) showed significant differences regarding IgA or IgM, compared to
the REF group (Supplementary Materials, Figure S2).
3.3. Mesenteric Lymph Node Lymphocytes Composition
The proportion of the main lymphocyte subsets in MLN was established during (day 14) and at
the end of (day 21) suckling period. On both days, most of the MLN cells (~75%) were T cells, the
majority of them being TCRαβ+ cells and only ~3% TCRγδ+ cells; B cells counted for about 15–18%,
NK and NKT cells represented subpopulations with less than 3% of total lymphocytes, and Treg cells
were ~4% (Table 2).
Table 2. Main lymphocyte subsets in mesenteric lymph nodes.
Reference TGF-β2 EGF FGF21
Day 14
T cells (%) 75.90 ± 1.80 77.90 ± 1.39 74.36 ± 1.88 79.60 ± 1.50
T TCRαβ+ (%) 72.90 ± 1.98 75.24 ± 1.29 71.22 ± 1.94 75.90 ± 1.20
T TCRγδ+ (%) 3.00 ± 0.20 2.66 ± 0.20 3.14 ± 0.23 3.70 ± 0.40
NK (%) 1.63 ± 0.30 1.22 ± 0.08 1.35 ± 0.12 1.42 ± 0.17
NKT (%) 1.15 ± 0.14 1.18 ± 0.20 0.94 ± 0.05 0.98 ± 0.06
B cells (%) 17.65 ± 1.65 16.19 ± 1.40 19.62 ± 1.23 15.86 ± 1.07
Day 21
T cells (%) 74.60 ± 1.36 75.86 ± 1.10 75.29 ± 1.20 76.41 ± 0.69
T TCRαβ+ (%) 71.57 ± 1.44 73.28 ± 1.14 72.93 ± 1.26 73.10 ± 0.77
T TCRγδ+ (%) 3.07 ± 0.15 2.58 ± 0.15 2.36 ± 0.13 *,Ψ 3.31 ± 0.13
NK (%) 0.95 ± 0.07 Ψ 0.79 ± 0.06 Ψ 0.77 ± 0.08 Ψ 1.05 ± 0.07
NKT (%) 1.57 ± 0.07 Ψ 1.55 ± 0.11 1.39 ± 0.21 1.63 ± 0.18 Ψ
B cells (%) 14.67 ± 0.71 14.30 ± 0.64 12.95 ± 1.19 Ψ 13.23 ± 0.62
Results are expressed as mean ± S.E.M (n = 9). * p < 0.05 vs. reference (REF) group at same age; Ψ p < 0.05 vs. day 14
at same group.
Although at 14 days there were no differences among the supplemented groups, some differences
could be seen at 21 days (Table 2). At the end of the suckling period, only the EGF supplementation
showed a significant decrease in the percentage of TCRγδ+ cells, compared to the REF group (p < 0.05).
Moreover, the REF and groups supplemented with TGF-β2 and EGF decreased the NK cell proportion,
in comparison to the same group at 14 days (p < 0.05). The animals from the REF and FGF21 groups
increased the percentage of NKT cells with age, and only those from the EGF group were able to
decrease the proportion of TCRγδ+ and B cell percentages at day 21 (p < 0.05 vs. day 14).
The percentage of CD8+ cells and the CD8αα/CD8αβ ratio from MLNs lymphocytes, were
determined as indicators of immune maturation (Figure 1). The proportion of CD8+ cells did not show
significant differences, either associated with age (day 14 vs. day 21) or to any of the supplementations,
compared to the REF group (Figure 1a). However, regarding the results from CD8αα/CD8αβ ratio, the
EGF supplementation induced a significant increase at 14 days (p < 0.05 vs. REF, Figure 1b). At day 21,
in all supplemented groups, the CD8αα/CD8αβ ratio had decreased when they were compared to
their respective group at day 14, but no differences among the interventions and the REF groups were
found (Figure 1b).
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Figure 1. Proportion of CD8+ cells and ratio CD8αα/CD8αβ in mesenteric lymph nodes at 14 and
21 days of life. (a) % CD8+ cells; (b) The ratio CD8αα/CD8αβ was calculated as the quotient of
the percentages of CD8αα cells and CD8αβ cells in CD8+ cells (%). Results are expressed as mean
± standard error of the mean (S.E.M) (n = 9). Statistical differences: * p < 0.05 vs. reference group
(REF group) at same age; Ψ p < 0.05 vs. same group at day 14. TGF-β2: transforming growth factor-β2.
EGF: epidermal growth factor. FGF21: fibroblast growth factor 21.
Further analysis of CD8+ and CD8− subsets revealed some changes associated with the
supplementations (Figure 2).
Regarding the TCRαβ+ subsets (CD8+ and CD8−, respectively, Figure 2a,b), no changes due
to supplementation were found either at 14 or at 21 days, with respect to the REF group. Only, the
supplementation with FGF21 decreased the proportion of TCRαβ+ CD8− (~8%), when values from
day 21 were compared to day 14 (Figure 2a, p < 0.05). The TCRγδ+ CD8− cell percentage (Figure 2c),
increased due to supplementation with EGF and FGF21 at 14 days, with only the latter achieving
statistical significance, but these changes were not observed at the end of the suckling period (day 21).
However, both interventions showed a 50% decrease in the TCRγδ+ CD8− cell proportion associated
with age (p < 0.05, day 21 vs. day 14). Moreover, the TCRγδ+ CD8+ cell proportion in the EGF group
(Figure 2d), was lower than the REF group at day 21 (p < 0.05). In relation to the NKT population (CD8-
and CD8+ subsets), only the NKT CD8− subset showed changes associated with age for all groups
(Figure 2e), but not due to the supplementations.
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Figure 2. Percentages of CD8+ and CD8− lymphocyte subsets in mesenteric lymph nodes at 14 and
21 days of life. (a) TCRαβ+ CD8−; (b) TCRαβ+ CD8+; (c) TCRγδ+ CD8−; (d) TCRγδ+ CD8+; (e) NKT
CD8−; (f) NKT CD8+; (g) NK CD8-; and (h) NK CD8+. Results are expressed as mean ± S.E.M (n = 9).
Statistical difference: * p < 0.05 vs. REF group at same age; Ψ p < 0.05 vs. same group at day 14.
However, NKT CD8+ cell proportions were not affected (Figure 2f). Results from the NK cell
population showed that in supplemented groups, there was a decrease in NK CD8- cell proportions
related to age (Figure 2g, p < 0.05, day 21 vs. day 14), and that only supplementation with TGF-β2
induced a significant decrease compared with the REF group at 21 days (Figure 2g, p < 0.05 vs. REF).
The phenotype of the intestinal NK cells based on CD8 expression, could be considered as immature
(NK CD8+) or more mature (NK CD8−). The three supplementations were able to decrease the
proportion of NK cells expressing CD8 at 14 days (Figure 2h), which reached similar values to those
from reference 21-day-old rats. Thus, only the REF group decreased its percentage of NK CD8+ cells at
21 days, with respect to day 14 (Figure 2h).
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The lymphocytes’ commitment to the mucosal compartment were studied by means of the
proportion of cells expressing two adhesion molecules of importance in the intestinal homing; thus, the
total percentage of cells bearing the selectin CD62L and the αE integrin were determined (Figure 3).
Figure 3. Surface expression of αE integrin and CD62L selectin, in mesenteric lymph nodes at 14 and
21 days of life. (a) CD62L/αE integrin surface expression at 14 days, (b) CD62L/αE integrin surface
expression at 21 days, (c) CD62L+ cells (%) and (d) αE+ cells (%). Results are expressed as mean ±
S.E.M (n = 9). Statistical difference: Ψ p > 0.05 vs. same group at day 14.
Figure 3a,b show the molecular pattern of αE/CD62L on day 14 and 21. The CD62L molecule was
expressed on both days in high proportion of cells (~60%). Although the percentage of CD62L+ cells
increased significantly with age in all studied groups (Figure 3a–c, p < 0.05), none of the supplemented
groups induced significant differences, when they were compared to the REF group at the same age.
The αE+ cells were present in a proportion lower than 5% at both studied times (Figure 3b–d) and
were not modified by any GFs administration (Figure 3d).
The percentages of integrin αE+ cells and selectin CD62L+ cells in CD8+, CD4+, and B cells were
further studied (Table 3). None of the supplemented groups showed significant differences, compared
to the REF group at the same age. All studied groups increased CD62L+ CD8+ and CD62L+ CD4+
percentages with age (p < 0.05, day 21 vs. day 14). The REF group increased (~15%) αE+ B cells
subset proportion, with respect to the same group at 14 days, whereas all supplemented groups
decreased (~20%) this subset with age (p < 0.05). In addition, the supplementation with EGF and
FGF21, decreased the percentage of αE expression in CD4+ cells with age. Although there was a
tendency to increase with age, the proportion of CD62L+ in B cells in all groups, it was only significant
in the TGF-β2 group (p < 0.05).
At the end of the suckling period, activated CD4 cells (Foxp3− CD25+ CD4+ cells) and Treg cells
(Foxp3+ CD25+ CD4+ cells) were also studied, and no changes were found due to diets (day 21), with
all groups together having a mean percentage of 1.22 ± 0.12 and 3.81 ± 0.11, respectively.
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Table 3. Surface expression of the αE integrin and the CD62L selectin in CD4+, CD8+, and B cells in
mesenteric lymph nodes.
14 Days
Reference TGF-β2 EGF FGF21
%αE
CD8+ 2.75 ± 0.72 2.92 ± 0.49 2.94 ± 0.52 2.88 ± 0.44
CD4+ 2.81 ± 0.39 3.07 ± 0.45 4.46 ± 0.34 3.80 ± 0.26
B cells 15.98 ± 1.61 18.33 ± 1.39 18.92 ± 2.50 20.32 ± 3.12
%CD62L
CD8+ 65.27 ± 1.56 62.38 ± 3.47 59.25 ± 2.52 59.21 ± 3.55
CD4+ 59.55 ± 1.76 55.41 ± 2.36 53.61 ± 1.37 53.65 ± 2.40
B cells 48.43 ± 2.77 46.6 ± 2.05 38.77 ± 2.08 37.29 ± 4.78
21 Days
Reference TGF-β2 EGF FGF21
%αE
CD8+ 3.84 ± 0.48 2.98 ± 1.04 3.70 ± 0.48 3.97 ± 0.66
CD4+ 2.83 ± 0.75 2.61 ± 0.52 1.94 ± 0.18 Ψ 2.52 ± 0.30 Ψ
B cells 18.43 ± 1.83 Ψ 13.03 ± 1.55 Ψ 14.95 ± 1.69 Ψ 15.75 ± 1.16 Ψ
%CD62L
CD8+ 71.49 ± 1.38 Ψ 72.10 ± 1.93 Ψ 70.78 ± 2.19 Ψ 72.88 ± 2.37 Ψ
CD4+ 66.02 ± 1.74 Ψ 68.24 ± 1.64 Ψ 66.66 ± 0.42 Ψ 66.80 ± 1.22 Ψ
B cells 56.79 ± 2.25 60.92 ± 2.17 Ψ 60.82 ± 3.92 57.61 ± 2.37
Results are expressed as mean ± S.E.M (n = 9). Ψ p < 0.05 vs. day 14 at same group.
3.4. Proliferation and Cytokine Production by Mesenteric Lymph Nodes Cells
To determine the functional capacity of MLN lymphocytes, we studied their proliferative response
and their ability to secrete cytokines on days 14 and 21. With regard to the proliferation of MLNs
cells on days 14 and 21, GFs supplementations were not able to significantly modify such lymphocyte
function induced by anti-CD3 and anti-CD28 mAbs (Supplementary Materials, Figure S3). However,
cytokine production was influenced by GFs supplementation (Table 4).
The pattern of cytokines released from MLNs cells at day 14, showed a high secretion of IFN-γ,
followed by IL-10. In the conditions tested, the secretion of IL-2, IL-4, IL-13, IL-17A, and TNF-α was
lower than 90 pg/mL. IL-10/TNF-α (anti-inflammatory/pro-inflammatory cytokines) and IFN-γ/IL-4
(Th1/Th2) ratios were also calculated. No changes in the cytokine pattern at day 14 were detected
by GFs supplementation. However, at day 21, some changes appeared due to supplementations and
due to age. IL-2 production was 5–10 times higher due to age in the REF, TGF-β2, and EGF groups
(p < 0.05 day 21 vs. day 14). IL-4 levels were ~50% lower in the EGF group at day 21, than those at
day 14 (p < 0.05). The groups that received EGF and FGF21 for 21 days, decreased the IL-10 content
~1.5 times with respect to their values at day 14 (p < 0.05). IL-13 secretion was lower at day 21 with
respect to day 14, in the EGF and FGF21 groups (p < 0.05), and the three GFs groups showed lower
values than those present in the REF group (p < 0.05). The lower levels of IFN-γ production at day
21 compared to day 14 were only significant in the REF group, which accounted for a 50% reduction
(p < 0.05). Moreover, TNF-α release decreased (~30%) with age in the REF, TGF-β2, and FGF21 groups,
whereas supplementation with EGF increased TNF-α production (p < 0.05 vs. REF group).
The IL-10/TNF-α ratio decreased according to age in the EGF and FGF21 groups, and in the EGF
group, values were significantly lower than the REF group (p < 0.05).
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Table 4. Cytokine production by mesenteric lymph node cells after in vitro stimulation.
14 Days
(pg/mL) Reference TGF-β2 EGF FGF21
IL-2 42.71 ± 5.96 39.24 ± 5.66 50.45 ± 6.66 56.72 ± 11.04
IL-4 89.82 ± 13.00 57.14 ± 7.81 82.65 ± 12.47 74.97 ± 12.18
IL-10 879.82 ± 239.40 688.01 ± 145.14 1450.87 ± 296.29 1326.99 ± 217.06
IL-13 25.38 ± 5.64 17.53 ± 3.03 31.91 ± 4.28 26.18 ± 4.03
IL-17A 71.98 ± 26.92 70.22 ± 20.16 60.12 ± 13.61 50.82 ± 9.53
IFN-γ 10323.26 ± 2391.46 8302.75 ± 1964.09 9329.17 ± 1662.87 7882.51 ± 2810.34
TNF-α 8.76 ± 0.98 9.48 ± 0.68 9.19 ± 1.16 7.40 ± 0.25
IL-10/TNF-α 115.00 ± 33.11 79.71 ± 21.80 170.87 ± 43.10 178.05 ± 29.25
IFN-γ/IL-4 110.35 ± 20.65 195.32 ± 61.39 124.85 ± 37.55 103.80 ± 26.93
21 Days
(pg/mL) Reference TGF-β2 EGF FGF21
IL-2 390.57 ± 141.49 Ψ 383.80 ± 89.21 Ψ 244.79 ± 80.37 Ψ 270.16 ± 114.54
IL-4 70.52 ± 10.51 52.21 ± 7.69 48.52 ± 1.91 Ψ 66.60 ± 8.80
IL-10 705.45 ± 63.95 514.70 ± 55.30 508.26 ± 61.43 Ψ 542.36 ± 78.82 Ψ
IL-13 19.51 ± 2.44 12.92 ± 0.74 * 9.91 ± 1.24 *,Ψ 9.83 ± 1.65 *,Ψ
IL-17A 59.97 ± 7.14 46.91 ± 4.03 52.30 ± 10.7022 41.24 ± 11.77
IFN-γ 4231.26 ± 365.41 Ψ 4488.50 ± 416.14 6900.74 ± 1129.78 4595.11 ± 1058.87
TNF-α 6.63 ± 0.11 Ψ 6.55 ± 0.20 Ψ 10.02 ± 0.40 * 5.91 ± 0.38 Ψ
IL-10/TNF-α 106.47 ± 9.73 80.13 ± 9.55 50.48 ± 5.72 *,Ψ 95.64 ± 17.03 Ψ
IFN-γ/IL-4 64.25 ± 9.61 111.99 ± 25.23 147.25 ± 27.9166 81.50 ± 25.37
Results are expressed as mean ± S.E.M (n = 9). * p < 0.05 vs. REF group at same age; Ψ p < 0.05 vs. day 14 at
same group.
4. Discussion
At birth, the immune system is immature, as evidenced by a poor antibody production and low
proliferative response of immune cells. In addition, there are mucosal immune impairments, such
as low intestinal IgA content, reduced number of B lymphocytes in the intestinal mucosa, and few
intestinal T cells [23]. Immune development is driven, among other factors, by components of breast
milk. It is known that growth factors, such as TGF-β2 and EGF, regulate the immune response in early
life and confer protective effects against gut mucosal inflammation by enhancing oral tolerance [1,2,7].
FGF21, which is also present in maternal milk, is a less-studied component and could be involved
in such effects as well [16]. The current study aimed to evaluate whether supplementation with
TGF-β2, EGF, or FGF21 had a role in immune maturation in early life. A rat pup model was used to
evaluate the effect of a daily supplementation with TGF-β2, EGF, or FGF21 during suckling on the
GALT, particularly in the MLNs, which is an inductor site of intestinal immune response. We assessed
the immune maturation by functions, such as lymphoproliferation, cytokine production ability, and
establishing lymphocyte MLNs composition.
Regarding growth, the body weight of pups was not modified due to supplementation with
any of the GFs studied. These results were in line with other investigations, in which rats receiving
either TGF-β2 [10] or EGF [24,25] during the first two weeks of life did not change their body weight.
Likewise, although a study showed that the body weight of FGF21-knockout mice compared to
wild-type 3-month-old mice was not different [26], its physiological role as a weight regulating factor
was discussed [18]. Overall, it seems that the tested GFs, under the conditions we used, did not have a
key role in the growth of neonates.
Intestinal length and weight are useful tools for evaluating the primary impact of a nutrient
on the maturation of the rat small intestine [27]. The GFs supplementation in the current study did
not affect these variables. However, it has been reported that suckling rats receiving intraperitoneal
administration of EGF (100 μg/kg) for only two days, increased stomach and intestinal weights [24];
and that rat pups receiving oral administration of EGF through formula at concentrations exceeding
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the reported concentrations of EGF in rodent milk, enhanced intestinal growth (weight and length) [15].
Thus, in agreement with our results, only high doses of these compounds seem to be able to modify
intestinal growth.
Although no impact on the body and intestinal growth due to any of these GFs was observed,
some effects of TGF-β2, EGF, or FGF21 on immune variables have been shown to be specific; and
therefore, the influence of each GF tested on MLN lymphocyte maturation will be discussed separately.
Transforming growth factor-β (TGF-β) has a wide range of biological activities and among
them, it has an important role in cell proliferation and differentiation. TGF-β acts as a cytokine
having predominantly suppressive effects on the growth of T and B lymphocytes. In this study,
the supplementation of suckling rats with TGF-β2 did not have a significant influence on unspecific
MLNs proliferative cell response. This result contrasted with a report showing that suckling rats
receiving a whey-enriched TGF-β formula, down-regulated the MLNs lymphocyte proliferative
response to specific antigen after being sensitized [28]. On the other hand, we observed that MLNs
cells after TGF-β2 supplementation did not modify the changes in IL-2 and TNF-α secretion associated
with age, but attenuated IL-13 production at day 21 with respect to reference animals. The attenuation
on IL-13 production, a Th2 cytokine linked to allergic processes [29–31], agrees with results showing
that Brown Norway rat pups receiving a formula with TGF-β2 between 4 and 18 days of life shifted the
immune response from a Th2 type towards a Th1 profile [13]. Likewise, it is known that low levels of
IL-13 in colostrum and mature milk are associated with less eczema in early life [32]. Thus, our results
suggested that early TGF-β2 intake could play an important role in the prevention of Th2 mediated
alterations, such as allergy.
In the current study, the TGF-β2 supplementation was already able to modulate MLN lymphocyte
composition in suckling rats. It decreases the proportion of the immature phenotype of the intestinal
NK cells (NK CD8+) on day 14 at levels observed later (day 21); which indicated a positive action
on the intestinal immune maturation. This developmental pattern, decreasing CD8 expression in the
NK cell surface with age, has previously described in rat neonatal intraepithelial lymphocytes (IEL)
and MLN cells [19,27]. In line with this, we found that, although no changes in total CD8+ cells were
observed due to TGF-β2 supplementation, a lower CD8αα/CD8αβ ratio at day 21, compared to day
14 appeared. This ratio has been described to be reduced according to age in healthy MLNs cells
from suckling rats [19], thus our results may suggested a promotion of the intestinal immune system
maturation. This contrasts with results in BALB/c mice pups, showing higher CD8+ T cell proportions
when their lactating mothers were treated with mAbs, against TGF-β twice a week from delivery until
weaning [33]. On the other hand, we did not find changes in the MLNs Treg (CD4+ CD25+ Foxp3+) cell
proportion. However, some authors have suggested that oral tolerance induced by breastfeeding could
depend on TGF-β signaling from breast milk, which would be able to up-regulate Foxp3+ cells [33].
Regarding the intestinal humoral immune response, it is known that IgA is poorly produced
by the neonate mucosal immune system [1,28], and that TGF-β1 and TGF-β2 from mammalian milk
are able to stimulate the synthesis of mucosal IgA [28,33]. Thus, TGF-β acting in synergy with IL-10,
can promote IgA production and oral tolerance induction [28]. However, our results did not show
significant changes in the intestinal IgA and IgM content of the suckling rats. This lack of effect could
be due to the fact that breast milk contains IgA and IgM, which are transferred to the pups, and then
these milk antibodies in the intestine would mask the pups’ own levels. For this reason, intestinal IgA
and IgM assessment cannot be a good marker of nutritional supplementation at this level.
Epidermal growth factor (EGF) is a peptide that modulates a variety of biological responses, such
as cell proliferation and differentiation [14]. It is known that it has a clear effect on epithelium, where it
accelerates maturation and stimulates cell proliferation [34–36]. However, in the current study, we have
not detected any effect of the EGF supplementation on the proliferative response of MLNs cells in the
suckling pups. There is evidence that EGF prevents and reduces the incidence and severity of NEC
by modulating important transcription factors for cytokine regulation [37], and it is known that the
balance of pro-inflammatory and anti-inflammatory cytokines may play a key role in the development
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of NEC [17]. This effect may be attributable to a down-regulation of pro-inflammatory IL-18 and to
an increase of anti-inflammatory IL-10 at the site of injury [17,37]. Here we found that, 21-day EGF
supplementation increased TNF-α and decreased IL-13 production by MLNs cells. The changes in these
two cytokines, contained in maternal milk [32,38], could be associated with positive effects. Indeed,
decreased IL-13 can be useful in the prevention of allergy, as stated for TGF-β2 [29–31]. Moreover,
EGF supplementation kept the levels of TNF-α on day 21 at the same level as that on day 14, which
could play in favor of its own effects because it is known that EGF receptor (EGF-R) is up-regulated by
TNF-α [39]. Regarding MLNs cell composition, EGF supplementation shares some maturate effects
with TGF-β2, such as the induction of lower levels of NK CD8+ cells and CD8αα/CD8αβ ratio.
Finally, focusing on fibroblast growth factor 21 (FGF21), recent studies showed that its function is
not limited to the regulation of metabolism, but that it is also involved in the protection of multiple
physiological processes, such as oxidation, inflammation, atherosclerosis, and aging processes [40].
A recent study demonstrated that, in the spleen of mice with collagen-induced arthritis (CIA), FGF21
reduces the expression of inflammatory cytokines, such as IL-17, TNF-α, IL-1β, IL-6, IL-8, and MMP3,
whereas IL-10 levels were increased, compared to PBS treated CIA mice [41]. In line with this, we have
not found any significant difference with respect to non-supplemented animals on MLNs inflammatory
cytokines, but the FGF21 supplementation decreased IL-13 at 21 days, as we also found with the other
GFs, suggesting, therefore, its role in preventing allergic events.
It is known that FGF21 is present in breast milk and does not contribute to systemic levels in
mouse neonates, but appears to act locally on the mouse neonatal intestine [16]; and it is unknown
whether this factor plays an important role in the maturation of the immune system. We found that
suckling rats receiving FGF21 promoted maturation of the early life intestinal immune system by
accelerating the decrease in the proportion of NK CD8+ cells and the decrease in the CD8αα/CD8αβ
cell ratio in MLNs, as well as TGF-β2 and EGF. This is the first time that the immunomodulatory effect
of FGF21 has been demonstrated in early life.
5. Conclusions
In conclusion, our study demonstrated that supplementation with TGF-β2, EGF, or FGF21 during
the suckling period had an immunoregulatory effect. Although some specific effects appeared, the
three growth factors were able to modulate similar aspects of MLN cells, such as promoting lymphocyte
maturation, as observed by increasing NK cells with a more mature phenotype (CD8−) and reducing
IL-13 production, which could be useful in avoiding allergic processes. Further studies should be
carried out to establish the effect of the supplementation of TGF-β2, EGF, or FGF21 on the response of
suckling pups in other parts of the intestinal immune system, such as in the intestinal epithelium or
even at the systemic level.
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monoclonal antibodies (mAbs) used for immunophenotyping the mesenteric lymph nodes (MLN) cells.
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Abstract: Currently, the effect of fermented milk on the T-helper 17 response in inflammatory bowel
diseases (IBDs) is unknown. The aim of the present study was to evaluate the effect of milks
fermented with Lactobacillus fermentum on the Th1/Th17 response in a murine model of mild IBD.
Exopolysaccharide (EPS), lactic acid (LA), and total protein (TP) contents and bacterial concentration
were determined. Male C57Bl/6 mice intragastrically received either raw (FM) or pasteurized (PFM)
fermented milk before and during a dextran sulfate infusion protocol. Blood, spleen, and colon
samples were collected at Weeks 6 and 10. IL-6, IL-10, and TNFα were determined in serum, and IL-17,
IL-23, and IFNγ were determined in intestinal mucosa and serum. The FM groups did not differ in cell
concentration, LA, or TP content (p > 0.05); FM-J28 had the highest EPS content. Spleen weight and
colon length did not differ among the FM groups (p > 0.05). In the FM-J20 and PFM-J20 groups, IL-17
and IFNγ decreased, and the IL-10 concentration was enhanced (p < 0.05) at Week 6. IL-6, TNFα, IL-23,
and IFNγ did not differ in serum and mucosa (p > 0.05), and IL-17 was lowest in FM-J28 and FM-J20.
Therefore, FM appears to potentially play a role in decreasing the Th17 response. However, further
studies are needed to elucidate the FM-mediated anti-inflammatory mechanisms in IBD.
Keywords: fermented milk; Th1/Th17 response; inflammatory process
1. Introduction
Inflammatory bowel diseases (IBDs) are characterized by chronic and uncontrolled inflammation
in the intestinal mucosa. Different factors have been evidenced to affect the immune system at
the mucosal level [1]. For example, inflammatory mediators such as cytokines play an important
role in the adaptive immune response at the intestinal mucosal level. The modulation of biological
cellular functions may initiate downstream signaling pathways and mediate cellular proliferation and
differentiation [2]. In particular, Th1 and Th17 cells have been implicated in the development of IBD.
Th1 is characterized by the presence of interferon-γ (IFNγ) and Th17 by the presence of interleukin
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(IL)-17, IL-21, and IL-22 [3]. Cytokines such as IL-6, TGF-β, and IL-23 promote the development of Th17
cells in IBD [4]. One study related Th1 and Th17 responses to the pathogenesis of IBD and suggested
that Th1 cells may enhance the production of Th17 cells. In this previous study, a higher concentration
of Th17 vs. Th1 cells was reported in a colitis model with CBirl TCR transgenic mice, which are
immunodominant susceptible to flagellin microbiota [5]. In contrast, another study examining the
cytokine profiles of Th1 and Th17 in a colitis model found that IL-4 and IL-10 levels were enhanced
while IL-17 levels were reduced [6].
In another study, the pathogenic action of IL-23 was demonstrated. In IL-23R-deficient mice,
reduced Reg3b protein expression in intestinal mucosa was shown to directly affect antimicrobial
activity. In addition, IL-23-dependent Reg3b triggers an influx of IL-22, regulating the number of
neutrophils in the lamina propia and restoring IL-22 secretion. This finding is important given the role
of IL-23 in neutralizing the Th17 response in IBD [7].
Moreover, the administration of probiotics was shown to possibly modulate the inflammatory
process through the Th1-Th2-Th17 response. Zheng et al. [8] reported that Bifidobacterium breve and
Lactobacillus rhamnosus reduce Th17 and increase the Th2 cell subset in human peripheral blood
mononuclear cells. In addition, the active components of probiotics were shown to be responsible
for enhancing the numbers of CD4 + FoxP3 + regulatory T cells in mesenteric lymph nodes and
for decreasing the cytokines tumor necrosis factor-α (TNFα), IFNγ, and IL-10 in Peyer’s patches
and the large intestine. In another study, probiotics were shown to play an important role in the
down-regulation of the nuclear factor kappa B (NFkB) pathway in RAW 264.7 cells to prevent TNFα
expression in a lipopolysaccharide-induced model [9].
Several additional studies have documented the regulation of the immune response in IBDs by
administering probiotics [10–14]. However, few studies have documented the effects of fermented
milk on the Th17 response, which regulates various inflammatory processes at the intestinal level.
In one case, Dahi-fermented milk containing a probiotic reduced myeloperoxidase (MPO) activity and
TNFα, IL-6, and IFNγ levels [14]. Meanwhile, milk with fermented Lactobacillus rhamnosus GG reduced
colonic inflammation and injury and stimulated the activation of epidermal growth factor receptor
(EGFR) and protein kinase B (Akt), which may be attributed to the release of p40 and p75 proteins
during fermentation [15].
These latter studies demonstrated the potential role of milk fermented with probiotics on the
inflammatory process. However, the effect of fermented milk on the Th1/Th17 response has not
been reported. The aim of the present study was to evaluate the effect of milk fermented with
Lactobacillus fermentum (J20 and J28) on the Th1/Th17 response in a murine model of inflammation.
2. Materials and Methods
2.1. Preparation of Fermented Milk
The Lactobacillus fermentum strains J20 and J28 were cultured in MRS broth (De Man, Rogosa
and Sharpe, Difco) for 12 h at 37 ◦C. Posteriorly, to elaborate the fermented milk, the strains
were sub-cultured twice in commercial milk (1% v/v) and incubated for 24 h and 12 h at 37 ◦C.
Then, commercial skimmed milk was inoculated (3% v/v) with the 12-h cultures and incubated for
48 h at 37 ◦C. Finally, the fermented milks (FMs) were placed in a cold water bath or submitted to
heat treatment (75 ◦C, 15 min) to obtain pasteurized fermented milk (PFM), which was subsequently
submersed in a cold water bath to inactivate bacteria. The samples were stored at 4 ◦C. A control pH
treatment was prepared with acidified milk (AM) by adding 800 μL of lactic acid (~90%, Sigma-Aldrich,
Mexico City, Mexico) to skimmed milk to obtain a similar lactic acid concentration as FM.
2.2. Characterization of Fermented Milk
Bacterial cell concentration, lactic acid (LA) content, and total protein (TP) content were
determined in the FMs and PFMs. The cell concentrations were determined at 48 h of fermentation
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by counts on plates of MRS agar. The LA and TP contents were determined by AOAC techniques
2000. The titratable acidity was expressed as percent LA titrated in 10 mL of fermented milk, using
NaOH (0.1 N) and phenolphtalein as the indicator. TP was quantified by the Kjeldahl method using a
nitrogen-to-protein conversion factor of 6.25.
2.3. Determination of Exopolysaccharide
The exopolysaccharides (EPS) were precipitated from the supernatant of FM at 48 h of
fermentation. Samples were centrifuged (3600× g, 60 min, 10 ◦C), and the supernatants were recovered.
Afterwards, trichloroacetic acid solution (20% v/v, Sigma-Aldrich) was added to the supernatants,
which were incubated for 2 h at 4 ◦C. Precipitated proteins were removed by centrifugation (3600× g,
60 min, and 10 ◦C). Next, the supernatants were treated with two volumes of cold ethanol, followed by
12 h of incubation at 4 ◦C. The EPS were recovered by centrifugation and posteriorly suspended in
1 mL of milli-Q water. The total EPS content was estimated for each sample by the phenol-sulfuric
method using glucose as the standard [16].
2.4. Animal Study
Seventy mice C57Bl/6 (weight 30 g, six weeks old) were obtained from BIOINVERT (Mexico City,
Mexico). The mice were randomly allocated into seven groups (n = 10/group) using a simple
randomization procedure (computerized random numbers) based on their initial weight to obtain
statistically equal groups (ANOVA, p > 0.05). Intestinal chronic inflammation was induced by the
administration of dextran sulfate sodium (DSS). The mice were divided into the following treatment
groups: (1) negative control (water); (2) DSS group; (3) AM + DSS (AM); (4) FM-J20 + DSS (FM-J20);
(5) PFM-J20 + DSS (PFM-J20); (6) FM-J28 + DSS (FM-J28); and (7) PFM-J28 + DSS (PFM-J28). Half of
the animals from each group were tested in a model of mild inflammation (six weeks) to evaluate
the course of inflammation. The other mice were tested up to the end of the experimental period
to evaluate chronic/systemic inflammation. Mice were housed in a controlled environment (22 ◦C,
12 h/12 h light/dark cycle) and fed a conventional diet and water ad libitum. This study, including the
corresponding animal experiment, was approved by the Bioethics Committee of the Research Center for
Food and Development (CIAD for its Spanish acronym), Hermosillo, Sonora, Mexico (CE/002/2015).
Mice were intragastrically fed 800μL/day/mouse of either FM or water (control groups) for 10 weeks.
To induce chronic inflammation, mice were intragastrically fed with 3% (w/v) DSS (40 kDa; Sigma-Aldrich)
dissolved in sterile water. Mice were treated with four cycles of DSS. For each cycle, mice were fed with
200 μL/day/mouse for seven days; subsequently, between each cycle, mice drank water normally for
seven days [6] (Figure 1). Body weight and water and food consumption were recorded daily. Half of
the animals per group were euthanized at Week 6, while the rest of the mice underwent two additional
rounds of DSS administration and milk feeding and were euthanized at Week 10.
The body weight initial ranged from 27.2 ± 4.9 g to 30.0 ± 3.1 g. The body weight gain was
4.2 ± 9.2 g and was highest for water group and lowest for the LFJ28 group.
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Figure 1. Experimental design. FM + DSS, PFM + DSS, and AM experimental groups of mice
received daily treatments from Week 1 to Week 10. Mice received DSS in Week 2, 4, 6, and 9.
*DSS administration period
2.4.1. Serum, Organ, and Mucosa Collection
After mice were euthanized (n = 5), the spleen and colon were removed. Spleens were weighed,
and the colon lengths were measured. Blood samples were collected by cardiac puncture. The blood
samples were allowed to clot at room temperature for 30 min before centrifugation (3500 rpm, 5 min,
4 ◦C), and the serum was collected and stored at −80 ◦C until further analysis.
For the mucosal collection, segments of the distal colon were removed from mice, cut open
longitudinally, and mixed with 1 mL of fresh RPMI 1640 medium (Sigma-Aldrich) supplemented
with penicillin–streptomycin (1%). Then, the samples were incubated at 37 ◦C for 24 h. The culture
supernatants were harvested by centrifugation (3600× g, 10 min, 10 ◦C), and stored at −20 ◦C until
being assayed [17].
2.4.2. Quantification of Cytokines
Murine IFNγ minimum detectable dose (MDD 1.8 pg/mL), IL-17 (MDD, 5 pg/mL), IL-22, and
IL-23 (MDD 2.28 pg/mL) were evaluated in samples of serum and mucosal tissues by ELISA (R&D
System). Serum samples were also used for quantification of IL-6 (MDD 1.4 pg/mL), IL-10 (MDD
6.8 pg/mL), TNFα (MDD 0.9 pg/mL), IFNγ (MDD 0.5 pg/mL), and IL-17 (0.8 pg/mL) (CBA kits, R &
D Systems, San Jose, CA, USA) by flow cytometry (BD FACSCantoTM II, San Jose, CA, USA).
2.4.3. Histological Analysis
A histological examination of distal colon samples was performed by triplicate observations of
three samples from the distal colon of each animal. Specifically, 0.5 cm of each sample were fixed in 10%
buffered formalin, dehydrated in ethanol, paraffin embedded, and continuously sliced. Then, samples
were deparaffinized, rehydrated, and stained with hematoxylin and eosin staining. The samples
were evaluated under a 10× light-fluorescent microscope (LEICA DM2000, Leica Mycrosystems Inc.,
Chicago, IL, USA) to observe morphological changes to colonic tissue and the imagens were processed
in the LEICA V2 program.
2.5. Statistical Analysis
EPS, LA, TP, cell concentration, spleen weight, and colon length were analyzed by one-way ANOVAs.
Differences among means per group were analyzed using Tukey–Kramer tests and were considered
significant when p < 0.05. The cytokine values were analyzed using the non-parametric Kruskal–Wallis test;
the data were presented as medians and considered significant when p < 0.05. The cytokine concentrations
were determined by ELISA using ELISAanalysis.com software; the concentrations from CBA kits were
analyzed using the BD FACSArrayTM bioanalyzer (Becton Dickinson, San Jose, CA, USA) Statistical
differences were analyzed in the Minitab V.16.1.1. package.
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3. Results and Discussion
Several studies have reported that an anti-inflammatory response may be attributed to the
presence of LA bacteria and their cell components [18]. Additionally, other components, such as EPS
released during the fermentation process [19] and LA present in the matrix of FM [20], may generate
an anti-inflammatory response. Therefore, cell concentration, LA, EPS, and TP content from both FMs
were analyzed and are described in Table 1. Notably, several bacteria are known to synthesize EPS; the
EPS are associated with the cell surface or are present as slime. Some studies have reported on the role
of EPS in protecting against desiccation and toxic compounds. In addition, an important characteristic
of probiotics is the presence of EPS, which allows adhesion to solid surfaces and biofilm formation [16].
Under fermentation conditions, it was previously suggested that EPS production was associated
with bacterial growth. In the present study, EPS production was determined at 48 h of fermentation,
which corresponded with the highest cell concentration (9 log CFU/mL) for both FMs. FM-J28 showed
the highest EPS concentration (p < 0.05). Some studies have described other conditions that may
influence EPS production, such as type of bacteria, carbon source, and temperature of incubation [21].
Moreover, it has since been suggested that EPS may enhance the anti-inflammatory effect [19].
We determined that Lactobacillus fermentum was able to produce EPS under these fermentation
conditions even though cell concentration, LA, and TP did not show significant differences (p > 0.05)
among the milks fermented with different strains or the milks fermented with different strains that
underwent pasteurization.









FM-J20 9.0 ± 0.01 a 0.72 ± 0.01 a 50.99 ± 0.10 a 2.80 ± 0.04 a
PFM-J20 ND 0.75 ± 0.03 a 61.00 ± 0.15 a 2.71 ± 0.09 a
FM-J28 9.04 ± 0.01 a 0.90 ± 0.01 a 79.59 ± 0.05 b 3.01 ± 0.05 a
PFM-J28 ND 0.87±0.01 a 77.30 ± 0.01 b 2.88 ± 0.07 a
ND = Not detected. The values are the means ± SD (n = 3). Different letters for a same parameter indicate statistical
differences (p < 0.05) among dietary groups. Statistical differences were established by one-way ANOVAs and
Tukey–Kramer Post Hoc tests. Raw (FM) and pasteurized (PFM) milks were fermented with Lactobacillus fermentum
strains J20 and J28.
3.1. Anti-Inflammatory Response
Previous studies have demonstrated that, after four or five cycles of DSS administration,
inflammation at the intestinal level may occur, affecting physiological parameters such as weight loss,
intestine length, and the weight of other organs [22]. In the present study, the spleen of the DSS group
had a significantly lower weight (p < 0.05) with respect to the water group at Week 6; however, it was not
different (p > 0.05) compared to the groups administered with either FM. Conversely, in the end assay,
the spleen weight did not significantly differ among groups (p > 0.05) (Figure 2). Furthermore, spleen
weight at Weeks 6 and 10 for each group presented statistical differences (p < 0.05); the highest weight
was found at Week 10 for the groups administered with DSS or FM + DSS.
The importance of the spleen as a secondary organ in the immune response may be highlighted.
It is one of the sites where the immune response may be regulated and also stores immunological
cells such as B and T cells, dendritic cells, and macrophages, which exert discrete functions [23].
Studies have demonstrated that, during inflammatory processes, spleen weight may increase because
of immune activation or infection, leading to the hyperactivity of the spleen [12]. In the present study,
the spleen weight increased in all treatments at Week 10, with exception of the water group; however,
these differences were not significant (p > 0.05), indicating that the effect of DSS and FM treatments
may be limited.
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Colon length did not differ significantly among all groups (p > 0.05) nor between Weeks 6 and 10,
which may indicate a low response to the inflammatory process during the study period.
The administration of DSS is known to reproducibly induce mild intestinal inflammation and
the development of ulcers in mice, increasing neutrophil counts in the intestine [24]. In this regard,
the capacity of Th17 cells to secrete IL-17 but not IFNγ or IL-4 has been described; these prior cells
play an important role in the mediation of the inflammation process and tissue destruction [25,26].
Therefore, it is important to know their functions and develop strategies that block their response at
local level, principally in IBDs [27].
The serum cytokine profiles at Week 6 showed a significant increase in IL-17 in the groups
subjected to DSS-induced inflammation with respect to the water group (p < 0.05) (Figure 3A).
Meanwhile, the concentration of IFNγ in the DSS group was enhanced compared to the water group at
Week 6, yet decreased by Week 10 (p < 0.05) (Figure 3B). The concentration of IFN-γ in serum samples
was enhanced at Week 6 for the DSS groups FM-J20 and PFM-J28. These values corresponded with an
enhancement in the Th1 response, as various reports have documented. The inflammation process,
as based on IL-17, was sufficient at Week 6; hence, by Week 10, the organisms were possibly able to
regulate the inflammation process. In our study, for example, the FM-J28 group at Week 6 showed
enhanced IL-17 but not IFN. This is a possible response mechanism to a low concentration of IFNγ.
Finally, IL-22 and IL-23 were not detected.
Figure 2. Effect of dextran sulfate sodium and fermented milk administration on spleen weight (A)
and colon length (B) at Weeks 6 (black) and 10 (grey). Bars with an uppercase letter indicate statistical
differences at Week 6 among treatments, and bars with a lowercase letter indicate statistical differences
at Week 10 according to the Tukey–Kramer test (p < 0.05). The values are the means ± SD (n = 5).
The groups administered with FM-J20 and PFM-J20 showed the lowest concentration of IL-17
(p < 0.05) at Weeks 6 and 10. FM-J20 and PFM-J20 differed in the presence of viable bacterial cells, yet
both FMs were able to decrease the concentration of IL-17, suggesting that different components from
FM are involved in this effect. However, no statistical difference was encountered at Week 10 with
respect to the DSS group (p > 0.05). Furthermore, IL-6 and TNFα did not show statistical differences
among treatments and the control (DSS and water) at Weeks 6 and 10 (p > 0.05) (Figure 3C,D).
However, the concentration of IL-10 cytokine did significantly differ (p < 0.05) (Figure 3E); the
groups administered with PFM-J20 and FM J28 presented the highest concentration at Weeks 6
and 10, respectively.
It was previously reported that the expression of the genes that encode for IL-6, IL-1β, IL-23A,
TGFβ, and STAT3 are involved in the differentiation of Th17 cells in a DSS-induced inflammation
model [28]. Furthermore, studies have demonstrated that Th17 cells require specific cytokines such as
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IL-23, which mediates the expansion of IL-17. On the other hand, low levels of IFNγ and IFNα may
enhance the gene expression of IL-17 and IL-17-producing cells generated by IL-23 stimulation [29].
The findings reported in the present work are in agreement with those of other studies.
For example, the administration of VSL#3 probiotics decreased TNFα and IL-6 and increased IL-10
serum levels in a DSS-induced colitis model of inflammation [10]. However, the concentration of
inflammatory cytokines in our study is minor compared with other studies, which may indicate that
the response following FM intake is lower in our inflammation model. Different compounds derived
from FM are responsible for the anti-inflammatory effect [30,31]. For instance, milk fermented with
Lactobacillus rhamnosus GG (LGG) was found to reduce colonic inflammation and injury and to also
stimulate the activation of EGFR and Akt pathways while suppressing cytokine-induced apoptosis.
This effect was attributed to the soluble proteins p40 and p75 present in milk fermented with LGG [15].
Furthermore, the immunoprotective effect of probiotic Dahi containing Lactobacillus acidophilus LaVK2
and Bifidobacterium bifidum BbVK3 on DSS-induced ulcerative colitis in mice was demonstrated to
significantly reduce TNFα, IL-6, and IFNγ cytokines in colonic tissue [14].
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Figure 3. Effects of DSS and fermented milk administration on: IL-17 (A); and IFNγ (B) in serum samples,
determined by ELISA; and on: IL-6 (C); TNFα (D); and IL-10 (E), determined by flow cytometry at
Weeks 6 and 10. Bars with an uppercase letter indicate statistical differences at Week 6 among treatments,
and bars with a lowercase letter indicate statistical differences at Week 10 (p < 0.05) according to the
Kruskal–Wallis test. The values correspond to medians ± interquartile ranges for n = 5.
Several reports have shown the different mechanisms of action involved in the anti-inflammatory
effect of probiotics, but few studies have demonstrated possible pathways at the cellular level.
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One possible mechanism of action may be related with cell viability or cell wall components, which
can be internalized into M cells, interact with dendritic cells, and then down-regulate the production
of the pro-inflammatory cytokines IL-1β, IL-6, IL-17, TNFα, and IFNγ [32,33]. Furthermore, bioactive
peptides have shown anti-inflammatory activity by down-regulating LPS-induced cytokine production
in monocytes cells via the NF-kB pathway [34].
Moreover, LA may induce different inflammatory responses in LPS-stimulated RAW 264.7 cells.
Some studies have reported its association with metabolic acidosis, which frequently complicates
sepsis and septic shock and may be deleterious for cellular function. In this study, the AM group
showed no statistical difference (p > 0.05) with respect to the control group and FM groups; however,
it is important to carry out further studies on LA and its role in inflammatory processes.
In the determination of cytokines in samples of intestinal mucosal (Figure 4), FM-J20, FM-J28,
and PFM-J28 showed statistical differences (p < 0.05) among treatments with respect to the controls
(DSS and water). However, IFNγ levels were not statistically different (p > 0.05), and IL-23 was not
detected at the mucosal level. These results correspond with those reported in other studies wherein
the presence of IFNγ inhibited IL-17 [5]. IL-23 is important for the expansion, stabilization, and
conditioning of the Th17 response; hence, the IL-23/17 axis may be considered as a hallmark and an
attractive probiotic therapeutic target in IBD [32]. The study by Jadhav et al. [14] showed the lowest
concentrations of TNFα, IL-6, and IFNγ in samples of colonic tissue from mice administered with Dahi
(fermented dairy) + DSS as well as a group administered probiotic + DSS.
This effect has also been observed in mice following the administration of milk fermented with
Bifidobacterium strains. In particular, these mice showed a lower concentration of TNFα in culture
supernatants, while IL-10 increased in the FM group and also reduced the histological score compared
to treatments with saline and unfermented milk [35]. A possible mechanism for the anti-inflammatory
effect may be related to the inhibition or modulation of the expression of several genes such as NF-kB,
RELB, and TNFα, which have been reported as active during inflammation processes [36].
Figure 4. The effect of DSS and fermented milk administration on IL-17 (A) and IFNγ (B) determined
by ELISA of colonic mucosa at Week 10. Different letters show statistical differences (p < 0.05) among
treatments according to the Kruskal–Wallis test. The values are medians ± interquartile ranges (n = 5).
The binding of IL-10 to its receptor triggers phosphorylation-dependent activation of the
transcription factor STAT3, which upregulates the gene expression of members of the SOCS family
and proinflammatory cytokines such as TNFα and macrophage inflammatory protein 2. However, this
process is possibly inhibited by the presence of bacteria or other components, such as EPS [37].
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Histological Analysis
The DSS inflammation process is characterized by histological findings such as edema, infiltration
of inflammatory cells into both the mucosa and submucosa, and destruction of epithelial cells [28].
Our results indicated that neither the administration of DSS or fermented milk affected the structure of
mucosa or submucosa (Figure 5). A low number of inflammatory cells infiltrated (Figure 5B) but did not
result in mucosal injury. Therefore, the histological analysis of samples confirmed that the inflammation
process was not extensive; this finding may suggest that the presence of pro-inflammatory cytokines
did not cause extensive changes. On the other hand, some studies have suggested that invasion of
inflammatory cells into the mucosa produces increased concentrations of inflammatory cytokines such
as TNFα, which then induce the expression of genes associated with inflammation [10]. In addition,
DSS may induce the expression of COX-2, an enzyme responsible for the formation of prostanoids [38]
that has been shown to be specifically induced in epithelial cells under IBD conditions [39].
Figure 5. Histological analysis of cross sections of colon tissue samples stained with hematoxylin–eosin
(10×): (A) water control group; (B) DSS group; (C) AM + DSS group; (D) FM-J20 + DSS group;
(E) PFM-J20 + DSS group; (F) FM-J28 + DSS group; and (G) PFM-J28 + DSS group.
These findings show that FM administration may prevent intestinal inflammation by stabilizing
mucosal immunity through different components or metabolites derived during the fermentation
process [13]. In particular, the present results show that the administration of FM could mediate the
Th1/Th17 response, but more studies are required to determine the possible metabolites involved
and the activation pathways. The interaction of derivative compounds from fermentation, such as
LA and EPS, as well as the presence of bacteria could result in an anti-inflammatory response that
stimulates IL-10 production and inhibits TNFα despite the interaction of TLR2 and TLR4 and activation
of NF-kB. For example, in one previous study, the presence of LA and Lactobacillus casei Shirota culture
supernatants suppressed phosphorylation and degradation of I-kB-α [40].
4. Conclusions
In the present study, several strategies to reduce inflammation in an IBD model employing
milk fermented with Lactobacillus strains were evaluated. The administration of milk fermented
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with Lactobacillus fermentum possibly decreased the inflammatory response at Week 6 because of
the metabolites or cell components present in this product. However, further studies are needed to
determine the modulation of Th1/Th17 by fermented milk. The findings in the present study show the
potential regulatory effect of FM on the inflammatory process, although this effect was minor, possibly
as a result of irregularity in the inflammatory process. Future studies are needed to establish an
adequate model of inflammation that allows the Th17 response to be evaluated considering the other
biomarkers involved in this response, including chemokines, transcription factors, and metabolites
released during fermentation, as well as cell differentiation, which may all be responsible for promoting
an anti-inflammatory response.
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Abstract: Complementary feeding transitions infants from a milk-based diet to solid foods, providing
essential nutrients to the infant and the developing gut microbiome while influencing immune
development. Some of the earliest microbial colonisers readily ferment select oligosaccharides,
influencing the ongoing establishment of the microbiome. Non-digestible oligosaccharides
in prebiotic-supplemented formula and human milk oligosaccharides promote commensal
immune-modulating bacteria such as Bifidobacterium, which decrease in abundance during weaning.
Incorporating complex, bifidogenic, non-digestible carbohydrates during the transition to solid foods
may present an opportunity to feed commensal bacteria and promote balanced concentrations of
beneficial short chain fatty acid concentrations and vitamins that support gut barrier maturation and
immunity throughout the complementary feeding window.
Keywords: weaning; oligosaccharides; non-digestible carbohydrates; metabolites; gut barrier;
tolerance
1. Introduction
The strategic introduction of prebiotic compounds during weaning presents an opportunity to
promote infant health and to support development via balanced co-maturation of the gut microbiome
and host. Between 4 and 6 months of age, nutrient demands of growing infants surpass what is
provided by breastmilk or formula alone [1–4]. Complementary foods accompany and gradually
replace breastmilk and formula throughout the weaning period, providing essential nutrients to the
developing digestive system and modulating microbial colonisation [1,5–8]. The young immune
system is influenced by the gut microbiome and supported by metabolites produced during the
microbial fermentation of prebiotic compounds, leading to a tolerance for commensal microbes
and specific responses to pathogens [9–15]. Prebiotic compounds in breastmilk and supplemented
formulas promote commensal immune-modulating bacteria, such as Bifidobacterium, and beneficial
metabolites, such as short chain fatty acids (SCFAs) and vitamins [16–21]. Introducing non-digestible
starches through complementary foods may present an opportunity to promote commensal bacteria
and support microbial production of beneficial metabolites throughout the complementary feeding
window, with lasting effects on health [22–24].
Prior to weaning, the healthy infant gut microbiome is shaped by maternal factors, such as mode
of birth, environment, and first foods: breastmilk and infant formula [10,25–33]. The establishment of
microbial species changes dramatically throughout the first 2–3 years of life before stabilising at an
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adult-like composition [7]. While individual variations in taxonomic composition persist, analogous
genes consistently and predictably fill similar functional and metabolic niches as new foods are
introduced and formula or breastfeeding ceases [7]. Commensal species that colonise the immature
gut modulate gene expression of epithelial and immune cells and, in turn, are regulated by adaptive
and innate immune responses in the mucosal immune system [14,26,31,34–42].
Breastmilk and some types of prebiotic-supplemented formulas provide non-digestible
oligosaccharides (NDOs) to the gut microbiome, which exert a strong influence on the microbial
composition and metabolism [43]. The introduction of starchy foods such as cereals, porridges,
and pureed tubers is common practice due to the neutral tastes, smooth textures, and ease of
swallowing as oral coordination develops [44]. The role of these starches in the community dynamics
of the immature and unstable infant microbiome remains unknown.
Based on investigations into human milk oligosaccharides (HMOs) and NDOs, prebiotic whole
foods may support immunity and immune development through a variety of direct and indirect
mechanisms. While poorly characterised compared to oligosaccharides, starches may act as receptor
analogues to pathogens, reducing the quantity of enteric pathogens that reach the gut epithelium and
subsequent infection [45]. Starches also promote populations of bacteria of which some strains directly
interact with immunomodulatory factors in the gut mucosa [46]. These and other commensal bacteria
also ferment starches into metabolites such as SCFAs and vitamins, which have known benefits to gut
barrier integrity, immune-regulation, and immune response [47].
This review summarises the current body of knowledge on the complementary feeding of
prebiotic starches for the microbiome with a focus on the interactions of commensal species, microbial
metabolites, and the development of the gut barrier and immune system.
2. The Need to Complementary Feed
Complementary feeding is the necessary inclusion of solid foods alongside the milk-based diet of
infants during the transition to adult foods. The inclusion of solid foods is recommended to coincide
with sufficient oral maturation and an imbalance between the nutrient requirements of infants and
the nutritional provisions of breastmilk and formula, as demonstrated in Figure 1 [44]. Previously, it
was thought that the inclusion of solid foods in the diet was driven by an increase in the demand for
energy and protein between 4 and 6 months of age. However, Krebs and Hambidge (1986) found that
infants’ absorption of zinc from breastmilk is inadequate to meet factorial estimates of requirements
based on healthy growth curves [3]. Similarly, iron requirements increase with erythrocyte mass and
myoglobin in lean tissue from 4–12 months of age, surpassing the low concentrations (0.2–0.4 mg/L)
of highly bioavailable (50%) iron in breastmilk at approximately 6 months of age [48].
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Figure 1. The percent of nutrient requirements based on the recommended daily intakes (RDIs) [49]
that are met via average daily breastmilk consumption (750 mL from 0–6 months and 800 mL from
7–12 months) [50].
Timing of the introduction of solid foods has been investigated in both low- and high-income
countries. Delaying solids until 6 months of age was previously thought to be associated with
lower body mass index in high-income countries and with lower rates of allergy and decreased
water-borne diarrheal disease in low- and middle-income countries [51,52]. However, recent studies
in larger cohorts have challenged this assertion, proposing that individual oral maturation, nutrient
requirements, and environmental disease burden should determine when to introduce solids [4].
Results from the PIAMA (Prevention and Incidence of Asthma and Mite Allergy) cohort in the
Netherlands suggest that a short duration of breastfeeding (4 months or less) is associated with an
increased risk for being overweight during childhood rather than the early introduction of solid foods,
and the risk is not different between breastfed and formula-fed infants [53]. However, this study does
not report on the types of solid foods that were introduced, the duration of the overlap of breastfeeding
and solid feeding, or the potential mechanisms of metabolic programming.
In addition to nutritional provisions, breastmilk also provides non-nutritive and
immune-modulatory factors that impart significant benefits, even in partial concentrations or
shorter durations [12]. The health promoting properties of breastmilk include varying levels and
types of carbohydrates, non-digestible HMOs, immunoglobulins (IgG, IgM, and isoforms of sIgA),
amino acids, polyunsaturated fatty acids, monoglycerides, leuric acid, linoleic acid, cytokines,
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chemokines, soluble receptors, antibacterial proteins/peptides, and intact immune cells that are
governed by maternal Lewis blood type, secretor status, and phase of lactation [54]. HMOs have
received significant attention in infant nutrition for their ability to influence a variety of gut functions:
epithelial integrity, mucosal integrity, susceptibility to pathogenic infection, microbial community
structure, SCFA production, and vitamin synthesis. Over 2000 distinct HMO structures (Figure 2a)
have been identified, with significant variation between individuals and phase of lactation, but a 9:1
ratio of galactooligosaccharides (GOS):fructoligosaccharides (FOS) is typical [55,56]. Infant formulas
are continuing to develop based on an increasing understanding of the roles of each of these factors in
microbiome maturation, brain development, and immunity. Synthetic and plant-derived GOS, FOS
(Figure 2b), inulin, pectin, and β-glucans, either alone or in comparable ratios, are well characterised
and have been primary targets of infant formula additive research and product development [56,57].
Staged and follow-on formulas that vary in composition according to the recommended daily
allowances and the introduction of complementary foods are also increasingly recommended [2].
 
Figure 2. (a) The core structures of human milk oligosaccharides (HMOs), common modification
pathways, and an example of a complex HMO, connected by β1-3 and β 1-6 linkages that are resistant
to enzymatic cleavage by human-derived enzymes. (b) The structure of galactooligosaccharide (long
chain) and fructooligosaccharide (short chain), which are common prebiotic molecules in supplemented
infant formulas: β1-2, β1-4, and β1-6 linkages are resistant to enzymatic cleavage by human derived
enzymes. (c) A model of dietary starch, characterized by glucose molecules connected by α1-6 linkages
in a complex higher structure, which contributes to incomplete enzymatic cleavage by human enzymes.
Infant digestive systems are uniquely suited to digest macronutrients provided by breastmilk.
The intestinal epithelium of neonates has narrow villi and small crypts (Figure 3), which duplicate
and expand with age, a process which is influenced by components in breastmilk and host-microbe
interactions [58]. The expansion of the epithelial surface during weaning is necessary to accommodate
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the increasing nutrient load, but dysregulation of this process can lead to hyperplastic crypts, blunted
villi, inflammatory responses in the mucosa, and subsequent malabsorption of nutrients [59].
The enzymatic dynamics of infant digestion are poorly characterised due to wide variations
between individuals over time and infrequent investigations with replicated results [60]. Lactose, fatty
acids, and proteins are the most abundant macronutrients in milk, which are absorbed and utilised
predominantly in the small intestine [20]. Lipase and trypsin (lipid and protein digestive enzymes) are
present in concentrations comparable to adults and are sufficiently active at the less extreme pH (3.2) of
the infant gut. However, amylase secretion and activity are distinct in infants. Compared to lipid and
protein digestion, the ability to digest carbohydrates is limited to simple carbohydrates such as lactose
and sucrose, rather than complex carbohydrates, until weaning. At weaning, salivary α-amylase and
pancreatic α-amylase are present at reduced concentrations compared to that of adults [61]. However,
glucoamylase (also referred to as amyloglucosidase), a brush border enzyme in the small intestine
capable of cleaving α1,4-glycosidic bonds, is produced at 100–150% of adult concentrations at birth,
which may compensate for the otherwise minimal starch hydrolysis [62,63]. Non-digestible structures
such as HMOs and non-digestible carbohydrates (NDCs) resist complete enzymatic degradation
and pass to the large intestine where they become available as a nutrient source for the enteric
microbiota [64]. Breastfed infants also receive varying amounts of maternal amylase, as well as small
concentrations of up to 50 other digestive enzymes, through breastmilk [65]. During weaning, infants
that continue to consume breastmilk may have increased capacity to digest dietary starches compared
to those receiving formulas, but this and the subsequent interactions with enteric microbes has yet to
be investigated.
3. Gut Barrier Development
The epithelial barrier of the gut is formed by enterocytes, the primary absorptive cells with
crypts and villi, connected by tight junctions (TJ). The absorption of nutrients occurs transepithelially
(through) and paracellularly (between tight junction pores of ~4Å in healthy epithelia), requiring
the specificity and structural functionality of TJ proteins [66]. Compromised barrier integrity is
characteristic of inflammation and can lead to aberrant immune responses that have been implicated
in the development of allergies [67]. Apart from the histomorphological analysis of tissue biopsies,
epithelial integrity is measured in healthy infants by feeding non-digestible sugars, lactulose and
mannitol, and then measuring their ratios in urine over a multi-hour collection to indicate paracellular
sugar translocation into the bloodstream and subsequent excretion [68]. Faecal calprotectin has
also been used as an indicator of barrier integrity; however, this is unreliable and highly variable
among and within individuals and populations [68,69]. Faecal calprotectin levels are higher in infants
than in adults, possibly indicative of the immature gut undergoing cellular division, replication,
and differentiation, and are higher in breastfed infants than formula-fed infants [70]. Clinical
investigations with reliable measurements of barrier integrity in infants are rare, particularly those
that are sufficiently powered to understand the effects of foods and nutrients. To understand the
mechanisms by which nutrients, probiotics, and microbial metabolites may affect epithelial integrity,
in vitro experiments using single cell monolayers of Caco-2 cell lines are common and ex vivo tissue
microscopy from porcine and murine models provide further insights but are limited in their ability to
translate directly to humans.
HMOs and NDCs support barrier integrity by increasing TJs and promoting crypt and villus
differentiation (Figure 3). The effects of prebiotics on structural integrity are best understood for GOS,
which prevents loss of structure in Caco-2 monolayers when challenged by deoxynivanol (DON),
a mycotoxin that inhibits protein synthesis and increases paracellular permeability [71]. Additionally,
the stabilisation of claudin3, a TJ protein, and suppressed cytokine synthesis have been detected in
GOS-treated media [72]. Formulations with higher ratios of short chain molecules provide the most
protection to the epithelium, suggesting that complex resistant starch structures may not have direct,
non-microbial mediated benefits on the epithelium [73].
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Mucus Membrane
At the luminal surface of the enteric epithelium, the mucus layer provides a structural and
functional barrier that provides lubrication and separates the microbiota from epithelial cells while
allowing for the transport of nutrients and metabolites. Mucus is a complex heterogeneous suspension
matrix with high concentrations of high molecular weight glycoproteins called mucins, which are
secreted by goblet cells, and contains antimicrobial peptides, such as defensins [41]. Different types of
mucins have different roles in the lumen: secreted mucins form the mucus layer over the epithelium,
transmembrane mucins appear to be involved in signaling pathways, and some species of bacteria rely
on mucins as an energy source [40].
Several bacterial products, including lipopolysaccharides and flagellin on gram-negative bacteria
and lipoteichoic acids on gram positive bacteria, have been found to upregulate the mucin gene
expression and to stimulate mucin secretion [74]. Some probiotics, such as specific strains of
Bifidobacterium and Lactobacillus, successfully adhere to mucins and reach epithelial surfaces using
non-flagellar appendages called tight adherence pili, which influence immune responses [75,76].
This contributes to differences between the discarded microbiome identified in faecal collections and
the microbiome in the mucosa and at the epithelial surface [77,78]. Probiotic treatment, particularly
with Lactobacillus, has been shown to increase mucin and defensin secretion in murine models and
in vitro cell monolayers [79].
Prebiotics influence the composition of mucus by increasing the concentration of glycans [24],
decreasing the luminal pH, and increasing mucin glycosylation and sulphation [80], which protects
mucins from being degraded by host proteases and bacterial glycosidases (Figure 3) [81]. Mucus,
specifically secreted MUC-2, has also demonstrated immune-regulatory signals by interfering with the
expression of inflammatory cytokines but not tolerogenic cytokines by inhibiting gene transcription
through nuclear factor NF-κB (the nuclear factor kappa-light-chain-enhancer of activated B cells)
in dendritic cells (DCs) [82]. The mucus layer plays a significant role in microbial signaling,
cross-feeding, microbe-host interactions, and enteric immunity but can only be partially simulated in
in vitro experiments.
4. Establishment of the Microbiome and Immune System in the First Year of Life
Microbial community composition during the first year of life is dynamic, unstable, and susceptible
to perturbations [6,83]. The gut is the largest immune organ in the human body, containing
approximately 65% of immunologic tissues and up to 80% of the immunoglobulin-producing tissues
of the body [84]. During gestation, the foetal immune system is downregulated, making neonates
particularly susceptible to infection and aberrant immune responses. The epithelial barrier, mucosa,
and environmental conditions, such as pH, provide the majority of protection against pathogens in
the neonatal period (Figure 3) [85,86]. Healthy immune development in infants is characterised by
a transition from innate type 1 immunity, dominated by non-specific macrophages and neutrophils,
to adaptive type 2 immunity, characterised by specific T cells and B cells, which is fundamental
to the establishment of tolerance: the ability to distinguish between beneficial commensal bacteria
and harmful pathogens, leading to the appropriate scale and duration of responses to actual threats
(Figure 3) [87]. Spatial and temporal interactions between the microbiome, microbial metabolites,
and gut epithelial cells in the lumen, on the surface of epithelial cells, and in the interior components
of the gut-associated lymphoid tissue (GALT), such as DCs, modulate balanced immune development,
immune response, homeostasis, and disease (Figure 3) [88].
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Figure 3. A schematic of multiple mechanisms by which prebiotics modulate immune and gut
development. A. Prebiotics bind to pathogens as receptor analogues, preventing adhesion to the
epithelial surface and subsequent infection. B. Prebiotics promote populations of commensal microbes,
which outcompete pathogens for resources D, reducing infections. C. Prebiotics act directly upon the
epithelium promoting the mRNA transcription of proteins involved in barrier integrity. E. Commensal
microbes produce metabolites, such as short chain fatty acids (SCFAs), that decrease the lumen pH
and increase mucus F, increase TJ proteins and crypt and villi development G, and serve as an
energy source for enterocytes that form the epithelium H. In infants, the immature gut is susceptible
to allergy and pathogen translocation I through leaky gut barrier. J. Non-specific immune factors,
such as macrophages and neutrophils attack commensals and pathogens alike in poorly regulated
inflammatory responses. During immune development, dendritic cells K sample commensal microbes,
through Toll-Like Receptor (TLR) recognition, allowing for antigen specific immunoglobin production
L and promoting the differentiation of T and B cells M, resulting in improved tolerance to commensals
and targeted response to pathogens N.
4.1. Immune Ontogeny
Innate immunity favours Th2 responses and macrophage and neutrophil inflammatory activity,
which use specific classes of Toll-Like Receptors (TLRs), such as TLR4, which are capable of recognising
structurally conserved molecules on microbes [89]. As the immune system develops, additional
mechanisms of microbe recognition with increased specificity and response cascades develop: C-type
lectin receptors, pattern recognition receptors, TLR2, and TLR9 are expressed by immune cells,
such as DCs, in the mucosa and epithelium [90]. These immune cells can be both upregulated and
downregulated by exogenous factors, such as microbial metabolites of starch fermentation, and they
demonstrate cross-regulatory activity amongst themselves by way of immune factors and regulatory
cytokines [90].
Due to the poor specificity of the young immune system, commensal bacteria are rapidly killed
by macrophages. However, DCs can retain small numbers of live commensals for several days,
protecting them from innate immune responses while selectively inducing a protective IgA response
that protects against mucosal penetration by commensals [91]. Mesenteric lymph nodes restrict these
commensal-loaded DCs to the mucosal immune compartment, which allows for localised immune
responses while preventing more damaging systemic responses [91]. DCs express TLRs, which
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have been implicated in gut homeostasis and inflammatory responses characteristic of food allergies,
intestinal inflammation, and infections when poorly regulated [92]. Insufficient TLR exposure to
commensals, as found through antibiotic-mediated dysbiosis in murine models, is also correlated with
increased susceptibility to viral infections [93]. Infant TLR responses to commensal microbes differ
from responses in adults, demonstrating the impaired production of inflammatory mediators and
heightened production of inflammatory cytokines, such as IL-10 [85,87].
TLRs are susceptible to modulation by dietary starches in in vitro models. Different starch
structures bind differentially to TLRs, activating NF-κB, and activator proteins (AP-1), but the strong
immune-stimulating effects may also be attenuated by starch-exposed intestinal epithelial cells [94].
B2→1 fructans and High Maize 260 mainly stimulate TLR2, whereas Novelose 330 binds to TLR2
and TLR5 [95]. High Maize 260, which has a smaller average particle size of 12.8 μm, smooth surface,
and high degree of molecular order was found to have a stronger regulatory effect on epithelial cells
than Novelose 330, which has a larger average particle size of 46.6 μm and consists of destroyed and
convoluted granules due to the retrogradation process. Despite the attenuating activity, TLRs continue
to produce Th1 cytokines [94]. High-maize 260 is also more effective than inulin and sugar pectin in
reducing chemokine release in response to Sphingomonas paucimobilis infections in vitro [96]. In vivo,
the mucosal matrix is expected to drastically alter the exposure of epithelial cells to starch structures,
limiting the applicability of these findings to in vivo mechanisms.
4.2. Microbiome Assembly
Pioneer species in the infant gut shape the early environment, which influences the dynamic
succession of subsequent microbes and immune cascades. Nutrients, digestive processes, gases,
and pH gradients throughout the gut modulate the microbial community, which in turn also influences
the characteristics of some of these attributes. Microbiota resembling maternal oral microbiota may
begin to colonise the infant gut in utero, for example low abundance commensal bacteria such as
Prevotella, Neisseria, and Escherichia Coli, which have been found through the sequencing of amniotic
fluids and placentas of preterm infants [97]. However, the mode of delivery is considered the first
major event confirmed to seed the infant microbiome with lasting colonisers [7].
Vaginally delivered infants are predominantly colonised by Bacteroides, Bifidobacterium,
Parabacteroides, and Escherichia/Shigella, several of which are obligate anaerobes. Infants delivered
by caesarean section are enriched with Enterobacter, Haemophilus, Staphylococcus, Streptococcus,
and Veilonella, which are associated with skin, oral, and environmental species [7], a larger proportion
of which are aerobic. The differences in microbial community structure and gene content (i.e.,
the metagenome) between caesarean- and vaginally-delivered infants gradually decrease over the first
year of life, but the differences in innate and adaptive immunity remain detectable for up to 2 years of
age. Caesarean-delivered infants have lower levels of IgA-, IgG-, and IgM-secreting cells, indicating
reduced adaptive immune responses, have lower levels of Th1 supporting chemokines, IFNy and
IL-8, and have decreased CD4+ T cell responses [12]. Caesarean-delivered infants, in particular those
who were born by elective caesarean delivery instead of emergency delivery, are at higher risk for
asthma, atopy, juvenile arthritis, and inflammatory bowel disease [98–100]. This effect is particularly
pronounced for developing obesity where any caesarean delivery has been associated with a 15%
increased risk for obesity, but there is a 30% increased risk in elective caesarean-delivered infants [101].
The risk for development of infectious diseases is not clear. Considering these differences, it is critical
that microbiome studies in infants consider the mode of delivery, and this will be strengthened by
accounting for differences between emergency and elective caesarean-delivered infants.
During the first several weeks of life, pioneer facultative anaerobic species, which have metabolic
flexibility in the presence of oxygen, shift the environment to favour obligate anaerobic species by
utilising oxygen to create a more anaerobic environment [102] and by reducing luminal substrates
through redox (oxygen)-dependent genetic pathways that produce metabolites, such as acetate,
which is often required or highly stimulatory for anaerobes [103]. The meconium of neonates is
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rich in facultative anaerobes such as E. Coli, but the faecal microbiota becomes more diverse with the
appearance of obligate anaerobes such as Bifidobacterium and Clostridium within the first week [104].
In a cohort of 19 healthy breastfed full-term Japanese infants, the averaged percentage of obligate
anaerobic bacteria in the gut progressed from 32% (1 day), 37% (7 days), 54% (1 month), 70% (3 months),
64% (6 months), to 99% at 3 years of age. Significant individual variations within this homogenous
cohort diminished by 3 years of age [105,106]. This study did not specify the delivery modes of
this cohort, and the consequent possibility of significant differences in the colonisation patterns of
facultative and obligate anaerobes.
The effects of breastmilk and formula feeding on the infant microbiome and immunity are a
popular topic of research. Breastfeeding has been associated with a decreased risk of necrotising
enterocolitis, infections, and diarrhoea in early life and with a lower incidence of inflammatory bowel
disease, type 2 diabetes, and obesity later in life compared to formula-fed infants [107]. Another
meta-analysis found no association between breastmilk consumption and allergy, asthma, high blood
pressure, or high cholesterol [108]. Considering the complexity of the immune-modulating factors
of breastmilk, the identifying characteristics of the microbiome that contribute to these benefits is
challenging. Bifidobacterium has consistently been found to exist in higher abundances in exclusively
breastfed infants, whereas Lactobacillus has been reported to be higher in formula-fed infants in some
studies [102,109], while at other times reported to be higher in breastfed infants [110]. Backhed et al.
associated exclusive breastfeeding with lower phylogenetic diversity dominated by Bifidobacterium
and Lactobacillus and lower relative abundances of Clostridiales and Bacteroides compared to mixed-fed
infants [7]. Some of these differences may persist throughout the weaning phase as breastmilk and
formula feeding continue with supplementation of solid foods.
In an effort to impart similar bifidogenic effects on formula-fed infants, the supplementation
of infant formula with prebiotics, or prebiotics and probiotics, has become common. A 9:1 ratio
of synthetic linear polymers of GOS:FOS is standard, but these prebiotics represent a simplistic
uniform version of the HMO structures found in breastmilk [20]. Abrahamse-Berkeveld et al. (2016)
found that a combination of short chain GOS (scGOS dp of 3–15), long chain FOS (lcFOS dp of 3–6),
and Bifidobacterium breve increased the abundance of Bifidobacterium from 48% to 60% of the total
bacterial species and reduced the percentage of Clostridium lituseburense/C. histolyticum from 2.6% to
2.0%. [46]. In an in vitro study, Leder et al. (1999) found that many different strains of Bifidobacterium
are capable of utilizing scGOS, but of the species analysed, only B. adolescentis can utilise lcFOS,
providing evidence of the selectivity between related commensal strains and prebiotic structures [111].
These investigations into the utilisation of HMOs and prebiotics in formula offer a starting point for
exploring the effects of prebiotics provided by whole complementary foods.
Oligosaccharides also provide additional protection against pathogenic infection by acting as
structural mimics of the pathogen binding sites that coat the surface of intestinal epithelial cells.
Pathogenic bacteria such as E. Coli bind to oligosaccharides in the lumen, reducing the pathogen load
available for adhesion to intestinal epithelial cells. In Caco-2 and human epithelial type 2 (Hep-2) cell
lines, purified GOS reduced adhesion by 70% and 65% respectively. This effect was dose-dependent
and reached a maximum at 16 mg/mL [45]. It is unclear if complex starches, such as resistant starch,
have the same effect.
4.3. Functional Transitions during Complementary Feeding
Investigations into the functional differences between modes of feeding at the metagenomic and
transcriptomic level are less common. Backhed et al. found differences in the relative abundance
of functional genes in the faecal microbiome of breastfed and formula-fed infant that accounted for
approximately 1.30% of the variation in KEGG Orthologs, which is substantial considering the expected
constitutive expression of most genes [7]. This study did not specify the types of formulas used in
this comparison, and the expression of genes during this dynamic age may be more facultative than
constitutive due to the inherent instability of the immature infant microbiome.
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The community structure and metabolic functions of the infant gut microbiota are strongly
influenced by dietary prebiotics. The bifidogenic nature of breastmilk is well-established and has
been attributed to HMOs [112]. HMO consumption has only been identified in select Bacteroides
(Bifidobacterium) and Lactobacillus species, and different species and subspecies have been found to
utilise different protein-substrate binding and enzymatic mechanisms to metabolise HMOs [113,114].
B. longum subsp. infantis, which is enriched in breastfed infants, express an overabundance
of proteins that transport HMO substrates into the cell, where they are broken up into their
constituent sugars before being metabolised. This limits the sugars that are available to other species
within the microbiota [115]. B. bifidum, however, relies on a set of diverse membrane-associated
extracellular glycosyl hydrolases, lacto-N-biosidase and endo-N-acetylgalactosaminidase [116], which
have comparable enzymatic affinities for HMOs but may release monosaccharides such as lactose,
fucose, and sialic acid into the lumen, which become available to other microbes [117].
Glycosylation patterns on HMOs influence the enzymatic activity that microbes employ. B. breve
has been found to have a preference for sialylated HMOs over neutral HMOs, engaging enzymes that
convert HMOs into multiple intracellular products, but it does not internalise the whole molecule [118].
B. longum has numerous genes for carbohydrate utilisation, including 30 glycosyl hydrolases that
are likely involved in HMO degradation, though adult strains have indicated a preference for plant
polysaccharides [119]. The transcriptomic analysis of B. longum SC596 when shifting from a neutral
HMO substrate to a fucosylated HMO substrate found the gene expression was altered to resemble
the intracellular import strategy of B. infantis, which may provide an example of the facultative gene
expression of infant microbiota in response to dietary factors [20]. A meta-transcriptomic analysis of
faecal samples from a single breastfed baby followed from birth to six months of age, during which
formula, dairy, and solid foods were introduced, found that the carbohydrate fermentation activity of
Bifidobacterium, based on β-galactosidase activity, decreases during weaning while that of the resident
Firmicutes increases, which corresponds with changes in relative abundance of major and minor
species [120].
At approximately 3 months of age, genes implicated in complex carbohydrate utilization are
enriched compared to meconium samples, which favour lactose/galactose and sucrose uptake and
utilisation based on a metagenomic analysis [6]. Just prior to introducing solid foods between 4
and 6 months of age, the gut microbiome derives energy through the degradation of simple sugars,
lactose-specific transport, and carbohydrate uptake, as is expected for a milk-based diet. However,
functional genes involved in plant-polysaccharide metabolism are present prior to the introduction
of complementary weaning foods [6]. By 12 months of age, the infant microbiome is highly enriched
with species and genes active in the degradation of complex sugars and starches [7]. For instance,
Bacteroides thetaiotaomicron, an anaerobic glycan degrading enzyme producer of the Bacteroidetes
phylum, can typically be detected at 12 months of age [6]. An additional study showed that the
increased abundance of Bifidobacterium and decreased abundance of Bacteroides and Clostridium in
breastfed infants compared to formula-fed and mixed-fed infants persists into the weaning phase [121].
Thompson et al. identified differences before and after the introduction of solid foods between
the microbiomes of exclusively breastfed and non-exclusively breastfed infants [122]. Veillonella,
Roseburia, and members of the Lachnospiraceae family appeared with the introduction of solids in
breastfed infants, whereas Streptococcus and Coprobacillus were identified after the introduction of
solids in non-exclusively breastfed infants [122]. Most notable of these findings was the increased
relative abundance of Bifidobacterium after the inclusion of solids in non-exclusively breastfed infants,
compared to a decreased relative abundance of Bifidobacterium after the inclusion of solids in exclusively
breastfed infants, which may reflect differential effects of dietary oligosaccharides and starches during
complementary feeding. Metabolic inferences using a PiCRUST analysis of this limited 16S dataset
showed that only 24 gene clusters encoding enzymes were overrepresented in exclusively breastfed
infants after the introduction of solid foods, including polysaccharide degradation, compared to 230
enzymatic gene clusters overrepresented in the non-exclusively breastfed microbiome, which were
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primarily involved in signal transduction regulatory systems [122]. This finding indicates differences
in metabolic plasticity between exclusively breastfed and non-exclusively breastfed infants, though
it is possible that the substantial immune factors in breastmilk have a stronger effect on which gene
clusters are overrepresented in this small cohort.
Human faecal microbiota may develop the capacity to degrade a specific type of starch (Type III
Resistant Starch) at weaning, as demonstrated in an in vitro fermentation study using faecal inoculum
collected from breastfed and formula–fed infants before and during weaning [123]. However, species
with the potential capacity to degrade starch have been found to be present at birth [6]. From a
metagenome perspective, microbial networks of infants at 4 months are drastically different to those at
12 months, but polysaccharide degradation has been found to be more pronounced after the cessation
of breastfeeding, rather than during the introduction of solid foods in breastfed infants [7]. It is
possible that the cessation of HMO substrates decreases the need for the expression of HMO-degrading
genes and reduces the competitive advantage of species selective for HMOs, allowing species with a
preference for polysaccharide substrates to assume a greater ecological niche. However, neither the
in vitro experiment nor the metagenomic analysis consider the nutrient availability and degradation
that occurs in the proximal regions of the large intestine prior to analysis of the faecal microbiome.
Starch degradation in the large intestine is a cooperative process that includes enzymatic starch
degradation into glucose, glycolysis leading to SCFAs and organic acids, and hydrogen production.
Starch binding capacity and enzyme specificity underpin the ability of amylolytic microbes to
metabolise starch structures [124]. The presence and function of cellulosomes, amylosomes, and starch
utilisation system gene clusters have been investigated in keystone species belonging to the Firmicutes
and Bacteroidetes families. Three broad classes of amylases have been identified in amylolytic bacteria
that hydrolyse starch into D-glucose: α-amylase for α-1,4 linkages, type 1 pullalanase for α-1,6
linkages, and amylopullalanases for α-1,4 and α-1,6 linkages [125]. Stable Isotope Probing (RNA-SIP),
which allows for the tracking of 13C-isotope labelled carbon utilisation through metabolite production,
has identified complex trophic structures that implicate primary starch degraders, such as Ruminococcus
bromii, in downstream carbon utilization by microbes found in the infant gut such as Prevotella,
Bifidobacterium, and Eubacterium rectale [126]. The association of amylolytic enzymes with the cell wall
and the ability to stabilize large molecules for cleavage may indicate the function of a given microbe
within the trophic network [127,128]. For instance, extracellular protein complexes on Bacteroides
thetaiotamicron imports starch molecules for internal degradation, limiting the extracellular release of
mono and di-saccharides, compared to outer membrane protein complexes on Clostridium butyricum
which degrade starches outside of the cell before importing the mono- and disaccharides for subsequent
metabolism into SCFAs [47,129,130]. This variety of enzyme structures and systems points to the
metabolic flexibility, which may be increased during dietary transitions such as weaning, that the
microbiome utilises to maximise energy harvest.
Fermentation profiles vary by substrate structure, which changes throughout enzymatic
degradation. Short oligosaccharide chains, such as scFOS, are more rapidly fermented than long
oligosaccharide chains, such as inulin [131]. The rate of fermentation as measured by the SCFA
production was highest during the first 4 hours in a faecal inoculum provided with scFOS substrate,
whereas long chain inulin produced the most SCFA between 12–24 h [131]. Warren et al. (2018)
expanded upon these findings by comparing digested to non-digested starches from a range of
processed, un-processed, digested, and un-digested starch and resistant starch substrates. This study
found that microbiota are able to ferment amorphous and crystalline starches equally well, perhaps
attributable to the range of amylolytic enzymes found in the microbiome, and found no difference
in the fermentation rates of the digested versus undigested substrates [132]. Both the 16S rRNA
gene amplicon sequencing analysis of the inoculum and the SCFA analysis revealed differentiations
according to time-points depending upon the classification of the starch substrate [132].
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4.4. SCFAs
SCFAs are the primary class of microbial metabolites of starch degradation and are implicated in
immune regulation. SCFAs function as an energy source for the host epithelium and other microbes,
affect lipid metabolism, protect against infection, have anti-inflammatory properties, influence the
gut-brain axis, facilitate immune cell metabolic reprogramming, and regulate immune cell transcription
through epigenetic modifications [133]. SCFA production varies throughout the colon because of
substrate availability, population dynamics, and microbial cross-feeding [134]. The fermentation of
starch substrates by the gut microbial community is characterised by high acetate production, followed
by propionate and relatively less butyrate, though ratios are highly variable [132,135]. RNA-SIP
studies show that lactate is a precursor to both acetate and propionate and that acetate is precursor for
butyrate via both the Co-A transferase pathway and the butyrate kinase pathway [136]. For example,
Bifidobacterium adolescentis can degrade resistant starch leading to the byproducts lactate and acetate.
Actetate is, in turn, used by Eubacterium spp., Roseburia spp., and Coprococcus catus, resulting in the
production of butyrate. Faecalibacterium prausnitzii, an abundant butyrate producer in adults, has not
been detected in infants younger than approximately 2 years of age [137]. Figure 4 demonstrates a
simplified ecological network in which multiple species of bacteria commonly identified in infants
perform parts of the metabolic pathways leading to biosynthesis of SCFAs.
Figure 4. A simplified schematic of the biosynthesis of SCFAs by microbial species identified in human
infants. Organic acid metabolites are outlined, and SCFAs are highlighted in black boxes. Species
of bacteria found in the infant gut microbiome that are implicated in the corresponding pathway
are italicised.
SCFAs begin shaping the enteric environment with the introduction of breastmilk and formula.
Exclusive breastfeeding is associated with lower absolute concentrations of all SCFAs, except
lactate [105]. Ratios of SCFAs within total concentrations have been found to be variable: exclusively
breastfed infants are more likely to have higher proportions of acetate, while partially breastfed and
formula-fed infants are more likely to have relatively higher proportions of propionate, and exclusively
formula-fed infants are likely to have relatively higher proportions of butyrate [138]. However,
measuring SCFAs in faecal samples only provides an indicator of the balance between SCFA production
and absorption. Absorption is likely to vary with epithelial barrier integrity and maturity, which is
known to be influenced by other factors in breastmilk [58,139].
SCFAs modulate immune factors through multiple mechanisms. They increase the expression
of antimicrobial peptides excreted by epithelial cells; modulate the production of cytokines and
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chemokines; regulate the differentiation, recruitment, and activation of immune cells; and modulate
the differentiation of T lymphocytes [21]. Commonly cited anti-inflammatory properties of SCFAs
can be attributed to their ability to reduce the production and activity of pro-inflammatory cytokines
such as TNF-α and IL-12, often by modulating activity of neutrophils, DCs, and macrophages [140].
Alternatively, SCFAs increase the production of other cytokines, such as IL-18, which has been
implicated in the repair and maintenance of epithelial integrity [141].
Acetate is a minor energy source for gut epithelial cells, a major energy source for muscles
and brain tissue, has anti-inflammatory properties, decreases the pH of the colon, and is used
by cross-feeding species as a co-substrate to produce butyrate [139,142]. Numerous species of
Bifidobacterium readily produce acetate from starchy substrates. Anti-inflammatory properties of acetate
have been linked to the SCFA-dependent modulation of NF-κB in the COLO320DM adenocarcinoma
cell lines, to decreased IL-6 protein release from organ culture, and to decreased LPS-stimulated
TNFα from neutrophils. However, these dose-dependent effects are less pronounced for acetate than
propionate and butyrate [143]. Acetate has also been identified as an important metabolite by which
some subspecies of Bifidobacterium protect against infection, possibly by inhibiting the translocation of
toxins from the gut lumen to the bloodstream [144]. Several in vitro studies suggest that the benefits of
acetate are largely due to the enhanced epithelial integrity, which imparts protection from infection and
inflammation. For instance, B. longum infantis 157F, which is found in breastfed infants and metabolises
glucose to acetate, was found to protect against harmful protein translocation across a Caco-2 epithelial
barrier in an in vitro cell-culture experiment [144].
Propionate has been associated with health benefits most particularly in adults [145]. Similar to
acetate, propionate is a minor energy source for gut epithelial cells, decreases the pH of the colon,
is anti-inflammatory, and has immune modulating properties that in vitro studies of TER in Caco-2
cell lines suggest are linked to beneficial effects on epithelial barrier integrity [146]. Additionally,
propionate decreases liver lipogenesis, serum cholesterol levels, and colorectal carcinogenesis in other
tissues. Insulin sensitivity improvements and increased satiety in adults has also been correlated with
increased propionate levels [139,142,145]. These effects have not been investigated in weaning infants.
Butyrate is the preferred energy source for gut epithelial cells, meaning that little butyrate
reaches systemic circulation. Butyrate also decreases the pH of the colon, promotes epithelial
proliferation, prevents colorectal cancer cell proliferation, reduces oxidative stress, is anti-inflammatory,
and improves gut barrier function by stimulating the production of mucins, antimicrobial peptides,
and TJ proteins [139,142]. Gantois et al. found that butyrate also downregulates the expression
of virulence genes in Salmonella enterica and typhimurium [147]. Butyrate producing bacteria, such
as Eubacterium rectale, Roseburia spp, and Faecalibacterium prausnitzii frequently utilise acetate as a
substrate [148]. The effects of butyrate have been found to be paradoxical where low concentrations
of butyrate (2 mM) promote gut barrier function, characterised by increased TER and decreased
mannitol flux, but high doses (8 mM) may induce cell apoptosis and disrupt the intestinal barrier,
as is characteristic of necrotising enteric colitis [149]. One study identified the benefits of butyrate
to be characteristic of cellular differentiation because of the increased dome formation and alkaline
phosphatase activity [146], whereas another identified cell migration, as is needed for epithelial repair,
as a beneficial mechanism [149]. Both studies found that the effects were dependent on protein
synthesis and gene transcription but not the beta-oxidation or activation of adenosine 3’, 5’-cyclic
monophosphate [146,149].
Most investigations into SCFAs have focused on adult populations. In infants, SCFAs are
considered beneficial, but faecal measurements are inappropriate to use as an indicator of a healthy
microbiome due to its paradoxical effects at high concentrations and the importance of considering the
balance of SCFA utilisation by epithelial cells and absorption into the blood stream.
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4.5. Vitamins
Vitamins are an additional class of secondary metabolites produced by the microbiota with effects
on immunity. Commensal bacteria have the capacity to synthesise essential vitamins, particularly from
the B and K groups, the expression of which is distinct in infants compared to adults. The microbiota in
neonates demonstrate the enrichment of genes involved in the production of Vitamin K2, retinol, folate,
pyroxidal (B6), and biotin (B7), which are involved in bone, vision, tooth development, and glucose
conversion are upregulated in the neonatal microbiome. Genes involved in the transport of B12, iron,
hemin, and heme are also enriched in neonates but decline markedly with age, corresponding with
increased nutritional demands for iron between 4 and 6 months of age. Throughout the weaning
months, genes involved in the biosynthesis of thiamine (B1), pantothenate (B5), cobalamin (B12),
and lysine increase [150]. Methionine degradation and leucine and tryptophan biosynthesis increase
to reach levels comparable to mothers by 12 months of age [7].
It has been estimated that B vitamins are produced by 40–65% of human gut microbes, with
some microbes having the capacity to produce all 8 B-vitamins and some demonstrating pathways
that complemented those of other organisms [151]. These estimates were determined by aligning
metagenomes from the human gut microbiome to an annotated genome on the PubSEED platform [151].
Bifidobacteriales contained the most conserved pattern of B1, B3, and B7 in approximately 35% of the
genomes, whereas Bacteroidetes demonstrated biosynthetic pathways of all 8 vitamins present in
51% of the genomes [151]. Prevotellaceaes produce B2, B5, and B7; Lactobacillales either contain no
biosynthetic pathways, or were limited to B2; and Clostridiales produce only B12 [151]. The full folate
biosynthesis (B9) pathway is present in 43% of genomes, which is distributed in nearly all Bacteroidetes
genomes, in most Fusobacteria and Proteobacteria, and in partial pathways occuring in Actinobacteria and
Firmicutes [151]. Vitamin K in one of two forms is reported to be produced by Bacteroides, Enterobacter,
Veillonella, and Eubacterium lentum, though the bioavailability of bacterially-derived Vitamin K has not
been established [152]. How these genes are differentially expressed in the infant microbiome and in
response to specific types of complementary foods has yet to be explored.
The interactions between microbially-derived vitamins and immune cells are varied and poorly
characterised. Of the known pathways, B6 has been found to serve as a cofactor in immunomodulatory
pathways [153], B9 has been implicated in the maintenance of regulatory T cells [154], and B12 has been
found to augment CD8+ T lymphocytes and NK cell activity in deficient patients [35,155]. Interestingly,
the byproducts from vitamin synthesis pathways have also recently been implicated in immune cell
recognition: mucosa-associated invariant T cells, which produce IL-17 and IFN-γ, are activated in
response to microbe-derived products of the riboflavin biosynthetic pathway that are presented by
a monomeric major histocompatibility complex class 1 (MHC-1)-like related molecule (MR1) [156].
These MHC and MHC-like molecules are imperative to discriminate self from non-self, enabling
protective immunity [157].
5. Discussion and Conclusions
Complementary feeding merges neonatal nutrition with diverse childhood nutrition during
a window of high variability and instability in the microbiome. Starchy foods are common
complementary foods based on texture and palatability, but the health-promoting benefits of complex
starches during this window are unknown. Currently, no harmful effects or negative outcomes of
starch consumption during complementary feeding have been reported. However, certain common
complementary foods that contain starch, such as rice and wheat, also contain nutrient-binding
compounds such as phytic acid, which can be altered during processing [158]. Based on the evidence
that prebiotic HMOs and NDCs alter the microbial community structure and microbial metabolism
and promoted immunity and immune development, investigations into prebiotic complex starches
are warranted. However, the utilisation and fermentation of starch structures occurs in a complex
trophic network governed by keystone species, cross-feeding dynamics, host-microbe interactions,
and biogeography of the gut lumen that are particularly dynamic during the rapid growth and
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colonisation phase of complementary feeding. Identifying the interactions and characteristics of a
healthy infant gut that result in beneficial clinical outcomes remains challenging.
The mechanisms by which starch may contribute to immunity and immune development are
varied. While some oligosaccharides are known to act as receptor analogues for pathogens, thus
preventing adhesion to the epithelium and consequent infection, this effect has not been explored
for complex starch structures from whole foods. Starch also promotes populations of commensal
bacteria with direct immunomodulatory activity in the mucosa and at the intestinal epithelium.
These commensal bacteria also produce metabolites, including SCFAs, vitamins, and small molecules
that may beneficially alter the environment, support structural immunity at the epithelial barrier,
and promote balanced and appropriate immune responses to commensals and pathogens. Building
upon extensive research into HMOs and prebiotic-supplemented formulas by investigating transitions
to more complex starch structures may offer functional insights into the mechanisms that underpin
balanced microbiome-mediated immune development during the complementary feeding window
and facilitate the development and application of functional complementary foods.
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Abstract: The classical functions of vitamin D are to regulate calcium-phosphorus homeostasis and
control bone metabolism. However, vitamin D deficiency has been reported in several chronic
conditions associated with increased inflammation and deregulation of the immune system, such as
diabetes, asthma, and rheumatoid arthritis. These observations, together with experimental studies,
suggest a critical role for vitamin D in the modulation of immune function. This leads to the
hypothesis of a disease-specific alteration of vitamin D metabolism and reinforces the role of
vitamin D in maintaining a healthy immune system. Two key observations validate this important
non-classical action of vitamin D: first, vitamin D receptor (VDR) is expressed by the majority
of immune cells, including B and T lymphocytes, monocytes, macrophages, and dendritic cells;
second, there is an active vitamin D metabolism by immune cells that is able to locally convert
25(OH)D3 into 1,25(OH)2D3, its active form. Vitamin D and VDR signaling together have a
suppressive role on autoimmunity and an anti-inflammatory effect, promoting dendritic cell and
regulatory T-cell differentiation and reducing T helper Th 17 cell response and inflammatory cytokines
secretion. This review summarizes experimental data and clinical observations on the potential
immunomodulating properties of vitamin D.
Keywords: vitamin D; immune system; gut microbiota; autoimmune diseases; T cells
1. Introduction
The role of vitamin D in the regulation of calcium-phosphate homeostasis and in the control of
bone turnover is well known. Vitamin D status significantly affects skeletal health during growth and
in adult age, its deficiency during growth leads to rickets [1], whereas during adult age it is responsible
of osteomalacia and various degree of osteoporo-malacia [2]. Low vitamin D status increases bone
turnover, decreases bone density, and is associated with increased fracture risk. In addition to the
well-known effect on skeletal health in the last two decades evidence has been accumulated on the
pleiotropic effect of vitamin D other than on bone health thanks to the findings that vitamin D receptor
(VDR) and the vitamin D activating enzyme 1-α-hydroxylase (CYP27B1) are expressed in several cells
outside the bone and kidney, such as in the intestine, platelets, pancreas, and prostate [3]. Several cells
involved in the immune function express VDR and CYP27B1, this observation suggests that the active
form of vitamin D, 1,25(OH)2D3, is able to control the immune function at different levels. Previous
reviews on the role of vitamin D in the regulation of immune system have been published in recent
years [4,5]. Here we summarize the recent evidence sexploiting authors’ expertise in both experimental
and clinical fields.
2. Vitamin D Metabolism
Vitamin D enters the body trough dietary intake (about 20% of vitamin D3 is assumed with diet)
or is synthetized by the skin (80%) from 7-dihydrocholesterol following UVB exposure. Vitamin D3
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becomes biologically active after hydroxylation in the liver by the enzymes cytochrome P450 2R1
(CYP2R1) and cytochrome P450 27 (CYP27A1) becoming 25(OH)D3. The fully-active metabolite
1,25(OH)2D3 is hydroxylated in the kidney by the enzyme CYP27B1, parathormone (PTH), and the
fibroblast growth factor 23 (FGF-23) control CYP27B1 synthesis and activity [6]. Synthesis of
1,25(OH)2D3 is strictly regulated in a renal negative feedback loop: high levels of 1,25(OH)2D3
and FGF-23 inhibit CYP27B1 and induce the cytochrome P45024A1(CYP24A1), which transforms
1,25(OH)2D3 into the inactive form 24(OH)D3 [7].
In addition to the kidney, CYP27B1 is expressed by other cell types, including immune cells.
These cells produce 1,25(OH)2D3 that has autocrine and/or paracrine effects, the high level produced
locally is thought to be responsible for immunomodulation. The regulation of CYP27B1 synthesis in
immune cells is different than the signals regulating kidney production of 1,25(OH)2D3. Inflammatory
signals, such as lipopolysaccharide (LPS) and cytokines, induce monocyte and macrophage production
of CYP27B1 [8–10]. These differences in the regulation of 1,25(OH)2D3 production point to an
autocrine/paracrine effect as immunomodulatory.
3. Vitamin D Status
Vitamin D status is defined by the blood measurement of its hydroxylated form 25(OH)D3,
however, there is no common agreement on the threshold levels to identify desirable vitamin D level.
Guidelines from different scientific societies and different countries established 50 nM/L or 75 nM/L
to consider vitamin D sufficiency [11–13], however, it is generally accepted that 25(OH)D3 levels lower
than 50 nM/L are associated with bone metabolism alteration, increased risk of falls, and myopathy in
adults [14–18]. Experts in the field generally agree to maintain 25(OH)D3 between 20 and 125 nM/L in
order to obtain the certain skeletal effects without toxic effects. Recent literature raises the suspicion
that administration of a bolus of vitamin D3 higher than 50,000 UI may result in an increased risk of
falls and fractures [19,20]; moreover, the mortality related to 25(OH)D3 is a “U shaped curve” and
25(OH)D3 levels higher than 150 nM/L are associated with increased mortality [21].
4. Vitamin D and the Innate Immune System: Antimicrobial Activity
The innate immune system is the first defense against infection, it is required to rapidly fight
against invading pathogens. The innate immune system comprehends components both from the
host and resident microbes (microbiota). The host defense comprises physical barriers to infection
(as skin, mucous surfaces, mucus, and vascular endothelial cells), enzymes expressed by epithelial
and phagocytic cells (as lysozyme), antimicrobial peptides and proteins (as defensins, cathelicidins,
and others expressed by phagocytes), inflammatory humoral components (as complement and
opsonins), and cell receptors that rapidly recognize pathogens (as toll-like receptors) and cellular
components (as mast cells, dendritic cells, macrophages, neutrophils cells and natural killer).
Interaction between microbiota a vitamin D will be analyzed in the following paragraph.
Vitamin D is a well-known regulator of innate immunity, the first data on this topic have been
generated on the treatment of diseases caused by mycobacteria, such as tuberculosis and leprosy [22,23],
however, the mechanisms responsible for these actions have been elucidated in more recent years.
1,25(OH)2D3 enhances the production of defensin β2 and cathelicidin antimicrobial peptide (CAMP)
by macrophage and monocyte keratinocytes increasing their antimicrobial activity [24–26]. Moreover,
1,25(OH)2D3 increases chemotaxis, autophagy, and phagolysosomal fusion of innate immune
cells [27,28]. The exposition of human monocytes to pathogens, such as M. tuberculosis and others,
up-regulates the expression of CYP27B1 and of VDR, thus enhancing both the cell ability to produce
1,25(OH)2D3 in the site of infection and to respond to this metabolite. However, macrophages are
heterogeneous, with different functions [29]. Macrophages formed after interleukin (IL)-15 stimulus
respond to vitamin D stimulus increasing their antimicrobial activity, whereas phagocytic macrophages
obtained after stimulus with IL-10 are weakly influenced by vitamin D levels regardless oftheir high
phagocytic activity [10,30].
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1,25(OH)2D3 up-regulates CAMP not only by monocytes/macrophages, but also in other cells
participating in the innate immune system as first-barrier defenses, such as keratinocytes, epithelial,
intestinal, lung and corneal cells, and placenta trophoblasts (see for a comprehensive review Wei and
Christakos, 2015) [4].
Data in humans on infections other than mycobacterial have been generated on urinary and
respiratory infections and on sepsis. A predisposition to urinary tract infection in children with low
vitamin D levels due to the reduced production of CAMP and defensing β2 has been suggested
by association studies [31,32]. Additionally, in chronic obstructive pulmonary disease (COPD)
patients’ levels of CAMP and other antimicrobial peptides were associated with increased risk of acute
exacerbations [33]. Consistent with this datum treatment with 1,25(OH)2D3 was effective in reducing
respiratory infections in asthma patients thanks to increased CAMP expression and inflammatory
cytokine modulation [34]. Data on the role of vitamin D status and vitamin D supplementation in
sepsis are also available both in pediatric and in adult patients: in pediatric patients a clear role
for 25(OH)D3 and CAMP was not demonstrated [35], whereas in adults lower levels of 25(OH)D3
were found in sepsis [36] and a high-dose of vitamin D3 increases circulating CAMP and reduces
inflammatory cytokines as IL-6 and IL-1β [37].
More recently data on a possible role of vitamin D in increasing resistance to HIV infection
have been published, in particular HIV-exposed seronegative individuals produced more CAMP in
oral-mucosa and peripheral-blood, and have higher CYP24A1 mRNA in vaginal-mucosa; CYP24A1 is
considered an indicator of high levels of 1,25(OH)2D3 [38]. Low serum vitamin D has been associated
with HIV/AIDS progression and mortality [39].
1,25(OH)2D3 is able to increase the production of other antimicrobial peptides, such as defensing
β2-4, this ability has been demonstrated both in vitro by monocytes stimulation [40,41] and in vivo in
pediatric patients’ blood [32].
Vitamin D is able to modulate innate immune system, also increasing the phagocytic ability on
immune cells [42,43] and by reinforcing the physical barrier function of epithelial cells. In particular
1,25(OH)2D3can enhance corneal [44] and intestinal [45] epithelial barrier function (Figure 1).
Taken together these data point to a role of vitamin D in defending the organism against pathogens
suggesting that vitamin D sufficiency has to be granted in patients affected by acute or chronic
infection. The ability of immune cells to hydroxylate 25(OH)D3 into its active form 1,25(OH)2D3
suggests administrating vitamin D3 rather than hydroxylated metabolites to patients affected by
infections in order to allow the autocrine/paracrine function of 1,25(OH)2D3 without overcoming local
hydroxylation and the feedback system.
5. Vitamin D and Microbiota: Increasing Host Defenses
The whole of the commensal, symbiotic, and pathogenic microorganisms living in different
areas of the human body has defined microbiota. Microbiota and the host have several relationships,
and the perfect balance between microbiota and the host is required for the development, maturation,
and properfunction of the immune system [46]. Several papers suggest that vitamin D is one of
the actors of the complex relationship between microbiota living in the gut (GM) and immune
system modulation. Vitamin D is responsible for the barrier function of the intestinal epithelium
and for the modulation of the bowel immune system, hence, low levels may be associated with
greater gut permeability and, consequently, with GM-induced metabolic endotoxemia that induces a
low-grade inflammation [47]. Moreover, vitamin D administration may influence GM composition,
and in vitro data demonstrate that vitamin D enhances macrophages’ ability to kill Escherichia coli. [48].
In animals with vitamin D depletion and the knockout of the VDR, the GM dysbiosis favors metabolic
disorders [49]. Other studies in mice demonstrated that VDR reduces the response to infection of the
intestinal epithelium [50].
Elegant studies in transgenic mice demonstrated that over-expression of VDR in the intestinal
epithelium induces resistance to colitis [51,52] and decreases mucosal inflammation suppressing
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epithelial cell apoptosis, boosting tight junction function [51,53]. On the other hand VDR selective
deletion in bowel favors a more severe form of colitis characterized by greater Th1 and Th17 mucosal
infiltration and inflammatory cytokines production [54]. In humans, observational studies suggest that
low levels of 25(OH)D3 are associated with increased risk of inflammatory bowel disease (IBD) [55–57]
and that high levels of 25(OH)D3 in these patients protect against Clostridium difficile infection [58].
The experimental data on the role of VDR in developing IBD have been confirmed by the finding of a
significant reduction of VDR expression (about 50%) in the colon epithelium in patients affected by IBD
with respect to healthy controls [51,53]. The reduction in VDR expression by IBD patients may explain
the different effect on GM composition of high oral dosages of vitamin D3 demonstrated in a small
cohort of patients affected by Crohn’s disease with respect to healthy controls [59], however, human
data on the effect of vitamin D supplementation on GM in IBD are still controversial, as other studies
did not confirm these results [60,61]. In the study by Luthold and coll. [61] dietary intake of vitamin D
and 25(OH)D3 were inversely correlated with Coprococcus and Bifidobacterium, however, thanks to their
ability to produce butyrate these bacteria are commonly considered as anti-inflammatory. A possible
explanation of these contradictory results may be the different effect of vitamin D on GM according
to the different gastro-intestinal tracts considered [62]. Recently, a double-blind placebo-controlled
study on patients affected by cystic fibrosis demonstrated that vitamin D insufficiency is associated
with different microbiota not only in the gut, but also in the airways, and that the administration of
50,000 IU of oral vitamin D3 weekly significantly affects microbiota composition [63]. Nevertheless,
the evaluation of clinical outcomes of microbiota change is still open.
Several data point to an effect of vitamin D on microbiota. Conversely, some recent reports suggest
that microbiota, per se, influences vitamin D metabolism mainly through FGF-23; germ-free (GF) mice
have low vitamin D and high FGF-23, whereas their colonization with bacteria results in increased
levels of tumor necrosis factor-α (TNF-α) and a decrease in FGF-23 with normalization of vitamin D
hydroxylated metabolites. Inhibition of FGF-23 in GF mice restores vitamin D metabolism without
bacterial colonization of the gut [64] (Figure 1).
The role of GM as an active player in the regulation of bone metabolism in humans is being
investigated more and more [46], and the role played by vitamin D is still under debate. Further studies
to clarify their interplay are needed.
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Figure 1. Effects of vitamin D on the innate immune system and gut microbiota. Abbreviations: EC,
enteral cells; GM, gut microbiota.
6. Vitamin D and the Adaptive Immune System
The adaptive immune system or acquired immune system is the second defense against infection.
It is required to specifically fight against pathogens, is activated by exposure to pathogens, and unlike
the innate immune system it is able to learn about the pathogen and enhance the immune response
accordingly, thanks to an immunological memory. The adaptive immune system is composed of T and
B cells and is also responsible for autoimmune reaction.
25(OH)D3 suppresses adaptive immunity [4,65]. In experimental models it down-regulates
the immune responses mediated by T helper (Th) 1 cells, thus inhibiting the production
of pro-inflammatory cytokines, such as Interferon-γ IFN-γ, IL-6, IL-2, and TNF-α [66,67].
Although experimental studies in vitro and in animals have yielded encouraging results on the
immunomodulatory effect of 1,25(OH)2D3, the same cannot be said about human studies, and few
studies have confirmed the suppressive effect of vitamin D on Th1 cells and inflammatory
cytokine production in different diseases and spinal tuberculosis [68], uremia [69], and autoimmune
thyroiditis [70]; whereas others in IBD [71], dialysis [72], and rheumatoid arthritis [73] do not confirm
these results. These discrepancies may be due to the different diseases considered and also to the
different type of treatment administered, mainly 1,25(OH)2D3 in vitro and in animals and vitamin
D3in vivo in humans. Moreover, when considering administration of vitamin D3 different doses were
used in different studies. Therefore, it is almost impossible to compare the results.
It has been suggested that 1,25(OH)2D3 acts as an immunomodulatory not only by suppressing
Th1 cells activation, but also modulating Th2 cells, T regulatory (Tregs) cells activity, and Th17 cells.
The majority of the in vitro studies assessing the effect of vitamin D on Th2 suggests that
1,25(OH)2D3 upregulates Th2 cells activity [74–76]. Amongst immunomodulatory effects of vitamin D
its ability to suppress Th17 and increase Treg cells has been recently demonstrated [77–79]. Th17 cells
produce IL-17 and have been implicated in the pathogenesis ofseveral autoimmune diseases, some
experimental studies suggest that 1,25(OH)2D3 suppresses Th17 formation and activity [67,80–83]
by blocking Nuclear Factor of Activated T-cells (NFAT) and Runt-related Transcription Factor 1
82
Nutrients 2018, 10, 1656
(RUNx1) binding to the IL-17 promoter and inducing Forkhead box P3 (FOXP3) [81], and by inhibiting
RAR-related Orphan Receptor Gamma2 (RORγt) which is the transcription factor of IL-17 [84].
More recently our lab showed no effect of the administration of a high bolus of vitamin D3
(300,000 UI) in the modulation of Th subset in patients affected by early rheumatoid arthritis [73],
as well as a study on hemodialysis patients [72].
It has also been suggested that the administration of oral vitamin D3 increases Tregs function
in patients with type 1 diabetes mellitus [85], however, in other diseases, such as early rheumatoid
arthritis, this effect was not confirmed [73].
The overall effect of vitamin D on Th cells differentiation may be mediated by its effect on
dendritic cells, these cells are antigen-presenting cells (APCs), responsible for T cell differentiation
into an effector cell with pro- or anti-inflammatory properties, thus, modulation of APCs is crucial in
initiating and maintaining adaptive immune response and self-tolerance [86]. In vitro differentiation of
dendritic cells in the presence of 1,25(OH)2D3 induces a “tolerogenic state” characterized by low levels
of inflammatory cytokines, such as IL-12 and TNF-α, with increased levels of the anti-inflammatory
IL-10, these cells induce the differentiation of Treg cells and induce apoptosis in the autoreactive T
cells [87–90] (Figure 2).
Taken together these data are not sufficient to prove a real role for vitamin D in the modulation
of adaptive immune system in humans, thus, the therapeutic use of vitamin D and its metabolites in
patients aiming to ameliorate the adaptive immune system is not sustained by sufficient data.
Figure 2. Effect of vitamin D on the adaptive immune system. Abbreviations: APC, antigen presenting
cell; IFN, interferon; IL, interleukin; Th1, T helper 1 cell; Th2, T helper 2 cell; Th17, T helper 17 cell;
TNF, tumor necrosis factor; Treg, T regulatory cell.
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7. Vitamin D and Autoimmune Diseases
Thanks to the evidences of immunomodulatory effect of vitamin D the role of vitamin D deficiency
and supplementation in autoimmune diseases has long been studied. Animal studies showed an
important role of 1,25(OH)2D3 supplementation in the control of autoimmune diseases, such as
experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). In these
two conditions 1,25(OH)2D3 prevents the initiation and reduces the disease progression [91–93].
Similarly, different mouse models of enterocolitis display a more severe phenotype during vitamin
D deficiency and reduced inflammation after administration of 1,25(OH)2D3 (see for a review
Alhassan et al., 2017) [94]. Despite solid experimental evidence human studies are less convincing:
some epidemiological data link increasing latitude and consequent decrease sunlight exposure
with higher prevalence of multiple sclerosis [95–97], type I diabetes [98–100], and IBD [101]. It is
clear that such differences may be due to genetic and lifestyle factors other than 25(OH)D3 levels.
Other epidemiological data reinforcing the hypothesis of a link between sun exposure, vitamin D
synthesis, and the risk of developing multiple sclerosis stem from the observation that subjects born in
months associated with lower 25(OH)D3 level in the northern hemisphere (April) are at higher risk
of developing the disease, whereas patients born in October (higher vitamin D levels) are at lower
risk [102].
Some studies correlated vitamin D dietary intake and the prevalence of autoimmune diseases as
rheumatoid arthritis [103] and type 1 diabetes mellitus [104,105], however, the correct evaluation of
vitamin D intake is challenging as it is based on patient recall. To bypass the challenging measurement
of vitamin D intake and sun exposure, levels of 25(OH)D3 in the serum can be useful, and, indeed,
low levels of 25(OH)D3 in the serum of patients affected by autoimmune diseases with respect to
healthy controls have been found [106–112]. Nevertheless, these studies demonstrated a correlation
and not a causal relationship.
Intervention studies with different doses of vitamin D3 in autoimmune diseases lead to different
outcomes, recently we demonstrated that a bolus of vitamin D3 (300,000 UI) in patients affected by
early rheumatoid arthritis is effective in ameliorating general health, however, we found no effect
on disease activity nor on inflammatory markers and T cells subset [73]. In patients affected by
type 1 diabetes clinical intervention studies with vitamin D3 or hydroxylated analogs have been
disappointing, as no clinical study has demonstratedan effect of vitamin D in ameliorating glucose
metabolism and insulin secretion [113,114], however, in a small prospective trial in children with type 1
diabetes autoantibodies 1,25(OH)2D3 administration decreased the serum glutamic acid decarboxylase
65 (GAD65) autoantibody, pointing to some immunomodulation of 1,25(OH)2D3 [115].
In addition to autoimmune diseases vitamin D has also been implicated in the control of other
inflammatory conditions, such as cardiovascular diseases: in animal models vitamin D3 administration
reduces macrophage production of pro-inflammatory cytokines, and decreases atherosclerosis and
inflammation in the epicardial adipose tissue [116,117]. In humans an association between low
25(OH)D3 level and increased activation of inflammatory pathway in epicardial adipose tissuein
patients affected by coronary artery disease has been described [118]. Vitamin D deficiency has been
linked to cardiovascular disease not only by the modulation of inflammatory pathways, but also
through the modulation of endothelial function, the effect on arterial stiffness, and a possible beneficial
role on atherosclerotic plaque formation. However, this topic is beyond the scope of this review.
For further insight in the role of vitamin D in the pathogenesis of cardiovascular disease see the review
by Apostolakis and coll. [119].
8. Conclusions
In summary, several studies point to an important role of vitamin D as an immunomodulator,
and strong data demonstrate a role for 1,25(OH)2D3 in increasing the ability of the innate immune
system to fight against pathogens, whereas data on the effect of 1,25(OH)2D3in the modulation of
acquired immune system are more controversial. There is no general consensus on the desired level of
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25(OH)D3 to achieve immunomodulatory effects, thus, there is no current indication for vitamin D3
supplementation in patients with infections and/or autoimmune diseases. Further studies are needed
to clarify the role of vitamin D as immunomodulator in humans.
Author Contributions: All three authors participated in the bibliographic search, discussion and writing of the
manuscript. The manuscript was finalized by P.D.
Funding: This research received no external funding
Conflicts of Interest: The authors declare that they have no conflict of interest.
References
1. Antonucci, R.; Locci, C.; Clemente, M.G.; Chicconi, E.; Antonucci, L. Vitamin D deficiency in childhood: Old
lessons and current challenges. J. Pediatr. Endocrinol. Metab. 2018, 31, 247–260. [CrossRef] [PubMed]
2. Uday, S.; Högler, W. Prevention of rickets and osteomalacia in the UK: Political action overdue.
Arch. Dis. Child. 2018, 103, 901–906. [CrossRef] [PubMed]
3. D’Amelio, P.; Cristofaro, M.A.; De Vivo, E.; Ravazzoli, M.; Grosso, E.; Di Bella, S.; Aime, M.; Cotto, N.;
Silvagno, F.; Isaia, G.; et al. Platelet vitamin D receptor is reduced in osteoporotic patients. Panminerva Med.
2012, 54, 225–231. [PubMed]
4. Wei, R.; Christakos, S. Mechanisms Underlying the regulation of innate and adaptive immunity by vitamin
D. Nutrients 2015, 7, 8251–8260. [CrossRef] [PubMed]
5. Altieri, B.; Muscogiuri, G.; Barrea, L.; Mathieu, C.; Vallone, C.V.; Mascitelli, L.; Bizzaro, G.; Altieri, V.M.;
Tirabassi, G.; Balercia, G.; et al. Does vitamin D play a role in autoimmune endocrine? A proof of concept.
Rev. Endocr. Metab. Disord. 2013, 18, 335–346. [CrossRef] [PubMed]
6. Borel, P.; Caillaud, D.; Cano, N.J. Vitamin D bioavailability: State of the art. Crit. Rev. Food Sci. Nutr. 2015, 55,
1193–1205. [CrossRef] [PubMed]
7. Anderson, P.H. Vitamin D Activity and Metabolism in Bone. Curr. Osteoporos. Rep. 2017, 15, 443–449.
[CrossRef] [PubMed]
8. Liu, P.T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B.H.; Krutzik, S.R.; Ochoa, M.T.; Schauber, J.; Wu, K.;
Meinken, C.; et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.
Science 2006, 311, 1770–1773. [CrossRef] [PubMed]
9. Stoffels, K.; Overbergh, L.; Giulietti, A.; Verlinden, L.; Bouillon, R.; Mathieu, C. Immune regulation of
25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J. Bone Miner. Res. 2006, 21, 37–47.
[CrossRef] [PubMed]
10. Krutzik, S.R.; Hewison, M.; Liu, P.T.; Robles, J.A.; Stenger, S.; Adams, J.S.; Modlin, R.L. IL-15 links
TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J. Immunol.
2008, 181, 7115–7120. [CrossRef] [PubMed]
11. Ross, A.C.; Manson, J.E.; Abrams, S.A.; Aloia, J.F.; Brannon, P.M.; Clinton, S.K.; Durazo-Arvizu, R.A.;
Gallagher, J.C.; Gallo, R.L.; Jones, G.; et al. The 2011 report on dietary reference intakes for calcium and
vitamin D from the Institute of Medicine: What clinicians need to know. J. Clin. Endocrinol. Metab. 2011, 96,
53–58. [CrossRef] [PubMed]
12. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.;
Weaver, C.M. Endocrine Society Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine
Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911–1930. [CrossRef] [PubMed]
13. Cesareo, R.; Attanasio, R.; Caputo, M.; Castello, R.; Chiodini, I.; Falchetti, A.; Guglielmi, R.; Papini, E.;
Santonati, A.; Scillitani, A.; et al. Italian Association of Clinical Endocrinologists (AME) and Italian chapter
of the American Association of Clinical Endocrinologists (AACE) position statement: Clinical management
of vitamin D deficiency in adults. Nutrients 2018, 10, 546. [CrossRef] [PubMed]
14. Valcour, A.; Blocki, F.; Hawkins, D.M.; Rao, S.D. Effects of age and serum 25-OH-vitamin D on serum
parathyroid hormone levels. J. Clin. Endocrinol. Metab. 2012, 97, 3989–3995. [CrossRef] [PubMed]
15. LeBlanc, E.; Chou, R.; Zakher, B.; Daeges, M.; Pappas, M. Screening for Vitamin D Deficiency: Systematic
Review for the U.S. Preventive Services Task Force Recommendation; Agency for Healthcare Research and Quality:
Rockville, MD, USA, 2014.
85
Nutrients 2018, 10, 1656
16. LeBlanc, E.S.; Zakher, B.; Daeges, M.; Pappas, M.; Chou, R. Screening for vitamin D deficiency: A systematic
review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2015, 162, 109–122. [CrossRef]
[PubMed]
17. Gillespie, L.D.; Robertson, M.C.; Gillespie, W.J.; Sherrington, C.; Gates, S.; Clemson, L.M.; Lamb, S.E.
Interventions for preventing falls in older people living in the community. Cochrane Database Syst. Rev. 2012.
[CrossRef] [PubMed]
18. Bhattoa, H.P.; Konstantynowicz, J.; Laszcz, N.; Wojcik, M.; Pludowski, P. Vitamin D: Musculoskeletal health.
Rev. Endocr. Metab. Disord. 2017, 18, 363–371. [CrossRef] [PubMed]
19. Sanders, K.M.; Stuart, A.L.; Williamson, E.J.; Simpson, J.A.; Kotowicz, M.A.; Young, D.; Nicholson, G.C.
Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial.
JAMA 2010, 303, 1815–1822. [CrossRef] [PubMed]
20. Bischoff-Ferrari, H.A.; Dawson-Hughes, B.; Orav, E.J.; Staehelin, H.B.; Meyer, O.W.; Theiler, R.; Dick, W.;
Willett, W.C.; Egli, A. Monthly high-dose vitamin D Treatment for the prevention of functional decline: A
randomized clinical trial. JAMA Intern. Med. 2016, 176, 175–183. [CrossRef] [PubMed]
21. Amrein, K.; Quraishi, S.A.; Litonjua, A.A.; Gibbons, F.K.; Pieber, T.R.; Camargo, C.A.; Giovannucci, E.;
Christopher, K.B. Evidence for a U-shaped relationship between prehospital vitamin D status and mortality:
A cohort study. J. Clin. Endocrinol. Metab. 2014, 99, 1461–1469. [CrossRef] [PubMed]
22. Airey, F.S. Vitamin D as a remedy for lupus vulgaris. Med. World 1946, 64, 807–810. [PubMed]
23. Herrera, G. Vitamin D in massive doses as an adjuvant to the sulfones in the treatment of tuberculoid leprosy.
Int. J. Lepr. 1949, 17, 35–42. [PubMed]
24. Wang, T.-T.; Nestel, F.P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.;
Hanrahan, J.W.; Mader, S.; et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial
peptide gene expression. J. Immunol. 2004, 173, 2909–2912. [CrossRef] [PubMed]
25. Gombart, A.F.; Borregaard, N.; Koeffler, H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a
direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin
D3. FASEB J. 2005, 19, 1067–1077. [CrossRef] [PubMed]
26. Dai, X.; Sayama, K.; Tohyama, M.; Shirakata, Y.; Hanakawa, Y.; Tokumaru, S.; Yang, L.; Hirakawa, S.;
Hashimoto, K. PPARγ mediates innate immunity by regulating the 1α,25-dihydroxyvitamin D3 induced
hBD-3 and cathelicidin in human keratinocytes. J. Dermatol. Sci. 2010, 60, 179–186. [CrossRef] [PubMed]
27. Liu, P.T.; Stenger, S.; Tang, D.H.; Modlin, R.L. Cutting edge: Vitamin D-mediated human antimicrobial
activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 2007,
179, 2060–2063. [CrossRef] [PubMed]
28. White, J.H. Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: Past, present and
future. J. Steroid Biochem. Mol. Biol. 2010, 121, 234–238. [CrossRef] [PubMed]
29. Bursuker, I.; Goldman, R. On the origin of macrophage heterogeneity: A hypothesis. J. Reticuloendothel. Soc.
1983, 33, 207–220. [PubMed]
30. Kim, E.W.; Teles, R.M.B.; Haile, S.; Liu, P.T.; Modlin, R.L. Vitamin D status contributes to the antimicrobial
activity of macrophages against Mycobacterium leprae. PLoS Negl. Trop. Dis. 2018, 12. [CrossRef] [PubMed]
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Abstract: This review offers a systematic understanding about how polyphenols target multiple
inflammatory components and lead to anti-inflammatory mechanisms. It provides a clear
understanding of the molecular mechanisms of action of phenolic compounds. Polyphenols regulate
immunity by interfering with immune cell regulation, proinflammatory cytokines’ synthesis, and
gene expression. They inactivate NF-κB (nuclear factor kappa-light-chain-enhancer of activated
B cells) and modulate mitogen-activated protein Kinase (MAPk) and arachidonic acids pathways.
Polyphenolic compounds inhibit phosphatidylinositide 3-kinases/protein kinase B (PI3K/AkT),
inhibitor of kappa kinase/c-Jun amino-terminal kinases (IKK/JNK), mammalian target of rapamycin
complex 1 (mTORC1) which is a protein complex that controls protein synthesis, and JAK/STAT.
They can suppress toll-like receptor (TLR) and pro-inflammatory genes’ expression. Their antioxidant
activity and ability to inhibit enzymes involved in the production of eicosanoids contribute as well to
their anti-inflammation properties. They inhibit certain enzymes involved in reactive oxygen species
ROS production like xanthine oxidase and NADPH oxidase (NOX) while they upregulate other
endogenous antioxidant enzymes like superoxide dismutase (SOD), catalase, and glutathione (GSH)
peroxidase (Px). Furthermore, they inhibit phospholipase A2 (PLA2), cyclooxygenase (COX) and
lipoxygenase (LOX) leading to a reduction in the production of prostaglandins (PGs) and leukotrienes
(LTs) and inflammation antagonism. The effects of these biologically active compounds on the
immune system are associated with extended health benefits for different chronic inflammatory
diseases. Studies of plant extracts and compounds show that polyphenols can play a beneficial role in
the prevention and the progress of chronic diseases related to inflammation such as diabetes, obesity,
neurodegeneration, cancers, and cardiovascular diseases, among other conditions.
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1. Introduction
Numerous studies have attributed to polyphenols a broad range of biological activities including
but not limited to anti-inflammatory, immune-modulatory, antioxidant, cardiovascular protective
and anti-cancer actions [1–5]. Polyphenols are ubiquitously made by plants and are present either as
glycosides esters or as free aglycones [6]. More than 8000 structural variants exist in the polyphenol
family. Polyphenols are bioactive compounds found in fruits and vegetables contributing to their color,
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flavor, and pharmacological activities [1]. They are classified according to their chemical structures
into flavonoids such as flavones, flavonols, isoflavones, neoflavonoids, chalcones, anthocyanidins, and
proanthocyanidins and nonflavonoids, such as phenolic acids, stilbenoids, and phenolic amides [7].
The majority of these molecules are metabolites of plants, they are made of several aromatic rings
with hydroxyl moieties [8]. Their chemical structures contribute to their classification into different
classes. Considering gastrointestinal digestion, some—but not all—polyphenols are absorbed in
the small intestine, for example, anthocyanins and the majority of remaining polyphenols except
flavonoids are usually stable; these later are unstable in the duodenum. Unabsorbed polyphenols must
be hydrolyzed first by digestive enzymes then glycosides with high lipid contents are absorbed by
epithelial cells [9,10].
In recent years, consumers prefer using natural food ingredients as additives because of their
safety and availability. Applications of phenolic compounds to multiple fresh perishable foods show
that they are worthy to be used as preservatives in foods and can be creditable alternatives to synthetic
food additives. In this sense, polyphenolic compounds start to substitute chemical additives in food.
Different methods like spraying, coating and dipping treatment of food are currently applied in food
technology preceding packaging as effective alternatives [11]. Grape seeds and olive oil polyphenols’
rich extracts can be used as food additives for their anti-oxidant properties [12]. Various polyphenols
like grape polyphenols demonstrate an efficient role as additives in fish and fish products for their
anti-oxidant properties in order to prevent lipid oxidation and quality deterioration of polyunsaturated
fatty acids [13]. In addition polyphenolic compounds like flavonols, p-coumaric, and caffeic acids can
be used as food preservatives for their antimicrobial activity [11].
Back to inflammation, continuous inflammation is known to be a major cause linked to
different human disorders involving cancer, diabetes type II, obesity, arthritis, neurodegenerative
diseases, and cardiovascular diseases [14,15]. Polyphenols derived from botanic origin have shown
anti-inflammatory activity in vitro and in vivo highlighting their beneficial role as therapeutic tools in
multiple acute and chronic disorders [16–20]. Accordingly, many epidemiological and experimental
researches have been studying the anti-inflammatory and immune modulation activities of dietary
polyphenols [15,21]. The ability of these natural compounds to modify the expression of several
pro-inflammatory genes like multiple cytokines, lipoxygenase, nitric oxide synthases cyclooxygenase,
in addition to their anti-oxidant characteristics such as ROS (reactive oxygen species) scavenging
contributes to the regulation of inflammatory signaling [22,23]. This review will discuss the
immunomodulatory effects of dietary polyphenols, their anti-inflammatory abilities, the different
mechanisms and pathways involved in reducing inflammation and their contribution to protect from
different chronic inflammatory diseases with a focus on their anti-cancer activity.
2. Polyphenols and Inflammation
The immune modulation effect of polyphenols is supported by different studies: some
polyphenols impact on immune cells populations, modulate cytokines production, and
pro-inflammatory genes expression [24,25]. For example, cardioprotective effects of resveratrol
present in red wine grape and nuts were mainly attributed to its anti-inflammatory properties.
In vivo and in vitro studies demonstrate that resveratrol can inhibit COX, inactivate peroxisome
proliferator-activated receptor gamma (PPARγ) and induce eNOS (endothelial nitric oxide synthase)
in murine and rat macrophages [26–28]. Likewise, a resveratrol analog, RVSA40, inhibits the
pro-inflammatory cytokines TNF-α (Tumor necrosis factor alpha) and IL-6 (interleukin-6) in RAW
(Murine macrophages cell line) 264.7 macrophages [29]. Another example is the non-flavonoid
curcumin found in turmeric plants and mustard. Curcumin was shown to reduce the expression
of inflammatory cytokines: TNF and IL-1, adhesion molecules like ICAM-1 (intercellular adhesion
molecule-1) and VCAM-1 (vascular cell adhesion molecule-1) in human umbilical vein endothelial
cells and inflammatory mediators like prostaglandins and leukotriens. It also inhibits certain
enzymes involved in inflammation like COX in mice (cyclooxygenase), LOX (lipoxygenase) in,
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human endothelial cells MAPK (mitogen-activated protein Kinase), and IKK (inhibitor of kappa
kinase). Moreover, curcumin downregulates NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells) and STAT3 (signal transducer and activator of transcription) and reduces the
expression of TLR-2 (toll-like receptor-2) and 4 while, in vivo, it upregulates PPARγ (Peroxisome
proliferator-activated receptor gamma) in male adult rats [30–35]. Caffeic acid phenethyl ester
suppresses TLR4 activation and LPS-mediated NF-κB in macrophages, Quercetin was also shown to
inhibit leukotriens biosynthesis in human polymorphonuclear leukocytes [36,37]. COX2 expression is
also attenuated by ECGC (Epigallocatechin gallate) in colon cancer cell and androgen-independent
PC-3 cells of human prostate cancer, gingerol in and piceatannol (EGCG analog found in Norway
spruces) leading to NFκ B inactivation [30,38–40]. Furthermore, polyphenols, such as Gingerol and
Quercetin can activate the production of adiponectin known for its anti-inflammatory effects [30,39].
Similarily, EGCG blocks NFκ B activation in human epithelial cells and downregulates the expression
of iNOS (inducible nitric oxide synthase), NO (nitric oxide) production in macrophages resulting in its
immunomodulation [38,40,41]. A series of in vitro studies found that other polyphenols like oleanolic
acid, curcumin, kaempferol-3-O-sophoroside, EGCG and lycopene inhibit high mobility group box1
protein, an important chromatin protein that interacts with nucleosomes, transcription factors, and
histones regulating transcription and playing a key role in inflammation [35]. All of these examples
support the anti-inflammatory effects of polyphenols.
Polyphenols’ use is associated with a direct change in the count and differentiation of specific
immune cells. An increase in T helper 1(Th1), natural killer (NK), macrophages and dendritic cells (DCs)
in Peyer’s patches and spleen is associated with oral administration of polyphenols extracted from the
fruit date in male C3H/HeN mice [24]. In humans, the count of regulatory T cells (Treg or suppressor T
cells) characterized by the (CD4 + CD25 + Foxp3+) phenotype and involved in immune tolerance and
autoimmune control can be boosted by polyphenols [42–44]. In vivo, Epigallocatechin-3-gallate, found
in green tea and injected to Laboratory inbred strain (BALB)/c mice, rises the number of functional Treg
in spleens, pancreatic lymph nodes, and mesentheric lymph nodes [45]. Similarly, in vitro treatment of
Jurkat T cells with EGCG or green tea upsurges the expression of Foxp3 and IL10. Baicalin, a flavone,
extracted from Huangqin herb, induces Foxp3 expression in HEK 293 T cells and triggers functional
Treg from splenic CD4 + CD25− T cells [46]. Additionally, flavonoids show an agonistic effect of aryl
hydrocarbon receptor (AhR) and bind xenobiotic-responsive elements in promoter regions of certain
genes, including Foxp3 rising its expression [47].
Th1 and Th17 populations are also affected by polyphenols: EGCG reduces the differentiation of
Th1 and reduces the numbers of Th17 and Th9 cells in specific pathogen-free C57/BL6 female mice [48].
Other polyphenols like Baicalin show a reduction of Th17 differentiation in vitro and a diminution of
IL-17 expression [49].
Macrophages are affected by polyphenols as well. Macrophages are known to be a key
player in the inflammatory response. They initiate inflammation by secreting pro-inflammatory
mediators and cytokines like IL-6 and TNF-α [50]. Polyphenols repress macrophages by inhibiting
cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), thus they reduce the production of
TNF-α, interleukine-1-beta (IL-1-β) and IL-6 expression [51]. Chinese propolis [52] containing ferulic
acid and coumaric acid, an extract of Lonicera japónica Thunb) [53] or Kalanchoe gracilis [54] are a good
example in this case as per demonstrated by in vitro studies using RAW 264.7 cells.
3. Polyphenol and Cytokine Modulation
Cytokines are important mediators’ proteins, essential in networking communication for immune
system. Cytokines can be produced by lymphocytes (lymphokines), or monocytes (monokines) with
pro-inflammatory and anti-inflammatory effects. Cytokines with chemotactic activities are termed
chemokines. The equilibrum between pro-inflammatory cytokines (IL-1β, IL-2, TNFα, Il-6, IL-8,
IFN-γ . . . ) and anti-inflammatory cytokines (IL-10, IL-4, TGFβ) are thought to be an important
parameter in immune response homeostasis and inflammation underlining many disease [55]. In vivo
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and in vitro studies demonstrate that polyphenols affect macrophages by inhibiting multiple key
regulators of inflammatory response such as the inhibition of TNF-α, IL-1-β, and IL-6 [51].
In humans, consumption of bilberries is associated with a decreased inflammation score in
patients’ blood, reflected by decreasing serum levels of IL-6, IL-12, and high sensitivity C reactive
protein [56]. Moreover, clinical trials have shown the ability of polyphenol-enriched extra virgin olive
oil to reduce IL-6 and C-reactive protein expression in stable coronary heart disease patients [57].
In lipopolysaccharide (LPS)-treated BALB/c mice, a model system of inflammation olive
vegetation water show ability to inhibit the production of tumor necrosis factor-alpha usually
activated by inflammation [58]. Flavonoids, as well, play an important anti-inflammatory effect
by influencing cytokines’ secretion. Several flavonoids are found able to inhibit the expression
of various pro-inflammatory cytokines and chemokines like TNFα, IL-1β, IL-6, IL-8, and MCP-1
(monocyte chemoattractant protein-1) in multiple cell types such as LPS-activated mouse primary
macrophages, activated human mast cell line, activated human astrocytes, human synovial cells, and
human peripheral blood mononuclear cells [59–64]. In murine RAW 264.7 macrophages stimulated by
LPS, Chinese propolis as well as extract of Lonicera japónica Thunb (Caprifoliaceae) or Kalanchoe gracilis
demonstrated inhibitory effects on TNF-α, IL-1-β, and IL-6 [52–54]. Similarly, certain polyphenol
analogs, like curcumin analog EF31, have shown the ability to inhibit the expression and secretion of
TNF-α, IL-1-β, and IL-6 in mouse Raw 264.7 macrophages [65].
Likewise, reduction of the secretion of TNF-α and IL-6 without IL-1β modulation is observed
with extracts of chamomile, meadowsweet, willow bark, and isolated polyphenols such as quercetin
existing in these extracts in THP1 macrophages [66]. Extract of Cydonia oblonga inhibits TNF-α and
Interleukin 8 while it increases IL-10 and IL-6 in THP-1monocytes stimulated with LPS. The reduction
in TNF-α levels limits the acute inflammatory response [67,68]. Other cytokines like IFNγ might also
be inhibited by certain polyphenols. For example, kaempferol reduces the production of IFN-γ in a
dose-dependent manner in spleen cells and T cell lines [69].
Certain polyphenols exert their effects on the balance between pro- and anti-inflammatory
cytokines production such as quercetin and catechins, they enhance IL-10 release while they
inhibit TNFα and IL-1β [59,70]. Extract of Cydonia oblonga also inhibits the effects of TNF-α and
Interleukin 8 (IL-8) while it raises IL-10 in the same type of monocytes [67,68]. Modulation of
inflammatory cytokines is one of many common mechanisms by which polyphenols in general
exert their immunomodulatory effects.
4. Polyphenols, Inflammation, and Modulation of Different Signaling Pathways
4.1. NFκ B Signaling Pathway
NF-κB or nuclear factor kappa-light-chain-enhancer of activated B cells is a complex protein that
plays a key role in deoxyribonucleic acid (DNA) transcription, cytokine production and cell survival.
It controls immune, inflammation, stress, proliferation and apoptotic responses of a cell to multiple
stimuli [58].
The expression of a large number of genes involved in inflammation is controlled by NF-κB such
as COX-2, VEGF (vascular endothelial growth Factor), pro-inflammatory cytokines (IL-1, IL-2, IL-6,
and TNFα), chemokines (e.g., IL-8, MIP-1α, and MCP-1), adhesion molecules, immuno-receptors,
growth factors, and other agents involved in proliferation and invasion [71].
NFκ B is located in the cytoplasm, it exists as an inactive non-DNA-binding form. Iκ B proteins
(Iκ Bs), are inhibitors proteins that are associated with NFκ B resulting in its inactivation. Iκ Bs include
Iκ Bα, Iκ Bβ, Iκ Bγ, Iκ Bε, Bcl-3, precursors p100 and p105 [72]. Under stimulatory conditions, Iκ B
kinase (IKK) phosphorylate IκB proteins leading to successive ubiquitination, consequent degradation
of the inhibitory proteins and release of NFκ B dimer. This later can translocate into the nucleus and
prompts the expression of particular genes [72]. Different mechanisms regulate NFκ B activity as per
the accumulation and degradation of Iκ B, the phosphorylation of NFκ B, the hyper-phosphorylation
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of IKK, and the processing of NFκ B precursors [73–75]. Thus, the inhibition of NFκB can be of
a great benefit in controlling inflammatory conditions [76]. Several polyphenols modulate NFκ B
activation and reduce inflammation [77,78]. Quercetin blocks the nuclear translocation of p50 and
p65 subunits of NFκ B and represses the expression of pro-inflammatory associated genes, NOS and
COX-2 in RAW264.7 macrophages [79]. It inhibits the phosphorylation of Iκ Bα protein both in vitro
(using macrophages) and in vivo (using dextran sulfate sodium (DSS) rat colitis model) leading to
inactivation of the NFκ B pathway [80]. In human mast cells, quercetin prevents the degradation
of Iκ Bα, as well as the nuclear translocation of p65 resulting in reduction of TNFα, IL-1β, IL-6 and
IL-8 [63]. It can modulate chromatin remodeling, for example it blocks the recruitment of a histone
acetyl transferase called CBP/p300 to the promoters of interferon-inducible protein 10 (IP-10) and
macrophage inflammatory protein-2 (MIP-2) genes in primary murine small intestinal epithelial cell.
As a result, it inhibits the expression of these pro-inflammatory cytokines [81]. Quercetin can block
the activation of IKK, NFκ B, and it reduces the ability of NFκ B to bind DNA in microglia treated
by LPS and IFN-γ in mouse BV-2 microglia [82]. Luteolin, too, blocks NFκ B activation and inhibits
pro-inflammatory genes expression and the cytokines production in murine macrophages RAW 264.7
and mouse alveolar macrophages; it also inhibits IKKs in LPS-induced epithelial and dendritic cells [83].
In addition, in co-cultured intestinal epithelial Caco-2 and macrophage RAW 264.7 cells, luteolin
represses NF-k B activation and TNF-α secretion [84]. Likewise, Genistein represses LPS-induced
activation of NF-k B in monocytes and reduces the inflammation by inhibiting NF-k B activation
upon adenosine monophosphate activated protein kinase stimulation in LPS-stimulated macrophages
RAW 264.7 [83,85]. Galangin, as well, stops the degradation of Ik Bα and the translocation of p65 NF-k
B, repressing the expression of TNF-α, IL-6, IL-1β, and IL-8 in mast cell [86]. EGCG counteracts the
activation of IKK and the degradation of Iκ Bα and inhibits NFκ B in culture respiratory epithelial
cells and in vivo in male Wistar rats [87,88]. Furthermore, EGCG blocks DNA binding of NFκ B which
reduces the expression of IL-12p40 and iNOS in murine peritoneal macrophages [89,90]. Catechin and
epichatechin reduce NFκ B activity in PMA-induced Jurkat T cells. Flavonoids can modulate NFκ B
activation cascade at early phases by affecting IKK activation and regulation of oxidant levels or at late
phases by affecting binding of NF-κ B to DNA in jurkat Tcells [91]. Hydroxytyrosol, and resveratrol
inhibit NFκ B activation, and the expression of VCAM-1 in LPS-stimulated human umbilical vein
endothelial cells [92]. In summary, polyphenols can modulate NFκ B activation cascade at different
steps such as by affecting IKK activation and regulating of the oxidant levels or by affecting binding of
NF-κ B to DNA leading to an important anti-inflammatory effect responsible for their potential value
in treating chronic inflammatory conditions (Figure 1).
Figure 1. Potential points of action of polyphenols within inflammatory cascade. NF-κ B: nuclear factor
kappa-light-chain-enhancer of activated B cells; IKK: IkB-kinase; ERK: extracellular signal-related
kinases; JNK: c-Jun amino-terminal kinases; p38 (or p38-MAPK): p38-mitogen-activated protein kinase;
COX: cyclooxygenase; LOX: lipoxygenase; AA: arachidonic acid; PLA2: phospholipase A2; PGs:
prostaglandins; LTs: leukotriens. For references see the text.
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4.2. MAPK Signaling Pathway
The mitogen-activated protein kinases (MAPK) are a highly conserved family of serine/threonine
protein kinases. They play a key role in a range of fundamental cellular processes like cell
growth, proliferation, death and differentiation. They regulate gene transcription and transcription
factor activities involved in inflammation. Extracellular signal-related kinases, like (extracellular
signal-related kinases (ERK))-1/2, c-Jun amino-terminal kinases (JNK1/2/3), p38-MAP kinase (α, β, δ,
and γ), and ERK5 are different groups of MAPKs expressed in mammals. These are later activated by
MAP kinase kinases (MAPKK) which might be triggered by some MAPKK kinases (MAPKKK) [93].
MAPK, in its turn, cross-talks with other pathways such as NFκB, thus the complexity of the MAPK
signaling pathway and its interactions. Stress and mitogens activate MAPK signaling: For example,
ERK1/2 route is triggered by mitogens and growth factors while JNK and p38 cascade are stimulated
by stress [94–97]. Preclinical data propose an anti-inflammatory role of JNK and p38 cascades
inhibitors [98,99].
Polyphenols’ activity is specific, it depends on the cell types as well as the structure of the
polyphenol itself [100]. Polyphenols can block TNF α release by modulating MAPK pathway at
different levels of the signaling pathway. Luteolin reduces TNFα liberation by LPS-activated mouse
macrophages, it blocks ERK1/2 and p38phosphorylation [100]. In epithelial cells, luteolin, as well
as other polyphenols such as chrysin and kaempferol block TNFα triggered ICAM-1 expression by
inhibiting ERK, JNK and P38 [100,101]. Quercetin blocks the phosphorylation of ERK, JNK in THP-1
activated human monocytes, while in murine macrophages RAW 246.7 triggered by LPS it blocks the
phosphorylation and the activation of JNK/SAPK (stress activated protein kinases), ERK1/2, and p38
leading to a reduction in the transcription and expression of TNF-α expression [102]. EGCG reduces
inflammation in various cell types by exerting an anti-MAPK activity. It reduces IL-12 expression in
LPS-activated murine macrophages by prohibiting p38 MAPK phosphorylation [89,103]. In addition,
EGCG is found to play a protective role in autoimmune-induced tissue damage caused by Sjogren’s
syndrome: it protects human salivary glands from TNF-α induced cytotoxicity by acting on p38
MAPK1. In vivo, in female ICR mice, EGCG inhibits phorbol ester-induced activation of NFκB and
CREB (cAMP response element-binding protein—a cellular transcription factor) in mouse skin by
blocking the activation of p38 MAPK [104]. Polyphenols concentration plays as well a role in their
modulatory activities on signaling pathways: in human coronary artery endothelial cells, the activation
of the MAPKs pathways (p38, ERK1/2, and JNK) and the repression of the plasminogen activator
inhibitor by catechin and quercetin is time and dose dependent [105]. The ability of polyphenolic
compounds to block MAPK pathways (Figure 1) endowed these bioactive substances with therapeutic
potential to protect against inflammation.
4.3. Arachidonic Acid Signaling Pathway
Arachidonic acid (AA) is liberated by membrane phospholipids upon phospholipase A2 (PLA2)
cleavage. Cyclooxygenase (COX) or lipoxygenase (LOX) metabolize it and produce, respectively,
prostaglandins (PGs) and thromboxane A2 (TXA2) by COX, and hydroxyeicosatetraenoic acids and
leukotrienes (LTs) by LOX [106]. The COX family involves different members (COX1, COX-2, and
COX-3). COX-2 is responsible of the production of important quantity of prostaglandins, its expression
is triggered by lipopolysaccharide and pro-inflammatory cytokines [107]. The ability of polyphenols
to reduce the release of arachidonic acid, prostaglandins, and leukotrienes is considered one of their
most important anti-inflammatory mechanisms (Figure 1). Their action is mainly realized by their
ability to inhibit cellular enzymes, such as PLA2, COX, and LOX [21,108–111]. Quercetin blocks COX
and LOX in various cell types such as rat peritoneal leukocyte, murine leukocytes, and guinea pig
epidermis [110,112,113]. Similarly, red wine reduces COX-2 expression in old male F344 rats [114].
In LPS activated murine macrophages, green tea polyphenols not only suppress NF-κB and MAPK
pathways but also constrain the expression of COX-2 and the release of prostaglandin (PGE2) in
RAW 264.7 macrophages [115,116]. Equally, a reduction in the release of PGE2 is observed with
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other polyphenols, such as kaempferol in culture of LPS-stimulated human whole blood cells [117].
Extra virgin olive oil rich with more than 30 phenolic compounds inhibit 5-LOX in human activated
leukocytes reducing leukotriene B4 and suppresses eicosanoids production by animal and human
cells in vitro [118,119]. Finally, certain polyphenols show structural and functional similarities with
specific anti-inflammatory drugs. A phenolic compound—oleocanthal—demonstrates a natural
anti-inflammatory property and exhibits structural similarities to the ibuprofen (a well-known
anti-inflammatory drug). Oleocanthal—like ibuprofen—inhibits COX-1 and COX-2 activities in a
dose-dependent manner [120].
5. Polyphenols, Oxidative Stress, and Inflammation
Higher production of reactive oxygen species (ROS) is associated with oxidative stress and
protein oxidation [121]. In its turn inflammatory molecules and different inflammatory signals
(i.e., peroxiredoxin2) are triggered by protein oxidations [122]. Furthermore, overproduction of
ROS can prompt tissue injury that might initiates the inflammatory process [123–127]. Therefore,
the classical antioxidant actions of polyphenols undoubtedly contribute to their anti-inflammatory roles
by interrupting the ROS-inflammation cycle (Figure 2). Polyphenols are known for their antioxidant
activities; they scavenge a wide-ranging selection of ROS. Polyphenols can scavenge radicals and
chelate metal ions, for example quercetin chelates iron ion [128]. They also inhibit multiple enzymes
responsible of ROS generation [129]. In fact, free metal ions, as well as highly reactive hydroxyl radical
release, is increased by the formation of ROS. To the opposite, polyphenols are able to chelate metal
ions like Fe2+, Cu2+, and free radicals which lead to a reduction of highly oxidizing free radicals [130].
Figure 2. Key polyphenolic anti-oxidant actions in relation to anti-inflammation. Polyphenols scavenge
radicals, chelate metal ions, inhibit ROS production and promote ROS detoxification. On the right
panel ROS contribution to inflammation. ROS: reactive oxygen species; RNS: reactive nitrogen
species; NOX: NADPH oxidase; SOD: superoxide dismutase; GSH-PX: glutathione peroxidase; ERK:
extra-cellular signal regulated kinases; PI3K/AkT: phosphatidylinositide 3-kinases/protein kinase B;
EGCG: epigallactocatechine gallate.
Transition metal ions, like Fe+2, Cu2+, Co2+, Ti3+, or Cr5+, results in OH• formation from
H2O2 [131,132]. Curcumin is able to chelate transition metal (Cu2+ and Fe2+) ions. Alike, EGCG
and quercetin chelate Fe2+ (iron ion) [128]. Polyphenols like apocynin, reservatol, and curcumin
can inhibit NOX (NADPH oxidase) causing a reduction in the generation of O2• during infections
consecutively in endothelial cells in THP1-monocytes [133–135]. Additionally, polyphenols can
attenuate the mitochondrial ATP synthesis by blocking the mitochondrial respiratory chain and
ATPase. As a result, ROS production is diminished. Curcumin [136], EGCG [137], phenolic acids [138],
capsaicin [139], quercetins [140], anthocyanins [140], and resveratrol analogs [141] inhibit xanthine
oxidase. Thus, they reduce ROS production. Polyphenols affect the activity of cyclooxygenase,
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lipoxygenase, and NOS (nitric oxide synthase) as per found in RAW 264.7 macrophes [142]. These
enzymes are known to metabolize arachidonic acid and their inhibition moderates the production
of key mediators of inflammation (prostaglandins, leukotrienes, and NO . . . ) [142]. Polyphenols
can also restrain LPS-induced iNOS gene expression in cultured macrophages, decreasing oxidative
harm [143]. Finally, they may act by upregulating endogenous antioxidant enzymes. In vivo, curcumin
can stimulate antioxidant enzymes like superoxide dismutase (SOD), catalase, and glutathione (GSH)
peroxidase (Px) which lead to ROS detoxification [144]. Likewise, EGCG rises SOD and GSH-Px
activities with augmented amount of cellular glutathione [145]. In conclusion, polyphenols exert
the anti-inflammatory action by different mechanisms: Radical scavenging, metal chelating, NOX
inhibition, tempering the mitochondrial respiratory chain, inhibition of certain enzymes involved in
ROS production, like xanthine oxidase and upregulation of endogenous antioxidant enzymes.
6. Polyphenols, Chronic Diseases and Cancer
Referring to the previously cited roles of polyphenols in maintaining tissue homeostasis by
targeting different signaling pathways and referring to their antioxidant, anti-inflammation, and
protection against pro-inflammation properties; polyphenols play a beneficial role in the prevention
and the process of chronic diseases related to inflammation.
Various polyphenolic compounds show protective actions in diabetes, obesity, neurodegeneration,
cancers, and cardiovascular diseases, among other conditions [30,146–154].
6.1. Polyphenols and Insulin Resistance
Polyphenols reduce insulin resistance. They promote glycolysis by activation of AMPK (AMP-
activated protein kinase) or inhibition of mTORC1 and PI3K/AkT in vivo (in rats), ex vivo (in rats’
muscles strips) and in vitro (in C2C12 myoblasts and HELA cells) [148,149,155,156]. Additionally,
AMPK activation by polyphenols increases glucose uptake by positively affecting eNOS imitating
muscle contraction and in vivo activity of insulin [148–150]. Similarly, it is found that polyphenols
lower insulin resistance by inhibiting PI3K/AkT and JNK of activation of the AMPK-SirT1-PGC1α axis
(i.e., gingerol and anthocyans, and their ability to protect from diabetes and reduce insulin resistance
using in vivo, ex vivo and in vitro studies [26–28,148,149,155]. In addition, polyphenols attenuate
glucose intake from carbohydrates by inhibiting rats’ α-glucosidase [157]. Lastly, polyphenols, like
falvonoids, can improve insulin secretion by reducing apoptosis of pancreatic β–cells [145].
6.2. Polyphenols and Inflammatory Cardiovascular Diseases (CVD)
Meta-analysis studies have reported that an intake of three cups of tea per day reduces CVD by
11% [151] while adequate intake of red wine is associated with 32% lower risk of cardiovascular disease
(CVD) [158]. Soy and cocoa flavonoids contribute to the prevention of CVD as per meta-analysis
of randomized controls trial [159]. Polyphenols exert their protective effects in CVD due to their
anti-hypertensive potentials. Resveratrol inhibits ACE (angiotensin converting enzyme) and PDE
(phosphodiesterase) and upregulates eNOS (endothelial NOS) resulting in a reduction in high blood
pressure as per multiple in vivo and in vitro studies [26–28,155,156,160]. In addition, flavanols and
flavonols exert their CVD prevention role by reducing the manifestations of age-related vascular injury.
They reduce nicotinamide adenine dinucleotide phosphate (NADPH) oxidase by affecting MAPK
signaling and downregulating NF-κB in aged rats [161–163]. At the end, the antioxidant action of
polyphenols and their ability to suppress LDL oxidation leads to endothelium-protective activity [164].
Certain polyphenols like resveratrol and anthocyanins protect from CVD by multiple mechanisms;
they have (1) antihypertensive properties, they inhibit eNOS, and (2) inhibit NFκB mediated expression
of VCAM and ICAM expression as per previously discussed [39,165]. Polyphenols can also reduce
LDL oxidation or improve LDL/HDL ratio. For example, flavanones such as hesperetin in orange
juice reduce LDL/HDL ratio while quercetin inhibits LDL oxidation with elevated paraoxonase and
eliminate atherogenic lesions referring to in vitro and in vivo studies (using human male subjects) [166].
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6.3. Polyphenols and Inflammatory Neurological Diseases
Polyphenols show protective effects in neurological disease [152,153]. High flavonoid intake
can reduce by 50% dementia and aging. More precisely, it lowers the incidence of Parkinson’s and
delays the onset of Alzheimer’s disease as per different epidemiological studies [167–170]. EGCG
has neuroprotective properties due to its antioxidant (SOD, GSHPx) activities and cellular GSH
contents and ability to reduce ROS contents. Similarly, anthocyanins neuroprotective characteristics
are related to the improvement of oxidative stress and reduction of Aβ deposition [38,171,172]. Other
mechanisms of polyphenols protection in neurodegenerative diseases is modulation of neuronal and
glial signaling pathways [173]. Polyphenols can downregulate NF-κB related with iNOS generation
in glial cells [174–176]. Moreover, their ability to inhibit monoamine oxidase plays a positive role in
cognition, depression, and learning ability in vivo in male laca mice [172].
6.4. Polyphenols and Inflammatory Obesity
Polyphenols exert their anti-obesity effect by activation of AMPK (5’ adenosine
monophosphate-activated protein kinase) leading to a reduction of cholesterol, fatty acid synthesis, and
triglyceride formation by inhibiting HMG-CoA reductase and acetyl CoA carboxylase. Furthermore,
they can inhibit genes involved in adipocyte differentiation and triglyceride accumulation. They
block mTORC1 and repress specific signals associated with diminished levels of PPARγ and C/EBP
α/δ mRNA throughout adipogenesis (in an experimental model of sepsis) and in vitro [30,146].
They can improve energy expenditure, stop the maturation of preadipocytes into adipocytes and
increase the expression of adiponectin (a hormonal protein with a role in regulating glucose levels and
breaking down fatty acids). For example, capsaicin enhances the energy spending in adipose tissue.
Capsaicin diminishes intracellular triglycerides and improves brown adipose tissue thermogenesis.
Furthermore, in clinical studies, capsaicin is found able to increase satiety [30,177,178]. EGCG
inhibits MEK/ERK and PI3K/AKT pathways leading to inactivation of preadipocytes maturation by
downregulating the expression of different genes like PPARγ and C/EBPα that are associated with
adipogenesis [38,41,146,179]. Certain polyphenols can increase adiponectin such as gingerol and
curcumin in serum of human subjects based on randomized controlled trial [180,181].
6.5. Polyphenols and Cancer
Clinical and epidemiological studies have reported that polyphenols have chemo-preventive
and anticancer efficacy [182–184]. Polyphenol compounds have the ability to inhibit the
proliferation of different types of cancer such as prostate, bladder, lung, gastrointestinal, breast,
and ovarian cancers [154]. For instance, quercetin, resveratrol, green tea polyphenols [185],
epigallocatechin-3-gallate [186], and curcumin [187] have demonstrated efficacy as anticancer
compounds. Several studies reported that polyphenols are able to prevent cancer initiation
(cyto-protective), progression, recurrence, and metastasis to distant organs (cytotoxic) as per different
epidemiological, in vitro, and in vivo studie [188–190]. However, a dichotomy exists between
polyphenols’ antioxidant effects in normal cells, and their potential pro-oxidant effects in cancer
cells [154,188].
Recent studies illustrated a direct correlation between ROS in intracellular signaling cascade
and carcinogenesis [191]. Oxidative stress targets proteins, lipids, and DNA/RNA causing changes
that increase the risks of mutagenesis. ROS/RNS (reactive nitrogen species) overproduction over a
prolonged period of time damages cellular structure and functions and causes somatic mutations
such as pre-neoplastic and neoplastic transformations that may lead to cell death by necrotic and
apoptotic processes [192]. Polyphenols compounds contain hydroxyl groups that donate their protons
to reactive oxygen species (ROS) [193]. Moreover, they reduce the activity of phase I enzymes, primarily
cytochrome P450 enzymes (CYPs), such as CYP1A1 and CYP1B1 which lead to prevent the formation
of reactive and carcinogenic metabolites in human bronchial epithelial cells [194]. They also can induce
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phase II enzymes that initiate the formation of polar metabolites which are readily excreted from the
body [195]. Certain dietary polyphenols such as flavonoids reduce cellular formation of ROS which
protects from the oxidation of DNA [193].
In addition to their anti-oxidant properties, pro-oxidant characteristic of polyphenols is important
in treating and preventing cancer. Pro-oxidant activity can be initiated by certain conditions such
as superoxide leakage [196]. The pro-oxidant activities of polyphenols in cancer cells can result in
inducing apoptosis [197], cell cycle arrest [198] and inhibiting the proliferation signaling pathways
(i.e., epidermal growth factor receptor/mitogen activated protein kinase, phosphatidylinositide
3-kinases/protein kinase B, as well as NF-kB) [199]. For example, polyphenols from apple are able
to inhibit the proliferation of human bladder transitional cell carcinoma (TCC, TSGH-8301 cells),
inducing G2/M cell cycle arrest, and promoting apoptosis [200]. In human papilloma virus-18-positive
HeLa cervical cancer cells, green tea polyphenols can induce cell cycle arrest at the subG1 phase and
apoptosis through caspases activation [201]. Flavonoids, such as quercetin, induce apoptosis in many
cancer cells such as leukemic U937 cell [202], prostate cancer cells [203], hepatic cancer cells [204],
among other types. A combination of quercetin with resveratrol and catechin inhibits breast cancer
progression in vitro and in vivo by inducing apoptosis in carcinogenic breast cells [205]. In addition,
polyphenols can reduce cancer metastasis such as quercetin [206,207].
Sufficient studies have reported that NF-κB signaling pathways are closely related to cancer
metastasis. Polyphenols can disrupt the metastatic potential of cancer by inhibiting NF-κB activity [208].
Curcumin is a good example [209–211] of decreasing cancer metastasis in mice by suppressing
NF-κB expression and down-regulating VEGF (vascular endothelial growth factor), COX-2, and
MMP-9 (matrix metallopeptidase-9) expression in tissues of the breast, brain, lung, liver, and
spleen [212,213]. Moreover, the strength of metastasis is associated to the epithelial-to-mesenchymal
transition (EMT) [214]. There is robust evidence that polyphenols compounds can modulate EMT
and its related signaling pathways [215]. For example, EGCG, a flavan-3-ol, induces apoptosis and
significantly reduces colony formation and cell migration in nasopharyngeal carcinoma (NPC) and
cancer stem cells (CSC) in different cell lines [216]. Luteolin and quercetin reverse the migration and
invasiveness of metastatic cells by reducing the expression of mesenchymal markers and transcriptional
factors on the cell membrane (i.e., twist, snail, and N-cadherin) and upregulating adhesion molecules
such as E-cadherin [217]. Thus, through variable mechanisms, polyphenols broadly downregulate
inflammation origination, progression, and evolution to cancers (Figure 3).
Figure 3. Anti-tumorigenic activities of polyphenols. MAPK: mitogen-activated protein kinase; NFκB:
nuclear factor kappa-light-chain-enhancer of activated B cells; PI3K: phosphatidylinositide 3-kinase;
ERK: extracellular signal-related kinases; ROS: reactive oxygen species; COX: cyclooxygenase; EMT:
epithelial mesenchymal transition; HIF-1α: hypoxia-inducible factor 1-aplha.
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In order to emphasize on the beneficial health effects of polyphenols, different medications
containing polyphenols are FDA-approved as pharmaceutical drugs. Polyphenon® E, a standardized
green tea polyphenol preparation, is an FDA-approved medication to treat genital warts [218]. Another
significant event in the use of polyphenols as pharmaceuticals is the FDA approval of crofelemer
(a medication rich in oligomeric proanthocyanidin) to manage HIV associated non-infectious diarrhea.
7. Conclusions
In conclusion, the vast number of published studies proved the immunomodulatory role of
polyphenols in vivo and in vitro. Different underlying regulatory mechanisms are now well elucidated.
These data highlight the promising role of polyphenols in prevention and therapy of diseases with
underlining inflammatory conditions, including cancer, neurodegenerative diseases, obesity, type
II diabetes, and cardiovascular diseases. However, the role of polyphenols in modulating multiple
inflammatory cellular pathways should be further investigated. Many questions remain unanswered
about the usage of polyphenols in clinical setting. The role of the microbiota in degrading these
polyphenols should be further studied. The notion of bioavailability and its impact on biofunctionality
should also be revisited. It is generally believed that polyphenol activity is principally located in the gut
where their immunoprotective and anti-inflammatory activities are initiated and subsequently ensuring
systemic anti-inflammatory effects. Since different polyphenols can have multiple intracellular
targets, additional data is needed to determine the consequences of the interaction or the synergistic
effects between multiple polyphenolic compounds or polyphenols and commonly used medications.
Moreover, further in vivo and meta-analysis studies in humans are necessary to fully reveal the
mechanisms of action of polyphenols in several physiological conditions in order to produce important
insights into their prophylactic and therapeutic uses.
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VEGF Vascular endothelial growth Factor
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Akt Protein kinase B
LDL Low density lipoprotein
HDL High density lipoprotein
RNS Reactive nitrogen species
PPARγ Peroxisome proliferator-activated receptor gamma
CYPs Cytochrome P450 enzymes
MMP-9 Matrix metallopeptidase-9
NPC Nasopharyngeal carcinoma
CSCs Cancer stem cells
EMT Epithelial-to-mesenchymal transition
FDA Food and drug administration
ICAM Intercellular adhesion molecule
VCAM Vascular cell adhesion molecule
HIV Human immunodeficiency diarrhea
HMG-CoA 3-Hydroxy-3-methyl-glutaryl-coenzyme A
VEGF Vascular endothelial growth factor
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NO Nitric oxide
eNOS Endothelial nitric oxide synthase
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Abstract: Vitamin E is a fat-soluble antioxidant that can protect the polyunsaturated fatty acids
(PUFAs) in the membrane from oxidation, regulate the production of reactive oxygen species (ROS)
and reactive nitrogen species (RNS), and modulate signal transduction. Immunomodulatory effects
of vitamin E have been observed in animal and human models under normal and disease conditions.
With advances in understating of the development, function, and regulation of dendritic cells (DCs),
macrophages, natural killer (NK) cells, T cells, and B cells, recent studies have focused on vitamin E’s
effects on specific immune cells. This review will summarize the immunological changes observed
with vitamin E intervention in animals and humans, and then describe the cell-specific effects of
vitamin E in order to understand the mechanisms of immunomodulation and implications of vitamin
E for immunological diseases.
Keywords: vitamin E; macrophages; T cells; dendritic cells; immunomodulation; infection
1. Vitamin E: Definition, Structure, Sources, and Functions
1.1. Definition and Structure
Vitamin E is the collective term for four tocopherols (α-, β-, γ-, and δ-tocopherols) and four
tocotrienols (α-, β-, γ-, and δ-tocotrienols) found in food. These forms have antioxidant activities,
but cannot be interconverted, and only α-tocopherol meets the human vitamin E requirement [1].
Tocopherols have a chromanol ring and a phytyl tail, while tocotrienols have a chromanol ring and an
unsaturated tail. The α-, β-, γ-, and δ- forms differ in the number and position of methyl groups on the
chromanol structure. Natural tocopherols have only RRR stereochemistry, but synthetic tocopherols
are mixtures of eight stereoisomers (RRR-, RSR-, RRS-, RSS-, SRR-, SSR-, SRS-, SSS-), because there are
three asymmetric carbon atoms (2R, 4’R, 8’R) present in the phytyl tail. The structures of tocopherols
and tocotrienols are shown in Figure 1.
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Figure 1. The structures of tocopherol and tocotrienols.
1.2. Sources
The major dietary sources of vitamin E are vegetable oils. Nuts are good sources of vitamin
E as well [2]. Soybean, sunflower, corn, walnut, cottonseed, palm, and wheat germ oils contain
relatively higher amounts (more than approximately 50 mg vitamin E/100 g oil) of vitamin E than
other oils. The proportions of α-, β-, γ-, and δ-tocopherols vary depending on the oil type. Safflower
and sunflower oils are high in α-tocopherol, soybean and corn oils contain mainly γ-tocopherol,
and cottonseed oil contains similar proportions of α- and γ-tocopherols. Therefore, the types of oils
consumed through the diet affect the dietary intake levels of α-tocopherol. Vitamin E supplements are
quite popular and contribute considerably to vitamin E intake among some populations. Either natural
or synthetic forms of α-tocopherol are used as supplements.
Despite the relatively higher intake of γ-tocopherol from the diet than α-tocopherol, α-tocopherol
is the major form of vitamin E in the circulation because α-tocopherol transfer protein (α-TTP) has the
preferential binding affinity for α-tocopherol. α-TTP is involved in the transfer of α-tocopherol to the
plasma membrane [1].
1.3. Functions
Vitamin E is a major fat-soluble antioxidant that scavenges peroxyl radicals and terminates the
oxidation of polyunsaturated fatty acids (PUFAs). In the presence of vitamin E, peroxyl radicals react
with α-tocopherol instead of lipid hydroperoxide, the chain reaction of peroxyl radical production
is stopped, and further oxidation of PUFAs in the membrane is prevented [1]. Tocopheroxyl
radicals—produced from α-tocopherol and peroxyl radicals—are reduced by vitamin C or glutathione,
form tocopherol dimers, undergo further oxidation, or act as prooxidants. The antioxidant activity of
vitamin E may be responsible for the regulation of several enzymes involved in signal transduction
because the activity of signaling enzymes is regulated by the redox state.
Vitamin E inhibits protein kinase C (PKC) activity by increasing PKC-α dephosphorylation
through the activation of protein phosphatase 2A. The inhibition of PKC by vitamin E has been
reported in various cells, and consequently, the inhibition of platelet aggregation; reduced proliferation
of monocytes, macrophages, neutrophils, and vascular smooth muscle cells; and decreased superoxide
production in neutrophils and macrophages have been observed [3,4].
Vitamin E may directly bind to the enzymes involved in the generation of lipid mediators or to
the transport proteins involved in signal transduction. Vitamin E may affect the membrane protein
116
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interaction and translocation of the enzymes to the plasma membrane and therefore change the activity
of signal transduction enzymes [4].
2. Modulation of Immune Responses and Infectious Diseases by Vitamin E Supplementation
2.1. Immune Responses in Animals
Dietary interventions of vitamin E at supplemental levels have been shown to enhance
cell-mediated and humoral immune responses in various species of animals. Increased lymphocyte
proliferation, immunoglobulin levels, antibody responses, natural killer (NK) cell activity,
and interleukin (IL)-2 production have been reported with vitamin E supplementation (Table 1).
2.2. Immune Responses in Humans
In humans, many intervention studies have reported increased lymphocyte proliferation
in response to mitogenic stimulation, enhanced delayed type hypersensitivity (DTH) response,
increased IL-2 production, and decreased IL-6 production with vitamin E supplementation above
the recommended levels. However, some studies showed no difference or decreased lymphocyte
proliferation responses and decreased chemiluminescence. (Table 2). Differences in dose of vitamin E
supplementation used, magnitude of vitamin E level changes with supplementation, age of subjects,
and methodology (determination of antibody levels with or without specific vaccination) might have
contributed to the different results observed.
2.3. Infectious Diseases in Animals
The immunostimulatory effect of vitamin E has resulted in enhanced resistance against several
pathogens. Animal studies in which infectious disease models were used to test the effects of vitamin
E supplementation are listed in Table 3.
The mechanisms involved with protection against infectious agents were increased macrophage
activity and antibody (Ab) production for D. pneumoniae type 1 [5], and higher NK activity and Th1
response for influenza virus [6,7].
2.4. Infectious Diseases in Humans
In humans, the effects of vitamin E on the natural incidence of infectious diseases have been
determined in several studies (Table 4). Many studies provided evidence that the immunostimulatory
effects of vitamin E confer improved resistance to infections. However, the magnitudes of the effects
were rather small, and in some studies, positive effects were only observed in subgroups of subjects.
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3. Vitamin E and Immune Cells
The immunomodulatory mechanisms of α-tocopherol in immune cells are depicted in Figure 2.
Figure 2. Immunomodulatory effects of vitamin E on immune cells. Abbreviations: PGE2,
prostaglandin E2; COX2, Cyclooxygenase 2; NO, Nitric oxide; CD, Clusters of Differentiation; DCs,
Dendritic cells; IL-12, Interleukin-12; Ab, antibody; NK, Natural killer.
3.1. Macrophages
Macrophages, important effector cells in the innate immune response, serve as antigen presenting
cells (APC) and regulate NK cells and T cells by producing cytokines, reactive oxygen species (ROS),
reactive nitrogen species (RNS), and prostaglandins. Cytokines produced by T cells and other immune
cells can shift the macrophages into different populations with distinct physiologies [60].
The effects of vitamin E on prostaglandin (PG)E2 production by macrophages from the aged
have been suggested as one of the mechanisms by which vitamin E improves the age-associated
decrease in the T cell-mediated immune response [61]. In a co-culture experiment in which purified
T cells and macrophages from young and old mice were cultured together, T cells from young mice
showed suppressed proliferation and IL-2 secretion when cultured with macrophages from old mice.
When macrophages from old mice were pre-incubated with 10 μg/mL vitamin E for 4 h, co-cultures
of old macrophages and young T cells showed significant improvement in proliferation. Vitamin E
pre-incubation of old macrophages improved proliferation and IL-2 production in co-cultures of old
macrophages and old T cells [62]. Macrophages from old mice produced significantly higher levels of
PGE2, which was due to higher cyclooxygenase (COX) activity. Macrophages from old mice expressed
higher levels of inducible COX2 protein and mRNA [63]. These increases in PGE2 synthesis and COX
activity were lowered by in vivo vitamin E supplementation [64]. Macrophages isolated from old
mice fed a diet containing 500 ppm vitamin E for 30 days produced lower amounts of PGE2 and
had lower COX activity than those from old mice fed a control diet containing 30 ppm vitamin E,
but the COX2 mRNA levels and protein expression of the control and supplemented groups did not
123
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differ. Thus, vitamin E’s effect on COX activity seemed to be through post-translational mechanisms
rather than through its effect at transcriptome or translational levels. In a subsequent study, it was
shown that vitamin E reduced COX activity in macrophages from old mice by decreasing peroxynitrite
production [65]. The inhibition of COX activity by vitamin E in old mice disappeared specifically with
the addition of a nitric oxide (NO) donor in the presence of a superoxide to elevate peroxynitrite levels
in the macrophage culture. There is a complex interplay between the nitric oxide synthase (NOS)
and COX pathways and NO increases COX2 activity, which seems to be due to the NO preventing
self-deactivation of COX by the superoxide as NO interacts with the superoxide [66].
In vivo supplementation of vitamin E (1500 IU D-α-tocopheryl acetate/day for 16 weeks)
in allergic asthmatic patients prevented the suppression of alveolar macrophage nuclear factor
(erythroid-derived 2)-like 2 (NRF2) activity after allergen challenge [67]. This study presented the
possibility of vitamin E’s protective role in allergies and asthmas through regulation of macrophage
NRF2 activity, but, further studies are needed to confirm the findings because of the small number of
patients (nine mild non-smoking allergic asthmatics) and the lack of appropriate controls.
3.2. Natural Killer Cells
NK activity seems to be related with vitamin E status. The NK activity of a boy with Shwachman
syndrome who had a severe vitamin E deficiency was low, but improved after eight weeks of 100 mg/d
α-tocopherol supplementation. When α-tocopherol supplementation was stopped, NK activity and
CD16+ CD56+ cells decreased. NK activity and CD16+ CD56+ cells were restored upon resuming
eight weeks of 100 mg/d α-tocopherol supplementation [68]. In 37 women aged 90–106 years old,
NK cell cytotoxicity was positively associated with plasma vitamin E concentration [69]. A two-week
supplementation of 750 mg vitamin E in colorectal cancer patients resulted in increased NK activity in
six out of seven patients. Vitamin E treatment did not result in changes in perforin expression or IFN-γ
production; therefore, mechanisms of improved NK activity by vitamin E could not be determined
from the study [70].
NO appears to be involved in the impairment of NK cell function. Co-culture of NK cells and
myeloid-derived suppressor cells (MDSCs) showed that NK cell cytotoxicity and IFN-γ were impaired
by MDSCs and that the inhibition of inducible nitric oxide synthase (iNOS) rescued the impairment
by MDSCs. Exposure of NK cells to NO by treatment with an NO producer caused the nitration of
tyrosine residues on CD16+ NK cells. These results suggested that MDSCs impair NK cell function
via the production of NO and the nitration of protein tyrosine residues [71]. Vitamin E might exert its
effects on NK cell function by modulating NO levels.
3.3. Dendritic Cells
Dendritic cells (DCs) are effective antigen-presenting cells that recognize pathogens and present
pathogen-derived antigens to T cells. The interaction of DCs with pathogen-associated molecular
patterns (PAMPs) or damage-associated molecular patterns (DAMPs) elicits the activation and
maturation of DCs. The increased expression of surface major histocompatibility complex (MHC)
molecules and co-stimulatory molecules and the increased production of cytokines occur with the
activation of DCs, which allows the effective induction of the T cell response [72–74]. DCs are also
involved in tolerance and autoimmunity. DCs might promote tolerance by the generation of Treg cells
and/or by the induction of T cell unresponsiveness. DCs might be involved in the pathogenesis of
autoimmune disease by promoting the priming or differentiation of self-reactive T cells [72]. Therefore,
understanding the regulation of DCs by vitamin E will provide insight into the mechanisms of vitamin
E’s immune response modulation and implications of vitamin E in immunological diseases.
Several studies have shown that vitamin E could regulate the maturation and functions of
DCs. Tan et al. [75] investigated the effects of α-tocopherol and vitamin C, alone or in combination,
on the phenotype and functions of human DCs generated from peripheral blood mononuclear cells
(PBMCs). During the differentiation of human PBMCs into DCs, various concentrations of α-tocopherol
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were treated in culture starting from day 2, cells were stimulated on day 5, and then the surface
phenotype was determined on day 6. The expression of human leukocyte antigen(HLA)-DR, CD40
CD80, and CD86 appeared to be increased with lower concentrations of α-tocopherol (<0.05 mM), but
the combination of vitamin E and C prevented DC activation, as the upregulation of surface markers
was not observed. DCs treated with 0.5 mM vitamin E and 10 mM vitamin C showed lower levels
of intracellular ROS and inhibition of the nuclear factor (NF)-κB, PKC, and p38 mitogen-activated
protein kinase (MAPK) pathways. When bone marrow-derived dendritic cells (BMDCs) from Balb/c
mice were treated with 500 μM of α-tocopherol for 2 h, upregulation of phosphorylated inhibitor of κB
(IκB) by lipopolysaccharide (LPS)-stimulation was suppressed. Vitamin E treatment for 24 h resulted
in a reduced number of CD11+CD86+ cells and ROS-positive cells, lower production of IL-12p70
and TNF-α, and decreased transwell migration of BMDCs. These effects of vitamin E on BMDCs
were partly dependent on Klotho expression. Vitamin E treatment on BMDCs resulted in higher
Klotho transcript and protein levels, and silencing of Klotho by transfection of Klotho siRNA abolished
the inhibitory effects of vitamin E on IL-12p70 production, number of ROS-positive cells, and DC
migration [76]. Klotho is a membrane protein that has been shown to mediate calcium transport into
the cells; regulate intracellular signaling pathways such as p53/p21, cyclin adenosine monophosphate
(cAMP), PKC, and Wnt; and inhibit the NF-κB pathway [77]. Therefore, the upregulation of Klotho
by vitamin E could be one of the mechanisms by which vitamin E modulates NF-κB mediated DC
function and maturation. However, the level of α-tocopherol used for in vitro treatment (500 μM) was
high and, therefore, further research is needed to elucidate the physiological relevance of vitamin E
treatment on the expression of Klotho and its involvement in the modulation of DC function.
In vivo supplementation of α-tocopherol at 150, 250, and 500 mg/kg diet in allergic female mice
reduced the lung CD11b+ DCs and mRNA levels of IL-4, IL-33, thymic stromal lymphopoietin (TSLP),
eotaxin 1 (CCL11), and eotaxin 2 (CCL24) in allergen challenged pups. Furthermore, when BMDCs
from 10-day-old neonates born to a control female were treated with 80 μM α-tocopherol for 24 h,
the number of CD45+ CD11b+ CD11+ DCs and the number of CD45+ CD11b+ CD11c+ Ly6c− MHCII−
DCs were reduced. Maternal supplementation with α-tocopherol was effective in decreasing allergic
responses in offspring from allergic mothers by affecting the development of subsets of DCs that
are critical for allergic responses [78]. On the other hand, γ-tocopherol supplementation exerted an
opposite response in the same model. In vivo supplementation of γ-tocopherol at 250 mg/kg diet in
allergic female mice resulted in a higher number of lung eosinophils, a higher number of lung CD11c+
CD11b+ DCs, and higher levels of lung lavage CCL11 in the offspring [79].
Modulation of the immune response by vitamin E has been observed in animal and human
studies, and DCs play a critical role in bridging innate and adaptive immune systems and initiating
adaptive immune responses. Despite the importance of DCs’ role in adaptive immune responses
and in diseases such as autoimmune diseases, few studies have investigated the DC-specific effect of
vitamin E.
3.4. T Cells
The effects of vitamin E on immune cells have been studied the most with T cells.
The dysregulation of immune function occurs with aging and the most significant changes are observed
in T cells. Age-associated changes in T cells include, but are not limited to, (1) defects in T cell receptor
(TCR) signal transduction such as a decrease in linker for the activation of T cells (LAT) phosphorylation
by zeta chain of T cell receptor associated protein kinase 70 (ZAP-70), (2) decreased intracellular influx
of calcium following stimulation, (3) diminished synapse formation, (4) diminished activation of the
mitogen activated protein kinase (MAP kinase) pathway, (5) decreased nuclear factor of activated
T-cells (NFAT) binding activity, and (6) a shift of the T cell population toward memory T cells [80]. As a
result, diminished production of IL-2 and reduced proliferative capacity of naive T cells are observed
and impaired T cell functions contribute to increased susceptibility to infectious diseases and poor
response to immunization.
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Vitamin E has been shown to increase the cell division and IL-2 producing capacity of naïve T
cells, increase the percentage of T cells capable of forming an effective immune synapse, and reverse
the age-associated defect in the phosphorylation of LAT in T cells from old animals [81–83].
In vitro pre-incubation with 46 μM vitamin E for 4 h increased proliferation and IL-2 production in
T cells purified from old mice stimulated with anti-CD3 and anti-CD28. Increased IL-2 production was
due to both an increase in the number of activation-induced IL-2+ cells and an increase in the level of
IL-2 accumulated per cell. Vitamin E specifically increased the naive T cells’ ability to progress through
the cell division cycle in old mice [81]. The gene expression profile of T cells isolated from young and
old mice fed a diet supplemented with 500 ppm vitamin E for four weeks provided evidence that
vitamin E influences cell cycle-related molecules at the gene expression level. Higher expression of
cell cycle-related genes Ccnb2, Cdc2, and Cdc6 was observed in stimulated T cells from old mice fed
the vitamin E-supplemented diet compared with those fed the control diet, which was not observed
in young mice [84]. Cyclin B2, encoded by Ccnb2, binds to cyclin-dependent kinase 1 (also known
as Cdc2) and regulates the events during both the G2/M transition and progression through mitosis.
Cdc6 is a key regulator in the early steps of DNA replication, as the binding of Cdc6 to chromatin is
a necessary and universal step in the acquisition of replication competences [85]. These alterations
in the expression of cell cycle-related genes observed with vitamin E might contribute to vitamin E
improving the proliferative ability of old T cells.
Marko et al. [82] showed that pre-incubation of CD4+ T cells isolated from old T cells with 46 μM
vitamin E for 4 h increased the percentage of CD4+ T cells displaying effective immune synapses.
Redistribution of Zap70, LAT, Vav, and phospholipase Cγ (PLCγ) into immune synapse increased
significantly with vitamin E treatment. This change was confirmed with in vivo supplementation
of vitamin E. In old mice fed a diet containing 500 ppm vitamin E for eight weeks, LAT and Vav
showed significantly higher redistribution into the T cell/APC contact area when purified CD4+
T cells were stimulated with murine CD3ε hybridoma. In a subsequent study, it was shown that
vitamin E could reverse the age-associated defect in the phosphorylation of LAT on tyrosine 191 [83].
The phosphorylation of LAT is required for the recruitment of adaptor and effector proteins. Therefore,
it plays a pivotal role in the assembly of microcluster structures in the initiation of T cell activation
signals. This evidence suggests that vitamin E can modulate the early stages of T cell activation.
Vitamin E seems to modulate Th1 and Th2 responses. The polarization of CD4 T cells to T
helper (Th)1 or Th2 cells has implications for the protection against different pathogens (intracellular
vs. extracellular pathogens) and the development of different types of chronic diseases (inflammatory
vs. allergic diseases). PBMCs isolated from allergic donors treated with vitamin E (12.5–50 μM)
showed dose-dependent decreases in IL-4 production [86]. IL-4 mRNA levels in activated PBMCs
were downregulated by 25 μM vitamin E treatment. Jurkat T cells treated with 50 μM vitamin E
exhibited downregulation of IL-4 promoter activity, which might be related to vitamin E blocking the
interaction of transcription factors with PRE-1 and P1. In vivo supplementation of vitamin E enhancing
the Th1 response has been observed in mice infected with influenza virus and in colorectal cancer
patients [6,87]. In colorectal cancer patients, two weeks of supplementation with 750 mg vitamin E
led to an increased frequency of IL-2 producing CD4+ T cells and increased IFN-γ production [87].
In old mice infected with influenza virus, 500 ppm vitamin E supplementation for eight weeks prior
to infection lowered the viral titer in the lung, and this protective effect of vitamin E was associated
with the enhancement of Th1 response. IFN-γ production levels correlated negatively with viral
titer, and old mice fed a vitamin E-supplemented diet produced significantly higher levels of IFN-γ
and IL-2 [6]. The gene expression profile of T cells isolated from young and old mice fed a diet
supplemented with 500 ppm vitamin E for four weeks provided evidence that vitamin E influences the
Th1/Th2 balance at the gene expression level. The increase in IL-4 expression following stimulation
was lower in T cells from old mice fed the vitamin E-supplemented diet compared with those fed the
control diet, and the ratio of IFN-γ and IL-4 expression levels was significantly higher in the vitamin E
group than in the control group [84].
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Vitamin E can affect activation-induced cell death in T cells. In vitro treatment of primary human
T cells with 25 μM vitamin E suppressed CD95L expression and activation-induced cell death [88].
The reduction of CD95L mRNA levels and the proportion of CD95L-positive cells were related to the
suppression of NF-κB and AP-1 binding to the CD95L promoter target site by vitamin E. On the other
hand, α-tocopheryl succinate was shown to trigger apoptosis in Jurkat cells with caspase-activation
involved [89].
3.5. B Cells
Vitamin E supplementation has been reported to enhance humoral responses. Higher antibody
responses have been observed in animals and humans [19,27]. However, it is hard to differentiate
whether vitamin E’s direct effect on B cells or indirect effect through T cells contributes to higher
antibody responses.
4. Conclusions
Vitamin E has been shown to enhance immune responses in animal and human models and
to confer protection against several infectious diseases. Suggested mechanisms involved with these
changes are (1) the reduction of PGE2 production by the inhibition of COX2 activity mediated through
decreasing NO production, (2) the improvement of effective immune synapse formation in naive T
cells and the initiation of T cell activation signals, and (3) the modulation of Th1/Th2 balance. Higher
NK activity and changes in dendritic function such as lower IL-12 production and migration were
observed with vitamin E, but underlying mechanisms need to be further elucidated
Several considerations are warranted for the advancement in our understanding of vitamin E’s
role in immunity. For in vitro studies to support implications for the regulation of immunological
diseases, the physiological relevance of vitamin E levels used for treatment should be considered.
Different forms of vitamin E exert differential effects on immune cells. Cell-specific effects of vitamin
E provide valuable evidence regarding the immunomodulatory mechanisms of vitamin E, but the
interplay between immune cells should not be ignored, because interactions between immune cells are
critical in the regulation of immune function.
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Abstract: This review provides evidence that not only the content of nutrients but indeed the
structural organization of nutrients is a major determinant of human health. The gut microbiota
provides nutrients for the host by digesting food structures otherwise indigestible by human enzymes,
thereby simultaneously harvesting energy and delivering nutrients and metabolites for the nutritional
and biological benefit of the host. Microbiota-derived nutrients, metabolites, and antigens promote the
development and function of the host immune system both directly by activating cells of the adaptive
and innate immune system and indirectly by sustaining release of monosaccharides, stimulating
intestinal receptors and secreting gut hormones. Multiple indirect microbiota-dependent biological
responses contribute to glucose homeostasis, which prevents hyperglycemia-induced inflammatory
conditions. The composition and function of the gut microbiota vary between individuals and
whereas dietary habits influence the gut microbiota, the gut microbiota influences both the nutritional
and biological homeostasis of the host. A healthy gut microbiota requires the presence of beneficial
microbiotic species as well as vital food structures to ensure appropriate feeding of the microbiota.
This review focuses on the impact of plant-based food structures, the “fiber-encapsulated nutrient
formulation”, and on the direct and indirect mechanisms by which the gut microbiota participate in
host immune function.
Keywords: carbohydrates; fiber; food structure; formulation; plant; microbiota; inflammation;
metabolism; nutrition guidelines
1. Introduction
The gut microbiota is a complex ecosystem residing in the gastro-intestinal (GI) tract and consists
of a diverse microbiotic community living in symbiosis with the host. A diverse microbiota is
considered a major positive regulator of the interdependent metabolic and immune function of the
host. The gut microbiota is shaped alongside the host immune system in a synergistic partnership [1].
Trillions of microorganisms participate in the maturation and regulation of immune function, energy
metabolism, and hormonal balance [2], including regulation of intestinal mucosal barriers, fermentation
of undigested nutrients, and synthesis of short chain fatty acids (SCFA) [3]. Furthermore, the microbiota
releases microbiota-derived antigens [4,5], vitamins [6,7], and other molecules, such as tryptophan
metabolites [8,9], that interact with the host biology.
The dynamic relationship between the microbiotic ecosystem and its host is emphasized by
the joint utilization of consumed nutrients. Diet is a shared substrate between the host and the gut
microbiota and the choice of diet affects host health both directly and indirectly by affecting the
abundance and composition of the microbiotic community [10,11].
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The structural organization of complex carbohydrates determines the site of digestion and
absorption in the GI tract [12], and hence the level of cross feeding [13], community organization,
and proliferation of specific microorganisms. Importantly, all plant cell walls consist of complex
carbohydrate structures that are digested selectively by microbiotic enzymes and not by host enzymes.
Thus, complex polysaccharides in plant cell walls function as both substrate for the microbiota and as
a sustained release delivery system of other plant-cell derived nutrients and biomolecules for both
microbiotic and host utilization. The structural properties of the cell wall vary between different plant
cells [14], and in theory determine the specific site of plant cell wall degradation and nutrient release.
Plant-based foods can be placed on a moving scale from whole foods (unrefined) to fully refined
foods, and currently no official distinction based on the degrees of refinement exists. Foods with added
refined nutrients (e.g., sugar, starch or oils) or any food, which has been structurally disrupted on the
macroscopic level are considered refined. The degree of refinement is thus determined by the degree of
macroscopic structural disruption (e.g., intact whole grain vs. ground whole grain vs. sifted flour) and
the degree of refined supplementation. When plant-based food structures are completely disrupted
requiring no microbiotic interaction for digestion we consider the food fully refined.
Microbiota composition varies greatly among different cultures and individuals [15,16],
and specific genera of bacteria are more abundant in healthy individuals as compared to individuals
in different disease states, as shown, for example, for Bifidobacterium and Lactobacillus [17–19], whose
functions include carbohydrate fermentation and vitamin synthesis [6,20,21]. The degradation and
utilization of complex carbohydrates rely on specific microbiotic enzymes secreted from the microbiota
in the lower intestine [22]. The fermentation process yields energy for microbiotic proliferation
and metabolites, e.g. SCFA [23] for regulation of inflammatory responses [24] and gut hormone
secretion [25] in the host. The latter is of great importance for glucose homeostasis and plays a major
role for the metabolic and inflammatory health of the host [26].
Microbiota composition is also closely connected to the integrity of our intestinal mucosal barrier.
Upon microbiota dysbiosis mucosal bacteria can impair epithelial function and cause increased gut
permeability with consequent immune dysregulation, leading to inflammatory disease states [27].
A number of disorders with an inflammatory component including obesity, inflammatory bowel
diseases (IBD), type 2 diabetes (T2D), colorectal cancer, and cardiovascular diseases have been linked
with dysbiosis [28–32]. This association presents the gut microbiota as a potentially modifiable factor
in the etiology of these conditions. It is therefore of great importance for public and individual health
to recognize that microbiota composition may be diversified within days or weeks upon introduction
of unrefined plant-based diets [16].
In clinical trials diets are often classified as low carbohydrate vs. high carbohydrate, and low
fiber vs. high fiber. These trials lack discrimination between refined and unrefined carbohydrates.
Acknowledging the degree of refinement would likely strengthen the reproducibility of diet
intervention studies for reasons discussed in the present review [33–35].
This paper analyzes the interplay between structures of plant-based foods or “fiber-encapsulated
nutrients”, the gut microbiota, and their joint impact on host nutrient bioavailability, immune function,
and metabolic function, and proposes a simple tool to select plant-based foods from a nutritional-
and microbiota-promoting perspective. The review provides a biological explanation of the health
superiority of structurally maintained and unrefined foods compared to nutrient-matched refined
foods, combining classic and current scientific knowledge within nutrition, pharmaceutical science,
microbiology, and plant biology. In addition, we add the perspective of “fiber as nutrient encapsulation”
to the well-established molecular benefits of fiber as microbiotic nutrient (prebiotic). This structural
perspective should be included in the current nutritional guidelines, which focus on nutrient and fiber
content rather than nutrient and fiber structure.
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2. Carbohydrates: Different Structures, Different Properties
The structural characteristics of dietary carbohydrates include the chemical composition,
physicochemical properties, and resistance to human digestive enzymes. Dietary polysaccharides
display a variety of linkages, branching, and polymerizations and must be broken down into their
corresponding monosaccharides (e.g., glucose, galactose, and fructose) before they can be absorbed
and metabolized by humans. This carbohydrate breakdown is initiated by α-amylase secreted by
salivary glands, continues with pancreatic amylase in the duodenum, and is completed by intestinal
enzymes (e.g., sucrase and lactase) located in the brush-border membrane of the enterocytes in the
small intestine [22]. Pancreatic amylase hydrolyzes α-linked glucose polymers such as starch and
glycogen, but humans lack the enzymes necessary to hydrolyze β-linked glucose polymers like those
present in resistant starches and dietary fibers found in plant structures [36].
Resistant starches include starch where (i) the granules are inaccessible to enzymes due to
conformation; (ii) the starch is retrograded or (iii) chemically modified. Importantly, starch may also
be digestion-resistant due to encapsulation in plant cell fiber matrices [37] and new perspectives on
this aspect are the main focus of this review.
Dietary fiber includes a large variety of carbohydrate polymers, e.g., xylans, β-glucans, fructans,
β-mannans, celluloses, hemicelluloses, and pectins [38]. Cellulose, hemicellulose, and pectin are
major components of plant cell walls, and starch [39] and inulin [40] are heavily represented in
plant carbohydrate storage. As such, the above-mentioned molecular carbohydrates are regarded as
prebiotics that may stimulate or alter the preferential growth of health-promoting bacterial species
already residing in the colon [41].
The microbiota encodes a broad spectrum of enzymes catalyzing the depolymerization and further
degradation of polysaccharides [22]. The structural properties of the carbohydrates are important
since the ability to utilize different substrates differs between bacterial species, for example, it has
been shown in vitro, that Roseburia spp. can utilize amylopectin starch and that Bifidobacterium spp.
cannot [42].
Plant polysaccharides can be separated based on origin (cereals and grains, fruits, vegetables
nuts, and legumes), and chemical compositions and physicochemical properties vary depending on
origin [14]. The physicochemical properties of plant polysaccharides include fermentability, solubility,
and viscosity, each of which impact site and degree of fermentation. Soluble fibers, such as short-chain
fructo-oligosaccharides and pectin are depolymerized by bacterial enzymes more proximally in the GI
tract, while fibers with a lower solubility, such as cellulose, are partially fermented in the distal colon
where transit time is slower and microbiotic density higher [12].
Simple carbohydrates, such as monosaccharides, disaccharides, and oligosaccharides can be
classified as host nutrition with direct utilization by host enzymes, whereas complex carbohydrate
polymers, such as plant polysaccharides and resistant starches are vital substrates for the microbiota.
Thus, a diet that includes a variety of unrefined plant structures can therefore promote proliferation
of a broader spectrum of bacteria with specific intrinsic properties. A diet rich in plant structure
variety also represents a diverse sustained release device for delivery of various nutrients and bioactive
molecules for metabolic and immunological stimulation, as described below.
3. Plant Cell Structure
The plant cell wall is the major difference between animal and plant cells. Except for the
cell wall, chloroplasts, and vacuoles, animal and plant cells share intracellular structures and
compartmentalization (Figure 1).
135
Nutrients 2018, 10, 1590
Figure 1. Schematic illustration of an animal and a plant cell. The cell wall (mainly complex
carbohydrates), vacuoles (usually starch or lipid storage, depending on cell type), and chloroplasts
are plant-cell specific structures that serve as nutrients for the microbiota, whereas the cellular content
serves as signal molecules for host metabolic and immune regulation as well as nutrients for both
host and microbiota. An intact plant cell is defined as unrefined food whereas the degree of structural
disruption (and the supplementation of additives) defines the degree of refinement.
The most characteristic component found in all plant cell walls is the fiber, cellulose [43], which
consists of a collection of β-1,4-linked glucan chains that interact with each other via hydrogen
bonds to form a crystalline microfibril [44]. In addition to cellulose, the primary plant cell wall
contains two categories of matrix polysaccharides-pectins and hemicelluloses, and several proteins
and glycoproteins, including various enzymes and structural proteins [45].
Intracellular plant compartments and their relative ratio constitute the macro- and micronutrients
in the plant and the dispersion of macronutrients varies from plant to plant, changing during aging
with a larger proportion of protein and lipids during early growth [46]. In addition to macronutrients
and vitamins, the encapsulated plant cells also contain phytonutrients, such as polyphenols (flavonoids
and stilbenes), carotenoids, plant sterols, and poly-unsaturated fatty acids (PUFA), many of which
are used as nutraceutical ingredients and exhibit beneficial effects on metabolic and cardiovascular
parameters [47].
Although monomers from the cell wall degradation process are absorbed via host transporters,
most of the plant-cell wall functions as microbiota substrate [12]. Furthermore, the mixture of
macronutrients, vitamins, and phytonutrients encapsulated within the plant cell membrane have
a two-tier function, with part of their host-health-promoting effects also benefiting the microbiota.
In other words, the microbiota and the host share both host-enzyme-resistant carbohydrates and
fiber-encapsulated macro- and micronutrients.
4. Microbiota Composition
In human adults, five bacterial phyla have been reported to be dominant in the gut microbiota
of healthy individuals: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia [48],
with more than 90% of the species belonging to Firmicutes and Bacteroidetes. Representatives of the
other phyla comprise from 2 to 10% with great interpersonal variation [49]. Changes in the relative
abundance of the two dominant bacterial divisions, Bacteroidetes and Firmicutes, have been associated
with an increased BMI [50]. An overrepresentation of butyrate-producing species, such as Roseburia spp.
and Eubacterium spp. within the Firmicutes phylum affects the metabolic potential of the microbiota,
i.e., the microbiotic capacity to harvest energy from the diet and produce SCFA available for host
consumption [51].
In humans, an abundance and diversity in polysaccharide-fermenting bacteria, such as species
within the Bacteroidetes phylum, are inversely related to obesity and other metabolic disorders
with an inflammatory component [52–55]. Members of Bacteroidetes express very large numbers of
genes that encode microbiotic enzymes and readily can switch between different energy sources
in the gut depending on substrate availability. Within the Bacteroidetes phyla, two genera are
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particularly dominant and mutual antagonistic; Bacteroides and Prevotella [56]. The relative ratio
between these two genera varies, with the Bacteroides-driven type reported as dominant in individuals
with a higher intake of protein and animal fat, and Prevotella more common in individuals who consume
more carbohydrate-rich diets [57,58] These findings represent distinct community composition
types—so-called enterotypes—based on genus composition [59], suggesting that such compositional
differences both reflect dietary intake and determine an individual’s response to different diets [55].
Long-term dietary habits have considerable effect on the gut microbiota as evidence by differences
in microbiotic compositions across geographical and/or cultural-dependent diets [28,57,60]. Microbiota
composition also respond to short-term macronutrient changes; moreover, functional traits linking
enterotypes to diet have been identified [57,58]. Animal and human studies show that an acute dietary
switch results in dramatic shifts in the gut microbiota within the course of 24 h [16]. An animal-based
diet increases the abundance of bile-tolerant genera (Alistipes, Bilophila, and Bacteroides) and decreases
the level of Firmicutes species capable of fermenting dietary plant polysaccharides. Microbiotic activity
mirrors differences between herbivorous and carnivorous mammals, reflecting trade-offs between
carbohydrate and protein fermentation [61]. Analyses of the relative abundance of taxonomic groups
have shown that short-term animal-based diets have a greater impact on microbiotic community
structure compared to plant-based diets [16], suggesting perhaps a default microbiotic setting favoring
plant-based diets.
As mentioned above, bacterial species have varying abilities to degrade fibers from different
sources. The ability to degrade a wider variety of complex carbohydrates therefore forms a more
diverse bacterial community. Moreover, the biodiversity, function, and abundance of a microbiotic
community also depend on cross-feeding among members, which is the process where essential
metabolites synthesized by a subset of the community provide substrate for growth of another/other
bacterial species [62]. These microbiotic interactions create a complex pattern of interconnected
metabolisms and link members of different genera/phyla together in communities.
Biodiversity therefore contributes to the stability and resilience of the bacterial communities.
A high level of resilience ensures renewal and reorganization of the community if a species is
lost, whereas communities with low biodiversity are more susceptible to loss of individual species.
Highly diverse ecosystems most likely contain species with redundant functions, making the loss of
a single species tolerable, because other functionally redundant species can take over [63]. Evidently,
the microbiotic composition and community organization are reflective of dietary habits and affect
host metabolic and immune processes. The distinction between enterotypes with distinct fermentation
kinetics should therefore be considered an environmental factor that contributes to both health
and disease.
5. Biological Journey and Destiny of Complex and Simple Carbohydrates
Monosaccharides can be absorbed via transporters in the human GI tract whereas polysaccharides
that are not encapsulated by a fibrous plant cell wall, undergo digestion in the upper GI tract devoid
of the microbiota. The more complex the carbohydrate the more glycosidase activity is necessary for
the depolymerization. Thus, the more complex the plant cell wall (nutrient delivery device), the more
microbiota interaction is needed. As a result, more caloric harvesting takes place and a larger intestinal
area is subject to nutrient absorption, enteroendocrine stimulation, and immunological maturation.
The human gut has the potential to absorb monosaccharides via several transporters located
in the absorptive epithelium. Apical sodium-dependent glucose cotransporter 1 (SGLT1) [64],
glucose transporter 2 (GLUT2) [65], and glucose transporter 5 (GLUT5) [66] facilitate absorption
of glucose and fructose from the intestine, and basolateral GLUT2 and GLUT5 facilitate the basolateral
monosaccharide secretion into the host interstitium. Upon ingestion of a sugar-enriched meal,
a transient upregulation of the absorptive monosaccharide transporters is induced, perhaps via
apical recruitment of GLUT2 [67–69]. Thus, sugar ingestion promotes host absorption and bypasses
caloric harvesting by microbiota.
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Throughout the GI tract the level of glucose transporters is highly regulated by hexose availability
and insulin levels [70–73]. In addition, the expression of glucose transporters has been shown to be
increased in e.g., obesity and diabetes [74,75] and as a result, certain individuals experience a larger
bioavailability of monosaccharides.
Despite individual differences in host digestive enzyme- and nutrient transporter expression,
a general notion must be highlighted: The density and diversity of the microbiota increases with the
distance from the stomach. The more complex the carbohydrate, the longer the journey until complete
fermentation, and therefore the more likely that carbohydrates are utilized by the microbiota and not
by the host.
6. The Plant Cell Wall Viewed as a “Pharmaceutical-Nutrient Formulation”
When applying the drug delivery perspective to unrefined plant-based foods, it is evident that
the polysaccharides of plant-cell walls [76,77] are more than just molecular nutrition for the host and
microbiota [78]. Unrefined plant-based food structures can be interpreted as a slow release device for
nutrients and bioactive molecules in the human GI tract, which has important implications for intestinal
absorption and local biological actions. The “device” releases a complex pool of molecules with
nutritional value for the host and the microbiota, and with biological effects that trigger the endocrine
and immunological maturation of the host. The release of nutrients from the fiber-encapsulated plant
cell is thus dependent on microbiota-specific plant cell wall fermentation.
In pharmaceutical drug discovery and development processes, both pharmacokinetic and
pharmacodynamic properties are carefully optimized. Whereas the optimized drug molecule
determines the specific pharmacological action, the site of action and the duration of action are
heavily influenced by the pharmaceutical formulation of the drug molecule. For example, a specific
formulation can be used to target sustained or fast absorption from the GI tract. In other words,
the drug molecule needs a relevant formulation to reach the relevant site of absorption and to obtain
the desired absorption kinetic [79].
Different saccharides (sugars, starches, and fibers) are used as coating material in oral drug
formulations to direct drugs through the GI infrastructure and deliver the drug molecule at the desired
site of action or absorption [80]. Salicylic acid is, for example, formulated for fast or sustained systemic
absorption using different formulation principles. Different cellulose coatings have been used to
deliver the drug to distal parts of the gut for local IBD therapy [81,82]. Basically, the microbiota
ferments the coating material and releases the drug distally for sustained release (or local treatment).
The diversity in fibrous plant cell structures therefore serves as both a saccharide delivery system for
bacterial species and as a fiber-encapsulated delivery device of other molecular nutrients (e.g., amino
acids, fatty acids, vitamins, and other bioactive molecules). These nutrients are released from the
plant cell upon plant-cell-wall fermentation, playing a major role for both host and microbiota biology
(Figure 2). Indeed, most bacteria, even Lactobacillus and Bifidobacterium, express lipid and amino acid
transporters [83–86] and regulate the expression dependent on the specific environment.
The biological properties of the microbiota are not solely dependent on the carbohydrate-based
prebiotic content, but indeed also on the content of lipids, proteins, amino acids, and vitamins [87].
In vitro studies of bacteria emphasize the perspective that plant-based nutrients beyond fibers are
important for microbiotic function. For example, the growth and adhesion properties of specific
microbial strains are different in two different media (soy bean media and MRS media) [88] and the
growth of Lactobacillus and Bifidobacterium depends on the media protein content [89,90]. Therefore,
a diversity of media is needed to actually culture a diversity of human gut microbiota and study their
selective and community properties [91]. Peptides and lipids that are not fiber-encapsulated would
most likely only reach the microbiota in limited amounts due to upper-intestinal host absorption. Thus,
a major source of amino acids and lipids for the microbiota is formulated in plant cells.
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Figure 2. Illustration of interactions between plant cells, microbiota, and the host epithelium. Plant cells
are encapsulated by the fibrous cell wall, which is a microbiota-selective nutrient. The cell wall also
serves as a transport vehicle for the additional plant cell contents as well as a vehicle for nutrients to be
shared between the microbiota and the host upon release from its plant cell structure. The microbiota
secretes glycosidases, peptidases, and lipases, thereby releasing molecular nutrients for transport into
epithelial or bacterial cells.
If plant cells have been refined, this organization does not remain intact, and even if the fibers
reach the microbiota (e.g., fiber supplements), only limited amounts of amino acids and lipids will
reach the microbes.
Some bacterial genera e.g., Bacteroides [92] and Lactobacillus [93] secrete both peptidases and
glycosidases and the more distal fiber-fermenting species Bacteroides thetaiotaomicron also express
dipeptidylpeptidases (DPPs) [94,95]. Interestingly, the DPP4 antagonist vildagliptin, used for the
treatment of T2D, induces a higher relative abundance of Bacteroidetes, a lower abundance of Firmicutes,
and thus a reduced ratio of Firmicutes/Bacteroidetes in rats [96]. This is one among many examples of
anti-diabetic drugs that has recently been shown to induce secondary health promoting actions via the
microbiota [97].
Another pharmaceutical exploration of the microbiota is the study of bacterial peptide transporters
with the aim to identify new antibiotic targets in virulent bacteria. Since blockage of peptide
transporters is a potent antibiotic pathway, specific bacteria are dependent on their endogenous
peptide transporters and on amino acid fuel [98]. In both gram negative and gram positive virulent
bacteria, two distinct vital types of peptide transporters exist, proton-dependent peptide transporters
(PRT or POT) [99] and ATP-binding cassettes (ABC transporters) [100].
As in the case of amino acids, energy dependent fatty acid transporters are also present in both
outer and inner membranes of bacterial strains. Even Lactobacillus expresses amino acid and fatty
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acid transporters [83], which supports the bacterial ability and need to consume fatty acids slowly
released from plant cells during the microbiotic digestion of the plant cell wall. In specific bacteria,
the process requires the outer membrane-bound fatty acid transport protein FadL and the inner
membrane associated fatty acyl CoA synthetase (FACS) [101,102].
The diversity in fiber-coated plant cell structures also serves as delivery system for local acting
biologically active substances, e.g., taste receptor agonist for distal enterocytes and the microbiota [103],
and maturation agents for the immune system [104] which will be discussed below.
7. Pro-Inflammatory Effects of Refined Foods
The consumption of unrefined plant-based foods maintains host health by engaging the
microbiota. The immunomodulatory effects of unrefined plant-based foods act through the
host-microbiota symbiosis and circumvent the pro-inflammatory effects of refined foods. Mono-
and disaccharides in a fibrous sustained release formulation do not produce significant increase
in blood glucose because they are partially consumed by the microbiota. The microbiota unwraps
molecules from the fibrous formulation in a time-consuming process. In contrast, industrial refinement
causes a lack of molecular engagement with the microbiota and distal enterocytes, and polysaccharide
molecules are rapidly monomerized and absorbed with the risk of elevated blood glucose levels [26].
Mounting epidemiological evidence suggests that intake of refined sugars and starch is associated
with the development and maintenance of several diseases. T2D, for example, is driven by insulin
resistance and β-cell dysfunction and manifested by increased risk and severity of hyperglycemic
events. The condition is associated with elevated risk of autoimmune and inflammatory diseases,
including rheumatoid arthritis [105] asthma [106], psoriasis [107], and cancer [108,109]. Drugs or
dietary regiments that normalize hyperglycemia do not surprisingly have a therapeutic effect on
immune diseases, e.g., psoriasis [110–112] and rheumatoid arthritis [113].
For diabetics as well as healthy individuals there is a relationship between the ingestion
of refined sugars and the risk of developing both obesity [114] and autoimmune/inflammatory
diseases, e.g., rheumatoid arthritis [115], asthma [116,117], IBD [118], chronic kidney disease [119],
and atherosclerosis [114,120].
Hyperglycemia influences inflammation and immune function through multiple mechanisms.
Chemical reactivity of glucose and other reducing sugars (fructose, mannose, galactose) towards
proteins [121], lipids, and nucleic acids [122] is important. Non-specific stochastic protein glycations
during incidents of hyperglycemia have the potential to initiate and potentiate several inflammatory
and immunomodulatory responses, involving activation of pattern recognition receptors (PRR), e.g.,
RAGE (receptors for advanced glycation end-products) [123,124]. Also, hyperglycemia-induced
cytokine release [125], formation of methylglyoxal and other auto-oxidation metabolites, e.g., reactive
oxygen species (ROS) and free radicals [126] maintains inflammatory responses. The activity of
auto-oxidation metabolites is prevented, for example, by antioxidants, which reduce the oxidative
damage induced by glucose metabolites and ROS [127]. The fact that antioxidants are prevalent in
plant-based food and synthesized by the microbiota [128] adds to the anti-inflammatory effects of
unrefined foods.
8. Anti-Inflammatory Effects of Unrefined Foods
The anti-inflammatory effects of unrefined foods are particularly mediated by their contribution
to a high gut biodiversity, which as mentioned above, contributes to the stability and resilience of
the bacterial communities. In contrast, the loss of diversity can cause an imbalance between the
inflammatory and the immunoregulatory taxa present in a given microbiota. The effects of a complex
microbiotic community are ascribed to the additive and synergistic effects of the bacterial species in
a microbiotic community. An example of this is monocolonization of a variety of organisms, which
cannot reverse the hyper-IgE phenotype in germ-free (GF) mice. However, complex polycolonizations
restore normal IgE levels [129].
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Imbalances in immunological homeostasis can occur due to the loss of habitat-specific species and
symbionts, resulting in an invasion of opportunistic species not normally able to colonize that specific
habitat within the intestinal mucosa. Such a mismatch between species and habitat triggers a potentially
pathogenic host response [130]. The detection of pathogens by the host is achieved through the families
of PRR localized in the intestinal epithelium. PRR recognize conserved molecular structures known as
microbe-associated molecular patterns and induce production of innate effector molecules [131,132].
The most well-known PRR are the toll-like receptors (TLR), RAGE, and the NOD-like receptors
expressed on the intestinal epithelial cells. Activation of TLR by bacterial products promotes epithelial
cell proliferation, secretion of IgA into the gut lumen, and expression of antimicrobial peptides,
thereby establishing a microorganism-induced system of epithelial cell homeostasis and repair in the
intestine [132].
Bacterial translocation, e.g., infiltration of lipopolysaccharide (LPS) through the intestinal barrier,
can promote local and systemic immune responses via PRR. Monocolonization of GF mice by
Escherichia coli is, for example, sufficient to induce macrophage infiltration, and polarization towards
pro-inflammatory phenotype of immune cells in the adipose tissue [133], contributing to a state of
low-grade inflammation in the adipose tissue. Disruption of intestinal barrier integrity by viable
bacteria has been attributed to various intestinal inflammatory diseases such as IBD, celiac disease,
irritable bowel syndrome, and colorectal cancer [32] as well as to diseases in extra-intestinal organs,
such as the liver [134].
The major microbiota-derived SCFA, butyrate, acetate, and propionate are implicated in multiple
anti-inflammatory mechanisms [135]. Besides being used by colonocytes as a source of ATP, SCFA can
act as extracellular signaling molecules that activate cell-surface free fatty acids receptors (FFAR)
(G-protein-coupled receptors (GPCR)) or inhibit histone deacetylases (HDAC) [136]. FFAR are
differentially expressed on adipocytes, immune cells, and enteroendocrine L-cells. Depending on the
location of the receptor and the amount and type of SCFA, the response can have multiple, variable
downstream effects [3]. FFAR, expressed on immune cells, such as macrophages, dendritic cells,
and neutrophils will upon activation by butyrate inhibit the release of pro-inflammatory cytokines, or
stimulate differentiation of T regulatory (Treg) cells [136].
Activation of FFAR2/GPR43 by butyrate on enteroendocrine L-cells of the ileum and colon induces
production and secretion of intestinal peptide YY (PYY), glucagon-like peptide 1 (GLP-1) [25,137].
An abundant production of SCFA can therefore indirectly regulate blood glucose levels via
the insulinotropic effect of GLP-1 and induce satiety by the anorexigenic effect of PYY on the
hypothalamus [138]. In addition, enteroendocrine cells in the duodenum are dependent on
microbe-mediated mechanisms to express cholecystokinin (CKK), a gut peptide hormone responsible
for stimulating fat absorption. GF mice have exhibited a reduced number of these cells with impact on
their fat absorption [139].
SCFA can also act by inhibition of histone deacetylase (HDAC) activity. HDAC is related to
a suppression of malignant transformation and a stimulation of apoptosis of precancerous colonic
cells [140] as well as to the stimulation of epithelial production of retinoic acid (RA) [141]. RA is
involved in many physiological processes, including regulation of IgA [142] and the polarization of
specialized mucosal myeloid cells [143].
Specific phytonutrients entail several immunomodulatory functions. Some are mediated by a shift
in microbiotic composition favoring the abundance of specific bacteria with health promoting effects
or create occupancy resistance to enteric pathogens with pro-inflammatory potential [144]. Others are
receptor-mediated, e.g., genistein, a flavonoid compound present in legumes, which can positively
effect β-cell mass and mitigate T2D in mice [145,146].
In summary, the biodiversity of the microbiotic community is critical for both inter-microbiotic
interactions and host-microbe engagements. In a healthy and proper fed microbiota the inflammatory
and immunoregulatory species are in balance and the diverse bacterial communities act together to
produce metabolites with direct effect on host health.
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9. The Interaction between Food, Microbiota, and Host
In the sections above, we have discussed how ingestion of unrefined plant-based food structures
implies that the host shares calories, saccharides, amino acids, fatty acids, and bioactive molecules
with the microbiota, which in return shares SCFA, vitamins, antioxidants, and other biomolecules
with the host. The microbiota also stimulates mucosal immune function upon ingesting an unrefined
diet; a diverse microbiota will express a multitude of different antigens, thereby promoting intestinal
bacterial recognition and shaping intestinal immune function.
In contrast, refined foods lack the fiber-encapsulation with the result that the host absorbs most
nutrients in a microbiota-independent manner. Refined food is thus directly absorbed through the host
GI mucosa without feeding the microbiota and without immunological engagement in the distal gut
(Figure 3). Furthermore, when bypassing the microbiota, glucose is rapidly absorbed creating a risk of
high blood glucose and associated pro-inflammatory effects.
Figure 3. Schematic overview of interactions between food, microbiota, and host. Most of a refined diet
bypasses the microbiota, providing a high nutrient bioavailability for the host. In contrast, unrefined,
plant-based food structures provide a lower nutrient bioavailability for the host, using the difference
to develop and maintain a healthy microbiota. The healthy microbiota provides short chain fatty
acids (SCFA), antioxidants, and vitamins for the host along with direct immunomodulatory effects.
The high monosaccharide bioavailability in refined foods introduces a risk of hyperglycemia, which
cause numerous direct and indirect pro-inflammatory actions [26] (not shown in figure).
10. Implications for Nutritional Guidelines
The mechanisms summarized above underscore the need to consider the microbiota when
evaluating human development, nutritional needs, physiological variations, and the impact of diet.
Historically, the processing of foods occurred to increase the caloric bioavailability but given the
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growing prevalence of non-communicable diseases, insulin resistance, overweight, and obesity [147],
it is obvious that current nutritional guidelines need to be revisited to re-establish the endogenous
microbiota-induced health promotion. The current nutritional guidelines are mainly based on optimal
molecular nutrient content for host metabolism, while establishment of synergies between food, host,
and microbiotic community are absent.
Nutritional guidelines need to consider both the content and the structure of carbohydrates,
because the microbiotic breakdown of carbohydrates strengthens our microbiotic ally in support of
host health. Furthermore, it should also reflect that consumption of “fiber-formulated nutrients”
is essential to maintain a healthy diverse microbiota to balance our nutritional, immunological,
and metabolic health.
We have developed a simple tool to visualize healthy microbiota-engaging food choices (Figure 4).
This tool divides foods into four categories depending on their carbohydrate content and the degree of
refinement. Healthy, unrefined foods with low relative carbohydrate content (green box) should make
up the plant-based bulk of an adult basic diet. These foods interact with the microbiota. Refined foods
or foods with high relative carbohydrate content (yellow boxes) should be considered carbohydrate or
energy supplementation, while the “comfort” foods in the red box, which are both refined and high in
carbohydrate content, should be used sparingly considering their potentially negative health impact
and their lack of microbiotic health promotion.
Figure 4. Novel classification of plant-based foods. Plant-based nutrition classified by microbiotic
interaction potential and by the potential to induce hyperglycemia. The illustration classifies
plant-based foods by the level of refinement and carbohydrate content. The green box represents
basic foods for the habitual diet, interacting with our gut microbiota and providing both nutrients and
bioactive molecules to microbiota and host. Foods from the green box are health promoting through
interaction with the microbiota, and these foods introduce no risk of hyperglycemia. Foods from the
green box should be combined to meet the needs for protein and lipid. Food from the yellow boxes
can induce hyperglycemia in insulin resistant individuals or be consumed as energy supplementation
for children and physically active individuals with a higher energy demand and a low risk of insulin
resistance. The yellow square to the left positively interacts with the microbiota whereas the yellow
square to the right only have limited microbiota interaction. The red box contains foods, which are
high in carbohydrate content and highly refined, introducing the risk of high blood glucose to most
people, not only insulin resistant individuals. The contents in the red box should be considered comfort
foods with no health promoting effects and with a potential to compromise health.
143
Nutrients 2018, 10, 1590
11. Conclusions
The increasing prevalence of non-communicable diseases with an inflammatory component has
led to the understanding of the gut microbiota as an intrinsic regulator of host immune responses.
There is a growing awareness of the role of microbiotic communities, microbiota-derived products,
and more particularly of the link between these components and disease states in humans. The ability
to target immune pathways relies on the understanding of both acute and long-term impacts on the
gut microbiota. The microbiotic communities can adapt to host diet in multiple ways by the interaction
among different bacterial species, loss or proliferation of specific species, and by interaction with the
host. Diet therefore presents itself as a microbiota-modulating factor and hence a health-modulating
factor. A revision of the current nutritional guidelines considering both the molecular content and
molecular structure of nutrients for insulin resistant and insulin sensitive individuals, could be valuable
for the restoration of beneficial bacteria and microbiota diversity, enabling a shift from disease to health
promoting states in the individual as well as in the general population.
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Abstract: Glutamine is the most abundant and versatile amino acid in the body. In health and
disease, the rate of glutamine consumption by immune cells is similar or greater than glucose.
For instance, in vitro and in vivo studies have determined that glutamine is an essential nutrient
for lymphocyte proliferation and cytokine production, macrophage phagocytic plus secretory
activities, and neutrophil bacterial killing. Glutamine release to the circulation and availability
is mainly controlled by key metabolic organs, such as the gut, liver, and skeletal muscles. During
catabolic/hypercatabolic situations glutamine can become essential for metabolic function, but its
availability may be compromised due to the impairment of homeostasis in the inter-tissue metabolism
of amino acids. For this reason, glutamine is currently part of clinical nutrition supplementation
protocols and/or recommended for immune suppressed individuals. However, in a wide range of
catabolic/hypercatabolic situations (e.g., ill/critically ill, post-trauma, sepsis, exhausted athletes),
it is currently difficult to determine whether glutamine supplementation (oral/enteral or parenteral)
should be recommended based on the amino acid plasma/bloodstream concentration (also known
as glutaminemia). Although the beneficial immune-based effects of glutamine supplementation are
already established, many questions and evidence for positive in vivo outcomes still remain to be
presented. Therefore, this paper provides an integrated review of how glutamine metabolism in key
organs is important to cells of the immune system. We also discuss glutamine metabolism and action,
and important issues related to the effects of glutamine supplementation in catabolic situations.
Keywords: nutrition; amino acids; leukocytes; skeletal muscle; gut; liver
1. Introduction
At the most basic level, amino acids are the building blocks of proteins in our cells and tissues,
and after water are the second most abundant compound in mammals. Amino acids can be obtained
from endogenous and/or exogenous (i.e., diet) proteins, and their availability is of fundamental
importance for cell survival, maintenance, and proliferation. Mammals, in particular, have developed
biochemical and metabolic pathways to control pathogen infection by increasing amino acid catabolism
to aid immune responses, thus restricting the availability of nitrogen-containing nutrients to invading
microorganisms [1]. This evolutionary mechanism also becomes advantageous for the host to control
its own inflammatory responses to infections.
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Among the 20 amino acids detailed in the genetic code, glutamine provides the best example
of the versatility of amino acid metabolism and immune function. Glutamine is the most abundant
and versatile amino acid in the body, and is of fundamental importance to intermediary metabolism,
interorgan nitrogen exchange via ammonia (NH3) transport between tissues, and pH homeostasis.
In almost every cell, glutamine can be used as a substrate for nucleotide synthesis (purines, pyrimidines,
and amino sugars), nicotinamide adenine dinucleotide phosphate (NADPH), antioxidants, and many
other biosynthetic pathways involved in the maintenance of cellular integrity and function [2–4].
Most cells in the body function with a constant turnover and/or supply of nutrients, however, cells
of the immune system frequently have to function under nutrient restricted microenvironments [1].
Although glucose is a vital metabolite, and the main fuel for a large number of cells in the body,
cells of the immune system, such as lymphocytes, neutrophils, and macrophages, utilize glutamine
at high rates similar to or greater than glucose under catabolic conditions, such as sepsis, recovery
from burns or surgery, and malnutrition, as well as high intensity/volume physical exercise [5,6].
This theory was first experimentally confirmed in the 1980’s by the laboratory of Eric Newsholme
(1935–2011, widely accepted now as the origin of hypotheses and evidence for the concept of
“immunometabolism”) [3,7] in the University of Oxford, and subsequently by many other laboratories
worldwide [4,8,9]. For this reason, glutamine is considered as a “fuel for the immune system”, where a
low blood concentration may impair immune cell function, resulting in poor clinical outcomes and
increased risk of mortality [10].
Currently, glutamine is routinely supplied as a component of clinical nutrition supplementation
for pre-and post-operative patients, and also for many elite athletes to restore immune functions.
Although there is a growing evidence in support of the immune mediating effects of glutamine
supplementation, several questions and specific considerations still remain. Therefore, the aim of the
present study is to provide an integrated review on how glutamine metabolism in key organs, such as
the gut, liver, and skeletal muscles, is important to cells of the immune system. These key organs
control glutamine availability and shed light on important considerations in regards to glutaminemia
(glutamine concentration into the bloodstream). The immune-enhancing properties and related
paradigms of glutamine supplementation in health and disease are also discussed herein.
2. A Brief Overview of Glutamine Metabolism
Glutamine is an L-α-amino acid containing five carbons; its molecular weight is 146.15 kDa and its
elemental composition comprises carbon (41.09%), hydrogen (6.90%), oxygen (32.84%), and nitrogen
(19.17%). With respect to its physiological pH, glutamine is classified as a neutral amino acid, whereas it
is nutritionally classified as a non-essential amino acid. Glutamine has two amino groups, namely the
α-amino group and the easily-hydrolysable side-chain amide group, and these features enable the
role played by glutamine as a nitrogen transporter and NH3 carrier. Glutamine is also a proteinogenic
amino acid, i.e., amino acids that are incorporated into proteins, and accounts for 5 to 6% of bound
amino acids [9].
Healthy individuals weighing about 70 kg have approximately 70 to 80 g of glutamine distributed
in the whole body [11]. Using isotopic and pharmacokinetic techniques, it has been estimated that
glutamine endogenous production is between 40 to 80 g/day [12,13]. In plasma obtained from blood
samples, glutamine concentration varies between ~500 to 800 μM/L (values recorded after 12-h in
a fasting state), which represents about 20% of the total free amino acids pool in the blood [9]. In
tissues, such as the liver and the skeletal muscles, glutamine concentration is even higher than in
plasma, representing about 40% to 60% of the total amino acid pool [14,15]. In both, plasma and
tissues, glutamine concentration is 10- to 100-fold in excess of any other amino acid, and for this reason,
glutamine is considered the body’s most abundant amino acid.
In the whole body, glutamine concentration and availability depends on the balance between its
synthesis and/or release, and uptake by human organs and tissues. The lungs, liver, brain, skeletal
muscles, and adipose tissue have organ tissue-specific glutamine synthesis activity. On the other hand,
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primarily glutamine-consuming tissues, such as the intestinal mucosa, leukocytes, and renal tubule
cells, have high glutaminase activity and cofactors capable of degrading glutamine. However, the liver
may become a glutamine-consuming site, and tissues, such as muscle tissue, may present reduced
glutamine synthesis under certain conditions, such as reduced carbohydrate [16] and/or amino
acid [17] intake, high catabolic situations, and/or diseases and stress [5]. Many other factors—mainly
glucocorticoids [18], thyroid hormones [19], growth hormone [20], and insulin [21]—can modulate the
activity performed by glutamine metabolism-regulating enzymes.
Several enzymes are involved in glutamine metabolism; the two main intracellular enzymes
are glutamine synthetase (GS, EC 6.3.1.2) and phosphate-dependent glutaminase (GLS, EC 3.5.1.2).
GS is responsible for triggering the reaction that synthesizes glutamine from ammonium ion (NH4+),
and glutamate through ATP consumption, whereas GLS is responsible for glutamine hydrolysis,
which converts it into glutamate and NH4+ again [22,23] (Figure 1). With respect to the intracellular
location, GS is primarily found in the cytosol, whereas GLS (in its active form) is mainly found within
the mitochondria. These locations are compatible with the enzymes’ functions: GS produces glutamine
for the synthesis of cytoplasmic proteins and nucleotides, whereas GLS catalyses glutamine conversion
to glutamate as an important step to the tricarboxylic acid cycle (TCA, also known as the Krebs cycle)
entry at 2-oxoglutarate as an energy source or source of metabolic intermediates [3].
Figure 1. Glutamine synthesis and hydrolysis. Glutamine is mainly synthesized by the enzyme
glutamine synthetase (GS) and hydrolysed by the enzyme, glutaminase (GLS). GS catalyses glutamine
biosynthesis using glutamate and ammonia (NH3) as a source. In this reaction, one ATP is consumed.
Glutamate can be donated by many amino acids obtained exogenously (i.e., diet) and/or from
endogenous amino acids’ catabolism. On the other hand, GLS is responsible for glutamine hydrolysis
to glutamate and ammonium ion (NH4). Almost all cells in the body express GS and GLS, and their
predominant expression and activity will dictate if the tissue is more likely to produce or consume
glutamine in health and disease.
Glutamine synthesis by the GS depends on glutamate availability. Glutamate, in turn,
is synthesized from 2-oxoglutarate NH4, through the action of the glutamate dehydrogenase, or even
from the catabolism of other amino acids, such as branched-chain amino acids (BCAAs), mainly
leucine [17,24]. Studies conducted with rats reported that BCAAs, such as leucine, can be almost
exclusively transaminated with α-ketoglutarate to form glutamate, which in turn can incorporate free
NH3 and under the action of GS form glutamine [6,24] (Figure 2).
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Figure 2. Intertissue glutamine production and utilisation in health and catabolic/hypercatabolic
situations. Filled arrows indicate tissues that exhibit GS activity and thus produce glutamine;
white arrows indicate tissues that exhibit GLS activity, and thus consume glutamine. In health and/or
fed states, glutamine stores are in equilibrium in plasma/bloodstream and tissues, and are maintained
constantly mainly by the liver and skeletal muscles, two major stores of glutamine in the body. On the
other hand, cells of the immune system are extremely dependent on glucose and glutamine in situation
(A), and even more in situation (B). Although the gut is a major site of glutamine consumption,
in situation (B), there is a dramatic increase in glutamine consumption from both the luminal and
basolateral membrane, when compared to situation (A). In addition, the liver switches the role of a
major producer to a major glutamine consumer to maintain gluconeogenesis, and the whole body
relies on the skeletal muscle’s ability/stores to maintain glutamine levels. However, this process is
usually accompanied by a dramatic increase in muscle proteolysis, atrophy, and cachexia. The lungs
and adipose tissue exhibit both GS and GLS enzymes, and hence can produce and consume glutamine
in situations (A) and (B). The brain and the kidneys do not exhibit GS, only GLS, and hence are mainly
dependent on plasma glutamine availability in situations (A) and (B).
Glutamine tissue and blood concentrations are dependent on GS or GLS activities. Endogenous
glutamine synthesis does not meet the human body’s demands in catabolic conditions, such as in
cancer [25], sepsis [4,26], infections [27,28], surgeries [8], traumas [10], as well as during intense and
prolonged physical exercise [29,30]. Glutamine assumes the role of a conditionally essential amino acid
in such deficiency conditions by promoting a concomitant increase in GLS expression and inhibiting
the GS action [14]. However, it is worth emphasizing that, although plasma glutamine concentration
is reduced from its normal concentration (i.e., 500–800 μmol/L) to 300–400 μmol/L, cells depending
on this amino acid, such as immune cells, are in fact poorly influenced in terms of proliferation
and function [6]. On the other hand, the high tissue catabolism leads to reduced glutamine stock
in human tissues, mainly in the muscle and liver (Figure 3). The low glutamine concentration in
human tissues affects the whole body since this amino acid provides nitrogen atoms to the synthesis
of purines, pyrimidines, and amino sugars [31]. If the high glutamine degradation in these tissues
persists, a large number of metabolic pathways and mechanisms that depend on glutamine availability
are affected, resulting in immunosuppression. More recently, studies reported that bacterial infections
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(e.g., Escherichia coli) can alter its metabolism and harness glutamine to suppress the effects of acid
stress and copper toxicity [32]. Hence, bacterial pathogens can adapt and survive by altering core
metabolic pathways important for host-imposed antibacterial strategies.
Figure 3. Glutamine inter-tissue metabolic flux starting in skeletal muscle, liver, and gut continues
in the immune cells. Abbreviations: Glutamine, GLN; glutamate, GLU; aspartate, ASP; arginine,
ARG; leucine, LEU; alanine, ALA; glucose, Gluc; pyruvate, Pyr; pyruvate dehydrogenase; PDC;
pyruvate carboxylase, PC; malate dehydrogenase, MD; glyceraldehyde-3-Phosphate, G3-P; lactate, Lac;
triacylglycerol, TG; ribose 5-phosphate, R5P; alanine aminotransferase, ALT; glutamate dehydrogenase,
GDH; glutamine synthetase, GS; glutaminase, GLS; inducible nitric oxide synthase, iNOS; intracellular
heat shock protein, iHSP; heat Shock Factor 1, HSF-1; heat shock elements, HSEs; sirtuin 1, SIRT1;
hexosamine biosynthetic pathway, HBP; ammonia, NH3; glutathione, GSH; oxidized GSH, GSSG;
glutathione S-reductase, GSR; protein kinase B, Akt; AMP-activated protein kinase, AMPK; mTOR
complex 1 and 2, mTORC1/2, extracellular signal-regulated kinases, ERK; c-Jun N-terminal kinases,
JNK; gamma-Aminobutyric acid, GABA.
3. Key Metabolic Organs in Glutamine Homeostasis
3.1. The Gut
Both the small and large intestines are capable of metabolizing large amounts of glutamine
supplied by both the diet and/or the bloodstream [33,34]. Glutamine for the gut is quantitatively more
relevant than glucose as an energy substrate. For example, in the enterocytes, the glutamine carbon can
be metabolized by two main pathways, namely: (i) By forming delta1-pyrroline-5-carboxylate; (ii) or by
conversion to alpha-ketoglutarate as an intermediary in the Krebs cycle. The first pathway enables the
formation of proline, ornithine, and citrulline from glutamine carbon by using approximately 10% of
the amino acid concentration found in the intestine. Another 10–15% of glutamine is incorporated into
the tissue protein; the highest proportion of it (approximately 75%) is metabolized in the Krebs cycle
for energy production purposes [14,35].
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The glutamine hydrolysis into glutamate, which is catalysed by GLS, corresponds to the first
reaction resulting from glutamine consumption [36]. Although the gut is the major site of glutamine
consumption, glutamine concentration in the intestinal tissue is low. This is due to the high GLS
activity (3–6 μmol/hour/mg of protein), and also high GLS affinity for the substrate, glutamine.
Interestingly, there is a correlation between the presence of GSL and the use of glutamine by certain
cell types. Almost all GLS found in the intestinal cells is bound to the mitochondrial membrane.
The modulation of GLS activity in the intestinal tissue is important to maintain the tissue integrity
and enable adequate absorption of nutrients, as well as to prevent bacterial translocation into the
bloodstream (i.e., septicaemia) [37]. Prolonged fasting and malnutrition states are associated with
reduced GLS activity; on the other hand, GLS activity increases in the postprandial period, after the
administration of enteral feeding of branched-chain amino acids and/or L-alanyl-L-glutamine [38].
The ATP-ubiquitin-dependent proteolytic pathway associated with proteasome is known to
degrade endogenous short-lived or abnormal proteins/peptides, as well as participating in the
regulation of the inflammatory response. The ATP-ubiquitin-dependent proteolytic pathway could be
important for the turnover of gut mucosal proteins, which are very short lived. Indeed, the nuclear
factor of kappa light polypeptide gene enhancer in B-cells inhibitor (IκB) ubiquitinylation allows the
nuclear factor kappa-light-chain-enhancer of activated B cells’ (NF-κB) translocation in the nucleus,
and thus transcription of proinflammatory genes [17,39,40] (Figure 3). Glutamine stimulates protein
synthesis and reduces ubiquitin-dependent proteolysis in the enterocyte since this amino acid reduces
ubiquitin gene expression. Glutamine can increase the gene expression of the arginine-succinate
synthase enzyme in Caco-2 cells (human colon epithelial-line cell). Glutamine activates the extracellular
signal-regulated kinases (ERKs) and the c-Jun N-terminal kinases (JNK) in the enterocyte, and it leads
to significant increase in c-Jun gene expression and in the activity of the transcription factor known
as activator protein 1 (AP-1) [41,42]. Such glutamine action potentiates the effects of growth factors
on cell proliferation and repair. Heat shock (43 ◦C) induces intestinal epithelial cell death, which can
be exacerbated due to the lack of glutamine. However, as it happens with muscle tissues, glutamine
supplementation enables a dose-dependent reduction in heat shock-associated cell death. This effect of
glutamine partly results from the amino acid capacity of increasing the gene expression of HSP 70 [37].
Dysregulation of cytokine production plays a major role in the pathogenesis of inflammatory
bowel disease (IBD). The gut mucosa of patients with IBD (Crohn’s disease or ulcerative colitis) has
been reported to produce high amounts of proinflammatory cytokines, such as interleukin (IL-)1β,
IL-6, IL-8, and tumour necrosis factor-alpha (TNF-α), in contrast to a less marked increase in the
production of anti-inflammatory cytokines, such as IL-10. For example, Coeffier, et al. [43] verified that
glutamine reduces pro-inflammatory cytokine production by human intestinal mucosa, probably by a
posttranscriptional pathway. Glutamine could be useful to modulate inflammatory conditions with
imbalanced cytokine production.
3.2. Skeletal Muscles
The body’s glutamine availability and metabolism are directly associated with the skeletal
muscle tissue. Skeletal muscles are quantitatively the most relevant site of glutamine stock,
synthesis, and release despite the relatively-low GS enzyme activity per muscle tissue-unit mass [11].
Thus, skeletal muscles play a fundamental role in glutamine metabolism, since it is one of the most
abundant tissues found in the human body [44]. The intramuscular glutamine content corresponds to
50–60% of the total free amino acids found in the skeletal muscle tissue. Approximately 80% of the
body glutamine is found in the skeletal muscle, and this concentration is 30 times higher than that
recorded for human plasma [45,46]. The free amino acid concentrations in the muscle tissue depend
on the muscle fiber type. Studies conducted in the skeletal muscle of rats showed that glutamine
concentration was three times higher in slow-twitch muscle fibers (type 1 fibers) than in fast-twitch
muscle fibers (type 2 fibers). High glutamine concentration in slow-twitch muscle fibers is due to the
high GS enzyme activity and ATP availability for glutamine synthesis [47].
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Hormones, such as insulin and insulin-like growth factors (IGFs), stimulate glutamine transport
into the intracellular environment, whereas glucocorticoids stimulate glutamine release into the
extracellular space. The transmembrane gradient for glutamine through the skeletal muscle is high,
a fact that restricts amino acid diffusion through the cell membrane. Glutamine is actively transported
into cells through a sodium-dependent channel system, whose outcome is a consumption of ATP.
The glutamine transport through the muscle cell membrane is faster than the transport of all other
amino acids [48]. Interestingly, the constant maintenance of glutamine availability in the intracellular
fluid, as well as the high glutamine concentration gradient across the cell membrane, is supported by
many pathways, such as the transport system affinity for the amino acid, its intracellular turnover
ratio and the extracellular supply, the intra- and extracellular sodium concentrations, and the influence
of other amino acids competing for carrier molecules [49,50].
During the post-absorptive state, approximately 50% of the glutamine synthesis in the skeletal
muscle takes place through glutamate uptake from the bloodstream, a fact that characterizes part of
the glutamine-glutamate cycle. In addition, muscle protein catabolism directly produces glutamine,
although it also leads to BCAAs, glutamate, aspartate, and asparagine release. The carbon skeletons of
these amino acids are used for glutamine de novo synthesis [51,52]. Glutamine and alanine correspond,
respectively, to 48% and 32% of the amino acids released by the skeletal muscle in the post-absorptive
state; the glutamine containing two nitrogen atoms per molecule is the main muscle nitrogen-release
source. The glutamine and alanine exchange rates exceed their abundance in the body, and their
occurrence in the muscle protein corresponds to 10–15%, thus indicating the constant need of glutamine
and alanine de novo synthesis in the skeletal muscle [4]. The glutamine synthesis rate in the skeletal
muscle (approximately 50 mmol/h) is higher than that recorded for any other amino acid. Thus,
glutamine and alanine should result from the interconversion of amino acids within the cell, in a
process that depends on the cell metabolic conditions, which are affected by human nutritional and
hormonal status, as well as by physical exercise [53,54].
One of the first studies about muscle glutamine metabolism in catabolic situations has recorded
that reduced glutamine concentration in the skeletal muscle is associated with the reduced survival
rate of sepsis-state patients. The severe muscle glutamine-concentration decrease in critically-ill
patients (80% reduction, on average, in the normal concentration due to protein degradation) is
accompanied by increased glutamine synthesis and release from the skeletal muscle. It happens
because of the increased messenger RNA (mRNA) and GS enzyme activity in the skeletal muscle
during severe catabolic states. Glucocorticoids may increase the amount of GS mRNA in the muscle
tissue through a glucocorticoid receptor-dependent process that happens in the cytosol. Once the
glucocorticoid is bound to its cytosolic receptor they are translocated to the nucleus, where they
bind to regions containing glucocorticoid-response elements, which induce GS gene transcription,
among others [55,56].
Although the GS activity increases in response to physiological stress, the protein amount may
not increase in parallel to that of the mRNA, thus indicating the activation of post-transcriptional
control mechanisms. Thus, the activity of the aforementioned enzyme appears to be controlled through
the intracellular glutamine concentration by means of a post-transcriptional control mechanism,
which increases the GS enzyme activity when the intracellular glutamine concentration decreases.
However, the GS enzyme is relatively unstable in the presence of glutamine; therefore, the increased
intracellular glutamine concentration leads to faster GS degradation. In addition, glucocorticoids and
intracellular glutamine depletion work synergistically by increasing the GS expression in the skeletal
muscle [57].
In vitro studies conducted with several cell types demonstrated that glutamine can also change the
gene expression of contractile proteins. According to one study, cardiomyocyte growth and maturation
were accompanied by increased mRNA contents in proteins, such as alpha-myosin heavy-chain
(α-MHC) and alpha-actin; both parameters were considered non-pathologic hypertrophy [58].
Other studies highlight the relevant role played by glutamine in mediating the activation of pathways,
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such as the mammalian target of rapamycin (mTOR), which is considered an essential tissue size and
mass regulator, either in healthy or ill patients. In fact, the use of amino acids, mainly of leucine,
as anabolic inducers in muscle cells has its action compromised via mTOR when glutamine is not
available [17]. Despite the essential role played by glutamine in regulating the expression of muscle
content-associated genes, there are no in vivo studies supporting the hypothesis that supplementation
applied alone can promote muscle mass increase.
Another significant role played by glutamine is associated with its capacity of modulating
protective and resistance responses to injuries, which are also known as antioxidant and cytoprotective
effects. The high oxidative stress generated in catabolism situations results in several effects that
culminate in pro-apoptotic stimuli through classic pathways, such as that of the NF-κB. Reactive oxygen
species (ROS), both the radical and the non-radical species, react to minerals, to phospholipid
membranes, and to proteins, among other relevant compounds, to cellular homeostasis [59].
Glutamine can modulate the expression of heat shock proteins (HSP). According to a study conducted
with acutely-inflamed mice (subjected to endotoxemia, which is a sepsis model), the increased
glutamine availability in the animals’ tissues helped to keep the HSP expression, mainly in the
70 (the most abundant form), 90, and 27 kDa family. Results concerning skeletal and liver muscles were
recorded at protein and gene expression levels. In addition, other genes were highly responsive to
glutamine, such as the heat shock factor 1 (HSF-1), which is important for HSP synthesis, and enzymes
linked to the antioxidant system (Figure 3). The glutamate resulting from glutamine is an essential
substrate for glutathione synthesis, a fact that changes the expression of genes, such as glutathione
S-reductase (GSR) and glutathione peroxidase 1 (GPx1). The glutamine cytoprotective and antioxidant
properties may be particularly important in high catabolism situations, in which the activity and the
expression of inflammatory pathways mediated by NF-κB are modulated [4,39].
3.3. The Liver
The liver is highly metabolic and has many functions, including the detoxification of blood
constituents arriving from the digestive tract, production of bile to aid digestion, metabolism of
carbohydrates, lipids, proteins, and drugs, blood pH balance, synthesis of plasma proteins, and the
storage and synthesis of glycogen and lipids. As indicated already, glutamine is an important
precursor for the generation of other metabolites, such as amino acids (glutamate), TCA components
(α-ketoglutarate), and nucleotides (AMP, purines, and pyrimidines), along with the activation of the
chaperone function (mediated by HSP response) and antioxidant defence (mediated by glutathione,
GSH). Therefore, glutamine is crucial for energy metabolism and proliferation of hepatocytes in the
liver. In addition, glutamine is an important precursor for gluconeogenesis, the process of glucose
production from other non-carbohydrate constituents, which is a central metabolic pathway in the
liver that allows maintenance of blood glucose levels in fasting and starvation conditions following
depletion of glycogen stores. During severe illness, the skeletal muscle is the major supplier of
glutamine, while the liver is a major consumer [28,60]. This consumption supports many of the
liver activities listed above, but as a key amino acid involved in nitrogen metabolism, the uptake of
glutamine in liver hepatocytes regulates the activity of the urea cycle due to its conversion to glutamate
NH3 by GLS [61]. Consequently, the liver regulates blood pH and the detoxification of NH3 via the
urea cycle using glutamine.
NH3 and NH4+ are toxic metabolic remnants of amino acid catabolism, and blood delivered to
the liver from the gut is rich in NH3/NH4+. In hepatocyte mitochondria, the reaction of NH3 with
ATP and the bicarbonate ion (HCO3−) leads to the formation of carbamoyl phosphate (CP) by CP
synthetase (CPS), a key intermediate in the urea cycle. Under the action of ornithine transcarbamylase,
ornithine reacts with CP to form citrulline. This subsequently undergoes various biochemical reactions
forming arginine, fumarate, and, ultimately, urea, which is excreted from the hepatocyte cytosol into
the blood. In the final urea-forming reaction, ornithine is regenerated to allow the cyclic continuation
of the urea cycle with additional NH3. Importantly, glutamine concentrations in the mitochondria
158
Nutrients 2018, 10, 1564
regulate flux through CP generation. High glutamine levels increase glutamate and NH3 through GLS
activity, with the NH3 reacting with ornithine to form CP. NH3 is also a co-activator of GLS in the
liver [62,63], and since liver GLS is not inhibited by glutamate [61,64], the glutamate produced can
form N-acetylglutamate, which is an activator of both GLS and CPS [65,66]. Consequently, both of
these biochemical mechanisms result in a high flux toward urea formation due to the elevated levels of
NH3 in the mitochondrial (sourced from digestive tract blood and glutamine degradation), the high
affinity of CPS for NH3, and the increased activity of GLS. However, the ultimate generation of urea
appears to be regulated by the sub-cellular level of glutamine and, consequently, its uptake from the
extracellular environment.
The intra-, inter-, and extracellular transport of glutamine in hepatocytes is central to the
conversion of the NH3/NH4+ to urea, its subsequent excretion, and blood pH balance due to effects
on HCO3−. The liver architecture is exquisitely designed such that periportal hepatocytes (near the
portal vein) receiving blood and nutrients from the gut are primarily responsible for urea production
using glutamine as outlined above. However, the distal hepatocytes near the hepatic vein (perivenous),
utilise any remaining NH4+ from the blood, including that bypassing the periportal hepatocytes, for
the re-synthesis and secretion of glutamine into the circulation. In this latter scenario, the NH3/NH4+
enters the perivenous hepatocytes and, using glutamate as a substrate, glutamine is generated by
GS. This process scavenges any NH3/NH4+ escaping the periportal process, while also replenishing
the glutamine that was used by periportal hepatocytes in the generation of urea and disposal of
nitrogen. The different functional regions of the liver were illustrated by the expression status of
glutamine-metabolizing enzymes, such that high levels of GLS were found in the portal region [67,68],
while only 7% of hepatocytes expressed GS, and these were found specifically around the central
hepatic veins [69].
The intercellular or liver compartmentalized cycling of glutamine between these liver regions
is also mediated by specific membrane transporters in periportal and perivenous hepatocytes.
These transport systems also control intra- and extracellular pH by the antiport translocation of
H+ on the entry of Na+ and glutamine. Glutamine from the diet is taken up by periportal hepatocytes
along with two Na+ ions, while one H+ is extruded in the opposite direction from the hepatocyte into
the extracellular space. This process is driven by the concentrations of glutamine and Na+ outside
the cell (i.e., in the blood), and also the intracellular concentration of H+. In essence, this directional
transport is also regulated by the relative pH difference between the intracellular and extracellular
space, such that periportal hepatic glutamine uptake leads to extracellular acidification and intracellular
alkalization, while glutamine export from perivenous hepatocytes leads to intracellular acidification
and extracellular alkalization [61]. Experiments in perfused rat livers have shown that a slight alkali
increase in extracellular pH (0.4 units) can enhance mitochondrial import of glutamine into hepatocytes,
as H+ is transported externally to possibly reduce extracellular pH and maintain equilibrium.
Mitochondrial glutamine concentration increased to about 15–50 mM, while the extracellular (0.6 mM)
and cytosolic (6 mM) glutamine concentrations remain unchanged in these perfusion models [70,71].
Therefore, the regulation and flux through GLS in periportal hepatocytes are regulated by the
sub-cellular concentration of glutamine, and not just the rate of glutamine entry from extracellular
sources. For perivenous hepatocytes, the synthesis and release of glutamine to the blood is facilitated
by the increased cytoplasmic, and lower extracellular concentration of glutamine, along with the less
acidic intracellular environment, which is countered by the antiport cytosolic influx of H+ [61].
Importantly, glutamine importation and exportation also affect osmotic balance and therefore
influences hepatocyte volume. This has additional consequences for hepatic function, including bile
synthesis and release [72], but also regulates anabolic processes, such as glycogen, lipid, and protein
synthesis [61]. Largely, glutamine uptake enhances hepatocyte cell swelling and hydration [73],
which leads to increased glycogen and fatty acid synthesis [74,75], and reduced proteolysis mediated
by P38 mitogen-activated protein kinases (p38 MAPK) signalling [76]. Other amino acids, such as
glycine and alanine, along with anabolic hormones, such as insulin, promoted hepatocyte swelling,
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leading to increased biosynthetic processes [77], while catabolic hormones, like glucagon, reduced
intracellular glutamine levels induced hepatocyte shrinkage [78]. Consequently, dehydration due
to reduced intracellular glutamine levels is characterized by decreased cell volume, initiation of the
catabolic process, and insulin-resistant conditions, and it was recently shown that hypertonic infusion
can cause glucose dysregulation in humans [79].
The liver is an insulin-sensitive organ and like skeletal muscle, is responsible for glucose disposal
via glycogen synthesis. Development of insulin resistance and subsequent glucotoxic conditions can
progress to chronic disorders, such as non-alcoholic fatty liver disease (NAFLD), characterized by
excessive lipid accumulation, and non-alcoholic steatohepatitis (NASH), characterized by increased
extracellular matrix (ECM) deposition [80,81]. These chronic disorders may lead to further hepatocyte
damage, manifesting as liver cirrhosis and possibly hepatocellular carcinoma. The liver can be
damaged in various ways, including infection (e.g., hepatitis B and C), alcoholism, metabolic disease,
and prolonged unhealthy diets. This damage elicits a pro-inflammatory hepatic environment,
which leads to liver tissue fibrosis, causing impaired hepatic function [80]. Untreated fibrosis ultimately
progresses to cirrhosis, which is mostly irreversible [80]. A key mediator of liver fibrosis is the hepatic
stellate cell (HSC), which is a mesenchymal, fibrogenic cell that resides in the sub-endothelial space
of Disse between the hepatocyte epithelium and the sinusoids. While normally in a quiescent state,
these cells become activated following liver insult, and they respond to cytokines and proliferate
to aid injury repair. However, overactivation or a failure to resolve their activation status (chronic
activation from continued exposure to pro-inflammatory stimuli) can lead to the increased ECM
deposition in the space of Disse that has a negative consequence for hepatocyte function and normal
liver architecture, such as loss of microvilli [80,82]. Kupffer cells, a liver macrophage, are also activated
in these conditions, and together with HSCs promote a pro-inflammatory hepatic environment.
Pro-inflammatory activators of these cells are beyond the scope of this manuscript, but it has been
demonstrated that HSCs require glutamine metabolism to maintain proliferation. It was shown
that activated HSC were dependent on glutamine conversion to ∝-ketoglutarate and non-essential
amino acids for proliferation, and reduction of glutamine significantly impaired HSC activation [82].
In addition, glutamine can be used as a precursor for proline synthesis, which is a key component of
collagen and ECM formation [82].
At present, there is some evidence to indicate that glutamine supplements slow NAFLD [83] or
NASH [84] progression, but most studies have been conducted in rodents. There is no convincing
evidence to indicate that glutamine supplements prevent NAFLD or NASH progression in humans,
which may be due to the complexity of multiple factors contributing to these disorders. The liver is a
remarkable organ and has the ability to regenerate, and some research has indicated that glutamine
supplementation may be advantageous for liver growth and repair after resection, but are again
limited to animal studies [85]. However, others have suggested that raised glutamine levels are
associated with liver failure, and the severity correlated with plasma glutamine [86]. Consequently,
the effects of glutamine on liver function beyond urea synthesis have not been fully explored, and the
administration of exogenous glutamine to those with compromised hepatic function needs to be
considered carefully [86].
4. Glutamine and Immune Cell Function
Glutamine was first considered a biologically important molecule in 1873 when indirect evidence
helped to characterize it as a structural component of proteins; then, in 1883, abundant free glutamine
was found in certain plants. Interestingly, the number of studies only increased after the research
conducted by Sir Hans Adolf Krebs (1900–1981) in the 1930s. At that time, and for the first time in
science history, Sir Krebs found that mammalian tissues can hydrolyse and synthesize glutamine [22].
In the 1950s, Eagle, et al. [87] reported that glutamine was utilized by isolated fibroblasts in quantities
greater than any other amino acid in the cell incubation medium. Further work at that stage was
hampered because glutamine was classified as a non-essential amino acid and it was difficult to
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measure the levels in plasma and tissues. Throughout the 1960s, 1970s, and 1980s, Hans Krebs, Philip
Randle (1926–2006), Derek Williamson (1929–1998), and Eric Newsholme (1935–2011) all worked on
metabolic regulation utilizing different research models, from isolated cells in vitro, to human and
in vivo experiments. Although glucose is a vital metabolite, and the main fuel for a large number of
cells in the body, in the early/mid-1980s, Eric Newsholme was able to advance evidence that glutamine
was an important modulator of leukocyte function, such as in lymphocytes [7] and macrophages [88].
One of the authors of this review, Newsholme P et al. (1986; 1987) [88–90], reported for the first
time that macrophages utilize glutamine actively. Pithon-Curi et al., in 1997 [91,92] described for the
first time the consumption of glutamine by neutrophils. The studies by Eric and Philip Newsholme
on glutamine metabolism in lymphocytes and macrophages, respectively, prompted many other
publications, which jumped from an average of two or three publications per year in the late 1960s and
early 1970s to about 50 publications per year in the last 20 years.
During infection and/or high catabolism, the rate of glutamine consumption by all immune
cells is similar or greater than glucose [89,90]. However, the increased demand for glutamine by
immune system cells, along with the increased use of this amino acid by other tissues, such as the
liver, may lead to a glutamine deficit in the human body. In addition, one of the most important
sites of glutamine synthesis, the skeletal muscles, reduce their contribution to maintaining plasma
glutamine concentration (Figure 2). This effect, depending on the situation may significantly contribute
to worsening diseases and infections, and/or increase the risk of subsequent infection, with possible
life-threatening implications [93].
In immune cells, glucose is mainly converted into lactate (glycolysis), whereas glutamine is
converted into glutamate, aspartate, and alanine by undergoing partial oxidation to CO2, in a
process called glutaminolysis [3] (Figure 3). This unique conversion plays a key role in the effective
functioning of immune system cells. Furthermore, through the pentose phosphate pathway, a metabolic
pathway parallel to the glycolysis pathway, cells can produce ribose-5-phosphate (a five-carbon
sugar), which is a precursor for the pentose sugars seen in the RNA and DNA structure, as well as
glycerol-3-phosphate for phospholipid synthesis [94]. On the other hand, the degradation of glutamine,
and thus formation of NH3, and aspartate leads to the synthesis of purines and pyrimidines of the DNA
and RNA. The expression of several genes in immune system cells is largely dependent on glutamine
availability [3]. For example, the role glutamine plays in the control of proliferation of immune system
cells occurs through activation of proteins, such as ERK and JNK kinases. Both proteins act on the
activation of transcription factors, such as JNK and AP-1, and it leads to the transcription of cell
proliferation-related genes. For instance, appropriate glutamine concentration leads to the expression
of key lymphocyte cells surface markers, such as CD25, CD45RO, and CD71, and the production of
cytokines, such as interferon-gamma (IFN-γ), TNF-α, and IL-6 [2,31,95,96]. Thus, glutamine acts as an
energy substrate for leukocytes and plays an essential role in cell proliferation, tissue repair process
activity, and intracellular pathways associated with pathogen recognition [97].
4.1. Neutrophils
The primary substrate for neutrophil survival endocytosis and ROS generation is glucose.
However, glucose is not the only energy metabolite source by these cells. Interestingly, when compared
to other leukocytes, such as macrophages and lymphocytes, neutrophils consume glutamine at the
highest rates [98,99]. Much of the glutamine is converted to glutamate, aspartate (via Krebs cycle
activity), and lactate in neutrophils. Under appropriate conditions, CO2, glutamine, and glutamate
play an important role in the generation of essential compounds for leukocytes’ metabolism and
function, including GSH. Neutrophils use protein structures composed of uncondensed chromatin
and of antimicrobial factors also called neutrophilic extracellular traps (NETs). The action of NETs
requires ROS formation, synthesis of enzymes, such as myeloperoxidase (MPO) and elastase, as well
as components capable of overriding virulence factors and destroying extracellular bacteria [100].
The process involving ROS depends on the activation of the NADPH oxidase 2 (NOX2) complex.
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Based on glutamine, the malate synthesis uses malic enzyme to produce substantial amounts of
NADPH, since it is necessary to form the superoxide anion (O2−), which presents antimicrobial activity.
Similarly, macrophages use glutamine for arginine and thus nitric oxide (NO) synthesis through the
action of the inducible NO synthase (iNOS) enzyme, by using NADPH as an energy source. Glutamine
increases superoxide generation through NADPH oxidase in neutrophils. 6-Diazo-5-oxo-L-norleucine
(DON), an inhibitor of phosphate-dependent glutaminase and thus of glutamine metabolism, causes a
significant decrease in superoxide production by neutrophils stimulated with phorbol myristate acetate
(PMA). PMA raises mRNA’s expression of gp91, p22, and p47, major components of the NADPH
oxidase complex. Glutamine increases expressions of these three proteins either in the absence
or in the presence of PMA. Glutamine enhances superoxide production in neutrophils, probably
via the generation of ATP and regulation of the expression of components of the NADPH oxidase
complex [101]. Glutamine plays a role to prevent the changes in NADPH oxidase activity and
superoxide production induced by adrenaline in neutrophils [102].
4.2. Macrophages
Metabolism of glucose and glutamine is profoundly affected during the macrophage
activation process [103,104]. The effects of thioglycollate (an inflammatory stimulus) and Bacillus
Calmette-Guérin—BCG (an activation stimulus) on macrophage glucose and glutamine metabolism
have been studied [105]. Either thioglycollate or BCG enhances activities of hexokinase and citrate
synthase, and also glucose oxidation whereas BCG markedly increases glutamine metabolism.
Lipopolysaccharide (LPS) administration also causes pronounced changes in macrophage metabolism
and function (for a review, see Nagy and Haschemi [106]. Glucose and glutamine metabolism is
also involved in polarizing signals that up-regulate the transcriptional programs required in the
macrophage capacity to perform specialized functions. Protein kinase B (PKB or Akt), mTOR complex
1 (mTORC1), mTORC2, and AMP-activated protein kinase (AMPK) play a critical role in metabolic
pathways and associated signalling activation [107,108]. For instance, extracellular glutamine may
function as the specific starvation-induced nutrient signal to regulate mTORC1. [17]. Synthesis and
secretion of pro-inflammatory cytokines, such as TNF-α, IL-1, and IL-6, by macrophages are also
regulated by glutamine availability.
Different populations of macrophages have now been identified, such as M1 and M2 [109–111].
The M1 and M2 are in fact two extremes of a still not completely known spectrum of macrophage
activation states [109,111,112]. Reprogramming signalling pathways are involved in the formation
of M1 or M2 phenotype macrophages. The metabolic reprogramming of macrophages include
key changes in glutamine and glucose metabolism [113]. No reports identified the requirement
of fatty acids for human macrophage IL-4 induced polarization [114]. This issue, however, remains
controversial. Interestingly, macrophages reprogram their metabolism and function to polarize for
pro- or anti-inflammatory cells, and this is a consequence of the environmental conditions and
stimuli [115]. Treatment of macrophages with LPS promotes a switch from glucose-dependent
oxidative phosphorylation to aerobic glycolysis—the Warburg effect [116]. Pyruvate kinase M2
regulates the hypoxia-inducible factor 1-alpha (Hif-1α) activity and IL-1β expression, being a key
molecule to induce the Warburg effect in LPS-activated macrophages [117]. Due to this mechanism,
M1 macrophages exhibit a quick increase in ATP formation that is required for the host defence
response [113,118,119]. The TCA cycle of M2 macrophages has no metabolic flux escape whereas
M1 macrophages (treated with LPS) have two points of substrate flux deviation, one occurring
at the isocitrate dehydrogenase step reaction and another one at post succinate formation. As a
result, there is an accumulation of TCA cycle intermediates (e.g., succinate, α-ketoglutarate, citrate,
and itaconate) that regulates LPS macrophage activation [119]. Itaconate has anti-inflammatory
properties through activation of nuclear factor erythroid 2-related factor 2 (Nrf2) via Kelch-like
ECH-associated protein 1 (KEAP1) alkylation [97]. The glutamine seems to be fully required for
IL-4 induction of macrophage alternative activation [120,121]. Liu, et al. [122] reported α-ketoglutarate,
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generated through glutaminolysis, promotes M2 macrophage differentiation. PPARγ has been
reported to be required for IL-4 induced gene expression and stimulation of macrophage respiration
and glutamine oxidation [123]. Macrophage metabolism feature varies with the specific-tissue
microenvironment, and this is of critical importance for the tissue-resident macrophage function.
The peritoneum is rich in glutamate, a product of glutamine metabolism that is used by resident
macrophage to induce specific metabolic changes under microbial sensing [121]. Taken as a whole,
glutamine metabolism does play a very important role as a synergistic supporter and modulator of
macrophage activation.
4.3. Lymphocytes
Lymphocyte activation is associated with specific metabolic pathways to optimize its function.
The integration of multiple extracellular signals affects transcriptional programs and signalling
pathways that determine, in CD4+ T cells, for example, multiple events that include modulation
of energy metabolism, cell proliferation, and cytokine production. Associated bioenergetic processes
are dependent on the activation of AMPK, indicating cross-talk between metabolism and signalling
pathways in immune cell differentiation. Greiner, et al. [124] reported in rat thymocytes that
the use of the anaerobic glycolytic pathway is strongly increased after antigenic stimulation with
Concanavalin (ConA). Eric Newsholme’s group was the first to report the utilization of glutamine
by lymphocytes [125]. Glutamine plays an important role for the function of these cells in
different ways. Pyruvate is a common product of glucose and glutamine metabolism in the cells.
Curi, et al. [126] described that mesenteric lymphocytes have increased pyruvate oxidation through
pyruvate carboxylase when stimulated with ConA, indicating that both glucose and glutamine are
involved in the control of lymphocyte proliferation and function. Mitochondria have been reported to
be able to regulate leukocyte activation. Succinate, fumarate, and citrate, metabolites of the Krebs cycle
and produced through glucose and glutamine metabolism, participate in the control of immunity and
inflammation either in innate and adaptive immune cells [97].
Most glucose molecules are transported via glucose transporter 1 (GLUT1), which is not observed
in non-activated lymphocytes [127]. GLUT1 is an important metabolic marker of lymphocyte activation
as it migrates rapidly to the cell surface after stimulation. Glucose deprivation causes a lower rate
of basal proliferation, as well as increased production of IL-2, TNF-α, INF-γ, and IL-4 by CD4+
T cells [128]. Activation of intracellular signalling by Akt beyond GLUT1 protein levels further
increases glucose uptake and T cell activation. mTOR and AMPK play important and distinct roles
in metabolism and immunity. The stimulation of lymphoid cells leads to increased GLUT1 uptake
of glucose by acting on mTOR protein [129]. This pathway is also involved in the differentiation
of CD4+ T-cell subsets since mTOR-deficient mice have a decrease in differentiation for effector T
lymphocytes [130,131]. In contrast, the AMPK pathway inhibits mTOR by suppressing the signalling of
this protein and promotes activation of mitochondrial oxidative metabolism rather than the glycolytic
pathway [132,133]. Glutamine is required for T and B-lymphocytes’ proliferation process, as well as for
protein synthesis, IL-2 production, and antibody synthesis rates presented by these cells. The evidence
has now accumulated that glutamine metabolism plays a key role in the activation of lymphocytes.
Glutamine is required for human B lymphocyte differentiation to plasma cell and to lymphoblastic
transformation [134].
The cell proliferation process requires both ATP for high-energy expenditure and precursors for
the biosynthesis of complex molecules, such as lipids (cholesterol and triglycerides) and nucleotides
for RNA and DNA synthesis. To perform rapid proliferation activity under the certain stimulus,
lymphocytes switch from oxidative phosphorylation to aerobic glycolysis plus glutaminolysis, and so
markedly increase glucose and glutamine utilization. The metabolic transition in a Th0 lymphocyte is
crucial for the activation of T cells, since glucose metabolism provides intermediates for the biosynthetic
pathways, being a prerequisite for the growth and differentiation of T cells [135]. Glycolysis plays an
important role in effector T cell functions associated with the production of inflammatory cytokines,
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mainly INF-γ and IL-2 [136]. The blockade of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA by the use of siRNA promotes a reduction of INF-γ in lymphocytes [136]. Therefore, the high
glycolytic activity is closely associated with the differentiation of Th0 to Th1 cells [132]. Inhibition of
the glycolytic pathway blocks this process whereas it promotes differentiation into Treg cells. Increased
glycolysis by proliferating cells is linked to increased uptake of glucose and increased expression and
activity of glycolytic enzymes, whereas glucose utilization in the oxidative phosphorylation pathway
(OXPHOS) is decreased. Therefore, the “metabolic switch” meets the higher energy requirements,
generates metabolic intermediates required for the biosynthesis of macromolecules, and suppresses the
metabolic features of rest lymphocytes. Inadequate nutrient delivery or specific metabolic inhibition
prevents the activation and proliferation of T cells since the inability to use glucose inhibits T cell
differentiation in vitro and in vivo [135,137]. Mitochondrial dynamics are closely associated with
T lymphocyte metabolism and function. Activated effector T cells have punctate mitochondria
and augmented the activity of anabolic pathways whereas memory T lymphocytes exhibit fused
mitochondria and enhanced oxidative phosphorylation activity [138]. HIF1-α plays a central role in
the maturation of dendritic cells and the activation of T cells. This factor controls leukocyte metabolism
reprogramming, through changes in gene expression, and thus immune cell functions [139].
Glycolysis and glutaminolysis are strongly associated to ensure appropriateness for lymphocyte
function. Hexosamine biosynthesis requires glucose and glutamine for the de novo synthesis of
uridine diphosphate N-acetylglucosamine (UDP-GlcNAc). This sugar-nucleotide inhibits receptor
endocytosis and signalling through promoting N-acetylglucosamine branching of Asn (N)-linked
glycans. Araujo, et al. [140] reported that high aerobic glycolysis and glutaminolysis activities in a
co-operative way decrease the UDP-GlcNAc synthesis and N-glycan branching in mouse T cell blasts
due to the low availability of these metabolites for hexosamine synthesis. As a consequence, growth
and pro-inflammatory TH17 features prevail over anti-inflammatory-induced T regulatory (iTreg)
differentiation. The latter process is promoted by IL-2 receptor-α (CD25) loss through endocytosis.
The authors then postulated that a primary function of concomitant high aerobic glycolysis and
glutaminolysis activities is to limit precursors to N-glycan biosynthesis. This metabolic feature of
T lymphocytes has marked implications in autoimmunity and cancer. Glutamine also serves as a
precursor for the synthesis of putrescine and the polyamines, spermidine and spermine. High levels of
polyamines are reported in tumour cells and in autoreactive B- and T-cells in autoimmune diseases.
Polyamines have been described to play a role in the control of normal immune cell function and have
been associated with autoimmunity and anti-tumour immune cell properties [141].
5. Immunomodulatory Properties of Glutamine Supplementation
Plasma glutamine concentration may be decreased during intense immune cell activity in patients
with critical disease conditions; as occurs in sepsis, burn, and injury. Skeletal muscle is the main
source of glutamine in mammals. This tissue synthesizes, stores, and releases this amino acid to be
used by several organs and cells, such as lymphoid organs and leukocytes [89], as mentioned above.
A decrease in plasma/bloodstream glutamine levels results of either insufficient glutamine production
in skeletal muscle or excessive consumption by utilizing-cells or both (Figure 2). The decrease in
plasma glutamine availability has been reported to contribute to the impaired immune function in
several clinical conditions. In fact, glutamine depletion reduces lymphocyte proliferation, impairs
expression of surface activation proteins on and production of cytokines, and induces apoptosis in
these cells [9]. Addition of glutamine to the diet increases experimental animal survival to a bacterial
challenge. Glutamine given through the parenteral route has been reported to be beneficial for patients
after surgery, radiation treatment, bone marrow transplantation, or injury [5,142]. Administration of
glutamine before the onset of infection prevents it in animals and humans, possibly by preventing
deficiency of this amino acid [143].
Concerning the mechanism of action, glutamine regulates the expression of several genes of
cell metabolism, signal transduction proteins, cell defence, and repair regulators, and to activate
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intracellular signalling pathways [2]. Glutamine action also involves signalling pathways’ activation
by phosphorylation, such as NF-κB and MAPKs [144]. Thus, the function of glutamine goes beyond
that of a metabolic fuel or protein synthesis precursor. This amino acid is also an important regulator
of leukocyte function, acting on either gene expression or signalling pathways’ activation.
5.1. Glutamine-GSH Axis and the Redox State of the Cell
GSH (γ-L-glutamyl-L-cysteinylglycine) is the most important and concentrated (0.5–10 mmol/L)
non-enzymatic antioxidant in mammalian cells. Around 85 to 90% of GSH is found in the cytosol, and
about 10 to 15% is located in organelles, such as the mitochondria, nuclear matrix, and peroxisomes.
GSH is an antioxidant that can directly react with ROS, generating oxidised GSH (GSSG), and can
also donate electrons for peroxide reduction, catalysed by glutathione peroxidase enzyme (GPx) [145].
The redox state of the cell can be obtained from the ratio between the intracellular concentration of
glutathione disulphide (GSSG) and GSH, which the ratio is [GSSG]/[GSH], resulting in a reduction
of GSH, and an increase in the amounts of GSSG [59]. The redox state of the cells is consequently
related to GSH concentrations, which are also influenced by the availability of amino acids. Glutamine
(via glutamate), cysteine, and glycine are the precursor amino acids for the synthesis of GSH. However,
among these three amino acids, glutamate represents the first and probably the most important step
in the synthesis of GSH intermediate compounds. Glutamate synthesis, in turn, is dependent on the
glutamine intracellular availability. Thus, a higher glutamine/glutamate ratio reinforces the substrates
availability for GSH synthesis [39].
Although all cell types in the human body can synthesize GSH, the liver is quantitatively the main
organ for the de novo synthesis of GSH (responsible for ~90% of the circulating GSH in physiological
conditions) (Figure 3). The elevated concentration of hepatic GSH is mainly due to the high activity of
the enzyme, glutathione reductase, in the γ-glutamyl cycle, also known as Meister’s cycle, in honour to
Alton Meister (1922–1995) [146]. This cycle provides GSH to be consumed locally by the liver, or under
hormonal regulation (e.g., glucagon, vasopressin, and catecholamines), and GSH can be exported into
the plasma and other tissues, such as the skeletal muscles. The intracellular and extracellular GSH
concentrations are determined by the balance between its synthesis and degradation, as well as by the
ability of the cell to transport GSH between the cytosol and the different organelles or the extracellular
space [147].
Free radicals and ROS production are essential for cell signalling and immune-mediated oxidative
bursts found in phagocytes, such as neutrophils and macrophages. Conversely, there is growing
evidence that chronic and/or exaggerated alterations in the redox balance play an important role in
many acute and chronic diseases, such as cancer, cardiovascular disease, diabetes, sepsis, and general
infections. For instance, in acute inflammatory situations, such as sepsis or viral infection, there is
a rise in the intracellular redox state, and all cell compartments are vulnerable to oxidative stress
(characterized by increased levels of ROS, and low removal by the antioxidant system) [10,39]. In this
situation, glutamine status becomes even more important in dictating the health/recovery outcome,
with low glutamine availability, leading to low antioxidant protection via the glutamine-GSH axis.
Indeed, many experimental [4,39,148,149] and observational [10,26] studies have already identified
that during high catabolism, the low plasma concentration of glutamine is an independent risk factor
for mortality [150].
5.2. Heat Shock Protein Response
The ability of all living organisms to respond with rapid and appropriate modifications against
physiological challenges is an essential feature for survival. At the most basic cellular level,
living organisms respond to unfavourable conditions, such as heat shock, toxins, oxidants, infection,
inflammation, and several other stressful situations, by changing the expression of stress-related
genes, also known as heat shock genes. This response involves the rapid induction of a specific set of
genes encoding for cytoprotective proteins, known as HSP’s [94]. HSP’s are a family of polypeptide
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proteins clustered according to their molecular weight, which have many intracellular functions.
Possibly, the most important function displayed by HSP’s are the action of a molecular chaperone.
This function assists protein transport, prevents protein aggregation during folding, and protects newly
synthesized polypeptide chains against misfolding and protein denaturation [151]. Although several
HSP families have been studied in the last couple of years (e.g., HSP10, HSP25, HSP27; HSP90), the most
famous and well described in the literature is the HSP70 (i.e., HSP72 + HSP73) family [29,151,152].
HSP70 acts as anti-inflammatory protein by virtue of turning NF-κB off and attenuating the production
of inflammatory mediators [153]. Moreover, HSP70 modulate autophagy by regulating the mTOR/Akt
pathway and block signalling pathways associated with protein-degradation [152].
Glutamine found at concentrations similar to those recorded for human plasma leads to a
significant HSP72 gene expression increase in peripheral blood mononuclear cells subjected to LPS
treatment. On the other hand, reduced glutamine concentration results in reduced HSP72 expression
in monocytes; this effect depends on mRNA stability. The preoperative administration of glutamine
can modulate HSP70 expression by reducing the activation levels of the cyclic AMP response element
binding protein (CREB), which is often associated with exacerbated inflammatory responses. This effect
depends on the iNOS activity and leads to an NO production increase. Other studies corroborated the
present results and presented similar mechanisms, as well as effects on the expression of other HSP’s,
such as HSP25, HSP27, and HSP90.
Glutamine plays a crucial role in the modulation of HSP’s expression through the
hexosamine biosynthetic pathway (HBP, Figure 3) [21,94]. In the HBP, glutamine leads to the
production of UDP-GlcNAc and (UDP)-N-acetylgalactosamine (UDP-GalNAc) through the enzyme,
fructose-6-phosphate amidotransferase (GFAT, the first and rate-limiting step of HBP). UDP-GlcNAc
and UDP-GalNAc, in turn, may be attached to serine or threonine hydroxyl moieties in nuclear
and cytoplasmic proteins by the enzymic action of O-linked-N-acetylglucosaminyl (O-GlcNAc)
transferase (a.k.a. OGT) [94]. The main donors for UDP-GlcNAc are glucose, glutamine, and uridine
triphosphate (UTP) from the HBP. Interestingly, both nutrients’ availability and cell stress affect
O-GlcNAc downstream signalling, and, not surprisingly, this mechanism is also altered in several
metabolic diseases, infection, and inflammatory processes [154,155]. O-GlcNAc synthesis leads to the
activation of many transcriptional factors, for instance, Sp1, phosphorylation of Eukaryotic Initiation
Factor 2 (eIF2), and sirtuin-1 (SIRT1) [156]. Both Sp1 and eIF2 are key transcription factors for the
induction of the main thermal shock eukaryotic factor, HSF-1 [157]. Alternatively, SIRT1 enhances
HSF-1 expression and prolongs its activation by binding to the promoters of HS genes, leading to the
HSP’s expression [94,158]. Although the O-GlcNAc/Sp1 pathway is considered the main mechanism
of the HSP’s gene expression and production, glutamine may also act on HBP via p38/MAPK,
leading to the HSP’s expression in cells, such as neutrophils. This response may explain the reduction
in neutrophils’ apoptosis after high-intensity physical exercise [144]. Furthermore, by increasing the
HBP flux, glutamine stimulates the HSP’s expression by blocking the glycogen synthase kinase 3 beta
(GSK-3β), an enzyme that constitutively inhibits HSF-1 activation by phosphorylating the transcription
factor at Ser303 [94,159].
In vitro [21,160] and in vivo [4,39,161–163] studies demonstrate that glutamine availability
maintains cell homeostasis and promotes cell survival against environmental and physiological
stress challenges through an enhanced protection mediated by intracellular HSP (iHSP) levels [94].
Interestingly, under severe infection and/or catabolism, low glutamine availability in the body can
eventually be accompanied by an aberrant iHSP and lead to the HSP’s release to the extracellular
space (eHSP) [4]. eHSP have a wide variety of effects on other cells, including impacting on a cell to
cell interaction and chemotaxis, and in some cases, act as a signal to the immune and inflammatory
responses. On the other hand, eHSP can also function as a stress signalling and pro-inflammatory
molecule by interacting with Toll-like receptors 2 (TLR2) and 4 (TLR4) [164]. This effect can
down-regulate iHSP in many cells, leading to apoptosis [4], and has also been associated with increased
insulin resistance in skeletal muscle cells [165], and β-cell failure in diabetic individuals. Currently, a
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novel and overall index of immunoinflammatory status, the extracellular to intracellular HSP70 ratio
index (H-index), measured in peripheral blood mononuclear cells (PBMCs) [94], has been established.
6. Clinical Translation of Glutamine Delivery
Glutamine is found in relatively high concentrations in vegetable and animal protein-based foods
(Table 1). Using a validated food frequency questionnaire (FFQ) of more than 70 thousand participants,
Lenders, et al. [166] showed that glutamine (6.85 ± 2.19 g/day), glutamate (7.27 ± 2.44 g/day), and
leucine (7.01 ± 2.27 g/day) accounts for the highest intake in protein-based diets. Therefore, a balanced
diet provides glutamine, and other essential and non-essential amino acids for homeostasis, growth,
and health maintenance. Furthermore, it is also important to state that in healthy individuals with
a balanced diet, glutamine supplementation does not increase the efficacy of immune surveillance
and/or prevent disease/sickness episodes.
Table 1. Total protein, glutamine, glutamate, and leucine (g/100g food) content in some animal and
vegetable foods using the gene sequencing method (adapted from [166]).
g/100g Food
Beef Skim Milk White Rice Corn Tofu
 
Egg
Total protein 25.9 3.4 2.7 2.5 6.6 12.6
Glutamine 1.2 0.3 0.3 0.4 0.6 0.6
Glutamate 2.7 0.4 0.2 0.05 0.7 1.0
Leucine 2.2 0.4 0.2 0.4 0.5 0.9
On the contrary, during major and/or critical illness, sepsis, trauma, and post-surgery
circumstances, patients suffer from chronic weakness and several nutritional limitations (e.g., state of
unconsciousness, gastrointestinal disturbances, and/or chew related problems), which impair
homeostasis, and are associated with poor clinical outcomes. Severe disturbances in amino
acid metabolism and/or intermediary metabolism followed by skeletal muscle proteolysis are
key characteristics of hypermetabolic/hypercatabolic states [167]. During hypercatabolism, some
non-essential amino acids, including glutamine, become conditionally essential. As previously
mentioned, glutamine is critical for cell homeostasis, and cells cannot survive and/or proliferate in an
environment where glutamine is lacking. Therefore, the administration of non-synthetic amino acid
supplements, such as glutamine, has been a research target in in the last many years and is currently
indicated for hypercatabolic and/or ill patients. However, the efficacy of glutamine supplementation
is frequently questioned due to confusing and controversial results [150,168,169].
Glutamine is usually administrated by utilizing its free form (also known as an isolated
amino acid), or bond with another amino acid, also known as the dipeptide form (Figure 4).
Several glutamine dipeptides with potential recovery health benefits have been described, such as
L-glycyl-L-glutamine (Gly-Gln) and L-arginyl-L-glutamine (Arg-Gln); however, the most well-known
is possibly L-alanyl-L-glutamine (Ala-Gln) [170]. Given parenterally, many clinical and experimental
studies and appropriate systematic reviews [168] have concluded that glutamine dipeptides can reduce
the rate of infectious complications [171–174], length of hospital stay [9,175], and mortality of critically
ill patients [10,176,177]. The choice for free glutamine or glutamine dipeptides largely depends on the
patient’s catabolic circumstance and/or the most suitable route of administration (e.g., enteral and
parenteral nutrition). For instance, in patients receiving total parenteral nutrition (TPN), glutamine
dipeptides offer several advantages, such as stability during sterilization, prolonged storage, and high
range of solubility (154 g/L H2O at 20 ◦C, 568 g/L H2O at 20 ◦C, respectively) when compared to free
glutamine (36 g/L H2O at 20 ◦C) [170]. Moreover, free glutamine is usually commercially available as a
crystalline amino acid powder and can be diluted into commercially available TPN solutions, however,
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this procedure requires daily preparations at a controlled temperature (i.e., 4 ◦C), aseptic conditions
followed by sterilization through specific membrane filtration, and the concentration should not exceed
1–2%. This is particularly important because, at a low concentration, TPN solutions will increase the
patient’s fluid intake to meet the daily glutamine recommendation, however, this cannot be feasible
for fluid restricted patients.
 
Figure 4. Mechanisms of enteral and parenteral glutamine (GLN) supply. Glutamine is an important
substrate for rapidly dividing cells, such as enterocytes. This is a major site of glutamine consumption
obtained from both exogenous/diet (luminal membrane) and/or endogenous glutamine synthesis
(basolateral membrane). Free glutamine supplementation is mainly metabolized in the gut and poorly
contribute to glutaminemia and tissue stores. On the other hand, glutamine dipeptides (e.g., Ala-Gln,
Gly-Gln, Arg-Gln) escape from the gut metabolization and quickly supply glutamine to the plasma
and target tissues. This effect is mainly attributed to the oligopeptide transporter 1 (Pept-1) located in
the luminal membrane of the enterocytes.
In both oral/enteral or parenteral nutrition, the typical glutamine daily administration (free
and dipeptide forms) may vary from a fixed dose of 20–35 g/24 h to an adjusted dose of <1.0 g
(usually 0.3 g–0.5 g) per kg of body weight [168]. As any other nutrient or medication administrated
directly into the bloodstream when free or dipeptide forms of glutamine are given parenterally,
the increase in plasma glutamine is superior when compared to oral/enteral feeds [178]. However,
it should be noted that although parenteral routes can secure nutrient delivery to target tissues, it is
always an invasive route and may increase the risk of infections per se. It is strongly recommended
that the decision to use parenteral solutions must be based on several nutritional parameters, such as
poor nutritional status, dramatic reduction of body weight and body mass index, low plasma albumin,
and/or severe loss of nitrogen and tissue function.
For individuals with regular enteral feeds at home or hospitals, and also elite athletes
where glutamine supplementation is eventually recommended, oral or enteral routes are always
more physiological. Furthermore, enteral solutions stimulate the intestinal cells to produce other
intermediary amino acid derivatives important for immunological functions, and also compromised
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in hypercatabolic patients, such as arginine and its downstream metabolites (e.g., ornithine and
citrulline) [179]. Experimental studies in animal models and humans have shown an increase
in glutaminemia between ±30 to ±120 min after oral/enteral free glutamine [50] or Ala-Gln
supplementation [50,177]. However, the peak concentration and the area under the curve promoted
by Ala-Gln tend to be superior when compared to free glutamine supply. This effect is largely due
to the expression of the human oligopeptide transporter 1 (Pept-1) located in the luminal microvilli
membrane of the enterocytes [180], and in a lesser extent, through paracellular mechanisms and
cell-penetrating peptides’ translocation [181,182] (Figure 4). Pept-1 is a high capacity, low-affinity
proton-coupled cotransporter of diverse di/tripeptides, which include the glutamine dipeptides.
Pept-1 is considered the main route of protein absorption in mammals’ intestines since the protein
is able to transport about 400 dipeptides and 8000 tripeptides derived from the 20 L-α amino
acids [180]. As a result, free glutamine and/or alanine deriving from enteral Ala-Gln administration
can be released into the bloodstream, thus making the amino acids available to target tissues,
including the liver [183], immune system [39], kidneys [184] and skeletal muscles [53] (Figure 4).
Interestingly, the effects promoted by Ala-Gln are also mediated by the presence of the amino acid,
alanine, in the peptide formulation. Oral free glutamine along with free alanine promoted similar
metabolic, antioxidant, and immunological effects when compared to Ala-Gln supplementation in
in vivo animal models submitted to infection [4,39], and exhaustive aerobic [30,45,53] and resistance
physical exercise [29,162]. Importantly, in all of these experiments, the supplemented groups received
isonitrogenous and isocaloric solutions, i.e., both containing 13.46 g of glutamine/100 mL and 8.20 g
of alanine/100 mL. Although the precise mechanisms are still unknown, it is clear that both amino
acids work in parallel, especially in absorptive cells (Figure 4). For instance, alanine is rapidly
metabolized via alanine aminotransferase to pyruvate, with concomitant production of glutamate
from 2-oxoglutarate, which contribute to antioxidant defence mediated by GSH. Although other free
amino acid combinations need to be tested, these important discoveries may lead to the design of new
formulations for specific hypercatabolic patients.
Oral/enteral or parenteral doses of glutamine supplementation have been tested in hundreds of
studies in both animal models and humans, and if offered as a single nutrient supplementation
(not combined with other additives), can be considered safe. In addition, there is no scientific
evidence demonstrating that glutamine supplementation can suppress and/or inhibit permanently its
endogenous production or de novo synthesis. However, as any other amino acid offered in excessive
doses, it can promote hyperaminoacidemia and result in poor clinical outcomes. It is considered not to
be the best practice to provide glutamine supplementation to patients without a proper evaluation
that is supported by a nutritional assessment and biochemical laboratory tests.
Glutamine metabolism and supplementation in cancer has also raised many concerns among
the scientific community, and deserve some comments. It is well established that cancer cells are
extremely dependent of glutamine metabolism and availability, however, the role played by glutamine
in cancer/tumours cells in vivo is still controversial, and thus the effects of the supplementation.
Cancer cells take advantage of aerobic glycolysis (also known as the Warburg effect), and therefore
glucose to maintain the supraphysiological survival and growth [185,186]. On the other hand, there is
an increasing evidence of the role of oncogenes and tumour suppressors in the regulation of nutrient
metabolism [187]. Aberrant mutations in these genes lead to altered nutrient metabolism, and can
significantly contribute to the development and/or progression of cancer cells [186]. For instance,
glucose, glutamine, lipids, and acetate can be utilized as carbon and energy sources [25]. To increase
the level of complexity, the nutrient sources may vary among different types of cancer and/or tumour
cells and are highly heterogeneous [25,187]. For example, lung cancer cell lines are highly dependent
of glutamine supply in vitro, however, in vivo experiments demonstrate that glucose is the preferred
source of carbons supplied to the Krebs cycle, through the action of pyruvate carboxylase [188],
with little changes in glutamine consumption [187]. Human and mouse gliomas exhibit high
rates of glucose catabolism, and use glucose to synthesize glutamine through glutamate-ammonia
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ligase (GLUL), which in turn promotes nucleotide biosynthesis via the pentose phosphate pathway
independently of circulating glutamine [189,190]. Conversely, prostate cancer cell lines exhibit aberrant
intracellular lipid metabolism [191], and an increased gene expression of glutaminolitic enzymes and
glutamine transporters, thereby stimulating cell growth via glutamine uptake [192].
The variances in cancer cells’ nutrient metabolism suggest that different nutritional approaches
should be taken into consideration. However, studies have also targeted whether a glutamine
exogenous supply may attenuate the side effects promoted by chemotherapy and radiation in cancer
patients [193]. In a systematic review, Sayles, et al. [194] reported that in 11 of 15 studies, oral glutamine
supplementation (dose range: 30 g/day in 3 divided doses, or 7.5–24 g/day) significantly reduced the
grade of mucositis (common in 90% of head/neck cancer patients) [193] and/or attenuated weight loss
in cancer patients. In a double-blind, placebo-controlled, randomized trial, colorectal cancer patients
undergoing chemotherapy were supplemented with 18 g/day of glutamine (five days before and
during the treatment). Glutamine treatment reduced the side-effects induced by chemotherapy, such
as intestinal absorption and permeability, diarrhea, and gut mucositis [195]. As a whole, it is important
to highlight that glutamine supplementation for cancer patients may also fuel certain types of cancer
cells, and have a negative impact on health. However, considering the strong ability of metabolic
switching of cancer cells, glucose and/or lipids can also induce similar effects, and therefore it would
be difficult for a human to survive and maintain immunity and/or immune surveillance without
these nutrients. As mentioned previously, a proper and possibly individualized patient evaluation is
required to determine the suitability of glutamine supplementation.
Low plasma glutamine level (hypoglutaminemia) is usually used as a parameter to indicate
the need for a glutamine exogenous supply. However, the correlation between the concentration of
glutamine in plasma and tissue vary significantly between hypercatabolic patients, and therefore
among studies [150]. For instance, muscle glutamine was dramatically reduced in abdominal surgery
patients, but no changes were detected in plasma [196]. In critically ill patients, however, there is
a profound drop in muscle glutamine, but a variable reduction in plasma [150]. Other important
glutamine sites, such as the gut and the liver, may show a concomitant plasma and tissue glutamine
reduction, or even an inverse relationship during major illness [86,197,198]. These findings are also
in agreement with data obtained in rats [29,45,183] and mice [4,199] submitted to infection and
exhaustive exercise.
The variations between plasma and tissue glutamine concentration are due to the fact that only
a small fraction of the total body free glutamine is in plasma. To add to the confusion, it is known
that cells of the immune system, such as lymphocytes maintained in a low glutamine availability
(similar to low plasma glutamine concentration, e.g., ±400 μM), still proliferate, when compared to
resting values (e.g., 600 μM) [4,7,90]. The rate of macrophages’ phagocytosis and cytokine production
by diverse peripheral blood mononuclear cells (PBMCs) is also dependent on glutamine availability,
with decreasing rates at ±<600 μM of glutamine [21,200]. Thus, for some catabolic/hypercatabolic
patients, the changes in glutamine concentration, especially in plasma, will not necessarily affect
and suppress immune functions, and possibly no significant changes might be observed in data
obtained from immune parameters and function, and mortality risk predictors, such as APACHE
II or SAPS III. Taken together, hypoglutaminemia can only be interpreted as an independent
variable of mortality and/or poor clinical outcome [10,93,168,169,174,201]. More in-depth studies
are required to explore the specific relationship between dramatic changes in plasma glutamine and
outcomes in critically ill patients. Currently, the decision of glutamine supplementation should be
based in a set of immune-inflammatory parameters allied with appropriate nutritional assessment,
and eventually, risk predictors. In addition, glutamine supplementation studies cannot be judged
on trials where only the very sickest patients (i.e., with two or more organ failures) were eligible for
this nutritional intervention, and in these situations, supraphysiologic doses are not an appropriate
nutritional solution.
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7. Conclusions and Future Perspectives
Immune cells largely depend on glutamine availability to survive, proliferate, and function,
and ultimately defend our body against pathogens. During catabolic/hypercatabolic circumstances,
the demand for glutamine increases dramatically, a fact that may lead to a glutamine deprivation and
severe impairment of the immune function. However, low glutamine availability is not observed in
every catabolic/ill or critically ill patient, and thus not all individuals will benefit from glutamine
supplementation. It is important to consider that like glycaemia, plasma glutamine and the inter-tissue
metabolic flux is maintained at constant levels even during high catabolism by key organs, such as
the gut, liver, and skeletal muscles. Not surprisingly, hypoglutaminemia conditions and severity vary
significantly between human and animal studies, and by itself do not provide a rational argument for
glutamine exogenous supply.
For some catabolic situations, and/or where there is a shortage of glutamine obtained from
the diet, amino acid supplementation might be required. In this regard, the immune properties of
glutamine supplementation have been extensively studied and new questions and perspectives are
formulated. For instance, studies should determine the frequency of nutritional intervention, optimal
doses associated with the disease or stress situation, and the concomitant administration with other
amino acids or dipeptide combinations. In addition, the evolving metabolomics era has the potential
to improve our understanding of the complex regulation of glutamine metabolism, identifying new
metabolites (e.g., Itaconate in macrophages) critical for cell function, thus going beyond the concept of
“the fuel for the immune system”.
Author Contributions: V.C. conceived the idea, and with the help of M.M.R. organised and designed the
manuscript. V.C., M.M.R., K.N.K. and R.C. wrote the first draft, which was reviewed and revised by P.N. Figures
and Table 1 were designed by V.C. All authors contributed significantly in the manuscript revision and agreed
with the final submitted version.
Funding: We thank the Department of Health Science, Torrens University, and the Curtin School of Pharmacy
and Biomedical Sciences for financial research support and excellent research facilities, respectively.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Grohmann, U.; Mondanelli, G.; Belladonna, M.L.; Orabona, C.; Pallotta, M.T.; Iacono, A.; Puccetti, P.; Volpi, C.
Amino-acid sensing and degrading pathways in immune regulation. Cytokine Growth Factor Rev. 2017, 35,
37–45. [CrossRef] [PubMed]
2. Curi, R.; Lagranha, C.J.; Doi, S.Q.; Sellitti, D.F.; Procopio, J.; Pithon-Curi, T.C.; Corless, M.; Newsholme, P.
Molecular mechanisms of glutamine action. J. Cell. Physiol. 2005, 204, 392–401. [CrossRef] [PubMed]
3. Curi, R.; Newsholme, P.; Marzuca-Nassr, G.N.; Takahashi, H.K.; Hirabara, S.M.; Cruzat, V.; Krause, M.;
de Bittencourt, P.I.H., Jr. Regulatory principles in metabolism-then and now. Biochem. J. 2016, 473, 1845–1857.
[CrossRef] [PubMed]
4. Cruzat, V.F.; Pantaleao, L.C.; Donato, J., Jr.; de Bittencourt, P.I.H., Jr.; Tirapegui, J. Oral supplementations
with free and dipeptide forms of l-glutamine in endotoxemic mice: Effects on muscle glutamine-glutathione
axis and heat shock proteins. J. Nutr. Biochem. 2014, 25, 345–352. [CrossRef] [PubMed]
5. Newsholme, P. Why is l-glutamine metabolism important to cells of the immune system in health, postinjury,
surgery or infection? J. Nutr. 2001, 131, 2514S–2523S. [CrossRef] [PubMed]
6. Cruzat, V.F.; Krause, M.; Newsholme, P. Amino acid supplementation and impact on immune function in
the context of exercise. J. Int. Soc. Sports Nutr. 2014, 11, 61. [CrossRef] [PubMed]
7. Ardawi, M.S.M.; Newsholme, E.A. Maximum activities of some enzymes of glycolysis, the tricarboxylic acid
cycle and ketone-body and glutamine utilization pathways in lymphocytes of the rat. Biochem. J. 1982, 208,
743–748. [CrossRef] [PubMed]
8. Flaring, U.B.; Rooyackers, O.E.; Wernerman, J.; Hammarqvist, F. Glutamine attenuates post-traumatic
glutathione depletion in human muscle. Clin. Sci. 2003, 104, 275–282. [CrossRef] [PubMed]
9. Roth, E. Nonnutritive effects of glutamine. J. Nutr. 2008, 138, 2025S–2031S. [CrossRef] [PubMed]
171
Nutrients 2018, 10, 1564
10. Rodas, P.C.; Rooyackers, O.; Hebert, C.; Norberg, A.; Wernerman, J. Glutamine and glutathione at icu
admission in relation to outcome. Clin. Sci. 2012, 122, 591–597. [CrossRef] [PubMed]
11. Newsholme, E.A.; Parry-Billings, M. Properties of glutamine release from muscle and its importance for the
immune system. J. Parenter. Enter. Nutr. 1990, 14, 63S–67S. [CrossRef] [PubMed]
12. Wernerman, J. Clinical use of glutamine supplementation. J. Nutr. 2008, 138, 2040S–2044S. [CrossRef]
[PubMed]
13. Berg, A.; Norberg, A.; Martling, C.R.; Gamrin, L.; Rooyackers, O.; Wernerman, J. Glutamine kinetics
during intravenous glutamine supplementation in icu patients on continuous renal replacement therapy.
Intensive Care Med. 2007, 33, 660–666. [CrossRef] [PubMed]
14. Labow, B.I.; Souba, W.W.; Abcouwer, S.F. Mechanisms governing the expression of the enzymes of glutamine
metabolism—Glutaminase and glutamine synthetase. J. Nutr. 2001, 131, 2467S–2486S. [CrossRef] [PubMed]
15. Cruzat, V.F.; Newsholme, P. An introduction to glutamine metabolism. In Glutamine; CRC Press: Boca Raton,
FL, USA, 2017; pp. 1–18.
16. Cooney, G.; Curi, R.; Mitchelson, A.; Newsholme, P.; Simpson, M.; Newsholme, E.A. Activities of some key
enzymes of carbohydrate, ketone-body, adenosine and glutamine-metabolism in liver, and brown and white
adipose tissues of the rat. Biochem. Biophys. Res. Commun. 1986, 138, 687–692. [CrossRef]
17. Tan, H.W.S.; Sim, A.Y.L.; Long, Y.C. Glutamine metabolism regulates autophagy-dependent mtorc1
reactivation during amino acid starvation. Nat. Commun. 2017, 8, 338. [CrossRef] [PubMed]
18. Ardawi, M.S. Glutamine metabolism in the lungs of glucocorticoid-treated rats. Clin. Sci. 1991, 81, 37–42.
[CrossRef] [PubMed]
19. Parry-Billings, M.; Dimitriadis, G.D.; Leighton, B.; Bond, J.; Bevan, S.J.; Opara, E.; Newsholme, E.A. Effects
of hyperthyroidism and hypothyroidism on glutamine metabolism by skeletal muscle of the rat. Biochem. J.
1990, 272, 319–322. [CrossRef] [PubMed]
20. Parry-Billings, M.; Dimitriadis, G.; Leighton, B.; Dunger, D.; Newsholme, E. The effects of growth hormone
administration in vivo on skeletal muscle glutamine metabolism of the rat. Horm. Metab. Res. 1993, 25,
292–293. [CrossRef] [PubMed]
21. Cruzat, V.F.; Keane, K.N.; Scheinpflug, A.L.; Cordeiro, R.; Soares, M.J.; Newsholme, P. Alanyl-glutamine
improves pancreatic beta-cell function following ex vivo inflammatory challenge. J. Endocrinol. 2015, 224,
261–271. [CrossRef] [PubMed]
22. Krebs, H.A. Metabolism of amino-acids: The synthesis of glutamine from glutamic acid and ammonia, and
the enzymic hydrolysis of glutamine in animal tissues. Biochem. J. 1935, 29, 1951–1969. [CrossRef] [PubMed]
23. Neu, J.; Shenoy, V.; Chakrabarti, R. Glutamine nutrition and metabolism: Where do we go from here?
FASEB J. 1996, 10, 829–837. [CrossRef] [PubMed]
24. Holecek, M. Branched-chain amino acids in health and disease: Metabolism, alterations in blood plasma,
and as supplements. Nutr. Metab. 2018, 15, 33. [CrossRef] [PubMed]
25. Altman, B.J.; Stine, Z.E.; Dang, C.V. From krebs to clinic: Glutamine metabolism to cancer therapy. Nat. Rev.
Cancer 2016, 16, 619–634. [CrossRef] [PubMed]
26. Kao, C.; Hsu, J.; Bandi, V.; Jahoor, F. Alterations in glutamine metabolism and its conversion to citrulline in
sepsis. Am. J. Physiol. Endocrinol. Metab. 2013, 304, E1359–E1364. [CrossRef] [PubMed]
27. Rogero, M.M.; Borges, M.C.; Pires, I.S.D.; Borelli, P.; Tirapegui, J. Ffect of glutamine supplementation
and in vivo infection with mycobacterium bovis (bacillus calmette-guerin) in the function of peritoneal
macrophages in early weaned mice. Ann. Nutr. Metab. 2007, 51, 173–174.
28. Karinch, A.M.; Pan, M.; Lin, C.M.; Strange, R.; Souba, W.W. Glutamine metabolism in sepsis and infection.
J. Nutr. 2001, 131, 2531S–2550S. [CrossRef] [PubMed]
29. Leite, J.S.; Raizel, R.; Hypolito, T.M.; Rosa, T.D.; Cruzat, V.F.; Tirapegui, J. L-glutamine and l-alanine
supplementation increase glutamine-glutathione axis and muscle hsp-27 in rats trained using a progressive
high-intensity resistance exercise. Appl. Physiol. Nutr. Metab. 2016, 41, 842–849. [CrossRef] [PubMed]
30. Cruzat, V.F.; Rogero, M.M.; Tirapegui, J. Effects of supplementation with free glutamine and the dipeptide
alanyl-glutamine on parameters of muscle damage and inflammation in rats submitted to prolonged exercise.
Cell Biochem. Funct. 2010, 28, 24–30. [CrossRef] [PubMed]
31. Curi, R.; Lagranha, C.J.; Doi, S.Q.; Sellitti, D.F.; Procopio, J.; Pithon-Curi, T.C. Glutamine-dependent changes
in gene expression and protein activity. Cell Biochem. Funct. 2005, 23, 77–84. [CrossRef] [PubMed]
172
Nutrients 2018, 10, 1564
32. Djoko, K.Y.; Phan, M.D.; Peters, K.M.; Walker, M.J.; Schembri, M.A.; McEwan, A.G. Interplay between
tolerance mechanisms to copper and acid stress in Escherichia coli. Proc. Nat. Acad. Sci. USA 2017, 114,
6818–6823. [CrossRef] [PubMed]
33. Wernerman, J. Feeding the gut: How, when and with what—The metabolic issue. Curr. Opin. Crit. Care 2014,
20, 196–201. [CrossRef] [PubMed]
34. Beutheu, S.; Ouelaa, W.; Guerin, C.; Belmonte, L.; Aziz, M.; Tennoune, N.; Bole-Feysot, C.; Galas, L.;
Dechelotte, P.; Coeffier, M. Glutamine supplementation, but not combined glutamine and arginine
supplementation, improves gut barrier function during chemotherapy-induced intestinal mucositis in
rats. Clin. Nutr. 2014, 33, 694–701. [CrossRef] [PubMed]
35. Souba, W.W.; Smith, R.J.; Wilmore, D.W. Glutamine metabolism by the intestinal tract. J. Parenter. Enter. Nutr.
1985, 9, 608–617. [CrossRef] [PubMed]
36. Holecek, M. Side effects of long-term glutamine supplementation. J. Parenter. Enter. Nutr. 2013, 37, 607–616.
[CrossRef] [PubMed]
37. Kim, M.H.; Kim, H. The roles of glutamine in the intestine and its implication in intestinal diseases. Int. J.
Mol. Sci. 2017, 18, 1051. [CrossRef] [PubMed]
38. Souba, W.W.; Herskowitz, K.; Salloum, R.M.; Chen, M.K.; Austgen, T.R. Gut glutamine metabolism. J. Parenter.
Enter. Nutr. 1990, 14, 45S–50S. [CrossRef] [PubMed]
39. Cruzat, V.F.; Bittencourt, A.; Scomazzon, S.P.; Leite, J.S.; de Bittencourt, P.I.H.; Tirapegui, J. Oral free and
dipeptide forms of glutamine supplementation attenuate oxidative stress and inflammation induced by
endotoxemia. Nutrition 2014, 30, 602–611. [CrossRef] [PubMed]
40. Aosasa, S.; Wells-Byrum, D.; Alexander, J.W.; Ogle, C.K. Influence of glutamine-supplemented caco-2 cells
on cytokine production of mononuclear cells. J. Parenter. Enter. Nutr. 2003, 27, 333–339. [CrossRef] [PubMed]
41. Coeffier, M.; Claeyssens, S.; Hecketsweiler, B.; Lavoinne, A.; Ducrotte, P.; Dechelotte, P. Enteral glutamine
stimulates protein synthesis and decreases ubiquitin mRNA level in human gut mucosa. Am. J. Physiol.
Gastrointest. Liver Physiol. 2003, 285, G266–G273. [CrossRef] [PubMed]
42. Jobin, C.; Hellerbrand, C.; Licato, L.L.; Brenner, D.A.; Sartor, R.B. Mediation by nf-kappa b of cytokine
induced expression of intercellular adhesion molecule 1 (icam-1) in an intestinal epithelial cell line, a process
blocked by proteasome inhibitors. Gut 1998, 42, 779–787. [CrossRef] [PubMed]
43. Coeffier, M.; Miralles-Barrachina, O.; Le Pessot, F.; Lalaude, O.; Daveau, M.; Lavoinne, A.; Lerebours, E.;
Dechelotte, P. Influence of glutamine on cytokine production by human gut in vitro. Cytokine 2001, 13,
148–154. [CrossRef] [PubMed]
44. Tirapegui, J.; Cruzat, V. Glutamine and skeletal muscle. In Glutamine in Clinical Nutrition; Rajendram, R.,
Preedy, V.R., Patel, V.B., Eds.; Springer: New York, NY, USA, 2015; pp. 499–511.
45. Cruzat, V.F.; Tirapegui, J. Effects of oral supplementation with glutamine and alanyl-glutamine on glutamine,
glutamate, and glutathione status in trained rats and subjected to long-duration exercise. Nutrition 2009, 25,
428–435. [CrossRef] [PubMed]
46. Walsh, N.P.; Blannin, A.K.; Robson, P.J.; Gleeson, M. Glutamine, exercise and immune function. Links and
possible mechanisms. Sports Med. 1998, 26, 177–191. [CrossRef] [PubMed]
47. Rowbottom, D.G.; Keast, D.; Morton, A.R. The emerging role of glutamine as an indicator of exercise stress
and overtraining. Sports Med. 1996, 21, 80–97. [CrossRef] [PubMed]
48. Curi, R.; Newsholme, P.; Procopio, J.; Lagranha, C.; Gorjao, R.; Pithon-Curi, T.C. Glutamine, gene expression,
and cell function. Front. Biosci. 2007, 12, 344–357. [CrossRef] [PubMed]
49. Rogero, M.M.; Tirapegui, J.; Pedrosa, R.G.; de Castro, I.A.; Pires, I.S.D. Effect of alanyl-glutamine
supplementation on plasma and tissue glutamine concentrations in rats submitted to exhaustive exercise.
Nutrition 2006, 22, 564–571. [CrossRef] [PubMed]
50. Rogero, M.M.; Tirapegui, J.; Pedrosa, R.G.; Pires, I.S.D.; de Castro, I.A. Plasma and tissue glutamine response
to acute and chronic supplementation with l-glutamine and l-alanyl-l-glutamine in rats. Nutr. Res. 2004, 24,
261–270. [CrossRef]
51. Wagenmakers, A.J. Muscle amino acid metabolism at rest and during exercise: Role in human physiology
and metabolism. Exerc. Sport Sci. Rev. 1998, 26, 287–314. [CrossRef] [PubMed]
52. Goldberg, A.L.; Chang, T.W. Regulation and significance of amino acid metabolism in skeletal muscle.
Fed. Proc. 1978, 37, 2301–2307. [PubMed]
173
Nutrients 2018, 10, 1564
53. Petry, E.R.; Cruzat, V.F.; Heck, T.G.; Leite, J.S.; Homem de Bittencourt, P.I.H.; Tirapegui, J. Alanyl-glutamine
and glutamine plus alanine supplements improve skeletal redox status in trained rats: Involvement of heat
shock protein pathways. Life Sci. 2014, 94, 130–136. [CrossRef] [PubMed]
54. Nieman, D.C.; Pedersen, B.K. Exercise and immune function. Recent developments. Sports Med. 1999, 27,
73–80. [CrossRef] [PubMed]
55. Anderson, P.M.; Broderius, M.A.; Fong, K.C.; Tsui, K.N.; Chew, S.F.; Ip, Y.K. Glutamine synthetase expression
in liver, muscle, stomach and intestine of bostrichthys sinensis in response to exposure to a high exogenous
ammonia concentration. J. Exp. Biol. 2002, 205, 2053–2065. [PubMed]
56. Austgen, T.R.; Chakrabarti, R.; Chen, M.K.; Souba, W.W. Adaptive regulation in skeletal muscle glutamine
metabolism in endotoxin-treated rats. J. Trauma 1992, 32, 600–607. [CrossRef] [PubMed]
57. Labow, B.I.; Souba, W.W.; Abcouwer, S.F. Glutamine synthetase expression in muscle is regulated by
transcriptional and posttranscriptional mechanisms. Am. J. Physiol. 1999, 276, E1136–E1145. [CrossRef]
[PubMed]
58. Xia, Y.; Wen, H.Y.; Young, M.E.; Guthrie, P.H.; Taegtmeyer, H.; Kellems, R.E. Mammalian target of rapamycin
and protein kinase a signaling mediate the cardiac transcriptional response to glutamine. J. Biolog. Chem.
2003, 278, 13143–13150. [CrossRef] [PubMed]
59. Galley, H.F. Oxidative stress and mitochondrial dysfunction in sepsis. Br. J. Anaesth. 2011, 107, 57–64.
[CrossRef] [PubMed]
60. Bode, B.P. Recent molecular advances in mammalian glutamine transport. J. Nutr. 2001, 131, 2475S–2486S.
[CrossRef] [PubMed]
61. Haussinger, D.; Schliess, F. Glutamine metabolism and signaling in the liver. Front. Biosci. 2007, 12, 371–391.
[CrossRef] [PubMed]
62. McGivan, J.D.; Bradford, N.M. Characteristics of the activation of glutaminase by ammonia in sonicated rat
liver mitochondria. Biochim. Biophys. Acta 1983, 759, 296–302. [CrossRef]
63. Hoek, J.B.; Charles, R.; De Haan, E.J.; Tager, J.M. Glutamate oxidation in rat-liver homogenate.
Biochim. Biophys. Acta 1969, 172, 407–416. [CrossRef]
64. Halestrap, A.P. The regulation of the matrix volume of mammalian mitochondria in vivo and in vitro and its
role in the control of mitochondrial metabolism. Biochim. Biophys. Acta 1989, 973, 355–382. [CrossRef]
65. Brosnan, J.T.; Brosnan, M.E. Hepatic glutaminase—A special role in urea synthesis? Nutrition 2002, 18,
455–457. [CrossRef]
66. Meijer, A.J.; Verhoeven, A.J. Regulation of hepatic glutamine metabolism. Biochem. Soc. Trans. 1986, 14,
1001–1004. [CrossRef] [PubMed]
67. Watford, M.; Smith, E.M. Distribution of hepatic glutaminase activity and mRNA in perivenous and
periportal rat hepatocytes. Biochem. J. 1990, 267, 265–267. [CrossRef] [PubMed]
68. Moorman, A.F.; de Boer, P.A.; Watford, M.; Dingemanse, M.A.; Lamers, W.H. Hepatic glutaminase mRNA
is confined to part of the urea cycle domain in the adult rodent liver lobule. FEBS Lett. 1994, 356, 76–80.
[CrossRef]
69. Gebhardt, R.; Mecke, D. Heterogeneous distribution of glutamine synthetase among rat liver parenchymal
cells in situ and in primary culture. EMBO J. 1983, 2, 567–570. [CrossRef] [PubMed]
70. Häussinger, D.; Soboll, S.; Meijer, A.J.; Gerok, W.; Tager, J.M.; Sies, H. Role of plasma membrane transport in
hepatic glutamine metabolism. Eur. J. Biochem. 1985, 152, 597–603. [CrossRef] [PubMed]
71. Lenzen, C.; Soboll, S.; Sies, H.; Haussinger, D. Ph control of hepatic glutamine degradation. Role of transport.
Eur. J. Biochem. 1987, 166, 483–488. [CrossRef] [PubMed]
72. Häussinger, D.; Hallbrucker, C.; Saha, N.; Lang, F.; Gerok, W. Cell volume and bile acid excretion. Biochem. J.
1992, 288, 681–689. [CrossRef] [PubMed]
73. Haussinger, D.; Lang, F. Cell volume in the regulation of hepatic function: A mechanism for metabolic
control. Biochim. Biophys. Acta 1991, 1071, 331–350. [CrossRef]
74. Gustafson, L.A.; Jumelle-Laclau, M.N.; van Woerkom, G.M.; van Kuilenburg, A.B.P.; Meijer, A.J. Cell
swelling and glycogen metabolism in hepatocytes from fasted rats. Biochim. Biophys. Acta 1997, 1318,
184–190. [CrossRef]
75. Baquet, A.; Gaussin, V.; Bollen, M.; Stalmans, W.; Hue, L. Mechanism of activation of liver acetyl-coa
carboxylase by cell swelling. Eur. J. Biochem. 1993, 217, 1083–1089. [CrossRef] [PubMed]
174
Nutrients 2018, 10, 1564
76. Vom Dahl, S.; Dombrowski, F.; Schmitt, M.; Schliess, F.; Pfeifer, U.; Häussinger, D. Cell hydration controls
autophagosome formation in rat liver in a microtubule-dependent way downstream from p38mapk
activation. Biochem. J. 2001, 354, 31–36. [CrossRef] [PubMed]
77. Vom Dahl, S.; Haussinger, D. Nutritional state and the swelling-induced inhibition of proteolysis in perfused
rat liver. J. Nutr. 1996, 126, 395–402. [CrossRef] [PubMed]
78. Häussinger, D.; Kubitz, R.; Reinehr, R.; Bode, J.G.; Schliess, F. Molecular aspects of medicine:
From experimental to clinical hepatology. Mol. Asp. Med. 2004, 25, 221–360. [CrossRef] [PubMed]
79. Jansen, L.T.; Adams, J.; Johnson, E.C.; Kavouras, S.A. Effects of cellular dehydration on glucose regulation in
healthy males—A pilot study. FASEB J. 2017, 31, 1014-2.
80. Friedman, S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol.
Chem. 2000, 275, 2247–2250. [CrossRef] [PubMed]
81. Ghazwani, M.; Zhang, Y.; Gao, X.; Fan, J.; Li, J.; Li, S. Anti-fibrotic effect of thymoquinone on hepatic stellate
cells. Phytomedicine 2014, 21, 254–260. [CrossRef] [PubMed]
82. Li, J.; Ghazwani, M.; Liu, K.; Huang, Y.; Chang, N.; Fan, J.; He, F.; Li, L.; Bu, S.; Xie, W.; et al. Regulation of
hepatic stellate cell proliferation and activation by glutamine metabolism. PLoS ONE 2017, 12, e0182679.
[CrossRef] [PubMed]
83. Lin, Z.; Cai, F.; Lin, N.; Ye, J.; Zheng, Q.; Ding, G. Effects of glutamine on oxidative stress and nuclear
factor-κb expression in the livers of rats with nonalcoholic fatty liver disease. Exp. Ther. Med. 2014, 7,
365–370. [CrossRef] [PubMed]
84. Sellmann, C.; Baumann, A.; Brandt, A.; Jin, C.J.; Nier, A.; Bergheim, I. Oral supplementation of glutamine
attenuates the progression of nonalcoholic steatohepatitis in c57bl/6j mice. J. Nutr. 2017, 147, 2041–2049.
[CrossRef] [PubMed]
85. Magalhaes, C.R.; Malafaia, O.; Torres, O.J.; Moreira, L.B.; Tefil, S.C.; Pinherio Mda, R.; Harada, B.A. Liver
regeneration with l-glutamine supplemented diet: Experimental study in rats. Rev. Col. Bras. Cir. 2014, 41,
117–121. [CrossRef] [PubMed]
86. Helling, G.; Wahlin, S.; Smedberg, M.; Pettersson, L.; Tjäder, I.; Norberg, Å.; Rooyackers, O.; Wernerman, J.
Plasma glutamine concentrations in liver failure. PLoS ONE 2016, 11, e0150440. [CrossRef] [PubMed]
87. Eagle, H.; Oyama, V.I.; Levy, M.; Horton, C.L.; Fleischman, R. Growth response of mammalian cells in tissue
culture to l-glutamine and l-glutamic acid. J. Biol. Chem. 1956, 218, 607–616. [PubMed]
88. Newsholme, P.; Curi, R.; Gordon, S.; Newsholme, E.A. Metabolism of glucose, glutamine, long-chain
fatty-acids and ketone-bodies by murine macrophages. Biochem. J. 1986, 239, 121–125. [CrossRef] [PubMed]
89. Newsholme, E.A.; Newsholme, P.; Curi, R. The role of the citric acid cycle in cells of the immune system and
its importance in sepsis, trauma and burns. Biochem. Soc. Symp. 1987, 54, 145–162. [PubMed]
90. Curi, R.; Newsholme, P.; Newsholme, E.A. Intracellular-distribution of some enzymes of the glutamine
utilization pathway in rat lymphocytes. Biochem. Biophys. Res. Commun. 1986, 138, 318–322. [CrossRef]
91. Curi, T.C.P.; de Melo, M.P.; de Azevedo, R.B.; Curi, R. Glutamine utilisation by rat neutrophils. Biochem. Soc.
Trans. 1997, 25, 249S. [CrossRef] [PubMed]
92. Curi, T.C.P.; DeMelo, M.P.; DeAzevedo, R.B.; Zorn, T.M.T.; Curi, R. Glutamine utilization by rat neutrophils:
Presence of phosphate-dependent glutaminase. Am. J. Physiol. Cell Physiol. 1997, 273, C1124–C1129.
[CrossRef]
93. Oudemans-van Straaten, H.M.; Bosman, R.J.; Treskes, M.; van der Spoel, H.J.; Zandstra, D.F. Plasma
glutamine depletion and patient outcome in acute icu admissions. Intensiv. Care Med. 2001, 27, 84–90.
[CrossRef]
94. Leite, J.S.M.; Cruzat, V.F.; Krause, M.; Homem de Bittencourt, P.I. Physiological regulation of the heat shock
response by glutamine: Implications for chronic low-grade inflammatory diseases in age-related conditions.
Nutrire 2016, 41, 17. [CrossRef]
95. Roth, E.; Oehler, R.; Manhart, N.; Exner, R.; Wessner, B.; Strasser, E.; Spittler, A. Regulative potential of
glutamine—Relation to glutathione metabolism. Nutrition 2002, 18, 217–221. [CrossRef]
96. Hiscock, N.; Petersen, E.W.; Krzywkowski, K.; Boza, J.; Halkjaer-Kristensen, J.; Pedersen, B.K. Glutamine
supplementation further enhances exercise-induced plasma il-6. J. Appl. Physiol. 2003, 95, 145–148. [CrossRef]
[PubMed]
97. Mills, E.L.; Kelly, B.; O’Neill, L.A.J. Mitochondria are the powerhouses of immunity. Nat. Immunol. 2017, 18,
488–498. [CrossRef] [PubMed]
175
Nutrients 2018, 10, 1564
98. Pithon-Curi, T.C.; De Melo, M.P.; Curi, R. Glucose and glutamine utilization by rat lymphocytes, monocytes
and neutrophils in culture: A comparative study. Cell Biochem. Funct. 2004, 22, 321–326. [CrossRef] [PubMed]
99. Pithon-Curi, T.C.; Trezena, A.G.; Tavares-Lima, W.; Curi, R. Evidence that glutamine is involved in neutrophil
function. Cell Biochem. Funct. 2002, 20, 81–86. [CrossRef] [PubMed]
100. Branzk, N.; Lubojemska, A.; Hardison, S.E.; Wang, Q.; Gutierrez, M.G.; Brown, G.D.; Papayannopoulos, V.
Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large
pathogens. Nat. Immunol. 2014, 15, 1017–1025. [CrossRef] [PubMed]
101. Pithon-Curi, T.C.; Levada, A.C.; Lopes, L.R.; Doi, S.Q.; Curi, R. Glutamine plays a role in superoxide
production and the expression of p47(phox), p22(phox) and gp91(phox) in rat neutrophils. Clin. Sci. 2002,
103, 403–408. [CrossRef] [PubMed]
102. Garcia, C.; Pithon-Curi, T.C.; de Lourdes Firmano, M.; Pires de Melo, M.; Newsholme, P.; Curi, R. Effects of
adrenaline on glucose and glutamine metabolism and superoxide production by rat neutrophils. Clin. Sci.
1999, 96, 549–555. [CrossRef] [PubMed]
103. Newsholme, P.; Costa Rosa, L.F.; Newsholme, E.A.; Curi, R. The importance of fuel metabolism to
macrophage function. Cell Biochem. Funct. 1996, 14, 1–10. [CrossRef] [PubMed]
104. Peres, C.M.; Procopio, J.; Costa, M.; Curi, R. Thioglycolate-elicited rat macrophages exhibit alterations in
incorporation and oxidation of fatty acids. Lipids 1999, 34, 1193–1197. [CrossRef] [PubMed]
105. Costa Rosa, L.F.; Safi, D.A.; Curi, R. Effect of thioglycollate and bcg stimuli on glucose and glutamine
metabolism in rat macrophages. J. Leukoc. Biol. 1994, 56, 10–14. [PubMed]
106. Nagy, C.; Haschemi, A. Time and demand are two critical dimensions of immunometabolism: The process
of macrophage activation and the pentose phosphate pathway. Front. Immunol. 2015, 6, 164. [CrossRef]
[PubMed]
107. Langston, P.K.; Shibata, M.; Horng, T. Metabolism supports macrophage activation. Front. Immunol. 2017, 8,
61. [CrossRef] [PubMed]
108. Vergadi, E.; Ieronymaki, E.; Lyroni, K.; Vaporidi, K.; Tsatsanis, C. Akt signaling pathway in macrophage
activation and m1/m2 polarization. J. Immunol. 2017, 198, 1006–1014. [CrossRef] [PubMed]
109. Martinez, F.O.; Sica, A.; Mantovani, A.; Locati, M. Macrophage activation and polarization. Front. Biosci.
2008, 13, 453–461. [CrossRef] [PubMed]
110. Gordon, S.; Taylor, P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5, 953–964.
[CrossRef] [PubMed]
111. Gordon, S.; Martinez, F.O. Alternative activation of macrophages: Mechanism and functions. Immunity 2010,
32, 593–604. [CrossRef] [PubMed]
112. Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008,
8, 958–969. [CrossRef] [PubMed]
113. O’Neill, L.A.; Pearce, E.J. Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med.
2016, 213, 15–23. [CrossRef] [PubMed]
114. Namgaladze, D.; Brune, B. Fatty acid oxidation is dispensable for human macrophage il-4-induced
polarization. Biochim. Biophys. Acta 2014, 1841, 1329–1335. [CrossRef] [PubMed]
115. O’Neill, L.A. A broken krebs cycle in macrophages. Immunity 2015, 42, 393–394. [CrossRef] [PubMed]
116. Warburg, O.; Wind, F.; Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8, 519–530.
[CrossRef] [PubMed]
117. Palsson-McDermott, E.M.; Curtis, A.M.; Goel, G.; Lauterbach, M.A.; Sheedy, F.J.; Gleeson, L.E.;
van den Bosch, M.W.; Quinn, S.R.; Domingo-Fernandez, R.; Johnston, D.G.; et al. Pyruvate kinase M2
regulates hif-1alpha activity and il-1beta induction and is a critical determinant of the warburg effect in
lps-activated macrophages. Cell Metab. 2015, 21, 65–80. [CrossRef] [PubMed]
118. Oren, R.; Farnham, A.E.; Saito, K.; Milofsky, E.; Karnovsky, M.L. Metabolic patterns in three types of
phagocytizing cells. J. Cell Biol. 1963, 17, 487–501. [CrossRef] [PubMed]
119. Tannahill, G.M.; Curtis, A.M.; Adamik, J.; Palsson-McDermott, E.M.; McGettrick, A.F.; Goel, G.; Frezza, C.;
Bernard, N.J.; Kelly, B.; Foley, N.H.; et al. Succinate is an inflammatory signal that induces il-1β through
hif-1α. Nature 2013, 496, 238–242. [CrossRef] [PubMed]
176
Nutrients 2018, 10, 1564
120. Jha, A.K.; Huang, S.C.; Sergushichev, A.; Lampropoulou, V.; Ivanova, Y.; Loginicheva, E.; Chmielewski, K.;
Stewart, K.M.; Ashall, J.; Everts, B.; et al. Network integration of parallel metabolic and transcriptional data
reveals metabolic modules that regulate macrophage polarization. Immunity 2015, 42, 419–430. [CrossRef]
[PubMed]
121. Davies, L.C.; Rice, C.M.; Palmieri, E.M.; Taylor, P.R.; Kuhns, D.B.; McVicar, D.W. Peritoneal tissue-resident
macrophages are metabolically poised to engage microbes using tissue-niche fuels. Nat. Commun. 2017, 8,
2074. [CrossRef] [PubMed]
122. Liu, P.S.; Wang, H.; Li, X.; Chao, T.; Teav, T.; Christen, S.; Di Conza, G.; Cheng, W.C.; Chou, C.H.;
Vavakova, M.; et al. Alpha-ketoglutarate orchestrates macrophage activation through metabolic and
epigenetic reprogramming. Nat. Immunol. 2017, 18, 985–994. [PubMed]
123. Nelson, V.L.; Nguyen, H.C.B.; Garcia-Canaveras, J.C.; Briggs, E.R.; Ho, W.Y.; DiSpirito, J.R.; Marinis, J.M.;
Hill, D.A.; Lazar, M.A. Ppargamma is a nexus controlling alternative activation of macrophages via glutamine
metabolism. Gen. Dev. 2018, 32, 1035–1044. [CrossRef] [PubMed]
124. Greiner, E.F.; Guppy, M.; Brand, K. Glucose is essential for proliferation and the glycolytic enzyme induction
that provokes a transition to glycolytic energy production. J. Biol. Chem. 1994, 269, 31484–31490. [PubMed]
125. Newsholme, E.A.; Crabtree, B.; Ardawi, M.S. Glutamine metabolism in lymphocytes: Its biochemical,
physiological and clinical importance. Q. J. Exp. Physiol. 1985, 70, 473–489. [CrossRef] [PubMed]
126. Curi, R.; Newsholme, P.; Newsholme, E.A. Metabolism of pyruvate by isolated rat mesenteric lymphocytes,
lymphocyte mitochondria and isolated mouse macrophages. Biochem. J. 1988, 250, 383–388. [CrossRef]
[PubMed]
127. Maciolek, J.A.; Pasternak, J.A.; Wilson, H.L. Metabolism of activated t lymphocytes. Curr. Opin. Immunol.
2014, 27, 60–74. [CrossRef] [PubMed]
128. Tripmacher, R.; Gaber, T.; Dziurla, R.; Haupl, T.; Erekul, K.; Grutzkau, A.; Tschirschmann, M.; Scheffold, A.;
Radbruch, A.; Burmester, G.R.; et al. Human cd4(+) T cells maintain specific functions even under conditions
of extremely restricted ATP production. Eur. J. Immunol. 2008, 38, 1631–1642. [CrossRef] [PubMed]
129. Wieman, H.L.; Wofford, J.A.; Rathmell, J.C. Cytokine stimulation promotes glucose uptake via
phosphatidylinositol-3 kinase/akt regulation of glut1 activity and trafficking. Mol. Biol. Cell 2007, 18,
1437–1446. [CrossRef] [PubMed]
130. Delgoffe, G.M.; Kole, T.P.; Zheng, Y.; Zarek, P.E.; Matthews, K.L.; Xiao, B.; Worley, P.F.; Kozma, S.C.;
Powell, J.D. The mtor kinase differentially regulates effector and regulatory T cell lineage commitment.
Immunity 2009, 30, 832–844. [CrossRef] [PubMed]
131. Lee, K.; Gudapati, P.; Dragovic, S.; Spencer, C.; Joyce, S.; Killeen, N.; Magnuson, M.A.; Boothby, M.
Mammalian target of rapamycin protein complex 2 regulates differentiation of th1 and th2 cell subsets
via distinct signaling pathways. Immunity 2010, 32, 743–753. [CrossRef] [PubMed]
132. Michalek, R.D.; Gerriets, V.A.; Jacobs, S.R.; Macintyre, A.N.; MacIver, N.J.; Mason, E.F.; Sullivan, S.A.;
Nichols, A.G.; Rathmell, J.C. Cutting edge: Distinct glycolytic and lipid oxidative metabolic programs
are essential for effector and regulatory cd4+ T cell subsets. J. Immunol. 2011, 186, 3299–3303. [CrossRef]
[PubMed]
133. Hardie, D.G.; Hawley, S.A.; Scott, J.W. Amp-activated protein kinas—Development of the energy sensor
concept. J. Physiol. 2006, 574, 7–15. [CrossRef] [PubMed]
134. Crawford, J.; Cohen, H.J. The essential role of l-glutamine in lymphocyte differentiation in vitro. J. Cell.
Physiol. 1985, 124, 275–282. [CrossRef] [PubMed]
135. Matarese, G.; Colamatteo, A.; De Rosa, V. Metabolic fuelling of proper t cell functions. Immunol. Lett. 2014,
161, 174–178. [CrossRef] [PubMed]
136. Chang, C.H.; Curtis, J.D.; Maggi, L.B., Jr.; Faubert, B.; Villarino, A.V.; O’Sullivan, D.; Huang, S.C.;
van der Windt, G.J.; Blagih, J.; Qiu, J.; et al. Posttranscriptional control of t cell effector function by aerobic
glycolysis. Cell 2013, 153, 1239–1251. [CrossRef] [PubMed]
137. Zheng, Y.; Delgoffe, G.M.; Meyer, C.F.; Chan, W.; Powell, J.D. Anergic T cells are metabolically anergic.
J. Immunol. 2009, 183, 6095–6101. [CrossRef] [PubMed]
138. Buck, M.D.; O’Sullivan, D.; Klein Geltink, R.I.; Curtis, J.D.; Chang, C.H.; Sanin, D.E.; Qiu, J.; Kretz, O.;
Braas, D.; van der Windt, G.J.; et al. Mitochondrial dynamics controls T cell fate through metabolic
programming. Cell 2016, 166, 63–76. [CrossRef] [PubMed]
177
Nutrients 2018, 10, 1564
139. Corcoran, S.E.; O’Neill, L.A. Hif1alpha and metabolic reprogramming in inflammation. J. Clin. Investig. 2016,
126, 3699–3707. [CrossRef] [PubMed]
140. Araujo, L.; Khim, P.; Mkhikian, H.; Mortales, C.L.; Demetriou, M. Glycolysis and glutaminolysis
cooperatively control T cell function by limiting metabolite supply to n-glycosylation. eLife 2017, 6, e21330.
[CrossRef] [PubMed]
141. Hesterberg, R.S.; Cleveland, J.L.; Epling-Burnette, P.K. Role of polyamines in immune cell functions. Med. Sci.
2018, 6, 22. [CrossRef] [PubMed]
142. Calder, P.C.; Yaqoob, P. Glutamine and the immune system. Amino Acids 1999, 17, 227–241. [CrossRef]
[PubMed]
143. Wilmore, D.W.; Shabert, J.K. Role of glutamine in immunologic responses. Nutrition 1998, 14, 618–626.
[CrossRef]
144. Lagranha, C.J.; Hirabara, S.M.; Curi, R.; Pithon-Curi, T.C. Glutamine supplementation prevents
exercise-induced neutrophil apoptosis and reduces p38 mapk and jnk phosphorylation and p53 and caspase
3 expression. Cell Biochem. Funct. 2007, 25, 563–569. [CrossRef] [PubMed]
145. Young, V.R.; Ajami, A.M. Glutamine: The emperor or his clothes? J. Nutr. 2001, 131, 2447S–2486S. [CrossRef]
[PubMed]
146. Meister, A.; Anderson, M.E. Glutathione. Ann. Rev. Biochem. 1983, 52, 711–760. [CrossRef] [PubMed]
147. Gaucher, C.; Boudier, A.; Bonetti, J.; Clarot, I.; Leroy, P.; Parent, M. Glutathione: Antioxidant properties
dedicated to nanotechnologies. Antioxidants 2018, 7, 62. [CrossRef] [PubMed]
148. Liu, N.; Ma, X.; Luo, X.; Zhang, Y.; He, Y.; Dai, Z.; Yang, Y.; Wu, G.; Wu, Z. L-glutamine attenuates apoptosis
in porcine enterocytes by regulating glutathione-related redox homeostasis. J. Nutr. 2018, 148, 526–534.
[CrossRef] [PubMed]
149. Da Silva Lima, F.; Rogero, M.M.; Ramos, M.C.; Borelli, P.; Fock, R.A. Modulation of the nuclear factor-kappa
b (nf-kappab) signalling pathway by glutamine in peritoneal macrophages of a murine model of protein
malnutrition. Eur. J. Nutr. 2013, 52, 1343–1351. [CrossRef] [PubMed]
150. Smedberg, M.; Wernerman, J. Is the glutamine story over? Crit. Care 2016, 20, 361. [CrossRef] [PubMed]
151. Heck, T.G.; Scholer, C.M.; de Bittencourt, P.I. Hsp70 expression: Does it a novel fatigue signalling factor from
immune system to the brain? Cell Biochem. Funct. 2011, 29, 215–226. [CrossRef] [PubMed]
152. Singleton, K.D.; Wischmeyer, P.E. Glutamine’s protection against sepsis and lung injury is dependent on heat
shock protein 70 expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292, R1839–R1845. [CrossRef]
[PubMed]
153. Jordan, I.; Balaguer, M.; Esteban, M.E.; Cambra, F.J.; Felipe, A.; Hernandez, L.; Alsina, L.; Molero, M.;
Villaronga, M.; Esteban, E. Glutamine effects on heat shock protein 70 and interleukines 6 and 10:
Randomized trial of glutamine supplementation versus standard parenteral nutrition in critically ill children.
Clin. Nutr. 2016, 35, 34–40. [CrossRef] [PubMed]
154. Kim, G.; Meriin, A.B.; Gabai, V.L.; Christians, E.; Benjamin, I.; Wilson, A.; Wolozin, B.; Sherman, M.Y. The heat
shock transcription factor hsf1 is downregulated in DNA damage-associated senescence, contributing to the
maintenance of senescence phenotype. Aging Cell 2012, 11, 617–627. [CrossRef] [PubMed]
155. Gabai, V.L.; Meng, L.; Kim, G.; Mills, T.A.; Benjamin, I.J.; Sherman, M.Y. Heat shock transcription factor hsf1
is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein
HUR. Mol. Cell. Biol. 2012, 32, 929–940. [CrossRef] [PubMed]
156. Dokladny, K.; Zuhl, M.N.; Mandell, M.; Bhattacharya, D.; Schneider, S.; Deretic, V.; Moseley, P.L. Regulatory
coordination between two major intracellular homeostatic systems: Heat shock response and autophagy.
J. Biolog. Chem. 2013, 288, 14959–14972. [CrossRef] [PubMed]
157. Martinez, M.R.; Dias, T.B.; Natov, P.S.; Zachara, N.E. Stress-induced o-glcnacylation: An adaptive process of
injured cells. Biochem. Soc. Trans. 2017, 45, 237–249. [CrossRef] [PubMed]
158. Lafontaine-Lacasse, M.; Dore, G.; Picard, F. Hexosamines stimulate apoptosis by altering sirt1 action and
levels in rodent pancreatic beta-cells. J. Endoc. 2011, 208, 41–49. [CrossRef] [PubMed]
159. Kazemi, Z.; Chang, H.; Haserodt, S.; McKen, C.; Zachara, N.E. O-linked beta-n-acetylglucosamine (o-glcnac)
regulates stress-induced heat shock protein expression in a gsk-3beta-dependent manner. J. Biol. Chem. 2010,
285, 39096–39107. [CrossRef] [PubMed]
178
Nutrients 2018, 10, 1564
160. Hamiel, C.R.; Pinto, S.; Hau, A.; Wischmeyer, P.E. Glutamine enhances heat shock protein 70 expression
via increased hexosamine biosynthetic pathway activity. Am. J. Physiol. Cell Physiol. 2009, 297, C1509–1519.
[CrossRef] [PubMed]
161. Singleton, K.D.; Serkova, N.; Beckey, V.E.; Wischmeyer, P.E. Glutamine attenuates lung injury and improves
survival after sepsis: Role of enhanced heat shock protein expression. Crit. Care Med. 2005, 33, 1206–1213.
[CrossRef] [PubMed]
162. Raizel, R.; Leite, J.S.; Hypolito, T.M.; Coqueiro, A.Y.; Newsholme, P.; Cruzat, V.F.; Tirapegui, J.
Determination of the anti-inflammatory and cytoprotective effects of l-glutamine and l-alanine, or dipeptide,
supplementation in rats submitted to resistance exercise. Br. J. Nutr. 2016, 116, 470–479. [CrossRef] [PubMed]
163. Smolka, M.B.; Zoppi, C.C.; Alves, A.A.; Silveira, L.R.; Marangoni, S.; Pereira-Da-Silva, L.; Novello, J.C.;
Macedo, D.V. Hsp72 as a complementary protection against oxidative stress induced by exercise in the soleus
muscle of rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279, R1539–R1545. [CrossRef] [PubMed]
164. Gupta, A.; Cooper, Z.A.; Tulapurkar, M.E.; Potla, R.; Maity, T.; Hasday, J.D.; Singh, I.S. Toll-like receptor
agonists and febrile range hyperthermia synergize to induce heat shock protein 70 expression and
extracellular release. J. Biolog. Chem. 2013, 288, 2756–2766. [CrossRef] [PubMed]
165. Krause, M.; Keane, K.; Rodrigues-Krause, J.; Crognale, D.; Egan, B.; De Vito, G.; Murphy, C.; Newsholme, P.
Elevated levels of extracellular heat-shock protein 72 (ehsp72) are positively correlated with insulin resistance
in vivo and cause pancreatic beta-cell dysfunction and death in vitro. Clin. Sci. 2014, 126, 739–752. [CrossRef]
[PubMed]
166. Lenders, C.M.; Liu, S.; Wilmore, D.W.; Sampson, L.; Dougherty, L.W.; Spiegelman, D.; Willett, W.C. Evaluation
of a novel food composition database that includes glutamine and other amino acids derived from gene
sequencing data. Eur. J. Clin. Nutr. 2009, 63, 1433–1439. [CrossRef] [PubMed]
167. Hermans, G.; Van den Berghe, G. Clinical review: Intensive care unit acquired weakness. Crit. Care 2015, 19,
274. [CrossRef] [PubMed]
168. Stehle, P.; Ellger, B.; Kojic, D.; Feuersenger, A.; Schneid, C.; Stover, J.; Scheiner, D.; Westphal, M. Glutamine
dipeptide-supplemented parenteral nutrition improves the clinical outcomes of critically ill patients:
A systematic evaluation of randomised controlled trials. Clin. Nutr. ESPEN 2017, 17, 75–85. [CrossRef]
[PubMed]
169. Gunst, J.; Vanhorebeek, I.; Thiessen, S.E.; Van den Berghe, G. Amino acid supplements in critically ill patients.
Pharmacol. Res. 2018, 130, 127–131. [CrossRef] [PubMed]
170. Furst, P.; Alteheld, B.; Stehle, P. Why should a single nutrient—Glutamine—Improve outcome?
The remarkable story of glutamine dipeptides. Clin. Nutr. Suppl. 2004, 1, 3–15. [CrossRef]
171. Grau, T.; Bonet, A.; Minambres, E.; Pineiro, L.; Irles, J.A.; Robles, A.; Acosta, J.; Herrero, I.; Palacios, V.;
Lopez, J.; et al. The effect of l-alanyl-l-glutamine dipeptide supplemented total parenteral nutrition on
infectious morbidity and insulin sensitivity in critically ill patients. Crit. Care Med. 2011, 39, 1263–1268.
[CrossRef] [PubMed]
172. Estivariz, C.F.; Griffith, D.P.; Luo, M.; Szeszycki, E.E.; Bazargan, N.; Dave, N.; Daignault, N.M.; Bergman, G.F.;
McNally, T.; Battey, C.H.; et al. Efficacy of parenteral nutrition supplemented with glutamine dipeptide
to decrease hospital infections in critically ill surgical patients. J. Parenter. Enter. Nutr. 2008, 32, 389–402.
[CrossRef] [PubMed]
173. Wang, Y.; Jiang, Z.M.; Nolan, M.T.; Jiang, H.; Han, H.R.; Yu, K.; Li, H.L.; Jie, B.; Liang, X.K. The impact of
glutamine dipeptide-supplemented parenteral nutrition on outcomes of surgical patients: A meta-analysis
of randomized clinical trials. J. Parenter. Enter. Nutr. 2010, 34, 521–529. [CrossRef] [PubMed]
174. Bollhalder, L.; Pfeil, A.M.; Tomonaga, Y.; Schwenkglenks, M. A systematic literature review and meta-analysis
of randomized clinical trials of parenteral glutamine supplementation. Clin. Nutr. 2013, 32, 213–223.
[CrossRef] [PubMed]
175. Dechelotte, P.; Hasselmann, M.; Cynober, L.; Allaouchiche, B.; Coeffier, M.; Hecketsweiler, B.; Merle, V.;
Mazerolles, M.; Samba, D.; Guillou, Y.M.; et al. L-alanyl-L-glutamine dipeptide-supplemented total parenteral
nutrition reduces infectious complications and glucose intolerance in critically ill patients: The french
controlled, randomized, double-blind, multicenter study. Crit. Care Med. 2006, 34, 598–604. [CrossRef]
[PubMed]
176. Weitzel, L.R.; Wischmeyer, P.E. Glutamine in critical illness: The time has come, the time is now. Crit. Care
Clin. 2010, 26, 515–525. [CrossRef] [PubMed]
179
Nutrients 2018, 10, 1564
177. Klassen, P.; Mazariegos, M.; Solomons, N.W.; Furst, P. The pharmacokinetic responses of humans to 20 g of
alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with
acute dengue fever. J. Nutr. 2000, 130, 177–182. [CrossRef] [PubMed]
178. Melis, G.C.; Boelens, P.G.; van der Sijp, J.R.; Popovici, T.; De Bandt, J.P.; Cynober, L.; van Leeuwen, P.A.
The feeding route (enteral or parenteral) affects the plasma response of the dipetide ala-gln and the amino
acids glutamine, citrulline and arginine, with the administration of ala-gln in preoperative patients. Br. J. Nutr.
2005, 94, 19–26. [CrossRef] [PubMed]
179. Krause, M.S.; de Bittencourt, P.I.H.J. Type 1 diabetes: Can exercise impair the autoimmune event?
The l-arginine/glutamine coupling hypothesis. Cell Biochem. Funct. 2008, 26, 406–433. [CrossRef] [PubMed]
180. Adibi, S.A. Regulation of expression of the intestinal oligopeptide transporter (pept-1) in health and disease.
Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285, G779–G788. [CrossRef] [PubMed]
181. Broer, S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol. Rev. 2008, 88,
249–286. [CrossRef] [PubMed]
182. Gilbert, E.R.; Wong, E.A.; Webb, K.E. Board-invited review: Peptide absorption and utilization: Implications
for animal nutrition and health. J. Anim. Sci. 2008, 86, 2135–2155. [CrossRef] [PubMed]
183. Petry, E.R.; Cruzat, V.F.; Heck, T.G.; de Bittencourt, P.I.H.; Tirapegui, J. L-glutamine supplementations
enhance liver glutamine-glutathione axis and heat shock factor-1 expression in endurance-exercise trained
rats. Int. J. Sport Nutr. Exerc. Metab. 2015, 25, 188–197. [CrossRef] [PubMed]
184. Alba-Loureiro, T.C.; Ribeiro, R.F.; Zorn, T.M.; Lagranha, C.J. Effects of glutamine supplementation on kidney
of diabetic rat. Amino Acids 2010, 38, 1021–1030. [CrossRef] [PubMed]
185. Cheng, T.; Sudderth, J.; Yang, C.; Mullen, A.R.; Jin, E.S.; Mates, J.M.; DeBerardinis, R.J. Pyruvate carboxylase
is required for glutamine-independent growth of tumor cells. Proc. Natl. Acad Sci. USA 2011, 108, 8674–8679.
[CrossRef] [PubMed]
186. Hensley, C.T.; Wasti, A.T.; DeBerardinis, R.J. Glutamine and cancer: Cell biology, physiology, and clinical
opportunities. J. Clin. Investig. 2013, 123, 3678–3684. [CrossRef] [PubMed]
187. Hensley, C.T.; Faubert, B.; Yuan, Q.; Lev-Cohain, N.; Jin, E.; Kim, J.; Jiang, L.; Ko, B.; Skelton, R.; Loudat, L.;
et al. Metabolic heterogeneity in human lung tumors. Cell 2016, 164, 681–694. [CrossRef] [PubMed]
188. Davidson, S.M.; Papagiannakopoulos, T.; Olenchock, B.A.; Heyman, J.E.; Keibler, M.A.; Luengo, A.;
Bauer, M.R.; Jha, A.K.; O’Brien, J.P.; Pierce, K.A.; et al. Environment impacts the metabolic dependencies of
ras-driven non-small cell lung cancer. Cell Metab. 2016, 23, 517–528. [CrossRef] [PubMed]
189. Choi, C.; Ganji, S.; Hulsey, K.; Madan, A.; Kovacs, Z.; Dimitrov, I.; Zhang, S.; Pichumani, K.; Mendelsohn, D.;
Mickey, B.; et al. A comparative study of short- and long-te (1) h mrs at 3 t for in vivo detection of
2-hydroxyglutarate in brain tumors. NMR Biomed. 2013, 26, 1242–1250. [CrossRef] [PubMed]
190. Tardito, S.; Oudin, A.; Ahmed, S.U.; Fack, F.; Keunen, O.; Zheng, L.; Miletic, H.; Sakariassen, P.O.;
Weinstock, A.; Wagner, A.; et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports
growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 2015, 17, 1556–1568. [CrossRef] [PubMed]
191. Deep, G.; Schlaepfer, I.R. Aberrant lipid metabolism promotes prostate cancer: Role in cell survival under
hypoxia and extracellular vesicles biogenesis. Int. J. Mol. Sci. 2016, 17, 1061. [CrossRef] [PubMed]
192. White, M.A.; Lin, C.; Rajapakshe, K.; Dong, J.; Shi, Y.; Tsouko, E.; Mukhopadhyay, R.; Jasso, D.; Dawood, W.;
Coarfa, C.; et al. Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate
cancer. Mol. Cancer Res. 2017, 15, 1017–1028. [CrossRef] [PubMed]
193. Marian, M.J. Dietary supplements commonly used by cancer survivors: Are there any benefits? Nutr. Clin.
Pract. 2017, 32, 607–627. [CrossRef] [PubMed]
194. Sayles, C.; Hickerson, S.C.; Bhat, R.R.; Hall, J.; Garey, K.W.; Trivedi, M.V. Oral glutamine in preventing
treatment-related mucositis in adult patients with cancer: A systematic review. Nutr. Clin. Pract. 2016, 31,
171–179. [CrossRef] [PubMed]
195. Daniele, B.; Perrone, F.; Gallo, C.; Pignata, S.; De Martino, S.; De Vivo, R.; Barletta, E.; Tambaro, R.; Abbiati, R.;
D’Agostino, L. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: A double blind,
placebo controlled, randomised trial. Gut 2001, 48, 28–33. [CrossRef] [PubMed]
196. Hammarqvist, F.; Wernerman, J.; Ali, R.; von der Decken, A.; Vinnars, E. Addition of glutamine to total
parenteral nutrition after elective abdominal surgery spares free glutamine in muscle, counteracts the fall
in muscle protein synthesis, and improves nitrogen balance. Ann. Surg. 1989, 209, 455–461. [CrossRef]
[PubMed]
180
Nutrients 2018, 10, 1564
197. Souba, W.W.; Herskowitz, K.; Klimberg, V.S.; Salloum, R.M.; Plumley, D.A.; Flynn, T.C.; Copeland, E.M.
The effects of sepsis and endotoxemia on gut glutamine metabolism. Ann. Surg. 1990, 211, 543–551.
[CrossRef] [PubMed]
198. Bode, B.P.; Fuchs, B.C.; Hurley, B.P.; Conroy, J.L.; Suetterlin, J.E.; Tanabe, K.K.; Rhoads, D.B.; Abcouwer, S.F.;
Souba, W.W. Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived
cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283, G1062–G1073. [CrossRef] [PubMed]
199. Rogero, M.M.; Borelli, P.; Fock, R.A.; Borges, M.C.; Vinolo, M.A.R.; Curi, R.; Nakajima, K.; Crisma, A.R.;
Ramos, A.D.; Tirapegui, J. Effects of glutamine on the nuclear factor-kappab signaling pathway of murine
peritoneal macrophages. Amino Acids 2010, 39, 435–441. [CrossRef] [PubMed]
200. Parry-Billings, M.; Evans, J.; Calder, P.C.; Newsholme, E.A. Does glutamine contribute to immunosuppression
after major burns? Lancet 1990, 336, 523–525. [CrossRef]
201. Roth, E.; Funovics, J.; Muhlbacher, F.; Schemper, M.; Mauritz, W.; Sporn, P.; Fritsch, A. Metabolic disorders in
severe abdominal sepsis: Glutamine deficiency in skeletal muscle. Clin. Nutr. 1982, 1, 25–41. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Immune Function and Micronutrient Requirements
Change over the Life Course
Silvia Maggini 1,*, Adeline Pierre 1 and Philip C. Calder 2,3
1 Bayer Consumer Care AG, 4002 Basel, Switzerland; adeline.pierre@bayer.com
2 Human Development & Health, Faculty of Medicine, University of Southampton,
Southampton SO16 6YD, UK; P.C.Calder@soton.ac.uk
3 NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust
and University of Southampton, Southampton SO16 6YD, UK
* Correspondence: silvia.maggini@bayer.com; Tel.: +41-582-727-516
Received: 28 September 2018; Accepted: 15 October 2018; Published: 17 October 2018
Abstract: As humans age, the risk and severity of infections vary in line with immune competence
according to how the immune system develops, matures, and declines. Several factors influence
the immune system and its competence, including nutrition. A bidirectional relationship among
nutrition, infection and immunity exists: changes in one component affect the others. For example,
distinct immune features present during each life stage may affect the type, prevalence, and severity
of infections, while poor nutrition can compromise immune function and increase infection risk.
Various micronutrients are essential for immunocompetence, particularly vitamins A, C, D, E, B2, B6,
and B12, folic acid, iron, selenium, and zinc. Micronutrient deficiencies are a recognized global public
health issue, and poor nutritional status predisposes to certain infections. Immune function may be
improved by restoring deficient micronutrients to recommended levels, thereby increasing resistance
to infection and supporting faster recovery when infected. Diet alone may be insufficient and tailored
micronutrient supplementation based on specific age-related needs necessary. This review looks at
immune considerations specific to each life stage, the consequent risk of infection, micronutrient
requirements and deficiencies exhibited over the life course, and the available evidence regarding the
effects of micronutrient supplementation on immune function and infection.
Keywords: adults; age-related immunity; deficiency; elderly; immunosenescence; infants; infection;
micronutrients; older people
1. Introduction
The immune system, which is integrated into all physiological systems, protects the body against
infections and other external and internal insults by utilizing three distinct layers, depending on the
nature of the threat: physical (e.g., skin, epithelial lining of the gastrointestinal and respiratory tracts)
and biochemical barriers (e.g., secretions, mucus, and gastric acid), numerous different immune cells
(e.g., granulocytes, CD4 or CD8 T and B cells), and antibodies (i.e., immunoglobulins). The first line of
defense is innate immunity, which combines physical and biochemical barriers with a non-specific,
leukocyte-mediated cellular response to defend against pathogens [1]. If the pathogen manages to
avoid these innate defenses, a more complex, adaptive, antigen-specific response is triggered, mediated
by T and B lymphocytes, which produces antibodies to target and destroy the pathogen (Figure 1) [1].
Both systems also protect against native cells that may be harmful, such as cancerous or precancerous
cells [2].
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Figure 1. Simple overview of the immune system. The three layers of the immune system (physical
and biochemical barriers; cells such as monocytes, granulocytes, lymphocytes, and B and T cells; and
antibodies or immunoglobulins) work together to protect the body against pathogens, utilizing the
innate and adaptive defense mechanisms. All three layers are involved in the innate and immune
systems. * The innate immune system comprises anatomical and biochemical barriers and an unspecific
cellular response mediated mainly by monocytes, neutrophils, natural killer cells and dendritic cells;
these work together to fight off pathogens before they can start an active infection. ** The adaptive
immune system involves an antigen-specific response mediated by T and B lymphocytes that is
activated by exposure to pathogens; this works with the innate immune system to reduce the severity
of infection. a The complement system can work with both the innate and adaptive immune systems;
b i.e., immunity from serum antibodies produced by plasma cells; c i.e., an immune response that
does not involve antibodies, but responds to any cells that display aberrant major histocompatibility
complex (MHC) markers, such as cells invaded by pathogens.
As humans age, the immune system evolves from the immature and developing immune
responses in infants and children, through to immune function that is potentially optimal in adolescents
and young adults, followed by a gradual decline in immunity (particularly adaptive processes) in older
people [1]. Age-related changes are compounded by certain lifestyle factors (e.g., diet, environmental
factors, and oxidative stress) specific to each life stage that can influence and modify, in some cases
suppressing, immune function. Accordingly, the risk and severity of infections such as the common
cold and influenza (the most common illnesses in humans [3]), pneumonia and diarrheal infections
also vary over a lifetime.
Optimal immune function is dependent on a healthy immune system. In turn, adequate nutrition
is crucial to ensure a good supply of the energy sources, macronutrients and micronutrients required
for the development, maintenance and expression of the immune response [3]. Micronutrients have
vital roles throughout the immune system that are independent of life stage (Table 1), and it has been
determined that those most needed to sustain immunocompetence include vitamins A, C, D, E, B2,
B6 and B12, folic acid, beta carotene, iron, selenium, and zinc [4]. There is a bidirectional interaction
among nutrition, infection and immunity: the immune response is compromised when nutrition
is poor, predisposing individuals to infections, and a poor nutritional state may be exacerbated by
the immune response itself to an infection [5]. It is clear that optimal immunocompetence depends
upon nutritional status [6]. It is recognized that micronutrient deficiencies and suboptimal intakes are
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common worldwide [7], and certain micronutrients may be more likely to be insufficient at different
stages of the life course. This can affect the risk and severity of infection, and in fact an individual’s
nutritional status can predict the clinical course and outcome of certain infections such as diarrhea,
pneumonia and measles [4]. Resistance to infection may be enhanced by adding the deficient nutrient
back into the diet and restoring immune function [4]. However, it is not always possible to achieve
good nutritional status via the diet alone. In developing countries, for example, it may be difficult to
find an adequate and varied supply of food. Even in industrialized nations, where it may be presumed
that healthy, nutritious food is easier to obtain, social, economic, educational, ethnic and cultural
backgrounds influence the diet and may adversely affect an individual’s micronutrient status [8].
This review looks at life-stage-specific immunity, risk of infection and micronutrient requirements,
from the perspective of industrialized countries where possible. The aim is to highlight the role of
tailored supplementation in restoring micronutrients to recommended levels and better supporting
immune needs that are specific to each life stage.
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2. The Immune System
2.1. Infants and Children
Prior to birth, babies lack significant antigenic exposure and so have not yet acquired
immunological memory and their adaptive immunity is not fully developed [5,10,11,19]. Therefore,
immune protection from pathogens such as bacteria and viruses immediately after birth relies on
two primary methods of defense, passive immunity and innate immunity. Passive immunity is
where maternal antibodies (antigen-specific immunoglobulins) are passed via the placenta before
birth, and in maternal colostrum and milk after birth [10]. The primary immunoglobulin (Ig) in
human maternal milk is IgA (which plays a crucial role in immune function at mucosal surfaces),
but IgG (which provides the majority of antibody-based immunity against invading pathogens) and
IgM (which eliminates pathogens in the early stages of B cell-mediated or humoral immunity before
there is sufficient IgG) are also present in smaller amounts [20]. Levels of all immunoglobulins in
maternal milk decrease in the days following birth [20], and babies and children are more susceptible
to infections until they are able to produce sufficient antibodies by themselves. Maternal milk is a rich
source of cells and compounds with immunological properties, depending on the stage of lactation,
and may facilitate immune development and maturation in infants [21,22]. These include leukocytes
(neutrophils, macrophages), cytokines, complement, and long-chain polyunsaturated fatty acids,
which variously have antimicrobial, tolerance/priming, immune development, and anti-inflammatory
properties [21,22].
The baby’s innate immune system is essential to defend against pathogens [10]. The innate system
is still functionally immature at birth, to allow the fetus to tolerate non-shared maternal antigens,
but also so that it is not constantly triggered by the considerable amount of stress and remodeling
that take place during development [19]. The neonatal innate immune system comprises different
protective cell populations compared with adults, as well as qualitative differences in the responses by
shared cell populations [23]. For example, innate immune cells such as monocytes and dendritic cells
produce less of the bioactive form of interleukin (IL)-12 and type 1 interferon in newborns compared
with adults, but similar or higher amounts of other interleukins (e.g., IL-6, IL-10, and IL-23) when
stimulated by the same pathogen [24]. Neonatal cells are also less able to produce multiple cytokines
in response to pathogenic stimulation [24]. Concentrations of NK cells are at their lowest in infants
compared with other life-stages [25]. Furthermore, serum concentrations of almost all circulating
components of the complement system are much lower (up to 80%) in newborns than in adults, with
diminished biological activity [19]. Levels increase after birth, with some complement factors reaching
adult concentrations within a month but others evolving much more slowly [19].
An adaptive immune response does occur in newborns, but it is slower and skewed towards
T helper-2 (Th-2) reactions against extracellular pathogens [24]. After birth, innate lymphoid cells,
which are critical regulators of innate immunity and inflammation at barrier surfaces (e.g., skin,
respiratory and gastrointestinal tracts), indirectly modulate adaptive immunity via interactions with
stromal cells in lymphoid tissues and epithelial cells at barrier surfaces [26]. Contact with the hostile
environment drives cells of the innate and the adaptive mucosal and systemic immune systems to
mature and expand, and the immunologic competence of the baby expands rapidly over the first
few months of life [11]. Defenses against intracellular pathogens and cell-mediated immunity rely on
Th-1 responses, which reach adult levels only after around two years of age [24]. Microbial antigens
are essential for the education of the immune system and development of Th-1 type responses and
breakdown in such immune education may predispose to allergic, inflammatory and autoimmune
diseases [5,10].
As children grow and develop, their immune systems continue to mature and acquire memory
after exposure to multiple foreign challenges including from pathogens, food and other environmental
components and vaccines [19]. Neutrophil concentrations are increased in children aged 1–6 years
compared with infants (but are still only half the adult levels), as are eosinophil and basophil
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concentrations (both then decrease with age); lymphocyte and platelet counts are lower in children
compared with infants and steadily decline with age [25]. Closer analysis of lymphocyte subtypes
indicates that the proportion of different lymphocyte subsets changes over time [25]. For example,
the percentage of CD3+ T cells (required for activation of CD4+ and CD8+ T cells) is significantly higher
in children than in infants. However, the proportion of CD4+ T cells is significantly lower in children
than in infants [25]. CD4+ helper T cells recognize peptides presented by major histocompatibility
complex (MHC) II molecules found on antigen-presenting cells, and subsequently secrete cytokines
that facilitate different immune responses according to the source of the antigen [27]. In contrast,
the percentage of CD8+ T cells is significantly higher in children than in infants and steadily increases
over time [25]. CD8+ cytotoxic T cells recognize peptides presented by MHC I molecules found on all
nucleated cells, and secrete cytokines like tumor-necrosis factor alpha or interferon gamma to help to
kill infected or malignant cells [27]. Analysis of B cells indicates that the proportion of CD19+ cells is
highest in infants and children and decreases significantly thereafter [25]. CD19 is an antigen that is
present on all B cells, is involved in signaling, and is a biomarker for B lymphocyte development [28].
Antibody production increases with age from infancy to childhood. For example, adult levels of
IgG (expressed on the surface of mature B cells, and the most prevalent immunoglobulin in serum)
are reached by the age of 11–12 years, with a further increase during puberty, while levels of IgA
(the second most prevalent immunoglobulin in serum, which can activate the complement pathway)
continue to increase past puberty until they reach adult levels; in contrast, adult levels of IgM (the first
immunoglobulin made by the fetus and virgin B cells challenged with antigen) are reached by the age
of four years [29].
2.2. Adolescents and Adults
After childhood, physical changes occur in lymphoid tissues, which support immune responses
and are responsible for producing lymphocytes and antibodies. For example, thymic tissue in the
thymus (the organ that is instrumental in the production and maturation of T cells before birth and
throughout childhood) is gradually replaced by adipose tissue after puberty and gives the impression
of being larger in children and becoming smaller after adolescence [27]. The functional portion of the
gland is considerably reduced (known as involution), but the thymus populates secondary lymphatic
organs and tissues with T cells [27]. T cells continue to be produced in the thymus throughout a
person’s lifetime, although to a much smaller extent [27], but it is thought that adults rely on the naïve
T cell pool produced mostly before puberty [30]. There is a progressive decline in the percentage of
total lymphocytes and absolute numbers of T and B cells in the blood from infancy to adulthood [25].
However, there is a significant increase in all T cell subsets (CD3+, CD4+, and CD8+) in adults compared
with children, and a decrease in the biomarker for B lymphocyte development, CD19 [25]. There is also
a significant increase in the number of NK cells in adolescents compared with infants and children, as
well as in adults compared with infants (but not children) [25].
It should be noted that the immune system reaches maturity by adulthood, and small decreases
or increases in single selected markers of immune function may not be clinically important after
that. In general, young, non-pregnant adults seem to be well equipped to cope with immune
challenges, which may reflect the procreative potential of young adults in the survival of the species [19].
However, there are some sex-specific differences that are evident in the prevalence of certain diseases.
For example, autoimmune disorders such as Sjogren syndrome, systemic lupus erythematosus and
autoimmune thyroid disease are higher in women [23]. The inflammatory immune response differs
between men and women, with females generating higher proinflammatory cytokine and chemokine
responses to the influenza virus and experiencing greater morbidity and mortality than males [31].
Women also initiate a higher humoral immune response to the influenza vaccine, and experience more
adverse reactions than men [31]. However, the raised immunity in females following vaccination leads
to greater cross-protection against novel influenza viruses compared with men [31]. It is thought that
women typically mount stronger immune responses than men because of the immunomodulatory
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effects of estrogen in women and the humoral immunity suppressing effects of testosterone in men;
however, the full extent of sex on functional immune responses remains unclear [23].
2.3. Older People
As the body ages, so does the immune system [32] and most older people over the age of
60–65 years (although not all) experience some immune dysregulation that makes them less able
to respond to immune challenges [33,34]. There is a loss of lymphoid tissue, particularly in the
thymus, with increasing age [25], and the ability to respond to pathogens, antigens and mitogens
decreases [5,33]. The development of long-term immune memory is also impaired, with a diminished
response to vaccination [5]. This is commonly referred to as immunosenescence, which mostly seems
to affect adaptive immunity but also the innate immune system to a lesser extent [32].
Immune cells are constantly renewed from hematopoietic stem cells but these mature with age
and become less able to produce lymphocytes; furthermore, the total amount of hematopoietic tissue
decreases [34,35]. A loss of immune cells and a decrease in the number of circulating lymphocytes are
characteristic in the immune systems of older people [23], consistent with reduced production of T cells
in the involuted thymus, as well as diminished function of mature lymphocytes in secondary lymphoid
tissues [34,36]. The proportions of naïve T cell subsets also change with age; for example, CD3+ and
CD8+ cytotoxic T cells decrease significantly in older people, but CD4+ helper T cells increase from
adolescence to adulthood and then stabilize in older people [25], suggesting that CD4+ cells are subject
to stricter homeostatic mechanisms given their importance in immune system function [1]. On the
other hand, memory T cells accumulate, especially late-stage differentiated CD8+ cells [30]. CD19+
cells decrease significantly from childhood to old age [25]. The total number of naïve B cells remains
unchanged with ageing; instead, there is a decrease in memory B cells that may occur secondary to
T cell deficiencies [34]. The incidence of autoimmune diseases also increases in later life, as the ageing
immune system becomes unable to fully tolerate self-antigens [19,37]. Age-related lymphopenia may
lead to a decrease in regulatory T cell function, an increase in T cells with increased affinity to self- or
neoantigens, an increased prevalence of autoantibodies, and decreased clearance of apoptotic cells by
macrophages [19,33].
Changes in the innate immune system also occur with increasing age. Skin and mucous
membranes—the first line of defense against invading pathogens—become less effective as skin
cell replacement declines and dermal and subcutaneous atrophy occurs [1]. After 60 years of age,
there is a decrease in secretory IgA, which forms part of the first line of defense against pathogens
that manage to invade the mucosal surfaces [38]. In older people, functional activity of immune cells
such as phagocytes and the intracellular respiratory burst necessary to kill pathogens are reduced [1].
Although healthy ageing does not seem to affect the overall number of dendritic cells, which are
responsible for the recognition and phagocytosis of pathogens, processing of antigens, priming of
naïve T cells and regulation of the response of B and NK cells [1], they are diminished in certain areas
such as Langerhans cells in the skin [39]. However, their ability to recognize invading pathogens is
impaired by compromised Toll-like receptors on dendritic cells, for example, which is known to occur
in ageing [40]. This reduces their ability to induce proinflammatory cytokine production and regulate
antigen presentation to naïve T cells, and to activate antigen-specific adaptive immune responses [41].
The number of NK cells increases significantly in older people compared with younger adults [1,25],
which may be the result of an accumulation of long-lived NK cells [42]. However, there is not an
accompanying increase in cytotoxicity, but instead a decrease in the functioning of the NK cells,
including a slower resolution of inflammatory responses [43].
In fact, a longer inflammatory process is induced in older adults [3]. Increased levels of circulating
pro-inflammatory cytokines (e.g., tumor-necrosis factor alpha, IL-1, and IL-6 [1,25]) characterize
low-grade chronic inflammation in older people, a process known as inflamm-aging [1]. Inflamm-aging
is a physiological response to lifelong antigenic stress and, if kept under control by anti-inflammatory
cytokines such as IL-10 [1] represents an efficient defense mechanism in older people. Increased
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production of anti-inflammatory molecules is an essential counter-regulatory process in ageing, as
inflamm-aging would otherwise be damaging [44]. Many of the most common chronic diseases
associated with ageing, such as atherosclerosis, Alzheimer’s disease, osteoporosis and diabetes [1], are
related to low-grade inflammation [32]. Oxidative stress also has a role in inflamm-aging, emphasizing
the role of oxidative stress in the complex mechanisms of ageing [44]. Immune cells, which contain a
high percentage of polyunsaturated fatty acids in their plasma membrane and so are susceptible to
lipid peroxidation, are particularly sensitive to changes in the oxidant–antioxidant balance [10]. Thus,
oxidative damage can compromise the integrity of immune cell membranes and alter transmission of
signals both within and between different immune cells, leading to an impaired immune response [10].
It has been suggested that, in older people, many immune markers of immunosenescence may actually
be more related to prolonged exposure to antigen stimulation and to oxidative stress involving the
production of reactive oxygen species (ROS), rather than to “ageing” of the immune system per
se [23,35,36]. For example, in modern industrialized populations, the cumulative effect of antigenic
exposure may be lower than in less hygienic societies [30]. One individual may experience different
environmental factors at different stages of life compared to another, and thus their immune profiles
will also differ [23]. Some older people age without any major health problems, known as healthy
ageing, and immune system dysfunction appears to be mitigated in this population [1]. Genetic and
environmental factors (e.g., good nutritional status) may play a role, but these have yet to be described.
It may be that the only truly universal age-related changes in immune markers are the reduction in the
numbers and proportions of peripheral blood naïve T cells, due mainly to thymic involution, reflecting
the aging of the hematopoietic stem cell system [36].
3. Response to Infection
The nature of the response of the immune system to a pathogen is initially dependent on whether
the innate immune defenses can eliminate the infectious organism. If not, previous experience with
the pathogen will determine how rapidly T and B cells in the adaptive immune system are able to
mount a defense against it, supported by the innate immune system. Certain factors may affect the
response of the immune system to infection.
3.1. Infants and Children
The developing immune system is still functionally immature in infants and young children.
The innate immune system is relatively susceptible to pathogens, while the adaptive immune
system is less able to quickly respond to T-cell-dependent antigens, especially in babies [19]. These
factors, combined with their greater potential for exposure to pathogens at nursery and school,
means that infants and young children are more susceptible to infections than adolescents and
adults [23]. Vaccinations have been developed to combat common but potentially deadly infections
(e.g., meningococcal bacteria, diphtheria, polio, pertussis, etc.), administered from around eight weeks
after birth (when passive immunity begins to wane) and throughout childhood.
Although most childhood infections happen only once (e.g., chickenpox, measles, and mumps),
followed by lifelong protection [19], many rhinoviruses can cause the common cold and reinfection is
common. For example, children less than one year old have been noted to experience an average of
six colds per year; the frequency decreases with age to about three colds per year in older children
(10–14 years) [45]. Males are more often affected than females before three years of age, while the
reverse is true in older children [45]. Infection with the seasonal influenza virus, which is caused
by a different influenza type each year, is also more common in children under the age of five
years [46]. In this age group, symptoms of flu can cause severe illness, complications and even
death [46]. Sickness and diarrhea frequently occur in childhood, with many children in industrialized
countries experiencing more than one episode of infective gastroenteritis per year, usually caused
by rotavirus [47]. The frequency is exacerbated by close contact with other children and often
less-than-optimal hygienic practices [47]. Lower respiratory tract infections (e.g., bronchitis and
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pneumonia) are more common in children under five years old than any other age group worldwide,
and risk factors include air pollution and suboptimal breastfeeding [48]. Micronutrient deficiencies
also have immunological consequences in infants and young children, and can increase morbidity and
mortality from many diseases, including pneumonia, diarrheal disease, and measles [4,49]. Infection
and undernutrition have a synergistic relationship, and micronutrient deficiencies cause specific
immune impairments that affect both the innate and adaptive immune systems, such as impaired
phagocyte and lymphocyte activity with zinc deficiency, or compromised development of neutrophils,
macrophages and NK cells with vitamin A deficiency [50].
3.2. Adolescents and Adults
Immunological maturity is achieved by adolescence, and young adults should be well fortified
against attack by pathogens [19]. Nevertheless, several lifestyle-related factors affect immune competence
in healthy adults and increase their risk of infection (Figure 2). In particular, nutritional status can
be compromised by a poor diet, which is often observed in adults with a hectic and stressful
lifestyle and ready access to fast food or energy-dense, micronutrient-poor convenience food. Essential
micronutrients such as vitamin B12 may be lacking in vegetarians and vegans, while adults in low-income
families may be unable to afford fresh, nutritious foods. As outlined in Table 1, micronutrients have
essential roles in the immune system and an inadequate intake may have deleterious effects [4].
A poor diet may be combined with a sedentary lifestyle, leading to obesity, suboptimal immune
response, and increased risk of infection [51]. However, prolonged and excessive exercise and
overtraining are also thought to impair immune function [52–54]. However, this view has recently been
disputed; instead, it is suggested that regular physical activities might be beneficial for immunological
health and limit or delay age-associated changes to the cellular composition of the adaptive immune
system (for example, by countering the expansion of memory T cells that may contribute to systemic
inflammation) [55]. Nevertheless, prolonged bouts of exercise and heavy training regimens in
adults may create an imbalance between ROS and antioxidant defenses [54], leading to oxidative
stress that alters signal transmission in the immune system and impairs the immune response [10].
Pollution and cigarette smoke certainly compromise immune function, particularly when combined
with poor nutrition [10]. Reactive oxygen species in, and caused by, pollution can also upset the
oxidant–antioxidant balance within the body and cause oxidative stress, which must be counteracted
by an adequate supply of antioxidants [10]. Chronic, psychological stress is another factor that can
impact immune function, suppressing cellular and humoral responses [56]. Alcohol consumption has
variable effects on immunity; moderate amounts of polyphenol-rich alcoholic beverages potentially
provide some immune protection while excessive consumption of alcohol can suppress many aspects
of immune function and consequently increase the risk of infection [57]. Sleep is an important
homeostatic regulator of immune function and plays a specific role in immunological memory [58].
Sleep disturbances and deprivation are therefore likely to have adverse effects on the immune system,
including dysregulation of NK cells and pro-inflammatory and anti-inflammatory cytokines [58].
These factors, alone or in combination, weaken the immune system in adults and can increase the
risk of infection. The incidence of common cold is lowest in adolescents compared with all other age
groups, but increases in adults aged 20–30 years [45]; the risk is likely to be greater in those who come
into close contact with children, who are at highest risk. Common cold is also more likely in those
suffering from psychological stress [59], while moderate physical exercise may decrease the risk [60].
Infection with influenza viruses other than the seasonal variety (e.g., H1N1) is more prevalent in young
to middle-aged, previously healthy adults [61]. In contrast to children, sickness and diarrhea in adults
are often caused by norovirus [62] and campylobacter [63]. Worldwide, norovirus causes 685 million
cases of acute gastroenteritis every year in adults [64].
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Figure 2. Life-style factors affecting immune function during adulthood. The risk of infection is also
influenced by gender, early programming, vaccination history, pathogen exposure, specific health
conditions, and diseases.
3.3. Older People
In older people, a lifetime of exposure to antigens and to numerous sources of oxidative stress
can cause immune dysregulation that makes them more susceptible to infections than any other age
group apart from young children [23,35,36]. Immune memory can be very long lasting, providing
protection against many infections for decades; however, people are living much longer than before,
and the pool of antigen-specific T cells may diminish over time [36]. In addition, thymic involution
and the relative paucity of naïve lymphocytes in older people means that they are less able to mount an
adequate defense against neoantigens and thus exposure to them is more hazardous than in younger
people [36].
Although certain infections are less likely in older people (for example, the incidence of common
cold has been shown to be the lowest those aged over 60 years [45]), the risk of many others such as
urinary tract infections, lower respiratory tract infections, skin and soft tissue infections, for example, is
greatly increased [65]. Furthermore, this age group is more likely to suffer prolonged infections, severe
symptoms and secondary complications [33]. Around two-thirds of older patients with common cold
develop lower respiratory illness [66], while older individuals are 2–10 times more likely to die of
infection than younger people [11]. In those aged 70 years or older, 1.27 million deaths were thought
to be caused by lower respiratory tract infections in 2015 [48]. Infection with seasonal influenza
viruses is normally greatest in older people and young children [46]. Although influenza is not a
life-threatening illness in most adults [67], in industrialized countries, influenza-associated deaths
occur most often among people aged 65 years or older [46]. The greater morbidity and mortality
associated with influenza in this age group occur because dysregulation in the immune response
predisposes them to secondary bacterial infection of the respiratory tract (e.g., bronchitis and bacterial
pneumonia) [68]. Protection against infection is dependent on T-cell-mediated responses and any
dysregulation can impair the ability to mount a T-cell response, especially if there is also infection with
cytomegalovirus [36]. This is the case in many older people, and these factors may explain why they
have a poorer response to vaccines than the young [1,36]. Nevertheless, influenza vaccination can
reduce severe illnesses and complications in people aged 65 years or older [46].
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4. Micronutrient Requirements and Reported Deficiencies
The development, maintenance and optional functioning of immune cells is dependent on
adequate nutrition, evident at all stages of life [4,5,33,49,69]. Key immunomodulatory roles of certain
micronutrients are outlined in Table 1. Immune defenses can be impaired by undernutrition, which
increases susceptibility to infection [4,5,70]. In turn, infection can cause a significant increase in the
demand for micronutrients, met by endogenous or exogenous (i.e., the diet) supplies [5,50]. Vitamins A
(and beta carotene), C, D, B2, and B12, folic acid, iron, zinc and selenium are just some micronutrients
that have immunomodulatory and/or antioxidant effects and thus influence the susceptibility of a
host to infectious diseases, as well as the course and outcome of infection [70].
4.1. Infants and Children
In babies and infants, breast milk is the major nutritional influence and is formulated to ensure
that nutritional needs are met [49,71]. Breastmilk contains various immunological components such as
antibodies (e.g., antigen-specific IgA), anti-inflammatory cytokines and other antimicrobial factors,
but also most of the micronutrients necessary to support neonatal development, including of the
immune system [49,71]. The concentrations of certain micronutrients in breastmilk (e.g., calcium,
magnesium, and copper) are regulated by maternal homeostatic mechanisms (i.e., independent of
maternal nutritional status and diet) to ensure they are sufficient to meet infant needs [72] and to
protect them against deficiency or excess [71,73–75]. However, human milk is a poor source of iron
and zinc and the needs of the child cannot be met by breast milk alone for zinc, or beyond six months
for iron [72]. In contrast, the excretion of fat- and water-soluble micronutrients (e.g., vitamin A,
and vitamins B1, B2, B6, B12, and C, respectively) into breast milk is dependent on maternal intake
and varies worldwide [71,74,75]. Furthermore, vitamin D content of human milk is low and usually
insufficient to meet requirements in exclusively-breastfed infants if the infant’s sunlight exposure is
limited [72,76]. During weaning and in the first years of life, both vitamin A and zinc play major roles
in immunity to infectious disease [77].
Children do not need micronutrients in the same intakes as adults [78] (Table 2), and lower
amounts are adequate to fulfill their various roles throughout the body, including within the immune
system. Nevertheless, micronutrient deficiencies are prevalent in infants and preschool children in
developing and low- to middle-income countries (e.g., [17,79–82]), and this age group is at the highest
risk of multiple micronutrient deficiencies [83]. Worldwide, the three most common deficiencies are for
iron, vitamin A and iodine [84], but zinc deficiencies are also common [83]. In young children, mainly
in industrialized countries, deficiencies may occur because many micronutrients (e.g., vitamin C
and B vitamins) are found in fruit and green, leafy vegetables and children are often fussy about what
they eat. However, there are few data on micronutrient levels in infants from high-income countries.
The available data suggest that, even in industrialized countries, some infants who are breastfed
may not be receiving optimal amounts of certain micronutrients, as the levels found in breastmilk,
maternal serum or urine did not always reach recommended levels in all women [73,85–95]. Reported
micronutrient deficiencies in Europe [96] compared with recommended dietary allowances (RDA) [78]
are shown in Table 2. It can be seen from the upper values that some children between the ages of
4 and 14 years had a surfeit of many micronutrients included in the table. However, the lower ranges
indicate that there were children who had an insufficient intake of vitamin D (all ages), vitamin A
(females 10+ years), vitamin E, folate, zinc (10+ years), iron (all ages) and selenium (all ages). Only the
intakes of vitamins C, B6 and B12 and copper were sufficient within this age range.
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4.2. Adolescents and Adults
An adequate amount of all micronutrients is required for optimal immune function in adolescents
and adults (and throughout life), but in higher amounts compared with infants and children [78]
(Table 2). It is especially important to ensure that antioxidant levels (e.g., vitamins C, E, and A) and
micronutrients that are components of antioxidant enzymes (e.g., zinc, copper, iron, and selenium)
are sufficient to combat the oxidative stress that is induced by many lifestyle factors common in this
group, and which has great impact on immune function [10,23,35,36,44]. An adequate supply of
micronutrients that affect the thymus is also important; for example, even marginal zinc deficiency is
known to result in thymic atrophy and can increase the risk of infection [97]. Vitamin D intake is usually
inadequate in most age groups worldwide, even in countries with mandatory food fortification [98],
which can increase the risk of infection, especially respiratory tract infections [71].
Micronutrient deficiencies have been recorded in adolescents and adults in Europe [96] (Table 2).
The lower ranges indicate that some adolescents had an insufficient intake of vitamin C (males
15–18 years), vitamin D, vitamin A (males 15–18 years; females 10–18 years), vitamin E, folate, zinc
(10–18 years), iron and selenium. Only the intakes of vitamins B6 and B12 and copper were sufficient
in all cases. In adults, there were insufficient dietary intakes for all micronutrients shown, apart from
vitamin B6 and copper. Intakes were particularly low in female adults for folate, iron and selenium.
4.3. Older People
Although the recommended dietary allowances for older people indicate that their energy needs
are lower than their younger counterparts, micronutrient requirements are mostly the same [78]
(Table 2). However, micronutrient deficiencies are common in older people; it has been estimated
that 35% of those aged 50 years or older in Europe, USA and Canada have a demonstrable deficiency
of one or more micronutrients [33]. Many older people have chronic health conditions requiring
hospitalization, live in care homes, or tend to eat less and make different food choices (e.g., choosing
low nutrient density, often cheaper, and foods) [99,100]. An insufficient intake of micronutrients
in older people has been reported both in the community (vitamins A, B12, D and zinc) and at a
higher prevalence in long-term care facilities (vitamins A, D, and E) [101], while lower food intake
has been associated with lower intakes of calcium, iron, zinc, B vitamins and vitamin E in older
people [100]. Overall, data from Europe [96] (Table 2) suggest that there is an insufficient intake of most
micronutrients in older people, apart from vitamin B12, iron and copper [96]. In particular, intakes
were low for vitamin D (females), vitamin E (males and females) and folate (males and females).
Older women, who usually have a longer life expectancy compared to men, are often at higher risk of
deficiency, especially for vitamins B12, A, C, and D, iron and zinc [99]. Furthermore, menopause affects
utilization of micronutrients; for example, vitamin C gradually decreases as menopause advances,
correlated negatively to body mass index [102]. As in younger adults, a sufficient supply of antioxidants
(e.g., vitamin C, selenium, and zinc) is required to combat the oxidative stress that is a major factor in
immune dysregulation in older people. However, older people lose their ability to produce endogenous
antioxidants compared with younger adults [103]. The skin of older adults is less able to synthesize
vitamin D, and synthesis is about 75% slower in people aged 65 years than in younger adults [17].
5. Clinical Impact of Micronutrient Deficiencies and Supplementation
An inadequate intake of micronutrients at any stage of life affects various functions within
the immune system, manifesting in decreased resistance to infections and an increase in the
severity of symptoms (Table 3). For example, zinc deficiency can increase thymic atrophy, decrease
lymphocyte number and activity, and increase oxidative stress and inflammation by altering cytokine
production [14,97]. As a result, the risk of all types of infection (bacterial, viral, and fungal),
but especially diarrhea and pneumonia, is increased [49]. A low vitamin C status also increases
susceptibility to infections such as pneumonia [71], possibly because low levels of antioxidants such as
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vitamin C are unable to counteract the oxidative stress observed in pneumonia [104]. Increased
production of ROS during the immune response to pathogens may decrease vitamin C levels
further [105]. Vitamin D deficiency increases the risk of infection and autoimmune diseases such as
multiple sclerosis and diabetes, probably related to activity of vitamin D receptors, which are found
throughout the immune system [106,107].
Considering the importance of micronutrients in immunity, and the fact that many people of
all ages have single or multiple micronutrient deficiencies that can have detrimental immunological
effects, there is a rationale for micronutrient supplementation to restore concentrations to recommended
levels, especially after an infection, and to support immune function and maintenance. To avoid any
unwanted side effects, it is of course important to ensure that supplementation does not exceed
recommended tolerable upper intake levels (Table 2), the highest level of daily nutrient intake that
is likely to pose no risk of adverse health effects in most people [78]. Although this is theoretically
possible, the reported micronutrient intake data in Table 2 suggest that over-supplementation is
unlikely with most micronutrients, perhaps with the exception of vitamin A in children. It should be
noted that the safety margins in micronutrient supplements ensure that proper consumption does not
result in over-supplementation, and that food supplement labels should be carefully read to avoid
misuse and the potential for over-supplementation.
As no single biomarker exists that accurately reflects the effects of supplementation on the immune
response, clinical outcomes are instead used to determine the effectiveness of supplementation [49,69].
197










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nutrients 2018, 10, 1531
5.1. Infants and Children
Micronutrient deficiencies are closely linked to infectious diseases that can cause substantial
morbidity and mortality in infants and children [49]. Worldwide, micronutrient supplementation
studies have looked at the effects of vitamins D, A and E and minerals such as iron, selenium and
zinc [49]. Zinc supplementation reduces morbidity and mortality from infectious diseases among
infants and children in developing countries [77]. In low-birthweight infants, supplementary zinc
can partly restore cell-mediated immunity [33]. Zinc can also reduce both the risk and duration
of pneumonia in children, help to manage infantile diarrhea, lead to fewer episodes of malaria,
and reduce the duration of diarrhea [3,17,71]. The duration and severity of common cold symptoms
can be reduced by zinc supplementation in children when taken within 24 h of symptom onset [108].
Similar results have been observed with vitamin C, which shortened the duration of a cold in children
(especially with higher doses) and reduced the severity of symptoms; a greater effect was observed
in children compared with adults, including a greater prophylactic effect of vitamin C [105]. Both
zinc and vitamin C may also improve the outcome of pneumonia, malaria and diarrheal infections in
children [9]. In children with vitamin A deficiency, supplementation can decrease the risk of morbidity
and mortality from infectious diseases [77], and reduce the incidence of diarrhea and measles [14,71].
5.2. Adolescents and Adults
Supplementation with vitamin C reduces the duration and severity of common cold symptoms
in adults [105]. In those under physical stress (e.g., at work, during sports, and under extreme
temperatures) [104], or in cases where vitamin C levels are slightly below recommended levels,
vitamin C supplementation reduces common cold incidence. For example, in young males with
marginal vitamin C deficiency, supplementation was shown to reduce the incidence of common
cold and the duration of cold symptoms compared with placebo, accompanied by improved activity
levels [109]. When used in combination with zinc, vitamin C supplementation can relieve symptoms
such as rhinorrhea in common cold [110], which is commonly regarded as the most frequent and
troublesome symptoms of the infection (along with nasal congestion) [111]. Supplementation with
vitamin D can protect against respiratory tract infections and reduce the risk of acute respiratory
illness and influenza, especially with once-daily dosing [112–115]. Benefits are particularly apparent
in those who are very vitamin D deficient [115]. In light of their positive effects on respiratory tract
infections, it has been suggested that there is a good rationale to combine vitamins C and D with
zinc to support immune functions and help minimize the risk of infection [3]. Supplementation with
multiple micronutrients has beneficial effects on the symptoms associated with the so-called “sick
building syndrome”, associated with prolonged contact with environmental factors that act as vehicles
for pollutants [10]. Significantly fewer adults who received the micronutrient supplement reported
headache, sore eyes, nasal congestion, throat inflammation, tiredness/pain, diarrhea or symptoms
associated with an acute respiratory tract infection, such as cough [10].
5.3. Older People
Impaired immunity in older people, often caused by multiple micronutrient deficiencies, is evident
in the increased incidence and severity of common infections that affect the upper and lower respiratory
tracts, as well as the urinary and genital tracts [33,116]. Supplementation with modest amounts of a
combination of micronutrients can have beneficial effects [33]. Higher levels of CD4+ and CD8+ T cells
and an increased lymphocyte proliferative response to mitogens have been observed with vitamin A,
C and E supplementation [117], while micronutrient supplementation with higher levels of vitamins C,
E and beta-carotene increased the number of various subsets of T-cells, enhanced lymphocyte response
to mitogen, increased IL-2 production and NK-cell activity, increased the response to the influenza
virus vaccine, and led to fewer days of infection [118]. Supplementation with a complex micronutrient
formulation in older people increased the number of various types of immune cells, including total
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lymphocytes, and induced a shift from memory T cells to naïve T cells [119]. Multiple micronutrient
supplementation in older people may also reduce antibiotic usage and lead to higher post-vaccination
immune responses [33].
Marginal zinc deficiency is common in older people, as their dietary intakes are generally lower and
plasma zinc concentrations decline with age, possibly connected to impaired absorption, alterations in
cellular uptake, and epigenetic dysregulation of DNA methylation or the methionine/transsulfuration
pathway, for example [14]. Supplementation with low to moderate doses of zinc in healthy older people
can help to restore thymulin activity, increase the numbers of cytotoxic T cells, reduce the number of
activated Th cells (which contribute to autoimmunity) and increase the cytotoxicity of NK cells [14],
immunological benefits that help to reduce the incidence of infections such as common cold, cold sores
and influenza [120], as well as the incidence and morbidity of pneumonia [121]. There are some reports
that an adequate zinc supply could prevent degenerative age-related diseases including infection
and cancer [122]. Sufficient vitamin C is also important in older people, who are at risk of vitamin
C deficiency, especially females [96]. Adequate vitamin C intakes can optimize cell and tissue levels
and help to protect against respiratory and systemic infections (e.g., reduced duration and severity of
pneumonia [71]), while higher levels are required during infection to compensate for the increased
inflammatory response and metabolic demand induced by the pathogen, and thus help to reduce
the duration and severity of symptoms [12]. Supplementation with vitamin E in older people has
been shown to significantly improve NK cytotoxic activity, neutrophil chemotaxis and the phagocytic
response, and enhance mitogen-induced lymphocyte proliferation and IL-2 production [123]. Vitamin E
can also improve T-cell-mediated immunity and increase the production of antibodies in response to
the hepatitis B and tetanus vaccines [124]. The risk of upper respiratory tract infections, especially
common cold, was significantly lower after vitamin E supplementation in nursing home residents,
although there was no apparent effect on lower respiratory tract infections [125]. However, not all
studies have reported beneficial effects on respiratory tract infections with vitamin E supplementation
in older people [14].
6. Conclusions
The immune system undergoes many changes over the life course—developing and maturing
during childhood, potentially achieving peak function in early adulthood, and gradually declining
in most people in older age (Figure 3). Distinct immune features are present during each life stage,
and specific factors differentially affect immune function, with a resulting difference in the type,
prevalence and severity of infections with age. A common factor throughout life is the need for an
adequate supply of micronutrients, which play key roles in supporting immune function. Multiple
micronutrient deficiencies are common throughout the world, with the likelihood increasing with
age. Tailored supplementation based on the specific needs of each age group may help to provide an
adequate basis for optimal immune function. The available clinical data suggest that micronutrient
supplementation can reduce the risk and severity of infection and support a faster recovery. However,
much more research is required into the effects of micronutrient supplementation on immune functions
and on clinical outcomes. Nevertheless, current knowledge regarding the importance of micronutrients
in immunity, the effects of micronutrient deficiencies on the risk and severity of infection, and the
worldwide prevalence of an inadequate micronutrient status form a sound basis for the use of a
targeted multiple micronutrient supplement to support immunity over a person’s lifetime.
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Abstract: Selenium is an essential micronutrient that plays a crucial role in development and a wide
variety of physiological processes including effect immune responses. The immune system relies
on adequate dietary selenium intake and this nutrient exerts its biological effects mostly through
its incorporation into selenoproteins. The selenoproteome contains 25 members in humans that
exhibit a wide variety of functions. The development of high-throughput omic approaches and novel
bioinformatics tools has led to new insights regarding the effects of selenium and selenoproteins
in human immuno-biology. Equally important are the innovative experimental systems that have
emerged to interrogate molecular mechanisms underlying those effects. This review presents a
summary of the current understanding of the role of selenium and selenoproteins in regulating
immune cell functions and how dysregulation of these processes may lead to inflammation or
immune-related diseases.
Keywords: selenocysteine; macrophage; T cell; antibody; inflammation; cancer
1. Introduction
Selenium was discovered by the Swedish chemist Jöns Jakob Berzelius in 1817 and was considered
a toxic element for humans and livestock for nearly 150 years [1]. However, in 1957, the benefits
of selenium for humans and other mammals were revealed in landmark studies by Klaus Schwartz
and Calvin Foltz who demonstrated that dietary selenium protected rats against liver necrosis [2].
Since then, the role of selenium as a trace mineral nutrient in human health and the mechanisms by
which it exerts its biological effects have become better understood. Adequate levels of bioavailable
selenium are functionally important for several aspects of human biology including the central nervous
system, the male reproductive biology, the endocrine system, muscle function, the cardiovascular
system, and immunity [3,4]. Many pathological conditions involving the immune system can be
affected by the selenium status in an individual, which can be influenced by several factors such as
the levels and forms of selenium ingested, the conversion of selenium compounds into metabolites,
and genetic characteristics that can impact the use of these metabolites. Selenium deficiency is rare in
the United States and Canada [5], but regions of China, New Zealand, and parts of Europe and Russia
have low levels of selenium in soil and food [6]. The extent to which immune-related diseases are
impacted by differences in selenium intake and how supplementation approaches may be utilized to
mitigate these health issues is not entirely clear. However, the development of new high-throughput
omic approaches and bioinformatics tools have improved our understanding of the effects of selenium
immuno-biology in humans. Additionally, novel experimental systems have provided valuable insight
into mechanisms underlying those effects.
The U.S. recommended dietary allowance for selenium for adults is 55 μg/day and most
individuals achieve this level while several other countries have higher recommended allowances
due to a lower average selenium status in their populations [7]. For example, adults in the U.K.
are recommended to ingest 60 μg/day for adult women and 75 μg/day for lactating women and
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adult men [8]. Commonly used measures of a selenium status include plasma and serum selenium
concentrations as well as selenoprotein P levels and glutathione peroxidase activity [9,10]. The average
plasma selenium concentration in the U.S. is 70 ng/mL, which is relatively high with selenium
intake found to be lower in areas within China and Europe, in New Zealand, and in other parts of
the world [11,12]. Dietary selenium is obtained through a wide variety of foods including grains,
vegetables, seafood, meat, dairy products, and nuts [13]. The predominant form of selenium ingested
by humans is selenomethionine. However, other forms of selenium are also present in foods. Selenium
gets metabolized into various small molecular weight seleno-compounds including some that may
exert biological effects through redox reactions that can affect cellular processes like DNA repair and
epigenetics [14,15]. These bioactive metabolites include hydrogen selenide and methylated selenium
compounds like methylseleninic acid, which exerts chemo-preventive effects [16]. Most of the effects
of dietary selenium on immune functions are attributable to the insertion of this element into a
family of proteins called seleno-proteins. What separates selenium from other nutritional elements
is the fact that it is incorporated directly into proteins as the 21st amino acid, selenocysteine (Sec).
The synthesis of selenoproteins within cells requires a dedicated set of protein and tRNA factors
assembled on ribosomes along with the selenoprotein mRNA, which contains unique structural
elements. The coordinated interaction of these elements leads to co-translational insertion of Sec into
the nascent polypeptide when the ribosome encounters a uridine-guanosine-adenosine (UGA) codon,
which is typically used as a stop codon in other mRNAs [17]. Under conditions of low selenium status,
this translational process stalls at the UGA codon and both the mRNA and truncated protein may get
degraded through two separate processes called nonsense-mediated decay (NMD) and destruction via
C-end degrons (DesCEND), respectively [18,19]. Certain mRNA characteristics potentially play a role
in NMD sensitivity such as the location of the Sec codon (UGA) relative to exon–exon junctions [18].
Therefore, the selenium status is directly related to levels of different selenoproteins in different
tissues. Given the combined effects of NMD and DesCEND, there appears to be a hierarchy of
selenoprotein synthesis that results in some family members having a higher priority of expression
under selenium-limiting conditions [20]. In addition, certain tissues like the brain, endocrine tissues,
and testes retain selenium under deficient conditions shed light on the priorities given to different
physiological systems when selenium levels are low.
In humans, 25 selenoproteins have been identified and 24 of those exist as Sec-containing
proteins in rodents [21], which highlights the value of rodent models for determining roles for
members of this protein family in immune responses. Selenoproteins exhibit a wide variety of
tissue distribution and functions [17]. While many members of the selenoprotein family function
as enzymes involved in redox reactions, some are likely not enzymes themselves and functions are
gradually becoming better understood for these non-enzymatic members. The most completely
characterized selenoprotein enzymes related to immune functions include glutathione peroxidases
(GPXs), thioredoxin reductases (TXNRDs), iodothyronine deiodinases (DIOs), methionine-R-sulfoxide
reductase B1 (MSRB1), and selenophosphate synthetase 2 (SPS2). For non-enzymatic selenoproteins,
the best characterized in terms of immune cell function is selenoprotein K (SELENOK). Table 1 lists
selenoproteins and their functions and a more detailed discussion of roles for individual selenoproteins
in different immune cells and tissues is provided below.
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As mentioned above, nearly all tissues are affected by changes in the selenium status or
selenoprotein expression. While the focus of this review is on the immune system, it is important
to first touch on other physiological systems impacted by the levels of selenium and selenoproteins.
Embryonic lethality arising from deletion of the trsp gene encoding the Sec-tRNA required for
translation [54] demonstrates the essential nature of selenoproteins. In fact, there have been four
individual selenoprotein knockout mice in which gene ablation was shown to result in embryonic
lethality: GPX4, TXNRD1 and 2, and Selenoprotein T (SELENOT) [32,51,55,56]. An essential role
for one of these selenoproteins in the area of development was demonstrated by the recent study,
which showed that GPX4 protects a critical population of interneurons from ferroptotic cell death [29].
In the muscular system, genetic maladies involving selenoproteins include multi-minicore diseases
(MmD) such as rigid spine syndrome (RSS) resulting from mutations in the human gene encoding
Selenoprotein N (SELENON) [57,58] and an associative dysfunction of the ryanodine receptor 1 (RyR1)
receptor [59]. Transgenic overexpression of some selenoproteins potentially regenerates wasted muscle
in mice [60]. Thyroid hormone metabolism is dependent upon the combined actions of the three
selenoproteins known as iodothyronine deiodinases 1-3 (DIO1-3) [61]. Thus, selenium deficiencies
can affect thyroid gland function and the many physiological systems impacted by thyroid hormone
activity. In the hepatic system, selenium is absorbed from the gastrointestinal tract and utilized for
biosynthesis of selenoproteins including Selenoprotein P (SELENOP), which is the primary plasma
selenium transport protein [62]. Several groups have observed that SELENOP inactivation results
in normal hepatic selenium levels while selenium content in other tissues decreases significantly.
This reduces the total GPX and TXNRD pools [63,64]. Consequently, those organs that rely on
SELENOP-mediated selenium delivery become deficient when some tissues are given ‘priority’ over
others for retention of this element since delivery through SELENOP decreases.
The central nervous system is appreciably dependent on an adequate selenium supply and,
as mentioned above, diets that are slightly deficient in selenium do not elicit neurological deficits
due to the preservation of selenium content in the central nervous tissue during dietary selenium
restriction [65]. On the other hand, a targeted reduction in brain selenium reduces SELENOP
bioavailability and causes spontaneous neurological deficits [66], which are reversed by selenium
supplementation [67,68]. Additionally, overexpression of TRX1 has been found to mitigate oxidative
challenges in the brain [69]. GPX1 was the first mammalian selenoprotein to be discovered [70,71]
and has been shown to protect the brain from oxidative insults. Like GPX1, GPX4 protects cortical
neurons from exogenous oxidative stress-inducing agents [72,73]. Importantly, the protein oxidation
product methionine-R-sulfoxide contributes to neurodegenerative diseases and can be repaired
by thioredoxin-dependent selenoenzyme MSRB1, which reduces methionine-R-sulfoxide back to
methionine [36]. Inactivation of MSRB1, however, does not produce neurological deficits [36]. In the
kidney, several studies have identified the expression of DIOs, thioredoxin reductases (TRs), and GPXs,
but their respective roles have not been fully elucidated. Burk et al. demonstrated that glutathione
(GSH) deprivation causes severe pathogenic nephropathy [74] while podocyte-specific ablation of the
trsp gene in diabetic mice did not enhance markers of nephropathic disease. Moreover, murine renal
expression of GPX1 has been reported not to be protective against diabetic nephropathy.
For clinically diagnosed disorders, Keshan disease (KD) is perhaps the most firmly established
selenium deficiency-based pathology. This cardiomyopathy was first described in rural areas
of China due to low selenium content in foods [75]. There is evidence in mouse models that
selenium deficiency promotes the conversion of nonvirulent coxsackievirus B3 strains into a more
virulent strain due to an increased oxidative stress [76], which suggests that this infectious agent
may be a cofactor. Selenoprotein deficiency may also promote osteochondral diseases including
Kashin-Beck disease (KBD). This disease is a poly-pathogenic, degenerative osteochondropathy leading
to chondrocyte necrosis [77] and apoptosis [78–80], which results in growth retardation and secondary
osteoarthrosis [81]. KBD is mainly endemic to Tibet, China, Siberia, and North Korea and is caused in
part by poor selenium levels in soil that usually affects children between the ages of 5 to 15 [81,82].
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In 1998, Moreno-Reyes et al. established the relationship between this osteoarthropathy and selenium
deficiency in rural Tibet [82].
2. Selenium and Immunobiology
The importance of adequate levels of dietary selenium and its efficient incorporation into
selenoproteins in immunity has been demonstrated in cell culture models, in rodent models, in livestock
and poultry studies, and in humans. Selenium deficiency can give rise to immune-incompetence that
leads to increased susceptibility to infections and possibly to cancers. There is some evidence that
selenium can modulate the pathology that accompanies chronic inflammatory diseases in the gut
and liver as well as in inflammation-associated cancers [83,84]. Selenium deficiency and suppressed
selenoprotein expression have been implicated in higher levels of inflammatory cytokines in a variety
of tissues including the gastrointestinal tract [85,86], the uterus [87], mammary gland tissues [88],
and others. However, some inflammatory processes actually increase when selenium intake changes
from deficient to sufficient levels. For example, a mouse model of allergic asthma showed that
selenium deficiency reduced airway inflammation while adequate selenium intake produced higher
levels of inflammation that were then decreased when supra-nutritional levels of selenium were
used [89]. In addition, increasing the selenium status through dietary delivery of sodium selenite
raised expression levels and translation of mRNAs encoding stress-related selenoproteins as well as
genes involved in inflammation and interferon γ IFNγ responses [90].
Selenium supplementation, for the most part, is immuno-stimulatory, which is measured by a
wide range of parameters including T cell proliferation, NK cell activity, innate immune cell functions,
and many others [91]. This depends on the baseline selenium status and the strongest effects can be
seen when supplementation boosts selenium levels from inadequate to adequate while the benefits
of increasing an adequate selenium level to supra-nutritional levels is less clear. The activation of
human blood leukocytes has been shown to increase in response to selenium-enriched foods [92].
Vaccine responses against pathogens such as poliovirus have been shown to improve with selenium
supplementation [93] even though results were mixed when analyzing the influenza vaccine in older
adults [94]. Similarly, integrated-omics analyses of pathways affected by the selenium status in rectal
biopsies from 22 healthy adults showed reduced inflammatory and immune responses and cytoskeleton
remodeling in the suboptimal selenium status group [95]. Similarly, selenium supplementation was
shown to modulate the inflammatory response in respiratory distress syndrome patients by restoring
the antioxidant capacity of the lungs, which moderated the inflammatory responses through interleukin
(IL)-1β and IL-6 levels and meaningfully improved the respiratory mechanics [96].
There have been few definitive reports of selenium and selenoprotein levels affecting
hematopoiesis and the development of the immune system. The deletion of the essential selenoprotein,
TXNRD2, does not impair lymphocyte development and maintenance [97]. However, a T cell-specific
knockout of all selenoproteins was found to reduce the number of mature T cells emerging from
lymphoid tissues [98]. Autoimmunity is an important issue related to immune system development
and there have been reports in humans of an increase in the prevalence of autoimmune thyroiditis
in low-selenium regions that are consistent with studies in mice [99,100]. While selenium is vital for
many immune cell functions (Figure 1), the benefits of applying wide scale selenium supplementation
as an approach to boost immunity in the general population have lacked definitive support over the
years. This suggests a need for a more refined evaluation of how selenium affects different types
of immune responses along with a deeper mechanistic understanding. In the following sections,
the effects of selenium on various aspects of immunity and its mechanisms of action will be discussed
in further detail.
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Figure 1. A summary of selenium and immune responses.
3. Leukocyte Functions
Adaptive immunity is affected by selenium intake including the activation and functions of T
and B cells. One immunological feature of selenium levels in vivo is the positive effect that higher
selenium has on the proliferation and differentiation of cluster of differentiation(CD)4+ T helper
(Th) cells. There are several reports of the skewing of T cell immunity toward Th1 phenotypes.
For example, our laboratory used a mouse model of viral antigen vaccination to test effects of low
(0.087 ppm), medium (0.25 ppm), and high (1.0 ppm) selenium diets and found that Th1 immunity was
enhanced along with the T cell receptor signal strength [101]. In a separate study, oral administration
of synthetic selenium nanoparticles induced a robust Th1 cytokine pattern after a hepatitis B surface
antigen vaccination in a mouse model [102]. Less information is available regarding the effects of
selenium on cytotoxic CD8+ T cells even though cytotoxic T cells from aged mice (24 months old)
showed enhanced mitogen-induced proliferation when treated with selenium supplementation [103].
Mouse knockout models have shown roles for selenoproteins in antibody production. In particular,
T cell deletion of the trsp gene responsible for the synthesis of all selenoproteins not only affected T cell
maturation and activation but reduced the T cell ‘help’ provided to B cells for secreting antibodies,
which is determined by low levels of serum immunoglobulin [98]. A small study in humans showed a
positive effect on antibody titers against the diphtheria vaccine with selenium supplementation that
correspond to increased lymphocyte counts [104]. In a more recent study involving Selenoprotein F
(SELENOF) knockout mice, elevated levels of immunoglobulins were detected in the sera that were
nonfunctional [38]. The authors of this study concluded that SELENOF functions as a gatekeeper of
immunoglobulins in the endoplasmic reticulum (ER), which supports the redox quality control of
these proteins and likely other proteins.
Innate immune cell functions have also been shown to be impacted by selenium levels.
Macrophages are affected by selenium levels in terms of their inflammatory signaling capacity
and anti-pathogen activities. Activation of macrophages through pathogen-associated molecular
patterns like lipopolysaccharide (LPS) generates an oxidative burst. Additionally, macrophage
activation involves the release of cytokine mediators and arachidonic acid-derived prostaglandins
like prostaglandin E2 (PGE2), thromboxane A2 (TXA2), and prostaglandin D2 (PGD2) as well as its
metabolite 15-Deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2). It was shown that selenium induces a
phenotypic switch in macrophage activation from a classically activated, pro-inflammatory phenotype
(M1) toward an alternatively activated, anti-inflammatory phenotype (M2) [105]. Regarding the latter
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phenotype, selenium was shown to be pivotal for cyclooxygenase-dependent 15d-PGJ2 generation
and M2-mediated clearance of helminthic parasite infections [106]. Evidence from several studies
demonstrated that selenium levels and selenoproteins regulate migration and phagocytosis functions in
macrophages [107,108]. Experiments involving golden Syrian hamster macrophages and Staphylococcus
aureus showed that higher levels of selenium in culture media led to significant increases in macrophage
phagocytic activity, nitric oxide production, and S. aureus killing [109]. Furthermore, pre-treatment of
RAW264.7 mouse macrophages with selenium supplementation prior to exposure to S. aureus led to
lower levels of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and
downstream inflammatory cytokine release [110]. Less information is available regarding selenium
levels and neutrophil function. However, one study demonstrated that increased selenium intake may
protect neutrophils from endogenous oxidative stress [111]. Natural Killer (NK) cells are impacted
by dietary selenium intake both directly and indirectly. Serum selenium concentration was positively
associated with peripheral CD16+ NK cells in older humans [112]. However, functional capacity
of these NK cells, e.g., cytotoxicity, was not determined. A separate study in mice showed that
selenium supplementation increased the cytotoxic functions of NK cells [113]. The inhibitory receptor,
CD94/Natural Killer G2A (NKG2A), was found to be sensitive to selenite treatment, which indicated
that NK cell activity may be indirectly increased using this form of selenium [114]. The use of selenium
to increase innate immunity may be enhanced when provided along with other nutritional antioxidants.
This was demonstrated in prematurely aging mice that exhibited improved macrophage and NK cell
functions with a cocktail of antioxidants that included selenium [115].
4. Immune Responses to Pathogens
Innate and adaptive immune responses against bacterial and parasitic infections rely on sufficient
selenium for eliminating these pathogens. For example, selenium deficiency in mice was shown to
impair innate immunity and induce susceptibility to Listeria monocytogenes infection [116]. In this
study, C57BL/6 mice fed adequate or deficient selenium diets were infected with L. monocytogenes
and it was found that mice maintained on a selenium deficient diet produced less IFNγ when
compared to mice that were fed the control diet. In addition, selenium supplementation decreased the
parasitemia of pregnant Wistar rats infected with Trypanosoma cruzi [117]. Selenium intake also affects
the plasticity of macrophages during immune responses to helminthic parasite infections. For example,
a mouse model of infection with Nippostrongylus brasiliensis, which is a gastrointestinal nematode
parasite, showed that higher levels of dietary selenium led to optimal expression of selenoproteins and
selenium-dependent production of cyclooxygenase (COX)-derived endogenous prostanoids crucial for
eliminating N. brasiliensis infection [118]. Similarly, mice infected with Heligmosomoides bakeri required
sufficient selenium intake to eliminate these helminthic pathogens and this correlated with increased
local expression of Th2-associated genes in infected small intestinal tissues [119].
Bacterial infections in neonates may be a particularly important outcome related to maternal
selenium status, which is suggested by studies in humans and rodent models [120–122]. These studies
do not necessarily distinguish between the effects of the selenium on the immune system and other
effects that selenium can have on infant health. In addition to the role of the selenium status on the
immune system, one must keep in mind the direct effects that selenium has on bacterial pathogens as
well the fact that many bacterial species express selenoproteins [123].
Selenium is one of many nutrients implicated in the severity and progression of tuberculosis
(TB) caused by the bacterium Mycobacterium tuberculosis [124]. Pulmonary TB patients have lower
selenium statuses when compared to healthy controls [125]. Interestingly, investigators also observed
that TB patients with concomitant HIV infection exhibited a significantly lower concentration of serum
selenium along with augmented wasting versus those without HIV infection. Intensified wasting in
TB patients was positively correlated with the severity of lung disease and was associated with low
serum selenium levels [126]. Following a two-month intervention study, selenium plus vitamin E
supplementation enhanced total antioxidant capacity in patients with pulmonary TB even though the
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effects on the immune system were not determined [127]. However, several researchers have pointed
out that some trace nutrients that may be used as supplements to restore immunity and lung function
may also be exploited by M. tuberculosis to promote growth of the pathogen [128]. This has been
supported by data involving the growth of this bacteria under different selenium concentrations [129].
The beneficial effects of a higher selenium status have been supported for some viral infections
even though there are some studies that do not conclusively demonstrate effective improvements in
anti-viral immunity [130]. Moreover, the antioxidant properties of some selenoproteins have been
suggested to contribute to boosting anti-viral immunity [131]. However, some selenoproteins that
have not been established as antioxidant enzymes like SELENOK can also play key roles in protecting
against viruses [42]. The chronic hepatitis C virus (HCV) has been shown to influence oxidative stress
levels in humans and an association between HCV load and the selenium status has been associated
with a documented selenium status [132]. Oxidative stress can have genomic altering effects on RNA
viruses that can lead to higher virulence of certain viruses themselves and this has been shown to
involve the selenium status in the case of coxsackievirus B3 [133]. Thus, the effects of selenium on
the virus in some cases may compound the influence of this micronutrient on the immune system.
Targeting individuals with low selenium intake or the elderly with a declining selenium status with
selenium supplementation may be an effective public health initiative for increasing vaccine responses
to viruses [134]. There is evidence to support a positive effect on adaptive immune responses to
vaccination against viral pathogens. This causes polio and influenza in populations with a low baseline
selenium status [93,135].
The most compelling data available regarding the role of selenium in anti-viral immunity are
those related to HIV infection, which is a global pandemic that particularly afflicts persons with
inadequate nutrition and directly impairs immunity [136]. Selenium is one micronutrient implicated
in disease progression. Low selenium intake has been associated with HIV prevalence [137,138] and
the status of CD4+ T cell numbers has been correlated with selenium levels in HIV+ patients [139].
There is some evidence that selenium malabsorption or overutilization in Acquired immune deficiency
syndrome (AIDS) patients may affect or be affected by disease progression [140,141]. In particular,
selenium-deficient HIV+ patients tend to present with disrupted hemodynamics such as depressed
selenium plasma and erythrocyte levels, diminished glutathione peroxidase activity, and stunted
cardiac selenium bioavailability. A plasma selenium status is conventionally assessed by SELENOP
levels and GPX activity as well as selenium levels, which respond differently to changes in selenium
consumption [142]. Thus, it is difficult to directly compare studies using different selenium status
readouts [143]. Anti-retroviral therapies may also confound the selenium status [144,145]. However,
some studies have not supported this notion [146]. Additionally, selenium is often combined with other
nutrients for intervention studies, which makes assessment of its impact difficult to distinguish from
other nutritional components. Several cohort studies have illustrated an association between selenium
deficiency and progression to AIDS-related mortality [147]. Remarkably, randomized controlled trials
demonstrated that selenium supplementation minimized hospitalizations and diarrheal morbidity and
improved CD4+ T cell counts [141,148]. Similarly, an inhibitory effect of selenium on HIV in vitro due to
the radical scavenger effects of glutathione peroxidase has been reported [141]. Glutathione peroxidase
and other antioxidant selenoenzymes along with catalase have been implicated in decreasing a viral
activation impact on redox control [141,149]. Thus, the potential benefits of selenium supplementation
for HIV infection likely resides in the redox regulating selenoenzymes and resides less with the
pro-oxidant seleno-metabolites that are found to affect cancer.
5. Selenium and Its Effects on a Shift toward Anti-Cancer Immunity
The effects of the selenium status on carcinogenesis or tumor progression have been intensely
studied and results have led to a wide variety of conclusions. In humans, there have been
several epidemiological studies as well as intervention studies involving different types of cancer,
which suggests beneficial effects of higher selenium status [150–152]. On the other hand, the selenium
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status was not found to be a factor in cancer progression in a number of other studies [153–156].
From the perspective of research in humans, it has proven difficult to separate the direct effects that
selenium has on carcinogenesis from its impact on the growth of established tumors as well as its
influence on cancer immunity. One of the direct anti-cancer effects of selenium is related to the ability
of seleno-compounds to induce oxidative stress and DNA damage accumulation and, consequently,
apoptosis [15]. Other direct effects of selenium on established tumors in humans are less clear and
this is particularly true for those effects that are exerted through the immune system. For example,
there is some evidence from one human study suggesting an inhibitory effect of selenium on the
epithelial-to-mesenchymal transition (EMT) that drives metastasis [157]. This was accompanied by the
capacity of higher levels of selenium to down-regulate expression of genes involved in wound healing
and inflammation, which are both related to EMT. The idea that selenium supplementation may be
used to support the immune system during cancer treatment has been supported by some studies
including those related to childhood leukemia and neutropenia [158,159]. Intervention studies showed
positive effects of selenium on mitigating neutropenia in children suffering from leukemia/lymphomas
as well as solid tumors [160].
There is evidence that GPX4 modulates hepatocellular carcinoma (HCC) in both humans and
rodent models. In humans, GPX4 expression in tumors positively correlated with patient survival and
was linked to pathways that regulate cell proliferation, motility, tissue remodeling, and immune
responses with a particular effect on M1 macrophage polarization [161]. Corroborative results
demonstrate that overexpression of GPX4 decreased the growth of human HCC cell lines using
xenotransplantation into immune-deficient non-diabetic (NOD) mice. These findings are consistent
with previous studies showing that inhibition of GPX4 expression by siRNA in HCC cells increased
the formation of Vascular endothelial growth factor (VEGF) and IL-8 cytokines [162], which are both
clinically relevant adverse prognostic factors in HCC patients [162,163]. However, since NOD mice do
not include a competent immune system, it is difficult to interpret how the immune relevant data from
the human gene arrays can be related to the rodent studies.
The polarization of tumor-associated macrophages away from tolerogenic phenotypes and toward
anti-tumor M1 macrophages suggested in the above experiments with GPX4 overexpression was also
supported in selenium nanoparticle studies [164]. However, how selenium levels affect macrophage
polarization in the tumor microenvironment in human cancers remains to be determined. As discussed
in a previous review [165], higher levels of selenium can increase NK cell activity by preventing the
non-enzymatic formation of parafibrin that surrounds tumor cells and hinders immune surveillance
and by activating the NK cell population in the tumor microenvironment. The anti-tumoral activity of
NK cells requires the expression of the activating receptor natural killer group 2 member D (NKG2D)
on NK cell surfaces [166]. The selenium metabolite known as methylselenol was found to upregulate
two NKG2D ligands on the surface of tumor cells [167]. However, it was not determined if this led
to increased NK cell killing of tumor cells. This feature is important for the detection of tumor cells
by CD8+ T cells since these cells also express NKG2D. In fact, major histocompatibility-I (MHC-I)
present tumor antigens to CD8+ T cells to activate their cytotoxic activities, which is also affected
by methylselenol in cancer cells. In particular, this selenium metabolite was shown to alter redox
metabolism in melanoma cells and lead to increased levels of MHC-I cell surface antigens [168].
This study showed that the actions of methylselenol mimic IFNγ signaling by also upregulating
members of IFNγ responsive genes. However, one must consider the detrimental effects of inducing
oxidative stress in some tissues such as the gut where this can promote tumorigenesis and tumor
progression [85].
Due to the ability to control experimental conditions, rodent models of selenium and cancer have
provided data that may be easier to interpret. However, unless specifically built into the study design,
it is difficult if not impossible to distinguish between the effects of the bioavailable selenium on the
cancer cells themselves versus the immune cells that are either trying to facilitate tumor progression or
trying to eradicate the cancer cells. The mixed results for rodent cancer studies when tumor growth
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is the primary endpoint for mouse studies highlight this confounding issue. For example, in our
mouse model study of syngeneic mesothelioma tumors that utilized immune competent animals,
we expected that increasing dietary selenium would hinder tumor progression due to enhanced
anti-cancer immunity. However, the tumors progressed at an accelerated rate in mice that were fed
higher selenium diets due to the pro-reducing capacity in the tumor cells themselves [169]. Other rodent
studies focused on melanoma or breast cancer found different results with higher selenium intake
leading to lower tumor growth concurrent with immune enhancing effects [170]. When immune
responses have been analyzed, the predominant effect is an enhancement of Th1 immunity and a
reduction in regulatory T cells (Tregs) and myeloid-derived suppressor cells that suppress anti-tumor
immunity [171,172]. There are many factors to consider when analyzing the results of the rodent
cancer studies including the type of cancer, strain, and immune status of the rodents, dose and form of
selenium used, and endpoints used for analyses. The generation of new xenograft models as well as
humanized rodents will facilitate these studies when the research field moves forward.
6. Specific Mechanisms by Which Selenoproteins Regulate Immunity
There have been some investigations into molecular mechanisms underlying the effects of
selenium on the immune system. Because selenium can impact so many cellular functions, it is
very difficult to dissect out the many different pathways and individual molecules regulated by this
micronutrient. Despite these caveats, the generation of transgenic and knockout mouse models has
revealed some intriguing mechanisms involving individual selenoproteins. Two examples shown
below involve roles elucidated for two selenoproteins in regulating immune cell functions.
MSRB1 is the lone Sec-containing member of the methionine sulfoxide reductase (MSR)
family of proteins, which also includes MSRA, MSRB2, and MSRB3. Reactive oxygen species
(ROS) can oxidize methionine residues in proteins to produce a mixture of S-stereoisomers and
R-stereoisomers of methionine sulfoxide, which are reduced by MSRA and MSRB enzymes,
respectively [173]. The first report of MSRB1 in macrophage biology described its role in regulating
actin polymerization during cellular activation that promoted functions like phagocytosis and cytokine
secretion [174]. Two methionine residues in actin are specifically converted to methionine-R-sulfoxide
by monooxygenase enzymes called Mical1 and Mical2 and are reduced back to methionine by
selenoprotein MSRB1, which supports actin disassembly and assembly, respectively. In this manner,
macrophages utilize a system of redox reactions during cellular activation by stimulating MSRB1
expression and activity as a part of innate immunity. There are two intriguing aspects of this
regulatory process. First, lipopolysaccharide (LPS) induces expression of MSRB1, but not other
MSRs, which suggests stereo-specificity in the reactions. Second, a follow-up study found that MSRB1
controls immune responses by promoting anti-inflammatory cytokine expression in macrophages [35].
It must be noted that bacteria have their own versions of MSRs and the importance of this was
shown in the case of Francisella tularensis, which replicates within macrophages during infection.
The F. tularensis MSRB (the only B isoform in bacteria) was crucial in promoting replication while
MSRA was not as important [175]. In fact, the roles of MSRB in the pathogenesis of several bacteria
have been investigated, but it must be noted that the bacterial enzyme contains cysteine (Cys) in place
of Sec and, therefore, these MSRBs are not selenoproteins. Overall, it remains to be determined how
the regulated expression of MSRB1 in humans affects infection with this bacterium or other pathogens
that replicate within macrophages, but this selenoprotein appears to be quite important in shaping
innate immune responses.
Our laboratory has studied SELENOK in the immune system for a number of years starting
with the finding that levels of this selenoprotein were relatively high in immune tissues of mice
and its expression increased with higher selenium intake [42]. SELENOK knockout mice showed
no overt phenotype and were fertile, but we found ~50% reduction in most immune cell functions
when the immune system was challenged [42]. We subsequently identified its role in promoting
calcium flux during immune cell activation by SELENOK complexing with the enzyme DHHC6
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(letters represent the amino acids aspartic acid, histidine, histidine, and cysteine in the catalytic
domain and 6 represents the 6th member of the family) to palmitoylate to the endoplasmic reticulum
(ER) calcium channel protein inositol-1,4,5-trisphosphate receptor (IP3R) [176]. SELENOK itself does
not function as an enzyme but instead binds to DHHC6 to stabilize the acylated intermediate of
this enzyme so that it is not hydrolyzed by water, which does not hydrolyze the thioester bond
between the acyl group and the cysteine residue in DHHC6 before it can transfer the acyl group
to target proteins like IP3R [177]. Other proteins involved in immune functions also depend on
SELENOK/DHHC6 for palmitoylation to carry out their activities including CD36 and Arf-GAP with
SH3 domain, ANK repeat and PH domain-containing protein 2 (ASAP2) [178,179]. Overall, SELENOK
plays an important, non-enzymatic role in regulating immunity by functioning as a cofactor for an
enzyme involved in critical post-translational modifications of proteins.
7. Conclusions
The immune system is one aspect of human health that is impacted by dietary selenium levels and
selenoprotein expression. Under conditions of selenium deficiency, innate and adaptive immune
responses are impaired. The benefits of selenium supplementation to boost immunity against
pathogens, vaccinations, or cancers have been explored and have not provided entirely clear results.
Some of the issues lie in the fact that some pathogens or tumor cells may themselves benefit from higher
levels of selenium. Manipulation of individual selenoproteins may offer a more precise approach
for enhancing the immune system or mitigating chronic inflammation. This approach will require
a comprehensive characterization of the roles for selenoproteins and an unmasking of molecular
mechanisms by which they regulate immune cell functions.
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Abstract: Maternal milk contains compounds that may affect newborn immunity. Among these
are a group of oligosaccharides that are synthesized in the mammary gland from lactose;
these oligosaccharides have been termed human milk oligosaccharides (HMOs). The amount of
HMOs present in human milk is greater than the amount of protein. In fact, HMOs are the third-most
abundant solid component in maternal milk after lactose and lipids, and are thus considered to
be key components. The importance of HMOs may be explained by their inhibitory effects on the
adhesion of microorganisms to the intestinal mucosa, the growth of pathogens through the production
of bacteriocins and organic acids, and the expression of genes that are involved in inflammation.
This review begins with short descriptions of the basic structures of HMOs and the gut immune
system, continues with the beneficial effects of HMOs shown in cell and animal studies, and it ends
with the observational and randomized controlled trials carried out in humans to date, with particular
emphasis on their effect on immune system development. HMOs seem to protect breastfed infants
against microbial infections. The protective effect has been found to be exerted through cell signaling
and cell-to-cell recognition events, enrichment of the protective gut microbiota, the modulation of
microbial adhesion, and the invasion of the infant intestinal mucosa. In addition, infants fed formula
supplemented with selected HMOs exhibit a pattern of inflammatory cytokines closer to that of
exclusively breastfed infants. Unfortunately, the positive effects found in preclinical studies have
not been substantiated in the few randomized, double-blinded, multicenter, controlled trials that are
available, perhaps partly because these studies focus on aspects other than the immune response
(e.g., growth, tolerance, and stool microbiota).
Keywords: human milk oligosaccharides; intestinal immune system; microbiota
1. Introduction
Breastfeeding has many beneficial effects in newborns. The relative risks of diarrhea incidence,
diarrhea mortality, pneumonia incidence, and pneumonia mortality are kept to a minimum in
exclusively breastfed infants. These protective effects, although less robust, are also observed in
partially breastfed infants when compared with milk formula-fed infants [1]. However, in addition
to protecting against infection, human milk has both short-term and long-term effects, such as
prevention and protection against allergic reactions; optimal behavioral, cognitive, and gastrointestinal
development; and, may protect against chronic diseases, such as diabetes, obesity, hypertension,
and autoimmune and cardiovascular diseases [2]. The long-term effects of human milk are related to
so-called early programming [3].
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Human milk contains many bioactive compounds that may affect immunity (e.g., cytokines,
growth factors, hormones, digestive enzymes, transporters, and antimicrobial factors). The latter
category of antimicrobial factors includes glycans, among which exists a group of oligosaccharides with
different structures that are synthesized from lactose in the mammary gland. These oligosaccharides
have been termed human milk oligosaccharides (HMOs). In addition, human milk contains probiotics,
which reside in the microbiota of the breast tissue and may also have a role in neonate immunity [4,5].
Although HMOs were originally described and referred to as “gynolactose” by Lespagnol and
Polonowski in 1930 [4], they have attracted considerable attention in recent years because of their
biological roles. The HMO fraction (5–15 g/L) that is present in human milk is greater than the protein
fraction (8 g/L). In fact, HMOs are the third-most abundant solid component in maternal milk after
lactose (70 g/L) and lipids (40 g/L), and accordingly, they are considered to be key compounds [4,5].
HMOs have been described to inhibit (i) the adhesion of microorganisms to the intestinal mucosa;
(ii) the growth of pathogens through the production of bacteriocins and organic acids; and (iii) the
expression of genes involved in inflammation [4–6]. Although many studies regarding the composition
of oligosaccharides in human milk have been published, there are few publications about the roles of
these compounds in general and in immunity in particular [5,7]. The aim of this review article was to
fill this gap by surveying the in vitro and in vivo effects of HMOs, focusing mainly on immunity.
2. Oligosaccharides in Human Milk
More than two hundred different HMOs have been identified to date. HMOs are composed of
monosaccharides and monosaccharide derivatives [4]: glucose (Glc), galactose (Gal), N-acetylglucosamine
(GlcNAc), fucose (Fuc), and sialic acid (Sia). All of the HMOs contain lactose at their reducing end,
which can be elongated by the addition of β1-3- or β1-6-linked lacto-N-biose (Galβ1-3GlcNAc-, type 1
chain) or N-acetyllactosamine (Galβ1-4GlcNAc-, type 2 chain). Elongation with lacto-N-biose appears
to terminate the chain, whereas N-acetyllactosamine can be further extended by the addition of
either of the two disaccharides. A β1-6 linkage between two disaccharide units introduces chain
branching. Branched structures are termed iso-HMOs; linear structures without branches are termed
para-HMOs. Lactose or the elongated oligosaccharide chain can be fucosylated with α1-2, α1-3, or α1-4
linkages, and/or sialylated with α2-3 or α2-6 linkages. Some HMOs occur in several isomeric forms,
e.g., lacto-N-fucopentaose or sialyllacto-N-tetraose [4]. HMOs with more than 15 disaccharide units
have been described; such HMOs form complex structural backbones that can be further modified by
the addition of Fuc or/and Sia [8,9]. HMOs are classified into three categories (Figure 1) [8,9]:
(a) Neutral (fucosylated) HMOs are neutral and contain fucose at the terminal position
(e.g., 2′-fucosyllactose (2′-FL) and lactodifucopentaose). They represent 35% to 50% of the
total HMO content.
(b) Neutral N-containing (nonfucosylated) HMOs are neutral, contain N-acetylglucosamine at the
terminal position (e.g., lacto-N-tetraose), and represent 42% to 55% of the total HMO content.
Neutral HMOs account for more than 75% of the total HMOs in human breast milk.
(c) Acid (sialylated) HMOs are acidic and contain sialic acid at the terminal position
(e.g., 2′-sialyllactose). They represent 12% to 14% of the total HMO content.
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Figure 1. Human milk oligosaccharides (HMO) basic structures.
The amount and composition of HMOs vary among women. The HMO composition is determined
genetically and mirrors blood group characteristics, which depend on the expression of certain
glycosyltransferases. Four milk groups can be assigned based on the Secretor (Se) and Lewis (Le) blood
group system, which is determined by the activity of two gene loci encoding α1-2-fucosyltransferase
(FUT2, encoded by the Se gene) and α1-3/4-fucosyltransferase (FUT3, encoded by the Le gene) [6–17].
Individuals with an active Se locus are classified as “secretors”. The milk of secretor women is abundant
in 2′-FL, lacto-N-fucopentaose I (LNFP I), and other α1-2-fucosylated HMOs. In contrast, non-secretor
women lack a functional FUT2 enzyme, and their milk does not contain α1-2-fucosylated HMOs.
Individuals with an active Le locus are classified as Le-positive. They express FUT3, which transfers
Fuc with a α1-4 linkage to subterminal GlcNAc on type 1 chains. In contrast, the milk of Le-negative
women lacks these specific α1-4-fucosylated HMOs, e.g., LNFP II [9,10,14]. Therefore, breast milk can
be assigned to one of the four groups based on the expression of FUT2 and FUT3: Le-positive secretors
(Le+Se+), Le-negative secretors (Le-Se+), Le-positive nonsecretors (Le+Se-), and Le-negative nonsecretors
(Le-Se+) (Table 1) [9,10,14]:
Table 1. Human milk oligosaccharide (HMO) groups.
Genes Lewis+ Lewis-
Secretor+ Se+Le+ Se+Le-
Able to secrete all HMOs Able to secrete 2´FL, 3FL, LNFP-I, LNFP-III
Secretor- Se-Le+ Se-Le-
Able to secrete 3FL, LNFP-II, LNFP-III Able to secrete 3FL, LNFP-III, LNFP-V
Abbreviations: FL, fucosyllactose; LNFP, lacto-N-fucopentaose. Taken from [18].
This classification, however, is an oversimplification. FUT2 and FUT3 compete for some of the
same substrates [19–21], and the levels of enzyme expression and activity translate into different
profiles throughout the population. Even the milk of Le-negative nonsecretor women who express
neither FUT2 nor FUT3 contains fucosylated HMOs, such as 3FL or LNFP III, suggesting that other Se-
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and Le-independent FUTs may be involved [14,22]. In addition, α1-2-fucosylated HMOs have been
found in the milk of nonsecretor women near the end of lactation, and Newburg et al. suggested that
FUT1 might also participate in HMO fucosylation [22]. In addition, fucosylation in preterm milk is
not as well regulated as in term milk, resulting in higher within and between mother variation in
women delivering preterm vs term. In fact, of particular clinical interest, the α1,2-linked fucosylated
oligosaccharide 2′-fucosyllactose, which is an indicator of secretor status, is not consistently present
across the lactation of several mothers that delivered preterm [23].
The amount and composition of HMOs also vary over the course of lactation. Whereas, colostrum
contains as much as 20–25 g/L of HMOs, as milk production matures, HMO concentrations decline to
5–20 g/L, which still exceeds the concentration of total milk protein [4]. The milk of mothers delivering
preterm infants has higher HMO concentrations than term milk [14], whereas preterm milk contains
lower levels of fucosylated HMOs than term milk [24], and no differences in neutral and acidic HMOs
are found between preterm and term milk [25].
3. The Intestinal Immune System
The intestinal immune system, also known as gut-associated lymphoid tissue (GALT), is a
secondary lymphoid organ that is responsible for the processing of the antigens that interact with the
intestinal mucosa and of the dissemination of the immune response [26]. There are two main locations
of lymphocytes in the intestine: the inductive sites, that is, where the immune response begins after
stimulation by an antigen, of which the Peyer patches are the most typical, and the effector sites, that is,
the ones that are responsible for executing and completing the response. There are also two main
lymphocyte populations in the gut: the lymphocytes of the lamina propria (LPL), located in the internal
part of the villus, and the intraepithelial lymphocytes (IELs), located among the enterocytes along the
villus. It is worth mentioning that, in addition to the Peyer patch lymphocytes (PPLs), the peritoneal
lymphocytes, particularly the B1 cells, are important precursors of one population of plasmatic cells
found in the lamina propria. Therefore, two main inductive populations may be found at the intestinal
level: the B2 cells, which reside in the Peyer patches, and the B1 cells, which reside in the peritoneum
(Figure 2) [27].
Figure 2. Main lymphocyte populations of the gut-associated lymphoid tissue (GALT). Modified with
permission from [26].
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The antigens that are present in the intestinal lumen are processed and transported into the
Peyer patches via the M cells, which are located among the enterocytes in the epithelium. Once in the
Peyer patches, the antigens interact with antigen-presenting cells (APCs), which are responsible for
presenting those antigens to immature B and T lymphocytes that are residing in both the germinal
centers and interfollicular regions. After their activation by antigens, the immature B and T cells
drain down the lymph nodes and migrate through the thoracic duct to the bloodstream. They may
circulate for a few days and later differentiate into mature effector cells that migrate to the lamina
propria or memory cells, which again travel to the Peyer patches [26,27]. The so-called dendritic cells
that are present in the Peyer patches and the lamina propria have been shown to form pseudopods
and interact directly with antigens that are present in the intestinal lumen, after which they process
the antigens and present them to other underlying cell lineages without the involvement of the
M cells [28,29]. Another population of effector cells consisting of IELs may interact with antigens
entering the gastrointestinal tract without following the course mentioned above. In recent years,
a new type of cells, innate lymphoid cells (ILCs), have been described along with their functions [30].
ILCs are present in the intestine and other mucosae and participate in tissue homeostasis, inflammation,
and autoimmunity, although their main function is the development of the gut barrier.
The potential beneficial effects of HMOs might be related to their capacity to interact with a
number of receptors that are located in intestinal immune cells [31].
4. Beneficial Effects of HMOs
Humans lack the enzymes (sialidases, fucosidases) that break down HMOs; therefore,
these compounds reach the colon intact, where they are digested by bacteria within the intestinal
microbiota. In this sense, HMOs are prebiotics and they promote the growth of a favorable microbiota.
Moreover, HMOs have been reported to confer additional benefits on the host, among which the three
main effects are described below.
4.1. Inhibition of Microorganism Adhesion to the Intestinal Mucosa
The formation of the gut microbiota ecosystem is a complex but continuous process that
is affected by endogenous and exogenous determinants of variability. An immediate effect
at the time of birth continues for several years during childhood through subsequent stages.
Streptococcus and Staphylococcus species are the most commonly identified bacterial genera in human
milk, followed by Bifidobacterium, Lactobacillus, Propionibacteria, Enterococcus, and members of the
Enterobacteriaceae family [32,33].
During early life, several external factors, such as delivery mode, feeding modality, environmental
influences, antibiotic exposure, and functional food intake can affect microbiota shaping and
composition [34]. The ability of the immune system to coevolve with the microbiota during perinatal
life allows for the host and the microbiota to coexist in a mutually beneficial relationship [34]. Metabolic
diseases are linked with disruption of both the innate and adaptive immune systems. There is
evidence that some cytokines (e.g., TNF-α and IL-1) contribute to insulin resistance, thereby promoting
diabetes [35] and leading to metabolic inflammation [36]. Likewise, Gram (−) lipopolysaccharide
(LPS) components [37] circulate in the blood transported by LPS-binding proteins and lipoproteins,
contributing to inflammation [34].
HMOs might protect breastfed infants against microbial infections due to their structural
similarities to cell surface glycoconjugates utilized by microbes [38–40]. Experimental results have
shown that oligosaccharides can provide protective effects through cell signaling and cell-to-cell
recognition events, the enrichment of protective gut microbiota, and the modulation of microbial
adhesion and invasion of the infant intestinal mucosa [41–45]. Most enteric pathogens use cell surface
glycans to identify and bind to their target cells, which is the critical first step in pathogenesis.
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Fucosylated HMOs have been reported to inhibit (i) the binding of several pathogens, such as
Campylobacter jejuni [46], Norwald-like virus [47], and Helicobacter pylori [48], and (ii) the heat-stable
enterotoxin of Escherichia coli [49] to intestinal cells.
The addition of HMOs was tested in T84 cell membranes to establish the inhibition of
enterotoxin-producing Escherichia coli. The administration of HMOs repressed E. coli guanylate cyclase
activity and cyclic GMP production in these cells [50]. Uropathogenic E. coli strains expressing P (Pap)
and P-like (Prs) fimbriae are responsible for infections of the urinary tract. The hemagglutination
that is mediated by these strains was inhibited by HMOs, especially by the sialylated fraction [51].
Fractions of HMOs were evaluated for their ability to inhibit the adhesion of E. coli serotype O119,
Vibrio cholerae, and Salmonella fyris in differentiated Caco-2 cells. The evaluated HMOs inhibited the
adhesion of these pathogens to epithelial cells [52]. Oligosaccharides from milk might block the action
of PA-IIL, a fucose-binding lectin of the human pathogen Pseudomonas aeruginosa, through competition
for the receptor and further binding [53]. In particular, a significant reduction in uropathogenic E. coli
internalization into HMO-pretreated epithelial cells was detected without observing any binding
to these cells [54]. HMOs from pooled human milk significantly reduced enteropathogenic E. coli
strain 2348/69 (serotype O127:H6) attachment to cultured epithelial cells [55]. Likewise, treatment
with HMOs reduced the invasion of human premature intestinal epithelial cells by C. albicans in a
dose-dependent manner [56].
Colonization and invasion require the attachment of trophozoites to the host’s mucosa.
HMOs reduce E. histolytica attachment and cytotoxicity; in fact, pooled HMOs detach E. histolytica
by more than 80%; moreover, HMOs rescue E. histolytica-induced destruction of human intestinal
epithelial HT-29 cells in a dose-dependent manner [57].
4.2. Short-Chain Fatty Acid Production by Bifidobacteria
Short-chain fatty acids (SCFAs) are an important source of energy for enterocytes and are key
signaling molecules for the maintenance of gut health. HMOs can indirectly increase the production of
SCFA, and these augmented levels are mediated by bifidobacteria species. SCFAs can interact with the
SCFA receptors GPR41 and GPR43, increasing the intestinal secretion of polypeptide YY (PYY) and
glucagon-like peptide 1 (GLP-1), respectively [58,59]. Propionate can increase free-fatty-acid uptake,
possibly by affecting the lipoprotein lipase (LPL) inhibitor angiopoietin-like 4 (ANGPTL4). Acetate
and propionate might also attenuate intracellular lipolysis by decreasing the phosphorylation of the
hormone-sensitive lipase (HSL) through its interaction with the SCFA receptor GPR43. Propionate and
butyrate could reduce the secretion of proinflammatory cytokines and chemokines, likely by reducing
local macrophage infiltration [58].
Breastfed infants are typically colonized by strains of bacteria that are thought to protect,
feed, and communicate with the developing intestine [60]. In 1954, Gyorgy et al. [61] conducted
several studies that indicated a unique activity of HMOs as a growth factor for a Bifidobacterium
that was isolated from the feces of an infant. Ward et al. [62,63] first demonstrated the selective
growth of bifidobacteria species on intact HMOs in vitro. A number of studies have characterized the
bifidobacterial moieties that specifically bind and catabolize HMOs [64–67].
B. infantis possesses a gene cluster that encodes transport systems and intracellular glycosyl
hydrolases [41,68,69]. However, B. bifidum employs a different mode of catalytic activity toward
HMO consumption: it exports sialidases, fucosidases, and a lacto-N-biosidase to release lacto-N-biose
from HMO structures, and lacto-N-biose is then transported and metabolized [70]. Recently, a study
revealed a multicomponent transcriptional regulation system that controls the HMO metabolism
pathways in B. breve UCC2003 [71].
4.3. Inhibition of Inflammatory Genes
Although HMO-mediated changes in the infant microbiota composition or intestinal epithelial
cell response may indirectly affect the infant immune system, many in vitro studies suggest that
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HMOs also directly modulate immune responses. HMOs may act either locally, on cells of the
mucosa-associated lymphoid tissues, or at a systemic level, as 1% of HMOs are absorbed and reach the
systemic circulation [4,72–74].
The transcriptional response of colonic epithelial cells that are treated with HMOs was investigated
in HT-29 cells. The expression of several cytokines (such as IL-1β, IL-8, colony-stimulating factor 2,
IL-17C and platelet factor 4 (PF4)), chemokines (such as CXCL1, CXCL3, CXCL2, CXCL6, CCL5, CCL20,
and CX3CL1), and cell surface receptors (interferon γ receptor 1, IFNGR1), intercellular adhesion
molecule-1 (ICAM-1), intercellular adhesion molecule-2 (ICAM-2), and IL-10 receptor a (IL10RA)
in HT-29 cells was influenced by the administration of HMOs [75]. The aforementioned cytokines,
chemokines, and cell surface receptors are implicated in the development and maturation of the
intestinal immune response [75].
Using a cellular model with intestinal epithelial cells (T84/HCT8/FHs74) and HeLa cells,
He et al. [76] investigated the effects of HMOs from colostrum in fetal human intestinal mucosa
cells. These authors identified networks controlling immune cell communication, intestinal mucosal
immune system differentiation, and homeostasis. HMOs treatment decreased cytokine protein levels,
such as IL-8, IL-6, monocyte chemoattractant protein-1/2 and IL-1β, while increasing the levels of
cytokines that are involved in tissue repair and homeostasis [76].
Gram-negative pathogenic bacteria might activate mucosal inflammation through the binding of
LPS to intestinal toll-like receptor 4 (TLR4) in epithelial intestinal cells (IECs). Under in vitro conditions,
IECs were treated with a strain of enterotoxigenic E. coli to evaluate the inhibitory effect of HMO
treatment on the secretion of IL-8. Both treatments (a mixture of HMOs and 2′-FL alone) successfully
decreased the LPS-dependent stimulation of IL-8 through the attenuation of CD14 induction.
CD14 expression mediates the LPS-TLR4 stimulation of portions of the “macrophage migration
inhibitory factors” inflammatory pathway via suppressors of cytokine signaling 2/signal transducer
and the activator of transcription (STAT) 3/NF-κB [76]. The effects of different oligosaccharide fractions
on leukocyte rolling and adhesion were determined. Two active compounds (3′-sialyl-lactose and
3′-sialyl-3-fucosyl-lactose) exhibit an inhibitory effect on leukocyte rolling and adhesion, decreasing
the incidence of inflammatory diseases due to their anti-inflammatory activities [77].
The administration of HMOs also demonstrated growth inhibition of Streptococcus agalactiae
(group B Streptococcus). This bacteriostatic activity was mediated through the action of a putative
glycosyltransferase that confers resistance to oligosaccharides [78]. The human epithelial cell lines
HEp-2 and HT-29 were infected with C. jejuni 81-176 and were treated with 2′FL to evaluate the degree
of infection and inflammatory response. Treatment with 2′-FL attenuated the majority of C. jejuni
invasion and decreased the release of IL-8 and IL-1b by 80–90% as well as decreasing the level of the
neutrophil chemoattractant macrophage inflammatory protein 2 (MIP-2) [79].
Bacterial strains are not the only pathogens that are inhibited by the action of HMOs. In addition,
some evidence suggests that HMOs act against viruses [6]. In particular, 2′-FL and 3-FL can
structurally mimic histo-blood group antigens and block the binding of norovirus, which can
cause acute gastroenteritis in humans [80]. The effects of 2′FL, 6′-sialyllactose, 3′-sialyllactose and
lacto-N-neotetraose on peripheral blood mononuclear cells (PBMCs) following respiratory viral
infection were investigated in vitro. The administration of 2′-FL significantly decreased the respiratory
syncytial viral load and cytokines that are associated with disease severity (IL-6, IL-8, MIP-1α) and
inflammation (TNF-α, MCP-1) in airway epithelial cells. Lacto-N-neotetraose and 6′-sialyllactose
treatments decreased the influenza viral load in airway epithelial cells, and only 6′-sialyllactose
decreased CXCL10 and TNF-α in respiratory syncytial virus-infected PBMCs [81]. Particularly,
HMOs containing more than one unit of fucose may exhibit stronger binding capacities when compared
with single fucose HMOs [82].
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5. Immunomodulation Mediated by HMOs: Animal Studies
The immunomodulatory effects of HMOs have also been demonstrated in animal studies.
The impact of HMOs on mucosal immunity and the response to rotavirus infection has been studied
in piglets by Li et al. [83]. The administration of HMOs to these animals decreased the duration of
diarrhea and enhanced the expression of IFN-γ and IL-10. HMO treatment failed to prevent the onset
of rotavirus infection [83].
Colostrum-deprived newborn pigs were fed HMO formula (2′-FL, lacto-N-neotetraose, 6′-sialyllactose,
3′-sialyllactose, and free sialic acid) or formula containing short-chain galactooligosaccharides and
long-chain fructooligosaccharides, and were then inoculated with porcine rotavirus strain OSU at
day 10. Pigs that received the HMO treatment had nearly twice as many natural killer cells and five
times as many basophils as formula-fed pigs. The authors hypothesized that altered immune cell
populations may mediate the effects of dietary HMOs on rotavirus infection susceptibility through
the direct stimulation of immune cells, alteration of intestinal bacterial populations, modulation of
intestinal barrier function, and the alteration of viral pathogenicity [84].
2′-FL is one of the most prominent short-chain oligosaccharides and it is associated with the
anti-infective capacity of human milk. A murine influenza vaccination model was used to determine
the effect of 2′-FL on vaccination responsiveness. 2′-FL treatment enhanced the delayed-type
hypersensitivity responses and increased the serum levels of immunoglobulin (Ig) G1 and IgG2a
and the expression of activation marker CD27 on splenic B cells. Finally, 2′-FL treatment had a direct
effect on the maturation status and antigen-presenting capacity of bone marrow-derived dendritic
cells [85]. Four-week-old male wild-type C57BL/6 mice were fed antibiotics to reduce their intestinal
microbiota and then inoculated with C. jejuni 81–176. The effect of treatment with 2′-FL on the resulting
acute transient enteric infection and immune response was evaluated. The ingestion of 2′-FL reduced C.
jejuni colonization and the induction of inflammatory signaling molecules of the acute-phase mucosal
immune response by 50–60% [79].
6. Effects of HMOs: Studies in Humans
The positive effects of HMOs found by in vitro and animal studies must be substantiated by
findings from clinical studies. The most reliable clinical studies for assessing the benefits of HMOs are
randomized, double-blinded, multicenter controlled trials (RCTs). To date, however, the number of
RCTs with HMOs is very scarce, and most have focused on aspects other than the immune response.
6.1. Observational Studies
HMOs containing α1,2-fucosyl linkages have been shown to promote the growth of bifidobacteria.
B. longum subsp. infantis and B. bifidum possess glycosyl hydrolase family 95 (GH95) fucosidases
that act on 2′-fucosylated HMOs [68,86,87]. Mothers with FUT2 (secretor mothers) and nonsecretor
mothers (with the nonfunctional enzyme) were recruited to evaluate the effects of maternal secretor
status on the developing infant microbiota. Bifidobacteria colonize earlier in infants that are fed by
secretor mothers than in infants fed by nonsecretor mothers. In addition, the majority of bifidobacteria
were isolated from secretor-fed infants who consumed 2′-FL. Feces with high levels of bifidobacteria
contained lower milk oligosaccharide levels and higher lactate levels [86]. The known HMO consumer
Bifidobacterium were more abundant in the children of secretor mothers than those of nonsecretor
mothers. The relative abundance of Bacteroides plebeius, a bacterium capable of utilizing sulfated
polysaccharides for growth, was decreased in these children [88]. In addition, the FUT2 gene might be
related to allergic disease in breastfed infants later in life. At two years of age, but not at five years,
a lower incidence of IgE-associated eczema was detected in C-section-born infants who were fed
breast milk containing FUT2-dependent oligosaccharides [89]. Additionally, although data suggest
that higher lacto-N-fucopentaose III concentrations are associated with the lack of development of
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cow’s milk allergy, they are not required to prevent cow’s milk allergy. Therefore, other mechanisms
must be in play [90].
HMOs have multiple immunomodulatory functions that influence child´s health [91]. Kuhn et al.
evaluated the effects of HMO from breast milk on the survival of uninfected children born to
HIV-infected mothers. Higher maternal breast milk concentrations of 2-linked fucosylated HMOs
(2′-FL and lacto-N-fucopentaose I, as well as 3FL and lacto-N-fucopentaose II/III) were significantly
associated with reduced mortality [91].
Breast milk samples were analyzed to determine the levels of 2-linked fucosyloligosaccharides
and their relationship with the incidence of moderate-to-severe diarrhea. The incidence of diarrhea was
lower in infants fed milk containing high levels of total 2-linked fucosyloligosaccharides. Campylobacter,
and calicivirus-induced diarrhea occurred less often in infants whose mother’s milk contained high
levels of 2′-FL and lacto-N-difucohexaose [92].
6.2. Randomized Controlled Trials
Marriage et al. [93] carried out a prospective, randomized, controlled, multicenter study at
28 sites throughout the United States involving 424 healthy full-term infants enrolled by day five
of life to examine infant growth and the tolerance of infant formulas with a caloric density that is
closer to that of human milk supplemented with HMOs and to study HMO uptake [93]. Infants were
randomly divided into three formula feeding groups: (a) EF1, starter formula (64.3 kcal/100 mL) with
galactooligosaccharides (GOS) (2.2 g/L) and 2′-FL at 0.2 g/L (n = 105); (b) EF2, starter formula
(64.3 kcal/100 mL) with GOS (1.4 g/L) and 2′-FL at 1 g/L (n = 111); and, CF, control formula
(64.3 kcal/100 mL) with only GOS (2.4 g/ L) (n = 101). A nonrandomized human milk-fed (HM) group
of infants was also enrolled as a reference (n = 107). The study duration was 119 days, and the primary
outcome was weight gain per day. Secondary outcomes included measures of tolerance and other
anthropometric measures, formula intake, parent responses to questions that are related to satisfaction
with the formula and their infant’s behavior, concentrations of 2′-FL in human milk in infant plasma
and urine, and relative absorption. No significant differences were observed among any groups in
growth parameters (weight, length, or head circumference) over the four-month study period. 2′-FL
was present in the plasma and urine of infants fed the two formulas containing 2′-FL (EF1, EF2).
No significant difference was observed in 2′-FL uptake relative to the concentration fed. All of the
formulas were well tolerated and comparable in terms of average stool consistency, number of stools
per day, and percentage of feedings associated with spitting up or vomiting. In conclusion, infants fed
a lower caloric formula with 2′FL show growth and 2′FL uptake like breast-fed infants [93].
The same authors investigated the effects of feeding formulas supplemented with the HMO
2′-FL on biomarkers of immune function in healthy term infants [94]. For this purpose, they used a
subpopulation of the infants that were enrolled in [93]. PBMCs were isolated for cellular phenotyping
and stimulated ex vivo with phytohemagglutinin to examine proliferation and cell cycle progression
or with respiratory syncytial virus (RSV). Cytokine concentrations were measured in plasma and in ex
vivo cultures. Both groups fed EF1 and EF2 exhibited significantly different inflammatory cytokine
profiles from those of the group fed the control formula (only GOS) (p ≤ 0.05) but not different from
those of breastfed infants or from each other. The plasma concentrations of the inflammatory cytokines
IL-1α, IL-1β, IL-6, and TNF-α, and the anti-inflammatory IL-1 receptor antagonist were significantly
higher in the control group (only GOS) than in breastfed infants or the groups fed EF1 and EF2
(p ≤ 0.05). In ex vivo RSV-stimulated PBMC cultures, breastfed infants were not different from either
of the groups fed the experimental formulas (EF1 and EF2), but they had lower concentrations of
inflammatory cytokines TNF-α and IFN-Υ (p ≤ 0.05) and tended to have lower IL-1ra, IL-6 and IL-1β
than infants fed the control formula. This study suggests that infants fed a formula containing 2′FL
have lower inflammatory cytokines, although being similar to those of breastfed infants [94].
Kajzer et al. [95] evaluated the gastrointestinal tolerance of infants fed infant formula
supplemented with 2′-FL and short-chain fructo-oligosaccharides (scFOS) in a prospective, randomized,
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multicenter, double-blinded, controlled study involving 131 full-term infants enrolled between 0 and
8 days of age [95]. Infants were randomly allocated to receive either milk-based infant formula not
containing oligosaccharides (n = 42) or milk-based infant formula containing 2′-FL (0.2 g/L) and
scFOS (2 g/L) (n = 46). A group of 43 breastfed infants were also included. The intervention was
performed for 35 days. The primary outcome was the average mean rank stool consistency (MRSC)
from study day 1 to visit 3, calculated from stool records. From study day 1 to visit 3, no difference in
stool consistency was observed. At visit 3, there were no differences between groups in the average
volume of study formula intake, the number of study formula feedings per day, anthropometric data,
or percentage of feedings with spitting up or vomiting. The conclusion of this study was that the
formula containing 2′FL was well tolerated in infants as evidenced by stool consistency, formula intake,
anthropometric data and percent feedings with spitup/vomit similar to that of infants fed a formula
without oligosaccharides or breast milk [95].
The effects of feeding infant formulas supplemented with two human milk-identical oligosaccharides,
2′FL, and lacto-N-neotetraose (LNnT), on infant growth, tolerability, gut microbiota, and medication
use were investigated in a randomized, controlled, multicenter trial in Italy and Belgium [96–98].
One hundred and seventy-five healthy, full-term infants were randomly allocated after birth (between
0–14 days of age) to one of the two formula feeding groups: intact cow’s milk-based whey-predominant
infant formula with the addition of 2′-FL (1.0 g/L) and LNnT (0.5 g/L) (test group, n = 88) or intact
cow’s milk-based whey-predominant infant formula (control group, n = 87). The formulas were given
up to six months of age (exclusive formula feeding up to four months). A group of 38 exclusively
breastfed infants were enrolled at three months as a reference (breastfed group). The primary endpoint
was weight gain through four months of age. The secondary endpoints were anthropometry, stool
characteristics, stool microbiota (at 3 and 12 months of age, obtained using 16S rRNA gene sequencing
and metagenomics), stool metabolic signature (at 3 and 12 months of age, obtained using proton
NMR-based metabolic profiling,), digestive tolerance, and morbidity (reported by parents) through
12 months of age. The weight gain up to four months of age of infants fed formula supplemented with
2′-FL and LNnT was not inferior to the weight gain of infants fed unsupplemented formula. The mean
weight, length, head circumference, and BMI up to 12 months of age of infants fed formulas with or
without 2′-FL and LNnT were close to the WHO Growth Standards and did not differ between the two
groups. Digestive tolerance was similar between the two groups. Infants receiving formula containing
2′-FL and LNnT had significantly fewer parental reports of lower respiratory tract infections (19.3% vs.
34.5%; OR 0.45, 95% CI 0.21–0.95; p = 0.027), particularly bronchitis (10.2% vs. 27.6%; OR 0.30, 95% CI
0.11–0.73; p = 0.004), up to 12 months of age (42% vs. 60.9%; OR 0.47, 95% CI 0.24–0.89; p = 0.016),
and lower medication (antibiotics up to 12 months of age, antipyretics (15.9% vs. 29.9%; OR 0.44; 95%
CI 0.2–0.98; p = 0.032) up to four months of age) than infants fed formula without 2′FL and LNnT [96].
In conclusion, feeding infant formula containing two HMOs (2′FL and LNnT) during the first six
months of age are safe, well-tolerated, and supports age-appropriate growth [81]. Also, the observed
effects on reduced morbidity and medication use in infants up to 12 months of age, when feeding
formula with HMOs, suggest that 2′FL and LNnT may provide immune benefits [81].
In a second work, these authors reported the effects of 2′-FL and LNnT on the infant gut
microbiota [97]. The microbiota composition of infants that were fed formula containing 2′-FL and
LNnT was significantly different from that of infants fed nonsupplemented formula (p < 0.001) at
the genus level and closer to that of breastfed infants at three months of age. Three main bacterial
genera (Bifidobacterium, Escherichia, and Peptostreptococcaceae) showed significant differences in infants
fed formula with or without 2 ‘FL and LNnT at three months of age: greater abundance of beneficial
Bifidobacterium (p < 0.01); and, lower abundance of potentially pathogenic Escherichia (p < 0.01) as well
as of unclassified Peptostreptococcaceae (p < 0.05) were observed in infants fed formula containing 2′-FL
and LNnT as compared to infants fed nonsupplemented formula. These values were closer to the levels
that were observed in breastfed infants. The biochemical composition of the stools was explored by the
quantitative profiling of major metabolites to gain additional information on the compositional aspects.
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The stool contents of some amino acids (phenylalanine, tyrosine, isoleucine), some SCFAs (propionate,
butyrate), and some organic acids (lactate) in infants fed formula with 2′-FL and LNnT tended to be
closer to those that were observed in breastfed infants than those in infants fed nonsupplemented
formula [97]. This study shows that a formula supplemented with 2′FL and LNnT shifts stool microbiota
and metabolic signatures of infants born at term closer to that of breastfed infants [97].
Finally, in a third work, the same authors found that, at three months, the microbiota composition
in the test group appeared closer to that of the breastfed group than to that of the control group
according to alpha (within group) and beta (between groups) diversity analyses of the microbiota
and the distribution of microbiota community types (A, B, and C). Supplementation with both HMOs
decreased the number of infants with formula-specific C-community (fecal community type/FCT C)
and increased those with the breastfed-specific B-community (FCT B). Cumulative antibiotic use up to
12 months was associated with the FCT distribution at three months. Infants with FCT B at 3 months
were less likely to be treated with antibiotics (OR 0.4 (95% CI, 0.17–0.93; p = 0.033)), while infants
with FCT C were more likely to be treated with antibiotics during the first 12 months (OR 3.3 (95% CI,
1.54–7.02; p = 0.0025)). The microbiota community type at three months was not associated with other
parent-reported infection-related morbidities [98]. This study confirms the microbiota results of the
previous one [97] and shows that infants with a breastfed specific microbiota community type (FCT B)
are less likely to need antibiotics.
7. Conclusions and Future Perspectives
HMOs have been described to exert immunomodulatory effects. Many in vitro studies suggest
that HMOs directly modulate immune responses, acting either locally on cells of the mucosa-associated
lymphoid tissues or systemically to inhibit the expression of inflammatory genes, mainly cytokines.
Studies in animals have shown that the administration of HMOs decreases the duration of diarrhea
and enhances the expression of cytokines. Observational studies in humans have documented that
certain HMOs promote the growth of bifidobacteria, which in turn affect the production of lactate and
SCFAs that mediate systemic effects, including immunomodulation. Likewise, the intake of 2-linked
fucosylated HMOs is associated with a reduced incidence of eczema, as well as reduced mortality
in children whose mothers were infected with HIV. Moreover, HMOs play a protective role against
bacterial and viral acute diarrhea. HMOs seem to protect breastfed infants against microbial infections
due to their structural similarities to pathogen cell surface molecular patterns, and the protective effect
has been found to be exerted through cell signaling and cell-to-cell recognition events, enrichment of
the protective gut microbiota, and the modulation of microbial adhesion and invasion of the infant
intestinal mucosa. Finally, infants fed formula supplemented with selected HMOs exhibit a pattern of
inflammatory cytokines that is closer to that of exclusively breastfed infants.
Although new analytical systems that take advantage of the separation of complex carbohydrates
by HPLC and identification by mass spectrometry have been developed in recent years, there is a
need for a simpler standardized methodology to estimate the HMO patterns and contents in human
milk worldwide.
Concerning the potential mechanisms of action of HMOs on immunity, new experimental
approaches using human cell intestinal lines and animal models are necessary. In particular, there is a
need to know how HMOs, either directly or indirectly though signaling cascade interactions, affect the
expression of genes that are involved in antigen tolerance, the development of the GALT, and the
response to pathogens, both bacteria and viruses.
A recent development in infant formulas is the incorporation of selected HMOs, mainly
neutral, due to new biotechnological processes that are can incorporate human mammary gland
glycosyltransferases. However, these formulas lack acidic HMOs, which are known to play relevant
biological roles in the inhibition of pathogen and toxin adhesion to the intestine.
The number of RCTs that have evaluated the influence of HMOs on infant health is very
scarce, and the number of subjects was calculated to determine the safety and tolerance of the
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HMO-supplemented formulas but not to generate actual evidence of the potential preventive effects of
HMOs against infectious diseases. Therefore, new RCT studies in infants with the appropriate power
should be designed to ascertain the roles of HMOs in the prevention of diarrhea, pneumonia, and other
respiratory diseases.
Author Contributions: All three authors participated in the bibliographic search, discussion and writing of
the manuscript.
Funding: This research received no external funding.
Acknowledgments: Julio Plaza-Diaz and Angel Gil are part of University of Granada, Plan Propio de Investigación
2016, Excellence actions: Units of Excellence; Unit of Excellence on Exercise and Health (UCEES).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Black, R.E.; Allen, L.H.; Bhutta, Z.A.; Caulfield, L.E.; de Onis, M.; Ezzati, M.; Mathers, C.; Rivera, J.; Maternal
and Child Undernutrition Study Group. Maternal and child undernutrition: Global and regional exposures
and health consequences. Lancet 2008, 371, 243–260. [CrossRef]
2. Dieterich, C.M.; Felice, J.P.; O’Sullivan, E.; Rasmussen, K.M. Breastfeeding and health outcomes for the
mother-infant dyad. Pediatr. Clin. N. Am. 2013, 60, 31–48. [CrossRef] [PubMed]
3. Koletzko, B.; Brands, B.; Grote, V.; Kirchberg, F.F.; Prell, C.; Rzehak, P.; Uhl, O.; Weber, M. Early Nutrition
Programming Project. Long-term health impact of early nutrition: The power of programming. Ann. Nutr. Metab.
2017, 70, 161–169. [CrossRef] [PubMed]
4. Bode, L. Human milk oligosaccharides: Every baby needs a sugar mama. Glycobiology 2012, 22, 1147–1162.
[CrossRef] [PubMed]
5. Musilova, S.; Rada, V.; Vlkova, E.; Bunesova, V. Beneficial effects of human milk oligosaccharides on gut
microbiota. Benef. Microbes 2014, 5, 273–283. [CrossRef] [PubMed]
6. Morozov, V.; Hansman, G.; Hanisch, F.G.; Schroten, H.; Kunz, C. Human milk oligosaccharides as promising
antivirals. Mol. Nutr. Food Res. 2018, 62, e1700679. [CrossRef] [PubMed]
7. Doherty, A.M.; Lodge, C.J.; Dharmage, S.C.; Dai, X.; Bode, L.; Lowe, A.J. Human milk oligosaccharides and
associations with immune-mediated disease and infection in childhood: A Systematic Review. Front. Pediatr.
2018, 6, 91. [CrossRef] [PubMed]
8. Zivkovic, A.M.; German, J.B.; Lebrilla, C.B.; Mills, D.A. Human milk glycobiome and its impact on the infant
gastrointestinal microbiota. Proc. Natl. Acad. Sci. USA 2011, 108, 4653–4658. [CrossRef] [PubMed]
9. Bode, L. The functional biology of human milk oligosaccharides. Early Hum. Dev. 2015, 91, 619–622.
[CrossRef] [PubMed]
10. Smilowitz, J.; Lebrilla, C.; Mills, D.; German, J.; Freeman, S. Breast milk oligosaccharides: Structure-function
relationships in the neonate. Annu. Rev. Nutr. 2014, 34, 143–169. [CrossRef] [PubMed]
11. Kunz, C.; Rudloff, S.; Baier, W.; Klein, N.; Strobel, S. Oligosaccharides in human milk: Structural, functional,
and metabolic aspects. Annu. Rev. Nutr. 2000, 20, 699–722. [CrossRef] [PubMed]
12. Kobata, A. Structures and application of oligosaccharides in human milk. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.
2010, 86, 731–747. [CrossRef] [PubMed]
13. Jantscher-Krenn, E.; Bode, L. Human milk oligosaccharides and their potential benefits for the breast-fed
neonate. Minerva Pediatr. 2012, 64, 83–99. [PubMed]
14. Bode, L.; Jantscher-Krenn, E. Structure-function relationships of human milk oligosaccharides. Adv. Nutr.
2012, 3, 383S–391S. [CrossRef] [PubMed]
15. Goehring, K.C.; Kennedy, A.D.; Prieto, P.A.; Buck, R.H. Direct evidence for the presence of human milk
oligosaccharides in the circulation of breastfed infants. PLoS ONE 2014, 9, e101692. [CrossRef] [PubMed]
16. Blank, D.; Dotz, V.; Geyer, R.; Kunz, C. Human milk oligosaccharides and Lewis blood group: Individual
high-throughput sample profiling to enhance conclusions from functional studies. Adv. Nutr. 2012, 3,
440S–449S. [CrossRef] [PubMed]
17. Austin, S.; De Castro, C.A.; Bénet, T.; Hou, Y.; Sun, H.; Thakkar, S.K.; Vinyes-Pares, G.; Zhang, Y.; Wang, P.
Temporal change of the content of 10 oligosaccharides in the milk of chinese urban mothers. Nutrients 2016,
8, 346. [CrossRef] [PubMed]
240
Nutrients 2018, 10, 1038
18. Kunz, C.; Meyer, C.; Collado, M.C.; Geiger, L.; Garcia-Mantrana, I.; Bertua-Rios, B.; Martinez-Costa, C.;
Borsch, C.; Rudloff, S. Influence of gestational age, secretor, and lewis blood group status on the
oligosaccharide content of human milk. J. Pediatr. Gastroenterol. Nutr. 2017, 64, 789–798. [CrossRef] [PubMed]
19. Kumazaki, T.; Yoshida, A. Biochemical evidence that secretor gene, Se, is a structural gene encoding a specific
fucosyltransferase. Proc. Natl. Acad. Sci. USA 1984, 81, 4193–4197. [CrossRef] [PubMed]
20. Johnson, P.H.; Watkins, W.M. Purification of the Lewis blood-group gene associated alpha-3/4-fucosyltransferase
from human milk: An enzyme transferring fucose primarily to type 1 and lactose-based oligosaccharide
chains. Glycoconj. J. 1992, 9, 241–249. [CrossRef] [PubMed]
21. Xu, Z.; Vo, L.; Macher, B.A. Structure-function analysis of human α1,3-fucosyltransferase. Amino acids
involved in acceptor substrate specificity. J. Biol. Chem. 1996, 271, 8818–8823. [CrossRef] [PubMed]
22. Newburg, D.S.; Ruiz-Palacios, G.M.; Morrow, A.L. Human milk glycans protect infants against enteric
pathogens. Annu. Rev. Nutr. 2005, 25, 37–58. [CrossRef] [PubMed]
23. De Leoz, M.L.; Gaerlan, S.C.; Strum, J.S.; Dimapasoc, L.M.; Mirmiran, M.; Tancredi, D.J.; Smilowitz, J.T.;
Kalanetra, K.M.; Mills, D.A.; German, J.B.; et al. Lacto-N-tetraose, fucosylation, and secretor status are
highly variable in human milk oligosaccharides from women delivering preterm. J. Proteome Res. 2012, 11,
4662–4672. [CrossRef] [PubMed]
24. Davidson, B.; Meinzen-Derr, J.K.; Wagner, C.L.; Newburg, D.S.; Morrow, A.L. Fucosylated oligosaccharides
in human milk in relation to gestational age and stage of lactation. Adv. Exp. Med. Biol. 2004, 554, 427–430.
[CrossRef] [PubMed]
25. Dotz, V.; Adam, R.; Lochnit, G.; Schroten, H.; Kunz, C. Neutral oligosaccharides in feces of breastfed and
formula-fed infants at different ages. Glycobiology 2016, 26, 1308–1316. [CrossRef] [PubMed]
26. Rueda-Cabrera, R.; Gil, A. Nutrición en inmunidad en el estado de salud. In Tratado de Nutrición; Editorial
Médica Panamericana: Madrid, Spain, 2017; Volume 4, ISBN 9788491101932.
27. Rumbo, M.; Schiffrin, E.J. Ontogeny of intestinal epithelium immune functions: Developmental and
environmental regulation. Cell. Mol. Life Sci. 2005, 62, 1288–1296. [CrossRef] [PubMed]
28. Coombes, J.L.; Powrie, F. Dendritic cells in intestinal immune regulation. Nat. Rev. Immunol. 2008, 6, 411–420.
[CrossRef] [PubMed]
29. Gil, A.; Rueda, R. Interaction of early diet and the development of the immune system. Nutr. Res. Rev. 2002,
15, 263–292. [CrossRef] [PubMed]
30. Klose, C.S.; Artis, D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis.
Nat. Immunol. 2016, 17, 765–774. [CrossRef] [PubMed]
31. Hardy, H.; Harris, J.; Lyon, E.; Beal, J.; Foey, A.D. Probiotics, prebiotics and immunomodulation of gut
mucosal defences: Homeostasis and immunopathology. Nutrients 2013, 5, 1869–1912. [CrossRef] [PubMed]
32. Pannaraj, P.; Li, F.; Cerini, C.; Bender, J.; Yang, S.; Rollie, A.; Adisetiyo, H.; Zabih, S.; Lincez, P.J.; Bittinger, K.;
et al. Association between breast milk bacterial communities and establishment and development of the
infant gut microbiome. JAMA Pediatr. 2017, 171, 647–654. [CrossRef] [PubMed]
33. Fernández, L.; Langa, S.; Martín, V.; Maldonado, A.; Jiménez, E.; Martín, R.; Rodríguez, J.M. The human
milk microbiota: Origin and potential roles in health and disease. Pharmacol. Res. 2013, 69, 1–10. [CrossRef]
[PubMed]
34. Putignani, L.; Del Chierico, F.; Petrucca, A.; Vernocchi, P.; Dallapiccola, B. The human gut microbiota:
A dynamic interplay with the host from birth to senescence settled during childhood. Pediatr. Res. 2014, 76,
2–10. [CrossRef] [PubMed]
35. Hotamisligil, G.S.; Peraldi, P.; Budavari, A.; Ellis, R.; White, M.F.; Spiegelman, B.M. IRS-1-mediated inhibition
of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science
1996, 271, 665–668. [CrossRef] [PubMed]
36. Bouloumié, A.; Curat, C.A.; Sengenès, C.; Lolmède, K.; Miranville, A.; Busse, R. Role of macrophage tissue
infiltration in metabolic diseases. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8, 347–354. [CrossRef] [PubMed]
37. Cani, P.D.; Amar, J.; Iglesias, M.A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A.M.; Fava, F.; Tuohy, K.M.;
Chabo, C.; et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56, 1761–1772.
[CrossRef] [PubMed]
38. Kunz, C.; Rudloff, S. Biological functions of oligosaccharides in human milk. Acta Pediatr. 1993, 82, 903–912.
[CrossRef]
39. Wold, A.E.; Hanson, L.A. Defence factors in human milk. Curr. Opin. Gastroenterol. 1994, 10, 652–658. [CrossRef]
241
Nutrients 2018, 10, 1038
40. Zopf, D.; Roth, S. Oligosaccharide anti-infective agents. Lancet 1996, 347, 1017–1021. [CrossRef]
41. Sela, D.A.; Chapman, J.; Adeuya, A.; Kim, J.; Chen, F.; Whitehead, T.; Lapidus, A.; Rokhsar, D.; Lebrilla, C.;
German, J. The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization
within the infant microbiome. Proc. Natl. Acad. Sci. USA 2008, 105, 18964. [CrossRef] [PubMed]
42. Barboza, M.; Pinzon, J.; Wickramasinghe, S.; Froehlich, J.W.; Moeller, I.; Smilowitz, J.T.; Ruhaak, L.R.; Huang, J.;
Lonnerdal, B.; German, J.B.; et al. Glycosylation of human milk lactoferrin exhibits dynamic changes during
early lactation enhancing its role in pathogenic bacteria-host interactions. Mol. Cell. Proteomics 2012, 11,
M111.015248. [CrossRef] [PubMed]
43. Chichlowski, M.; De Lartigue, G.; German, J.B.; Raybould, H.E.; Mills, D.A. Bifidobacteria isolated
from infants and cultured on human milk oligosaccharides affect intestinal epithelial function. J. Pediatr.
Gastroenterol. Nutr. 2012, 55, 321–327. [CrossRef] [PubMed]
44. Newburg, D.S. Do the binding properties of oligosaccharides in milk protect human infants from
gastrointestinal bacteria? J. Nutr. 1997, 127, 980S. [CrossRef] [PubMed]
45. Varki, A. Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 1993, 3, 97–130.
[CrossRef] [PubMed]
46. Ruiz-Palacios, G.M.; Cervantes, L.E.; Ramos, P.; Chavez-Munguia, B.; Newburg, D.S. Campylobacter jejuni
binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human
milk inhibit its binding and infection. J. Biol Chem. 2003, 278, 14112–14120. [CrossRef] [PubMed]
47. Huang, P.; Farkas, T.; Marionneau, S.; Zhong, W.; Ruvoen-Clouet, N.; Morrow, A.L.; Altaye, M.;
Pickering, L.K.; Newburg, D.S.; Le Pendu, J.; et al. Noroviruses bind to human ABO, Lewis, and secretor
histo-blood group antigens: Identification of 4 distinct strain-specific patterns. J. Infect. Dis. 2003, 188, 19–31.
[CrossRef] [PubMed]
48. Xu, H.T.; Zhao, Y.F.; Lian, Z.X.; Fan, B.L.; Zhao, Z.H.; Yu, S.Y.; Dai, Y.P.; Wang, L.L.; Niu, H.L.; Li, N.;
et al. Effects of fucosylated milk of goat and mouse on Helicobacter pylori binding to Lewis b antigen.
World J. Gastroenterol. 2004, 10, 2063–2066. [CrossRef] [PubMed]
49. Newburg, D.S.; Pickering, L.K.; McCluer, R.H.; Cleary, T.G. Fucosylated oligosaccharides of human milk
protect suckling mice from heat-stabile enterotoxin of Escherichia coli. J. Infect. Dis. 1990, 162, 1075–1080.
[CrossRef] [PubMed]
50. Crane, J.K.; Azar, S.S.; Stam, A.; Newburg, D.S. Oligosaccharides from human milk block binding and
activity of the Escherichia coli heat-stable enterotoxin (STa) in T84 intestinal cells. J. Nutr. 1994, 124, 2358–2364.
[CrossRef] [PubMed]
51. Martín-Sosa, S.; Martín, M.J.; Hueso, P. The sialylated fraction of milk oligosaccharides is partially responsible
for binding to enterotoxigenic and uropathogenic Escherichia coli human strains. J. Nutr. 2002, 132, 3067–3072.
[CrossRef] [PubMed]
52. Coppa, G.V.; Zampini, L.; Galeazzi, T.; Facinelli, B.; Ferrante, L.; Capretti, R.; Orazio, G. Human milk
oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae,
and Salmonella fyris. Pediatr. Res. 2006, 59, 377–382. [CrossRef] [PubMed]
53. Perret, S.; Sabin, C.; Dumon, C.; Pokorná, M.; Gautier, C.; Galanina, O.; Ilia, S.; Bovin, N.; Nicaise, M.;
Desmadril, M.; et al. Human milk oligosaccharides shorten rotavirus-induced diarrhea and modulate piglet
mucosal immunity and colonic microbiota. ISME J. 2014, 8, 1609–1620. [CrossRef]
54. Lin, A.E.; Autran, C.A.; Espanola, S.D.; Bode, L.; Nizet, V. Human milk oligosaccharides protect bladder
epithelial cells against uropathogenic Escherichia coli invasion and cytotoxicity. J. Infect. Dis. 2014, 209,
389–398. [CrossRef] [PubMed]
55. Manthey, C.F.; Autran, C.A.; Eckmann, L.; Bode, L. Human milk oligosaccharides protect against
enteropathogenic Escherichia coli attachment in vitro and EPEC colonization in suckling mice. J. Pediatr.
Gastroenterol. Nutr. 2014, 58, 165–168. [CrossRef] [PubMed]
56. Gonia, S.; Tuepker, M.; Heisel, T.; Autran, C.; Bode, L.; Gale, C.A. Human milk oligosaccharides inhibit
candida albicans invasion of human premature intestinal epithelial cells. J. Nutr. 2015, 145, 1992–1998.
[CrossRef] [PubMed]
57. Jantscher-Krenn, E.; Lauwaet, T.; Bliss, L.A.; Reed, S.L.; Gillin, F.D.; Bode, L. Human milk oligosaccharides
reduce Entamoeba histolytica attachment and cytotoxicity in vitro. Br. J. Nutr. 2012, 108, 1839–1846. [CrossRef]
[PubMed]
242
Nutrients 2018, 10, 1038
58. Canfora, E.E.; Jocken, J.W.; Blaak, E.E. Short-chain fatty acids in control of body weight and insulin sensitivity.
Nat. Rev. Endocrinol. 2015, 11, 577–591. [CrossRef] [PubMed]
59. Hur, K.Y.; Lee, M.S. Gut Microbiota and Metabolic Disorders. Diabetes Metab. J. 2015, 39, 198–203. [CrossRef]
[PubMed]
60. Du, X.-L.; Edelstein, D.; Rossetti, L.; Fantus, I.G.; Goldberg, H.; Ziyadeh, F.; Wu, J.; Brownlee, M.
Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway
and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl.
Acad. Sci. USA 2000, 97, 12222–12226. [CrossRef] [PubMed]
61. Gyorgy, P.; Norris, R.F.; Rose, C.S. Bifidus factor. I. A variant of Lactobacillus bifidus requiring a special growth
factor. Arch. Biochem. Biophys. 1954, 48, 193–201. [CrossRef]
62. Ward, R.E.; Ninonuevo, M.; Mills, D.A.; Lebrilla, C.B.; German, J.B. In vitro fermentation of breast milk
oligosaccharides by Bifidobacterium infantis and Lactobacillus gasseri. Appl. Environ. Microbiol. 2006, 72,
4497–4499. [CrossRef] [PubMed]
63. Ward, R.E.; Ninonuevo, M.; Mills, D.A.; Lebrilla, C.B.; German, J.B. In vitro fermentability of human milk
oligosaccharides by several strains of bifidobacteria. Mol. Nutr. Food Res. 2007, 51, 1398–1405. [CrossRef]
[PubMed]
64. Garrido, D.; Ruiz-Moyano, S.; Jimenez-Espinoza, R.; Eom, H.J.; Block, D.E.; Mills, D.A. Utilization of
galactooligosaccharides by Bifidobacterium longum subsp. infantis isolates. Food Microbiol. 2013, 33, 262–270.
[CrossRef] [PubMed]
65. LoCascio, R.; Ninonuevo, M.; Freeman, S.; Sela, D.; Grimm, R.; Lebrilla, C.B.; Mills, D.A.; German, J.B.
Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific,
preferential consumption of small chain glycans secreted in early human lactation. J. Agric. Food Chem. 2007,
55, 8914–8919. [CrossRef] [PubMed]
66. Marcobal, A.; Barboza, M.; Sonnenburg, E.D.; Pudlo, N.; Martens, E.C.; Desai, P.; Lebrilla, C.B.; Weimer, B.C.;
Mills, D.A.; German, J.B.; Sonnenburg, JL. Bacteroides in the infant gut consume milk oligosaccharides via
mucus-utilization pathways. Cell Host Microbe 2011, 10, 507–514. [CrossRef] [PubMed]
67. Ruiz-Moyano, S.; Totten, S.M.; Garrido, D.A.; Smilowitz, J.T.; German, J.B.; Lebrilla, C.B.; Mills, D.A. Variation
in consumption of human milk oligosaccharides by infant gut-associated strains of Bifidobacterium breve.
Appl. Environ. Microbiol. 2013, 79, 6040–6049. [CrossRef] [PubMed]
68. Sela, D.A.; Garrido, D.; Lerno, L.; Wu, S.; Tan, K.; Eom, H.-J.; Joachimiak, A.; Lebrilla, C.B.; Mills, D.A.
Bifidobacterium longum subsp. infantis ATCC 15697 α-fucosidases are active on fucosylated human milk
oligosaccharides. Appl. Environ. Microbiol. 2012, 78, 795–803. [CrossRef] [PubMed]
69. Sela, D.A.; Li, Y.; Lerno, L.; Wu, S.; Marcobal, A.M.; German, J.B.; Chen, X.; Lebrilla, C.B.; Mills, D.A.
An infant-associated bacterial commensal utilizes breast milk sialyloligosaccharides. J. Biol. Chem. 2011, 286,
11909–11918. [CrossRef] [PubMed]
70. Kitaoka, M. Bifidobacterial enzymes involved in the metabolism of human milk oligosaccharides. Adv. Nutr.
2012, 3, 422S–429S. [CrossRef] [PubMed]
71. James, K.; Motherway, M.O.; Penno, C.; O’Brien, R.L.; van Sinderen, D. Bifidobacterium breve UCC2003
employs multiple transcriptional regulators to control metabolism of particular human milk oligosaccharides.
Appl. Environ. Microbiol. 2018, 10, 278–279. [CrossRef] [PubMed]
72. Rudloff, S.; Pohlentz, G.; Diekmann, L.; Egge, H.; Kunz, C. Urinary excretion of lactose and oligosaccharides
in preterm infants fed human milk or infant formula. Acta Paediatr. 1996, 85, 598–603. [CrossRef] [PubMed]
73. Rudloff, S.; Pohlentz, G.; Borsch, C.; Lentze, M.J.; Kunz, C. Urinary excretion of in vivo 13C-labelled milk
oligosaccharides in breastfed infants. Br. J. Nutr. 2012, 107, 957–963. [CrossRef] [PubMed]
74. Gnoth, M.J.; Rudloff, S.; Kunz, C.; Kinne, R.K. Investigations of the in vitro transport of human milk
oligosaccharides by a Caco-2 monolayer using a novel high performance liquid chromatography-mass
spectrometry technique. J. Biol Chem. 2001, 276, 34363–34370. [CrossRef] [PubMed]
75. Lane, J.A.; O’Callaghan, J.; Carrington, S.D.; Hickey, R.M. Transcriptional response of HT-29 intestinal
epithelial cells to human and bovine milk oligosaccharides. Br. J. Nutr. 2013, 110, 2127–2137. [CrossRef]
[PubMed]
76. He, Y.; Liu, S.; Kling, D.E.; Leone, S.; Lawlor, N.T.; Huang, Y.; Feinberg, S.B.; Hill, D.R.; Newburg, D.S.
The human milk oligosaccharide 2′-fucosyllactose modulates CD14 expression in human enterocytes, thereby
attenuating LPS-induced inflammation. Gut 2016, 65, 33–46. [CrossRef] [PubMed]
243
Nutrients 2018, 10, 1038
77. Bode, L.; Kunz, C.; Muhly-Reinholz, M.; Mayer, K.; Seeger, W.; Rudloff, S. Inhibition of monocyte, lymphocyte,
and neutrophil adhesion to endothelial cells by human milk oligosaccharides. Thromb. Haemost. 2004, 92,
1402–1410. [CrossRef] [PubMed]
78. Lin, A.E.; Autran, C.A.; Szyszka, A.; Escajadillo, T.; Huang, M.; Godula, K.; Prudden, A.R.; Boons, G.J.;
Lewis, A.L.; Doran, K.S.; et al. Human milk oligosaccharides inhibit growth of group B Streptococcus.
J. Biol. Chem. 2017, 292, 11243–11249. [CrossRef] [PubMed]
79. Yu, Z.T.; Nanthakumar, N.N.; Newburg, D.S. The human milk oligosaccharide 2′-fucosyllactose quenches
Campylobacter jejuni-induced inflammation in human epithelial cells HEp-2 and HT-29 and in mouse intestinal
mucosa. J. Nutr. 2016, 146, 1980–1990. [CrossRef] [PubMed]
80. Weichert, S.; Koromyslova, A.; Singh, B.K.; Hansman, S.; Jennewein, S.; Schroten, H.; Hansman, G.S.
Structural basis for Norovirus inhibition by human milk oligosaccharides. J. Virol. 2016, 90, 4843–4848.
[CrossRef] [PubMed]
81. Duska-McEwen, G.; Senft, A.P.; Ruetschilling, T.L.; Barrett, E.G.; Buck, R.H. Human milk oligosaccharides
enhance innate immunity to respiratory syncytial virus and influenza in vitro. Food Nutr. Sci. 2014, 5,
1387–1398. [CrossRef]
82. Hanisch, F.G.; Hansman, G.S.; Morozov, V.; Kunz, C.; Schroten, H. Avidity of α-fucose on human milk
oligosaccharides and blood group-unrelated oligo/polyfucoses is essential for potent norovirus-binding
targets. J. Biol. Chem. 2018, 293, 11955–11965. [CrossRef] [PubMed]
83. Li, M.; Monaco, M.H.; Wang, M.; Comstock, S.S.; Kuhlenschmidt, T.B.; Fahey, G.C., Jr.; Miller, M.J.;
Kuhlenschmidt, M.S.; Donovan, S.M. Human milk oligosaccharides shorten rotavirus-induced diarrhea and
modulate piglet mucosal immunity and colonic microbiota. ISME J. 2014, 8, 1609–1620. [CrossRef] [PubMed]
84. Comstock, S.S.; Li, M.; Wang, M.; Monaco, M.H.; Kuhlenschmidt, T.B.; Kuhlenschmidt, M.S.; Donovan, SM.
Dietary human milk oligosaccharides but not prebiotic oligosaccharides increase circulating natural killer
cell and mesenteric lymph node memory t cell populations in noninfected and rotavirus-infected neonatal
piglets. J. Nutr. 2017, 147, 1041–1047. [CrossRef] [PubMed]
85. Xiao, L.; Leusink-Muis, T.; Kettelarij, N.; van Ark, I.; Blijenberg, B.; Hesen, N.A.; Stahl, B.; Overbeek, S.A.;
Garssen, J.; Folkerts, G.; et al. Human milk oligosaccharide 2′-fucosyllactose improves innate and adaptive
immunity in an influenza-specific murine vaccination model. Front. Immunol. 2018, 9, 452. [CrossRef]
[PubMed]
86. Lewis, Z.T.; Totten, S.M.; Smilowitz, J.T.; Popovic, M.; Parker, E.; Lemay, D.G.; Van Tassell, M.L.; Miller, M.J.;
Jin, Y.S.; German, J.B.; et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities
of breastfed infants. Microbiome 2015, 3, 13. [CrossRef] [PubMed]
87. Ashida, H.; Miyake, A.; Kiyohara, M.; Wada, J.; Yoshida, E.; Kumagai, H.; Katayama, T.; Yamamoto, K.
Two distinct alpha-L-fucosidases from Bifidobacterium bifidum are essential for the utilization of fucosylated
milk oligosaccharides and glycoconjugates. Glycobiology 2009, 19, 1010–1017. [CrossRef] [PubMed]
88. Smith-Brown, P.; Morrison, M.; Krause, L.; Davies, P.S. Mothers secretor status affects development of
childrens microbiota composition and function: A pilot study. PLoS ONE 2016, 11, e0161211. [CrossRef]
[PubMed]
89. Sprenger, N.; Odenwald, H.; Kukkonen, A.K.; Kuitunen, M.; Savilahti, E.; Kunz, C. FUT2-dependent breast
milk oligosaccharides and allergy at 2 and 5 years of age in infants with high hereditary allergy risk.
Eur. J. Nutr. 2017, 56, 1293–1301. [CrossRef] [PubMed]
90. Seppo, A.E.; Autran, C.A.; Bode, L.; Järvinen, K.M. Human milk oligosaccharides and development of cow’s
milk allergy in infants. J. Allergy Clin. Immunol. 2017, 139, 708.e5–711.e5. [CrossRef] [PubMed]
91. Kuhn, L.; Kim, H.Y.; Hsiao, L.; Nissan, C.; Kankasa, C.; Mwiya, M.; Thea, D.M.; Aldrovandi, G.M.; Bode, L.
Oligosaccharide composition of breast milk influences survival of uninfected children born to HIV-infected
mothers in Lusaka, Zambia. J. Nutr. 2015, 145, 66–72. [CrossRef] [PubMed]
92. Morrow, A.L.; Ruiz-Palacios, G.M.; Altaye, M.; Jiang, X.; Guerrero, M.L.; Meinzen-Derr, J.K.; Farkas, T.;
Chaturvedi, P.; Pickering, L.K.; Newburg, D.S. Human milk oligosaccharides are associated with protection
against diarrhea in breast-fed infants. J. Pediatr. 2004, 145, 297–303. [CrossRef] [PubMed]
93. Marriage, B.; Buck, R.; Goehring, K.; Oliver, J.; Williams, J. Infants fed a lower caloric formula with 2′FL show
growth and 2′FL uptake like breast-fed infants. J. Pediatr. Gastroenterol. Nutr. 2015, 61, 649–658. [CrossRef]
[PubMed]
244
Nutrients 2018, 10, 1038
94. Goehring, K.; Marriage, B.; Oliver, J.; Wilder, J.; Barrett, E.; Buck, R. Similar to those who are breastfed,
infants fed a formula containing 2′-Fucosyllactose have lower inflammatory cytokines in a randomized
controlled trial. J. Nutr. 2016, 146, 2559–2566. [CrossRef] [PubMed]
95. Kajzer, J.; Oliver, J.; Marriage, B.F. Gastrointestinal tolerance of formula supplemented with oligosaccharides.
FASEB J. 2016, 30, 671.
96. Puccio, G.; Alliet, P.; Cajozzo, C.; Janssens, E.; Corsello, G.; Sprenger, N.; Wernimont, S.; Egli, D.; Gosoniu, L.;
Steenhout, P.L. Effects of infant formula with human milk oligosaccharides on growth and morbidity:
A randomized multicenter trial. J. Pediatr. Gastroenterol. Nutr. 2017, 64, 624–631. [CrossRef] [PubMed]
97. Steenhout, P.; Sperisen, P.; Martin, F.-P.; Sprenger, N.; Wernimont, S.; Pecquet, S.; Berger, B. Term infant
formula supplemented with human milk oligosaccharides (2′-fucosyllactose and lacto-N-neotetraose) shifts
stool microbiota and metabolic signatures closer to that of breastfed infants. FASEB J. 2016, 30, 275–277.
98. Berger, B.; Grathwohl, D.; Alliet, P.; Puccio, G.; Steenhout, P.; Sprenger, N. Stool microbiota in term infants
fed formula supplemented with human milk oligosaccharides and reduced likelihood of antibiotic use.
J. Pediatr. Gastroenterol. Nutr. 2016, 63, S407.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Wiebke Alker 1,2 and Hajo Haase 1,2,*
1 Department of Food Chemistry and Toxicology, Berlin Institute of Technology, 13355 Berlin, Germany;
alker@tu-berlin.de
2 TraceAge—DFG Research Unit on Interactions of Essential Trace Elements in Healthy and Diseased Elderly,
Potsdam-Berlin-Jena, Germany
* Correspondence: Haase@tu-berlin.de; Tel.: +49-30-314-727-01
Received: 25 June 2018; Accepted: 24 July 2018; Published: 27 July 2018
Abstract: Sepsis, defined as a “life-threatening organ dysfunction caused by a dysregulated
host-response to infection” is a major health issue worldwide and still lacks a fully elucidated
pathobiology and uniform diagnostic tests. The trace element zinc is known to be crucial to ensure an
appropriate immune response. During sepsis a redistribution of zinc from serum into the liver has
been observed and several studies imply a correlation between zinc and sepsis outcome. Therefore the
alterations of zinc concentrations in different tissues might serve as one part of the host’s defense
mechanism against pathogens during sepsis by diverse mechanisms. It has been suggested that zinc
is involved in nutritional immunity, acts as a hepatoprotective agent, or a differentiation signal for
innate immune cells, or supports the synthesis of acute phase proteins. Further knowledge about
these events could help in the evaluation of how zinc could be optimally applied to improve treatment
of septic patients. Moreover, the changes in zinc homeostasis are substantial and correlate with the
severity of the disease, suggesting that zinc might also be useful as a diagnostic marker for evaluating
the severity and predicting the outcome of sepsis.
Keywords: zinc; sepsis; biomarker; supplementation; homeostasis
1. Introduction
Zinc is of fundamental importance for the immune system and is involved in different pathologies.
In recent years, indications have appeared that zinc homeostasis might be an important factor
during sepsis. The following review focuses on the alterations of zinc homeostasis during sepsis
and possible physiological functions of this process. It further discusses potential risks and benefits of
zinc supplementation as well as a possible approach for using serum zinc as a biomarker for sepsis.
1.1. Sepsis
The term “sepsis” in relation to a disease has already been used by Hippocrates, but to this day it
remains a challenge to compile a definition comprising its complexity [1]. This results from the fact
that sepsis is rather a syndrome than an illness, showing a not yet fully elucidated pathobiology, and
with uniform diagnostic tests still lacking [2]. Sepsis is responsible for about 6 million deaths per year,
making it a critical illness and one of the major causes of mortality worldwide [3,4]. Its epidemiological
burden is assumed to be much higher in low- and middle-income countries and the mortality rate is
affected by the global national income [3,5].
There is an urgent need for an easily understandable definition in order to establish public
awareness, as well as for improved and uniform diagnostic guidelines for an early recognition of
sepsis [2,3]. In the past, different task forces have approached these issues [6,7]. A recent consensus
defined sepsis as a “life-threatening organ dysfunction caused by a dysregulated host-response to
infection” (Sepsis-3) [2]. To diagnose organ dysfunction in the clinical setting, Singer et al. recommend
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the Sequential Organ Failure Assessment (SOFA) score. It includes parameters to evaluate the functions
of respiration, the liver, the cardiovascular system, the central nervous system, the kidneys, and
coagulation. An elevation of the total SOFA score of 2 points or more indicates organ dysfunction [2,8].
Sepsis is initiated by an infection [2]. The pathogen triggers an immune response, comprising
pro-inflammatory mechanisms to defeat the pathogen and regenerate the affected tissue, as well
as subsequent anti-inflammatory mechanisms to counteract the pro-inflammatory actions in order
to limit collateral damage in healthy tissue [9,10]. A dysregulation of this immune response, as
it appears during sepsis, leads to an over-reaction of the immune system, which can affect both
mechanisms described. Hyper-inflammation in the form of a systemic inflammatory response
syndrome (SIRS) can lead to a damage of the host’s own tissue. Immune-suppression, also known
as compensatory anti-inflammatory response syndrome (CARS), leaves the host more vulnerable
to secondary infections [2,11,12]. A wealth of literature is provided about sepsis and its symptoms,
diagnostics, and possible medical treatment approaches (e.g., [10,11,13,14]), to which the reader is
referred for more detailed information on these aspects of sepsis.
1.2. Zinc
Zinc is an essential trace element [15,16]. In the body it functions, for example, as a co-factor for a
high number of enzymes or as a structural element for a variety of proteins [17]. Zinc deficiency can
result in growth retardation, dermatitis, and hypogonadism, or symptoms such as delayed wound
healing, thymic atrophy or lymphopenia, and high incidence of infection; the latter points are due
to its particular importance for the immune system [18–20]. Consequently, zinc deficiency results
in multiple immunological changes, including what seems to be a shift toward a predominantly
innate immune response when the availability of zinc is limited [21]. One particularly important
effect of zinc is a modulation of the production of inflammatory cytokines [22]. Moreover, zinc is
crucial for the functioning of virtually all immune cells. For example, the differentiation of immature
T-cells depends on zinc, because thymulin, a hormone involved in T-cell differentiation, depends
on zinc as a co-factor [23,24]. In addition, the maturation of T-cells is influenced by their zinc
status. On the one hand a deficiency results in altered ratios of Th1- and Th2-cells, an increased
apoptosis-rate of immature T-cells, and consequently a decrease in T-cells in total [21,25–27]. On the
other hand, zinc supplementation has also been shown to promote regulatory T-cell development
and to suppress the maturation of Th17-cells, therefore having an inhibitory effect on Th17-mediated
autoimmune-diseases [28–30].
On the molecular level, some functions of zinc have been linked to its role as a second messenger
in immune cells. It has been shown that alterations in the intracellular free zinc-concentration function
as a “zinc signal”. Such a change in the intracellular free zinc concentration is induced by the binding
of various ligands to their respective receptors, such as lipopolysaccharide (LPS) to Toll-like receptor
4 (TLR-4), or the corresponding antigens to immunoglobulin E when it is present on the high-affinity
immunoglobulin E-receptor (FcεRI). Different kinds of immune cells vary in their expression of
receptors that utilize zinc; consequently zinc signals mediate diverse events, for example, formation
of pro-inflammatory cytokines by monocytes [31], presentation of major histocompatibility complex
(MHC) class II molecules at the surface of dendritic cells [32], formation of neutrophil extracellular
traps by neutrophil granulocytes [33], or proliferation of T-cells [34].
The essentiality of zinc for the immune system has been known since the 1960s and the
corresponding mechanistic knowledge has been expanding ever since. Its importance for the immune
system is based on various different mechanisms, each in its own way essential to ensure the
functionality of the immune system and the accurate processes of immune response, especially for
inflammatory processes. As a complete summary would exceed the scope of this article, the reader
is referred to recent review articles on the subject of zinc and immunity for more comprehensive
information [35,36] as well as to a recent review on the protective role of zinc during sepsis [37].
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2. Zinc Homeostasis during Sepsis
Zinc has not only a crucial role in ensuring a proper immune response. Another observation
in the context of zinc and the immune system is an altered zinc homeostasis of the host during an
infection, which is discussed below.
2.1. Changes in Zinc Homeostasis
The host’s response to an infection or injury is referred to as an acute phase reaction (APR).
This process aims to defeat the insult, take actions against ongoing tissue damage, and re-establish
homeostasis. One of the characteristics of APR is hypozincemia. To study the time course of
hypozincemia and examine possible underlying mechanisms, Gaetke et al. injected LPS to healthy
volunteers in order to induce an inflammatory response. Subsequently, an increase in serum tumor
necrosis factor α (TNF-α) and interleukin-6 (IL-6) was observed, followed by a decrease in serum
zinc concentrations. To explain hypozincemia in their model of infection the authors suggested an
internal redistribution of zinc, mediated by cytokines [38]. The analysis of serum from sepsis patients
in the intensive care unit (ICU) revealed that serum zinc concentrations were reduced compared
to a healthy control group or the normal physiological range [39–41]. Probably these differences
were not caused by a zinc-deficient state due to malnutrition, but redistribution of zinc within the
patients’ bodies. Consistently, a study by Hoeger et al. showed a time-dependent decline of the
serum zinc concentrations after induction of sepsis in a porcine model [42]. In order to reveal the
mechanisms responsible for the observed hypozincemia, Luizzi et al. used a mouse model and
induced inflammation either by turpentine or LPS. Zrt-, Irt-like protein (ZIP)14 mRNA was the
transporter transcript that was upregulated the most. This upregulation was liver-specific and an
increase of ZIP14 on the plasma membrane of hepatocytes was shown. Further studies indicated a
role of the inflammatory cytokines IL-6 and IL-1β in the upregulation of ZIP14. Also, an increase in
metallothionein (MT)-1 mRNA in the liver has been observed [43,44]. This observation of enhanced
MT expression has been described before in the context of APR [45–47]. As reviewed in detail before,
MTs function as intracellular metal-binding proteins and are crucial to maintain the intracellular zinc
homeostasis. Their expression is induced by a number of metals, one of them zinc [48]. The increased
liver zinc concentrations accompanying hypozincemia lead to an enhanced need for zinc-binding
proteins in order to ensure the intracellular zinc homeostasis. The production of MT in the liver
seems to be regulated by cytokines as well as zinc [49]. Using a murine model, the already-described
decline in serum zinc concentration and an increase in liver zinc level were observed after induction
of sepsis. The analysis of the time-course of mRNA expression in the liver first showed a successive
upregulation of ZIPs 4, 6, and 10 within the first day, which then returned to near normal levels at 72 h
after induction of sepsis. The mRNA expression of ZIP14 increased at 9 h and stayed upregulated for
the time of the investigation (72 h), which is in line with the observations described previously and
supports a major role for ZIP14 in the redistribution of zinc during sepsis [50]. Taken together, the
APR comprises a fundamental change in liver zinc homeostasis and apparent zinc deficiency in the
serum [50,51].
The studies mentioned so far aimed, among other things, on understanding the mechanisms
responsible for the observed hypozincemia and to track the redistribution of zinc in the body.
An alternative approach to broaden the understanding of how certain processes are changed during
sepsis is gene expression analysis. The method allows insights into the impact of sepsis at the
translational level. The analysis of blood samples from pediatric septic shock patients showed a
regulation of genes that are involved in a large number of signaling pathways and gene networks,
especially those related to immunity and inflammation. Also, it has been shown that up to 12% of
the gene probes that showed a significantly decreased expression compared to the control group
are associated with the categories of “zinc, zinc finger, metal-binding and zinc-ion binding” [52].
These results suggest a repression of genes involved in zinc homeostasis, or depending on an intact
zinc homeostasis, as a significant feature of pediatric septic shock [52–55]. Further, the question arises
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as to whether differences in gene expression in pediatric septic shock survivors and non-survivors
can be observed. Regarding zinc homeostasis, two isoforms of MT have been identified that showed
an increased expression in non-survivors compared to survivors. In addition, non-survivors had a
significantly lower serum zinc concentration compared to survivors. Considering the zinc-binding
properties of MT, Wong and colleagues interpret these results to indirectly imply that increased MT
expression in non survivors might affect zinc homeostasis and thereby serum zinc concentration [53].
Taken together, different approaches imply a contribution of zinc and its altered homeostasis to
the pathobiology of sepsis.
2.2. Possible Reasons for the Redistribution of Zinc
With respect to the considerable differences of serum zinc concentrations between sepsis patients
and the corresponding control groups, as well as the finely tuned alterations of zinc homeostasis, it
can be assumed that these are part of a directed process that aims to benefit the host in defeating the
pathogen. This process includes a decrease in serum zinc concentration as well as an increase in liver
zinc concentration, whereas both aspects seem to benefit the host’s defense against pathogens. Figure 1
gives a brief overview of the processes causing the alterations in zinc concentrations, as well as the
possible beneficial effects.
Figure 1. Possible functions of zinc in sepsis. During the APR of sepsis zinc is redistributed from serum
to liver. This process results in decreased serum zinc concentration and increased liver zinc. The altered
zinc concentrations seem to serve different functions and to be a part of the host’s defense against
pathogens. APR: acute phase reaction; IL: interleukin; TNF: tumor necrosis factor; MT: metallothionein;
APP: acute phase proteins.
Research on zinc homeostasis in the context of sepsis delivered a variety of explanations for the
beneficial effects of a redistribution of zinc. The respective studies are discussed below.
One of the main effects of the redistribution of zinc is an accumulation of zinc in the liver.
Hence, it seems as is if a higher liver zinc level might benefit the host during infection. Among other
things, the APR is not only characterized by the previously mentioned redistribution of zinc, but also
by production of acute phase proteins (APP) and the release of cytokines [56,57]. Zinc serves as an
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important structural element for many proteins and is required by enzymes involved in transcription
and translation. Therefore, the higher synthesis rate of APP in the liver could cause an increased
requirement for zinc during APR [56–58]. With respect to cytokine production a knockout (k.o.) of
ZIP14 in mice, a transporter important for the regulation of zinc homeostasis in hepatocytes, showed
lower mRNA expression of TNF-α, IL-6, IL-1β, and IL-10 in the liver compared to wild-type (w.t.)
mice after induction of sepsis in a murine model. Simultaneously, plasma levels of TNF-α, IL-6,
and IL-10 were significantly higher in k.o. than in w.t. mice. The results indicate a disadvantage of
the ZIP14 k.o. mice during sepsis based on increased markers of inflammation and an influence of
zinc, transported by ZIP14, on the production of cytokines during APR. However this observation is
surprising, because a decrease in mRNA expression would be expected to result in lower cytokine
levels. Possible explanations would be elevated cytokine expression elsewhere in the body, or an
impact on mechanisms mediating the expression of antagonists of the pro-inflammatory cytokines [50].
Other studies suggest that the altered zinc supply during endotoxemia has a major influence
on energy production in the liver. Injection of LPS caused an increase in hepatic zinc and MT in w.t.
mice, whereas zinc levels stayed unchanged in MT k.o. mice. At the same time the liver glucose of the
former stayed unchanged while the levels in MT k.o. mice decreased significantly. These results imply
a lack of hepatic gluconeogenesis in the MT KO mice and a role for MT, and most likely also for zinc,
in maintaining glycaemia after induction of an infection [59].
A protective role of zinc for the liver has also been suggested. Using murine models it was shown
that after injection of endotoxin, zinc-deficient nutrition resulted in enhanced lipid peroxidation in
the liver compared to the zinc adequate group [60]. Another study showed that zinc pre-treatment of
mice resulted in an increased intracellular availability of zinc in liver cells and was accompanied
by decreased accumulation of superoxide and necrotic cell death in the liver after injection of
LPS [61]. Both experimental observations support a protective role of zinc in the liver during infection.
Interestingly, after injection of endotoxin, Sakagouchi et al. saw an increase in MT only in the zinc
adequate group, but not in zinc-deficient animals, and therefore suggested a relation between zinc
concentration, endotoxin-induced MT and lipid peroxidation [60]. In contrast, Zhou et al. observed the
protective effects of zinc pre-treatment on liver cells in w.t. mice as well as MT k.o. mice, leading them
to propose an effect of zinc independent of MT [61]. These results are not necessarily contradictory,
but could imply that the protective effect of zinc on the liver could work in more than one way.
Further studies on this topic would be useful, since organ dysfunction is one of the hallmarks of
sepsis and a better understanding of its mechanisms is the basis of a possible prevention. In summary,
studies show multiple and diverse functions of zinc in the liver during the onset of sepsis, suggesting
a physiological basis for the accumulation of zinc.
The redistribution of zinc and accumulation in the liver is accompanied by a decrease in serum
zinc concentration. With regard to the host’s defense against pathogens, this effect might have some
benefits as well. One protective mechanism of the host is referred to as nutritional immunity. Pathogens,
just like all living organisms, require transition metals for their survival. The host’s strategy is to restrict
the pathogens’ access to essential transition metals, for example by lowering their concentrations in
the serum or secretion of metal ion binding proteins. This process is not limited to zinc but has been
described for other micronutrients, such as iron or manganese [62].
A decrease in the serum zinc concentration has also been shown to influence the respective
number and maturation of immune cells. Therefore, the alteration of serum zinc during the APR might
function as a signal. Using a murine model of zinc deficiency, a downregulation of lymphopoiesis
and upregulation of myelopoiesis was found [19,21,27,63]. In line with this observation, a decrease
of intracellular zinc occurred as a result of homeostatic changes during monocytic differentiation of
HL60 cells. Moreover, experiments simulating zinc deficiency showed that lower zinc levels promoted
the development of HL-60 cells along the myeloid lineage into functionally mature macrophages [64].
The immune cells that benefit from a decline of serum zinc are part of the innate immune system.
They represent the first line of host defense and provide a faster response than the cells of the adaptive
250
Nutrients 2018, 10, 976
immune system. Fraker and King proposed the hypothesis of a “reprogramming of the immune
system” during zinc deficiency in the form of a shift from adaptive immunity to predominantly innate
immunity [65]. Here, limited resources would be directed toward an immediate defense on the expense
of long-term protection. In the context of sepsis, the reduction of serum zinc as a promoting signal for
the innate immune system might be an attempt to focus the defense mechanisms toward a fast innate
immune reaction in the face of a potentially overwhelming infection.
The various aspects by which zinc homeostasis seems to be involved in the body’s defense
against pathogens suggest that the redistribution of zinc in the course of sepsis could serve multiple
physiological purposes. However, further research will be required to evaluate the physiological
significance of the different processes, thereby widening our understanding of the zinc-dependent
endogenous defense mechanisms. This knowledge is required to develop medical approaches in order
to support the host’s body and its defense during sepsis.
2.3. Possible Adverse Effects of Zinc-Redistribution
Despite the potential physiological roles of the redistribution of zinc, this process might also
cause some adverse effects, especially the decrease in serum zinc concentration. Possible symptoms
of a low serum zinc concentration due to zinc deficiency caused by malnutrition are higher levels of
pro-inflammatory cytokines, higher markers of oxidative stress, and oxidative damage to proteins,
lipids, and DNA [66–70]. Notably, zinc deficiency and sepsis show several parallels in addition to low
serum zinc concentrations. The severe effects of zinc deficiency on the functionality of the immune
system have already been described in the introduction, including a decrease in T-cell numbers
and function [20]. Dysfunction and apoptosis of T-cells have also been observed in the context
of sepsis [71–73]. Other symptoms of zinc deficiency have been found during sepsis as well, for
example the overproduction of pro-inflammatory cytokines and SIRS, which is a hallmark of sepsis
and a major factor in the host’s dysregulation to an infection during sepsis [11]. Furthermore, effects
such as lipid peroxidation and oxidative damage of DNA, proteins, and mitochondria have been
observed [74–76]. In light of the parallels between symptoms of zinc deficiency and sepsis, further
research should elucidate the question whether the body’s reaction to an infection might cause a
decrease in bioavailable zinc severe enough to contribute to, or maybe even cause, these common
symptoms during sepsis.
In this context it is of interest to mention that several studies have shown a correlation between a
patient’s serum zinc concentration and the severity of the inflammatory response or sepsis. In critically
ill patients, those with a high SOFA score showed a significantly lower serum zinc concentration
than patients with a low SOFA score, whereby a higher SOFA score was associated with higher
mortality [2,58]. In line with these results serum zinc concentrations were found to be inversely
correlated with the SOFA score in other studies, as well [39,77]. Yet another study revealed a
significantly lower serum zinc concentration in sepsis patients who developed a recurrent sepsis
compared to those that did not. Additionally, sepsis non-survivors had a significantly lower serum
zinc concentration than survivors [41]. Because zinc fulfils a great number of crucial functions in the
body, and especially the immune system, it seems reasonable that a decrease of bioavailable zinc in the
serum could contribute to some adverse effects, thereby aggravating sepsis.
3. Zinc Supplementation
The correlation between low serum zinc concentrations and a higher mortality rate or chance of
recurrence raises the question, if supplementation of zinc might be a treatment option to improve the
outcomes of sepsis. Table 1 gives an overview of zinc supplementation studies in the context of sepsis in
humans. In these studies zinc supplementation took place after the onset of sepsis. Some of them show
a beneficial effect of zinc in form of a lower mortality rate and a better neurological development of
neonates [78–80]. However, it was also observed that supplementation did not result in any significant
differences between the zinc group and the control group [81] or even showed a harmful effect [82].
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The published animal studies mostly examined the effects of prophylactic zinc supplementation
(Table 2). In several of them the supplementation of zinc prior to induction of sepsis showed beneficial
effects, such as improved survival, lower serum concentrations of pro-inflammatory cytokines, lower
bacterial burden or improved pulmonary function compared to the control-group [50,83–85]. However,
for the animal studies the results are also not consistent and a missing effect of zinc supplementation is
reported [86] as well as a harmful outcome in a case where zinc was applied during the acute phase [87].
The negative results of zinc supplementation may be explained by the fact that the reduction of zinc
levels during sepsis may occur for a reason, such as the above-mentioned physiological functions.
High doses of zinc were shown to have a pro-inflammatory effect [88] and might therefore aggravate
inflammation, or zinc supplementation could potentially interfere with nutritional immunity, one of
the endogenous defense mechanisms based on a shortage of zinc in the serum [62].
Another important factor is the bioavailability of serum zinc. Albumin is the major zinc-buffering
protein [89] as well as a negative APP [56,90]. Its concentration decreases during sepsis, leading to a
decreased zinc-binding capacity of the serum [42]. As a consequence, supplementing sepsis patients
until the “normal” total serum zinc concentration is restored would result in a supraphysiological
concentration of free, and thereby bioavailable, zinc in these patients.
Correcting zinc deficiency prior to sepsis is certainly beneficial, but difficult to realize, as in
most cases sepsis cannot be predicted. Moderate supplementation during sepsis might, in some
cases, turn out to be helpful, as well. This may be particularly so in patients with pre-existing zinc
deficiency that is so pronounced that the liver cannot accumulate sufficient amounts to exert the
abovementioned protective effects of zinc. However, as the reduction of serum zinc seems to be a
necessary physiological process, in these cases extreme care needs to be taken in order not to exceed
the zinc-binding capacity of the serum to avoid negative effects, such as counteracting nutritional
immunity or aggravating inflammation.
The endogenous processes, which are supposed to be affected by the supplementation of zinc,
are quite complex and fine-tuned. As illustrated by the divergence of the study results, effective zinc
supplementation has to be just as elaborate with regard to timing as well as dosage in order to achieve
optimal results.
252

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nutrients 2018, 10, 976
4. Serum Zinc Concentration as a Possible Biomarker for Sepsis
In addition to a potential therapeutic value of zinc supplementation, the altered zinc homeostasis
could have potential to be utilized for establishing a biomarker based on the serum zinc level of a
patient. In a porcine model of sepsis, the decline of the serum zinc concentration was the first marker
of inflammation, already statistically significant one hour after induction of sepsis. Thereby, it was an
earlier indicator for inflammation than the increase of the pro-inflammatory cytokines IL-6 and TNF-α,
which reached statistical significance two hours after induction of sepsis [42]. However, hypozincemia
is activated in non-infectious as well as infectious inflammation. The ability to discriminate between
the different causes for hypozincemia would be relevant for a use of zinc as a biomarker for sepsis.
So far the studies vary in their results as to whether there is a significant difference in the serum
zinc concentration of sepsis patients and a critically ill control group, surgical control group, or
trauma patients [39,41,91]. Further studies would be required to evaluate the potential of serum zinc
concentration as a biomarker for sepsis, including large clinical studies and the evaluation of clinical
data sets to proof its validity and prospective value.
According to Singer et al., a diagnostic marker for sepsis should be easily to obtain and available
promptly at reasonable cost [2]. Provided the evaluation studies on serum zinc concentration as a
biomarker for sepsis turn out to be positive, this marker would fulfil Singer et al.’s demands [2]:
It would allow for early recognition, which is crucial to improve the patient’s outcome and decrease
the sepsis-related mortality rate. Also, patient serum is easily to obtain and the parameter could be
monitored closely once the patient is under medical supervision. If the required infrastructure is
available, an analysis of the serum zinc concentration delivers fast results at reasonable cost.
One hindrance for the use of zinc as a marker in sepsis might be the necessary infrastructure.
Presently, atomic absorption spectrometry or inductively-coupled plasma mass spectrometry are being
used to quantify zinc. Even with the required instruments available the quality of the results strongly
depends on the analytical abilities of the performing personnel or laboratory [92]. If this sophisticated
equipment is not available, e.g., in rural areas or countries with a less developed infrastructure, sending
the samples to external labs might cause significant delay in obtaining these time-sensitive results,
nullifying the advantage of an early diagnostic marker. Some basic work on easier point-of-care
devices to measure the serum zinc concentrations has been reported, but these still have to reach
clinical applications [93,94].
Other tools widely used to detect zinc in biological samples are fluorescent probes [95]. However,
they have only sparsely been used in the context of sepsis thus far. One example is the application of
Zinpyr-1 by Hoeger et al. in serum samples from a porcine model of sepsis [42]. It should be noted that
these probes do not measure total zinc, but determine the amount of free zinc in the sample. Still, this
parameter might be interesting to look at in the context of sepsis, because it represents the amount of
bioavailable zinc and has been suggested as an alternative biomarker for a person’s zinc status [96].
Some aspects regarding the mechanism mediating the redistribution of zinc have not been fully
revealed yet. Once understood, they might contribute to an even better use of zinc homeostasis as a
diagnostic parameter in sepsis. Hoeger et al. observed a continuous decline of serum zinc concentration
from one hour after induction of sepsis in vivo. However, for up to two hours no induction of mRNA
expression of MT-1, MT-2, and ZIP14 was observed in an in vitro model of hepatoma cells after
incubation with IL-1β, IL-6, or LPS [42]. Wessels et al. reported the lowest serum zinc concentration
in their sepsis model at 9 h after induction whereas the upregulation of ZIP14 in the liver and the
increase in liver zinc have been observed from hour 9 on after induction [50]. These studies raise
further questions, mainly as to how the decline of serum zinc concentration is mediated in the initial
phase, and if zinc may be located in some other part of the body in the period from its disappearance
from the serum until it is finally detected in the liver.
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5. Conclusions
Zinc is an essential trace element and has been shown to be crucial for ensuring an adequate
immune response. In the context of sepsis the host’s zinc homeostasis is altered. Various study results
imply some of the alterations to be part of the host’s defense mechanism against pathogens (Figure 1).
There are indications that a patient’s zinc supply and serum zinc concentration is associated with
severity, outcome, and recurrence of sepsis. Zinc seems to have potential to be used as a biomarker
or even as a starting point for a therapeutic approach. Further research is required to broaden the
understanding of zinc homeostasis during sepsis and the underlying mechanisms as well as to evaluate
the possible clinical applicability of this knowledge.
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Abstract: Immunomodulatory protein hydrolysate consumption may delay or prevent western
immune-related diseases. In order to purposively develop protein hydrolysates with an optimal
and reproducible immunomodulatory effect, knowledge is needed on which components in protein
hydrolysates are responsible for the immune effects. Important advances have been made on this
aspect. Also, knowledge on mechanisms underlying the immune modulating effects is indispensable.
In this review, we discuss the most promising application possibilities for immunomodulatory protein
hydrolysates. In order to do so, an overview is provided on reported in vivo immune effects of protein
hydrolysates in both local intestinal and systemic organs, and the current insights in the underlying
mechanisms of these effects. Furthermore, we discuss current knowledge and physicochemical
approaches to identify the immune active protein sequence(s). We conclude that multiple hydrolysate
compositions show specific immune effects. This knowledge can improve the efficacy of existing
hydrolysate-containing products such as sports nutrition, clinical nutrition, and infant formula.
We also provide arguments for why immunomodulatory protein hydrolysates could be applied to
manage the immune response in the increasing number of individuals with a higher risk of immune
dysfunction due to, for example, increasing age or stress.
Keywords: protein hydrolysate; bioactive peptide; immunomodulation; Toll-like receptor; functional
foods
1. Introduction
Protein hydrolysates are commonly used as an alternative protein source in commercial products.
They consist of a mixture of different proteins and peptides which is formed by the hydrolysis
of intact proteins. During this process, peptide bonds of intact proteins are broken (Figure 1A),
which results in the formation of a range of peptides of different sizes. Depending on their properties,
protein hydrolysates are applied in different products. Mildly hydrolyzed proteins are, for example,
used in clinical and sport nutrition to support digestibility, while extensively hydrolyzed proteins are
used in infant formulas as a hypo-allergenic alternative for intact cow’s milk proteins (Figure 1B).
Furthermore, protein hydrolysates are recognized as a potent source of bioactive peptides.
Different peptides with, for example, anti-thrombotic, anti-hypertensive, anti-microbial, anti-cancer,
anti-oxidative, and many immunomodulatory effects have been identified [1]. Consuming protein
hydrolysates containing these peptides might be helpful in the management of many western
diseases [2,3]. Since many of these diseases are immune-related, immunomodulatory products have
gained special attention from both academical and industrial researchers for the management and
amelioration of, for example, inflammatory bowel diseases, allergies, and diabetes [4,5].
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Figure 1. The process of protein hydrolysis and its products. (A) chemical reaction of protein hydrolysis;
(B) different hydrolysates serve different purposes.
Purposively deploying the immunomodulating effects of protein hydrolysates in existing or
new dietary products is an attractive opportunity to manage immune-related diseases. In order
to achieve this, the identification of specific peptides and a better understanding of their working
mechanisms is required. This review aims to provide an overview of studies on reported in vivo
immune effects of hydrolysates in both local intestinal and systemic organs. The current insights
in underlying mechanisms are also discussed. As the design of effective protein hydrolysates may
benefit from the identification of specific bioactive peptides, we review current knowledge and
physicochemical approaches to identify the protein sequence(s). Based on the discussed topics,
we provide our view on the possible application of immunomodulatory protein hydrolysates or
peptides in specific target groups.
2. Immune Effects of Hydrolysates
In 1984, immune effects were detected for the first time in a fraction of a casein hydrolysate [6].
The studied protein fraction was found to both increase the production of hemolytic antibodies in
mice splenocytes, and to enhance the phagocytic capacity of murine macrophages against sheep
red blood cells in vitro. In vivo, the protein fraction protected mice against a lethal infection with
Klebsiella pneumoniae. Since then, measuring lymphocyte proliferation and macrophage phagocytosis
capacity have been the main in vitro assays used to study the immune effects of protein hydrolysates.
An increase in lymphocyte proliferation was observed after stimulation with other protein
hydrolysates which were derived from soy, wheat, whey, casein, and mollusk [7–13]. Not all protein
hydrolysates were found to stimulate proliferation. Hydrolysates derived from egg white were shown
to decrease instead of enhance lymphocyte proliferation [14]. Different hydrolysates from casein were
found to possess either proliferation increasing [10] or inhibiting effects [15], showing that individual
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protein hydrolysates from the same protein source also have remarkably different immunomodulating
properties. Phagocytosis modulation was source dependent as well. Most protein hydrolysates were
found to increase macrophage phagocytosis capacity in vitro, for example, soy, egg, wheat, and casein
hydrolysates had such an effect [9,12,16,17]. However, a rice protein hydrolysate was found to inhibit
the phagocytic activity of RAW264.7 macrophages [18].
These early in vitro experiments investigating the immune effects of protein hydrolysates have
led to many more in vitro and in vivo studies on the effects of protein hydrolysates on immunity.
In the sections below, these in vivo studies are reviewed (an overview of the studies is given in Table 1).
In this part, a distinction was made between local intestinal immune effects and systemic effects.
All effects discussed below are also visualized in Figure 2. To start with, protein hydrolysates have an
effect on the epithelial cells aligning the gut and by that induce crosstalk between the epithelial cells
and immune cells [5].
Figure 2. Overview of immune effects induced by protein hydrolysates on the (A) intestinal epithelial
cells; (B) intestinal immune cells; (C) mesenteric lymph nodes; (D) systemic immune system.
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3. Effects of Protein Hydrolysates on the Gut Barrier
Epithelial cells form a first layer of defense against harmful pathogens and molecules in the
intestinal lumen. These cells are covered by a layer of mucus. Together, this forms a physical barrier
between the luminal content and the human body [46]. Protein hydrolysates and bioactive peptides in
the lumen of the intestine were found to affect barrier function in multiple ways (Figure 2A). First,
protein hydrolysates are able to strengthen the epithelial barrier. Second, they enhance the production
of mucus and so-called anti-microbial proteins that delete pathogens.
Barrier enhancing effects by protein hydrolysates were shown by Visser et al., [19,20], who fed
diabetes prone rats casein hydrolysates for up to 150 days and measured the barrier function by
determining the lactulose-mannitol ratio in urine. They showed that casein hydrolysate intake
decreased the epithelial permeability compared to a diet with sole amino acids. In the ileum of
diabetic rats on the casein hydrolysates, a normalization of the tight junction mRNA expression,
including myosin IXb, claudin-1, and claudin-2, was observed, together with an upregulation of the
regulatory cytokine Interleukin (IL)-10. Multiple other dairy derived peptides have been found to
increase the amount of goblet and Paneth cells in the intestine [21–23], which are specialized epithelial
cells regulating the production of mucus and anti-bacterial peptides. The consumption of yoghurt
peptides did not only increase the amount of these cell types, but also increased the expression of
Muc2 and 4, as well as the anti-bacterial factors lysozyme and rdefa5 [21].
Another function of epithelial cells is sampling the lumen and skewing the differentiation of
immune cells in the lamina propria accordingly, mainly by basolateral cytokine secretion [47]. In a
healthy situation, egg yolk peptide digest consumption in mice was able to increase IL-6 production
in epithelial cells ex vivo [24]. IL-6 has been described to affect both innate and adaptive immune
responses [48,49], meaning that protein hydrolysates might influence the immune system via epithelial
cells in this way. However, due to the pleiotropic nature of this cytokine [50], its impact is different in
different cell types and conditions, and the overall effect of increased IL-6 is difficult to predict.
4. Effects of Protein Hydrolysates on the Intestinal Immune System
One of the most studied immune effects in the intestine after hydrolysate administration
in vivo is the level of IgA (Figure 2B). This typical intestinal immunoglobulin can easily be
measured in the faeces and is instrumental in the clearance of toxins, pathogens, and other harmful
molecules [51]. Hydrolysate intake can cause an increase in IgA, as shown for a common carp egg
hydrolysate [25]. Corresponding to this, studies investigating intestinal immunity after pacific whiting,
shark hydrolysate, and yellow field pea hydrolysate consumption in mice detected an increased
amount of IgA+ B cells [26–28]. Leblanc et al. studied IgA secretion in an infection mouse model
fed Lactobacillus helveticus-fermented milk, and found an increase of IgA both in the intestinal fluid
and blood, together with an increased amount of IgA+ cells in the lamina propria [29]. Increased IgA
levels seem to be a general effect of hydrolysate intake and seem to be independent of the hydrolysate
protein source.
Besides enhancing IgA production, protein hydrolysates have more effects on the immune system
which might lead to a more matured and developed immune response. Levels of multiple cytokines,
including IL-4, IL-10, IL-6, IFNγ, IL-12, and TNFα, have been found to be elevated in healthy mice
after consuming egg yolk, fish, and yellow pea hydrolysate [24,26,27]. For the shark hydrolysate,
these increased cytokine levels were associated with a better response of the mice against E. Coli
infection [28]. The enhancement of IL-4, IL-10, IFNγ, and IL-12 suggests that T cells in the intestine are
activated by the hydrolysate. To understand what the administration of protein hydrolysates could
mean in situations such as pathogenic infections or inflammatory bowel disease, it would be helpful to
know which types of T cells are stimulated. To this end, Leblanc et al., compared the amount of IL-4
(Th2) and IFNγ (T helper (Th)1) in the intestine of a mouse model fed Lactobacillus helveticus-fermented
milk, and found a predominant Th2 response after feeding the milk peptides [29].
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Anti-inflammatory properties are another often observed feature of protein hydrolysates. This is a
characteristic mainly attributed to the hydrolysates of bovine milk. To study these effects, experimental
models with colitis and ileitis have been used. In all cases, oral pretreatment of the animals with casein
hydrolysate or a casein glycomacropeptide reduced damage to the intestine, leading to a decrease in
weight loss [30–33]. They also observed a decrease in the pro-inflammatory cytokines IL-1β, IL-17,
TNFα, and IFNγ, while in one study, an increase of the regulatory cytokine IL-10 was observed [31].
Similar outcomes were observed when egg white peptides were administered to pigs with dextran
sodium sulphate (DSS) induced colitis [34].
The effects of protein hydrolysates in the Peyer’s patches (PP), which are part of the gut-associated
lymphoid tissue, have been studied to a lesser extent but are essential as this tissue is the central
immune sampling and signaling site in the gut. Egusa et al. studied the effects of a specific soybean
protein digest in the PP [35]. After five weeks of feeding mice a soybean hydrolysate enriched diet,
the genome wide gene expression of PP derived cells was examined. They found that several genes
related to innate immunity and host defense were upregulated. They observed the upregulation of
Igh-4 and Aqp8, which enhance phagocytosis, and of Dmbt1, Slpi, and Mx1, which are anti-bacterial
and anti-viral components [52–54]. When looking at adaptive responses in the PP, we found in our
own study that sensitization with a partially hydrolyzed whey protein prevented the increase of Th1,
Th17, and regulatory T cells (Treg) in the PP after a challenge with intact whey [36].
5. Effects of Protein Hydrolysates on the Mesenteric Lymph Nodes (MLN)
Tolerance induction and other antigen presenting dependent processes occur predominantly
in the MLN [55]. Antigen loaded dendritic cells from the PP and lamina propria in the intestine
migrate to the MLN and subsequently activate T and B cells. Depending on the nature of the antigen,
either an immune response is evoked or tolerance is induced via the formation of Treg. A number
of studies investigating the effects of bovine milk hydrolysates or peptides in murine sensitization
models assessed which cell types were present in the MLN of the mice after hydrolysate consumption
(Figure 2C). When mice were fed milk peptides, either alone or in combination with indigestible
oligosaccharides, before the start of the sensitization against intact whey, the number of Treg in the
MLN increased [37,38]. One study showed that the number of dendritic cells responsible for the
transport of antigens from the lamina propria to the MLNs, i.e., the CD11b+ and CD103+ dendritic cells,
was increased [37]. Casein derived glycomacropeptide consumption increased ex vivo tolerogenic
IL-10 production in MLN cells of a DSS induced colitis mouse model [32], which also suggests an
increase in Treg here. However, in a rat model for ileitis, the glycomacropeptide did not influence
MLN cytokine levels [33]. This might be explained by differences in species, inflammation models,
or glycomacropeptide dosing.
Not only T cell responses are induced in the MLN, but also B cells can be activated, after which
they expand in specialized follicles. It was found that sensitization with a partially hydrolyzed whey
protein increased the number of IgA+ B cells [36]. However, since the role of the MLN in intestinal IgA
production is still under debate, more research is needed to evaluate the contribution of this observed
phenomenon to intestinal and systemic IgA levels [56].
6. Effects of Protein Hydrolysates on Systemic Immunity
Protein hydrolysates do not only affect the immune response locally in the intestine, but also
have effects on the systemic immunity, mostly measured in splenic and peritoneal cells, and in the
blood (Figure 2D). Small peptides are probably able to pass through the gut barrier and have been
detected in the blood of volunteers who consumed dairy and soy products, [57,58] allowing a direct
impact on immune cells in the systemic circulation. Administration of many protein hydrolysates
made from casein and other milk products, oyster, salmon, and fish [17,27,39–41] increased the ex vivo
phagocytotic capacity of macrophages isolated from the peritoneal cavity of mice. Oyster, salmon,
and common carp egg were furthermore found to increase NK cell activity in the spleen [25,39,41].
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Similar to results after direct in vitro stimulation of splenocytes, oral administration of protein
hydrolysate derived from oyster, tuna cooking drip, salmon, and multiple common carp egg
hydrolysates increased ex vivo splenocyte proliferation [25,39,41,42]. Some of these studies looked
into the cell types present in the spleens of these animals in more detail. Alcalase common carp egg
hydrolysate was found to increase CD4+ and CD8+ cells in the spleen [25], while salmon hydrolysate
only increased CD4+ [41]. These cells were expected to be both Th1 and Th2 cells, since both Th1 (IL-2,
IFNγ) and Th2 (IL-4, IL-5) cytokines were detected in the blood of these animals. These effects might
differ between protein hydrolysates, since a tuna cooking drip hydrolysate was found to increase IL-2
and IL-10 [42], and sensitization with a partial whey hydrolysate increased Treg in the spleen [36].
Together with an increase in Treg, an increase in regulatory B cells (Breg) was observed in the
spleen after whey hydrolysate administration [36]. Breg are increasingly recognized to be important in
regulatory immune responses and induce the differentiation of T cells into Treg [59]. Another study
also found an increase in IL-10 producing Breg when inducing oral tolerance using intact casein in
casein-allergic mice [60]. Here, casein might be digested in the intestine of the mice, after which the
newly formed bioactive peptide(s) derived from casein increased Breg. An adoptive transfer of these
Breg could even prevent the onset of allergy in recipients [60], demonstrating the importance of this
cell type in tolerance induction.
Other evidence that hydrolysate consumption affects B cell responses is the observation of
increased antibody levels observed in the blood. A soy protein hydrolysate was found to induce IgG
and IgA in the blood of rats [7], while the common carp egg hydrolysate increased IgA in mice [25].
Therefore, it is likely that protein hydrolysates not only affect B cell differentiation, but also induce
class-switching and antibody production.
Only a few studies investigated the effects of protein hydrolysates on immune parameters in the
blood of humans. The effect of a single dose of soybean hydrolysate was studied in a small group of
volunteers, and it was found to change leukocyte numbers and increase granulocytes. More specifically,
it significantly increased CD11b+ (macrophages and/or dendritic cells) and CD56+ cells (NK cells)
in blood [43]. When nine subjects were fed a wheat hydrolysate for six days, an increase in NK
cell activity was observed [44]. A larger group of undernourished Indian children was given a fish
hydrolysate for 120 days. After this period, the CD4/CD8 ratio and antibody levels were measured,
but no significant differences were detected [45]. These studies show that protein hydrolysates
have immunomodulatory effects in humans, which are similar to some of the previously mentioned
in vitro and in vivo effects, although the protein hydrolysates used are different. However, in these
studies, only a few immunological parameters were measured, and/or only included a small group of
volunteers, which makes it difficult to draw firm conclusions. Well-designed, extensive human studies
are lacking at the moment, but are needed to better understand the effects of protein hydrolysates
in humans.
7. Understanding Hydrolysate Compositions
A mandatory assignment for the coming years for researchers in the field is to identify the
exact peptide sequence(s) responsible for the reported effects described above. This will make
the design of formulations possible for specific health effects. Currently, protein hydrolysates are
mainly characterized by determining their degree of hydrolysis (DH). The DH is a measure for
how extensively a protein has been hydrolyzed, and therefore gives an indication of the size of the
peptides present in the hydrolysate. The DH is calculated by determining the amount of cleaved
peptide bonds [61]. Different methods have been developed to obtain the DH, including the pH-stat,
trinitrobenzenesulfonic acid (TNBS), o-phthaldialdehyde (OPA), trichloroacetic acid soluble nitrogen
(SN-TCA), and formol titration methods [62].
However, the DH does not give any indication of the presence or absence of specific bioactive
peptides. Protein hydrolysates with a similar DH can still have a different peptide composition.
Therefore, protein hydrolysates are often further characterized by using techniques to separate the
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peptides in the hydrolysate based on their physicochemical properties, mainly size, hydrophobicity,
or a combination thereof. Techniques which are often used to characterize peptide composition are,
for example sodium, dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), size exclusion
chromatography, and High Performance Liquid Chromatography (HPLC) [63]. All these techniques
are used to obtain a molecular weight distribution, which gives an overall indication of the hydrolysate
composition based on size. One can focus on a specific fraction of the protein hydrolysates by choosing
the most appropriate technique and optimizing the settings used.
HPLC, especially Reverse Phase-HPLC, has, for a long time, been found to be useful in separating
peptides from protein hydrolysates based on their size and hydrophobicity [64]. When this method
is coupled to a mass spectrometer (MS), it is also possible to determine the amino acid sequence of
the detected peptides [65]. In this way, a very detailed characterization of the hydrolysate can be
obtained, which can be used to identify structure-effector relationships between, for example, immune
effects and specific peptides in a hydrolysate. However, protein hydrolysates consist of thousands of
different peptides, which will all be detected by HPLC-MS when a complete hydrolysate is analyzed.
Therefore, studies aiming for the identification of bioactive peptides often compare the bioactivity
of size-based fractions of the hydrolysate first [66,67], after which the bioactive fraction alone can be
further analyzed using HPLC-MS. Ultimately, the peptides present in the bioactive fraction should be
tested individually for bioactivity in order to obtain the peptide responsible for the observed effect [65].
Using this and similar methods has led to the discovery of a range of bioactive peptides from
protein mixtures, as reviewed by Sanchez et al., and Lafarga et al., [1,68]. However, most of the identified
bioactive peptides possess anti-hypertensive, anti-microbial, or anti-oxidative effects, but peptides with
immunomodulatory properties have not widely been identified yet. Comparing the characteristics of the
immunomodulatory peptides that have been identified generated new knowledge about which peptide
properties are associated with immune effects. It is known that immunomodulatory peptides are mostly
two to 20 amino acids long and hydrophobic [61]. Chalamaiah et al., concluded by listing known
peptides with immunomodulatory effects that glycine (Gly), valine (Val), leucine (Leu), proline (Pro),
phenylalanine (Phe), negatively charged amino acid glutamic acid (Glu), and aromatic amino acid
tyrosine (Tyr) were most frequently present in peptides with immune effects [69].
Recently, we also found that larger fractions in whey and soy protein hydrolysates can have
immunomodulatory effects. These fractions have a size of over 1000 kDa and were composed of
aggregates which are formed during the hydrolysis process [66]. In this process, the proteins are
heated, which is a known cause of protein denaturation and aggregation [70]. By performing PAGE
under different conditions, it was found that these aggregates were formed due to electrostatic forces
and disulfide bridges between single proteins and induce responses in human dendritic cells. The fact
that these aggregates were found in both a whey and soy hydrolysate suggests that aggregate formation
is not protein source specific and might be present in a wide range of different protein hydrolysates.
8. Underlying Mechanisms of Immunomodulatory Effects
In order to understand the immune effects that can be induced by protein hydrolysates and to
ultimately apply protein hydrolysates in specific conditions, it is of crucial importance to understand
exactly how the observed immune effects come about. Up to now, only a few studies have focused
on elucidation of the underlying mechanisms of immunomodulatory effects by protein hydrolysates
and are reviewed below. Recent research suggests that hydrolysate peptides bind to specific
immune-receptors and that multiple receptors might be involved (Figure 3A).
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Figure 3. Overview of mechanisms described in the literature via which peptides can exert
immunomodulatory effects in the cell. Peptides can (A) directly stimulate receptors; (B) be taken
up in the cell via a peptide transporter and interfere with inflammatory signaling pathways; or (C) be
taken up into the cell via endocytosis and inhibit inflammatory signaling pathways.
9. Receptor Binding
One of the most studied receptor types in immune signaling is Toll-like receptors (TLRs). This is a
family of pathogen recognition receptors. They are not only expressed by most immune cells [71,72],
but also by epithelial cells [73]. Multiple protein hydrolysates were found to affect TLRs, but the
effects were very hydrolysate dependent. By studying a range of cow’s milk hydrolysates in a TLR
reporter cell platform, we previously found that especially mildly hydrolyzed whey hydrolysates were
able to activate multiple TLRs, including TLR2, 3, 4, 5, 7, 8, and 9 [74]. This activation does lead to
the production of TNFα, IL-10, and IL-8 in human peripheral blood mononuclear cells (PBMCs).
The protein source of the hydrolysates was crucial for its final effects, as it was observed that
casein hydrolysates only inhibited TLR activation. Which TLRs were inhibited also differed per
hydrolysate, but TLR5 and 9 were the most profoundly inhibited. Other studies focused mainly on
TLR2 and 4. Tobita et al., described that a casein phosphopeptide was able to induce proliferation
and IL-6 production in CD19+ cells from mice after stimulation in vitro. This effect was gone after the
administration of an anti-TLR4 antibody, suggesting that the effects were induced via TLR4 [75].
A primary culture of murine intestinal epithelial cells was also thought to secrete IL-6 via the
stimulation of both TLR2 and TLR4 when the mice were fed with yellow pea hydrolysate [26] and shark
protein hydrolysate [28]. A pressurized whey hydrolysate was able to suppress lipopolysaccharide
(LPS) induced IL-8 production in respiratory epithelial cell lines, likely via binding to TLR4 [76].
There is evidence that other transmembrane receptors are also involved in immune effects by
protein hydrolysates. Tsuruki et al., described that a peptide derived from the soybean β-conglycinin
A’ subunit, which stimulated phagocytosis in human neutrophils, showed a low affinity for the
N-formyl-methionyl-leucyl-phenylalanine (fMLP) receptor [77]. The phagocytosis stimulating effect
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disappeared when this receptor was blocked. The authors discuss that its low affinity for the fMLP
receptor allows it to stimulate the immune response in a safe way, without causing inflammation.
Peptides derived from many different food protein sources are known to bind opioid receptors [78].
Although endogenous opioid peptides have a main function as neurotransmitters, they are also known to
modulate innate and acquired immune responses [79]. Opioid receptor signaling can, for example, skew T
cell differentiation, increase antibody production in B cells, and affect phagocytosis in macrophages [80–82].
These effects have also been described in immune cells after hydrolysate administration. Therefore,
it cannot be excluded that protein hydrolysates also modulate the immune system via opioid receptors.
10. PepT1 Dependent Intracellular Effects
Multiple bioactive tri- and tetrapeptides derived from soy and whey have been found to induce
anti-inflammatory effects after being taken up into the cell [83–85]. This cellular uptake, and therefore
the anti-inflammatory effects of the peptides, depends on the peptide transporter PepT1 (Figure 3B).
PepT1 is an H+ coupled oligopeptide transporter, mediating the uptake of a broad range of di-and
tripeptides in intestinal epithelial cells in order to transport the peptides into the bloodstream.
Normally, it is expressed in the small intestine, but during inflammation, it is also upregulated
in the colon [86]. Treatment with the soy peptides KVP and VPY and the whey peptide IPAV all
showed a decrease in the production of the pro-inflammatory cytokines IL-6, IL-8, and TNFα in Caco2
cells. This effect disappeared when PepT1-activity was inhibited, indicating that transport via PepT1 is
necessary for the anti-inflammatory effects. Once taken up in the cytosol, the peptides were shown
to inhibit the main inflammatory signaling pathways in order to decrease the pro-inflammatory
cytokine secretion. A decrease in phosphorylated nuclear factor kappa-light-chain-enhancer of
activated B cells (NFκB), mitogen-activated protein kinase (MAPK), extracellular signal-regulated
kinase (ERK)1/2, c-Jun N-terminal kinase (JNK)1/2, p38, and spleen tyrosine kinase (SYK) was
observed after pretreatment with the bioactive peptides.
As described above, gut epithelial cells can influence the immune response in the intestine [47].
Therefore, an anti-inflammatory status of the epithelial cells is expected to also regulate the underlying
immune cells [87]. Furthermore, the soy and whey proteins can be transported over the epithelial
barrier and interact directly with immune cells. The soy peptide VPY was also found to induce
anti-inflammatory effects in THP-1 human monocytes [84], while the soy peptide KVP showed
anti-inflammatory effects in T cells [83]. Interestingly, both monocytes and T cells express the PepT1
transporter [88], suggesting that the bioactive peptides might induce anti-inflammatory effects in
innate and adaptive immune cells via a similar mechanism as described for epithelial cells.
The relevance of these effects in vivo was shown by treating mice with DSS and TNBS induced
colitis with the bioactive soy peptides [83,84]. In these models, KVP and VPY were shown to reduce
colitis symptoms, reduce body weight loss, and decrease pro-inflammatory cytokines in the intestine.
11. Endocytosis
Once immunomodulatory peptides are taken up in epithelial or immune cells, they can exert their
effects by interfering with signaling pathways. However, not all peptides and protein can be internalized
via the PepT1 transporter, since this transporter is specific for di- and tripeptides. Larger food derived
peptides, which are too large for the PepT1 transporter, can also be taken up into the cell by fluid phase
endocytosis (Figure 3C), which is a non-specific form of vesicle mediated internalization. In this type of
endocytosis, hydrophobic interactions between the peptide and the cell membrane are involved in the
internalization of the peptide [89]. Differences in physicochemical properties of peptides, including size,
hydrophobicity, and charge determine the kinetics of uptake of individual peptides.
The involvement of this type of peptide uptake in immunomodulation by peptides was confirmed
by Regazzo et al., [90]. They showed that a relatively large, hydrophobic casein peptide which
showed multiple stimulating effects in immune cells, could be taken up in a layer of Caco2 cells via
endocytosis. They did not see a difference in casein peptide uptake when they used an inhibitor for
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the PepT1 transporter or cytochalasin D to open the tight junctions (and increase the paracellular
route), but found a significant inhibitory effect on peptide uptake after treatment with wortmannin,
which inhibits endocytosis [90]. When the peptide is translocated over the epithelial cells via this
mechanism, it may affect immune cell functioning in the lamina propria or in the blood.
A study investigating the well-characterized soy peptide lunasin showed that endocytosis is
also used by immune cells to take up immunomodulatory peptides [91]. Lunasin is a 43-amino
acid peptide which was shown to interact with the αVβ3 integrin, which led to inhibiting αVβ3
integrin-mediated pro-inflammatory markers and to downregulation of the Akt-mediated NF-κB
pathway. By using different inhibitors, it was found that lunasin was mainly taken up by endocytic
mechanisms that involve integrin signaling, clathrin-coated structures, and macropinosomes [91].
Interestingly, this lunasin uptake was increased under inflammatory conditions.
12. Possibilities for Hydrolysate Application
Since immune effects were found to be hydrolysate specific, many immune-related conditions
could potentially benefit from hydrolysate administration by selecting specific protein hydrolysates.
However, up to now, research has mainly focused on the discovery of immune effects in vitro and
animal studies, while follow up studies in humans are rare. To develop an immunomodulatory
product containing a hydrolysate, these studies are indispensable in order to investigate the safety,
bioavailability, and inducible immune effects in the human body. Protein hydrolysates with the most
promising effects should be chosen for further research. Based on the knowledge on immune effects
and the underlying mechanisms involved, of which an overview was given above, protein hydrolysates
can be selected for application in specific products.
13. Existing Products
Existing hydrolysate containing products can benefit from applying a different protein hydrolysate
with the same nutritional value as the currently used protein hydrolysates, but with an additional
immune modulating effect (Figure 4). Hypo-allergenic infant formulas are the main market for protein
hydrolysates nowadays. By hydrolyzing proteins, epitopes which are recognized by the immune
system of allergic infants are destroyed. Therefore, infant formulas containing extensively hydrolyzed
proteins can be tolerated by allergic infants [92]. However, allergic reactions may also be reduced
by modulating the immune system [5]. When the allergic reaction develops, the intestinal immune
system induces an inappropriate immune response against a harmless food molecule [93], which is
characterized by an increased Th2 response [94] (Figure 5). Since multiple cow’s milk hydrolysates
have been described to induce Treg cell differentiation in the MLN and spleen [36,38] which reduces
the Th2 response [95], these protein hydrolysates might help to reduce allergic symptoms.
T cell differentiation can be regulated via TLRs [96,97]. Therefore, protein hydrolysates might
affect the T cell response via TLRs, as they have been found to modulate TLR signaling [74].
This knowledge could help in selecting allergy reducing protein hydrolysates, since TLR signaling of
protein hydrolysates can be measured in reporter cell platforms [74]. Furthermore, protein hydrolysates
have also been found to reduce the permeability of the intestinal epithelial barrier [19]. This might
provide an alternative mechanism for reducing the allergic reaction, since it reduces the uptake of
antigens and prevents the interaction of lamina propria immune cells with antigens.
Another product in which protein hydrolysates are already used is clinical nutrition. In general,
a high protein intake was found to decrease mortality in hospitalized patients [98]. Protein hydrolysates
are used instead of intact proteins because of their ease of digestion. Anti-inflammatory protein
hydrolysates might have an additional benefit in patients consuming clinical nutrition because of
intestinal inflammation, because many studies have found beneficial effects of anti-inflammatory
protein hydrolysates in multiple colitis mouse models [30–33]. Therefore, anti-inflammatory protein
hydrolysates may be expected to reduce symptoms of, for example, inflammatory bowel disease and
irritable bowel syndrome in patients.
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Figure 4. Summary of the application possibilities of protein hydrolysates. These hydrolysates are
currently being used in sport nutrition, clinical nutrition, and infant formula, mainly because of their
good digestibility and hypoallergenicity. Recent research indicates that specific protein hydrolysates
could optimize the current products in multiple ways. Also, there is evidence that new protein
hydrolysate products could be beneficial for specific target groups.
Figure 5. Overview of T helper cell subsets and their interactions and their relation to specific diseases.
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Intestinal inflammation is also a common side-effect of chemotherapy [99]. Therefore, individuals
undergoing chemotherapy could be another target group for anti-inflammatory protein hydrolysates.
Interestingly, some chemotherapeutic agents induce inflammation via specific TLRs [100,101].
During chemotherapy, intestinal epithelial cells are damaged, which leads to the release of Damage
associated molecular patterns (DAMPs). DAMPs are able to activate TLR activation, which initiates an
inflammatory response [102,103]. Therefore, inhibiting TLR signaling protects against chemotherapy
induced inflammation. It was indeed found that the intake of food molecules could reduce the
inflammation caused by the chemotherapeutic agent doxorubicin, by the inhibition of TLR2 [104].
Since protein hydrolysates can also inhibit TLRs [74], they might elicit similar effects.
Protein hydrolysates are also applied in sport nutrition. Proteins are known to be essential
in the recovery after exercise [105], and peptides are more rapidly taken up compared to intact
protein [106]. Reducing inflammatory responses was found to reduce muscle pain and aid in the
recovery after exercise. This can be done by taking anti-inflammatory food products, for example,
tart cherry juice, which decreased pain and increased muscle recovery after running long distances
when ingested prior to the exercise [107,108]. Protein hydrolysates with an anti-inflammatory effect
could therefore simultaneously provide a protein source needed for muscle anabolism, and aid in
the recovery due to anti-inflammatory effects. Some studies indeed suggest that the administration
of whey protein hydrolysate or wheat gluten hydrolysate prior or after exercise decreased muscle
damage, improved muscle repair, and improved the performance [109–111]. Furthermore, excessive
exercise may result in impaired immunity [112]. Immune modulating protein hydrolysates could also
be beneficial for athletes in this respect.
14. Target Groups for New Products
Protein hydrolysates could also be used to develop completely new products with immunomodulatory
effects (Figure 5). Many studies showing a new immunomodulating effect of a hydrolysate suggest that
the hydrolysate could be used as a nutraceutical or functional food. Both terms are used for food products
with an additional health effect besides their nutritional value. As outlined in the introduction, we
and others feel that immunomodulating products will be particularly useful in modern Western society,
since the occurrence of immune-related diseases is currently increasing [113].
As mentioned before, protein hydrolysates have a good chance of ameliorating symptoms in
local intestinal diseases like inflammatory bowel disease and irritable bowel syndrome. In addition,
patients suffering from systemic immune diseases are likely to benefit from hydrolysate consumption.
Type 1 diabetes is an example of an autoimmune disease with a rapidly increasing prevalence [114].
Animals studies suggest that casein hydrolysate can prevent autoimmune diabetes by modulating
multiple immune responses in the intestine [19,20]. Management of autoimmunity to delay or prevent
disease may therefore be another promising field of application for specific protein hydrolysates.
In our view, some specific target groups might also specifically benefit from specific
immunomodulatory protein hydrolysates in order to delay or prevent disease. The number of elderly
in the population is increasing. With increasing age, the immune system deteriorates and becomes
more proinflammatory. This leads, for example, to more infections, and therefore a higher mortality
rate [115]. The innate immune response is affected in multiple ways during immunoscenesence.
An altered cytokine production by monocytes and macrophages has been found, together with a
decreased phagocytotic capacity and a reduced TLR expression [116,117]. Since it was found that
specific protein hydrolysates are able to modulate these immune aspects [27,74], protein hydrolysates
might be beneficial in keeping the elderly healthy for a longer period of time. This improves quality of
life and reduces health care costs.
Stress is another common cause of immune dysfunction [118]. Currently, an increasing number
of people experience significant levels of stress, leading to more immune-related diseases [119,120].
Both acute and chronic stress has been found to induce immune dysfunction, resulting in inflammatory,
autoimmune, and allergic diseases [121,122]. Effects associated with the development of immune diseases
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due to stress are increased pro-inflammatory cytokines, more Th2-related cytokines, and changes in
leukocyte number and distribution [123–126]. As described above, specific protein hydrolysates are able
to counteract these effects. Therefore, functional food containing protein hydrolysates may contribute to
healthy immunity in people experiencing significant stress levels.
15. Conclusions
A wide range of protein hydrolysates have immunomodulatory capacities. However, before
protein hydrolysates can serve as functional foods, physicochemical approaches to identify the protein
sequence(s) are needed to be able to design effective protein hydrolysates. Also, specific target groups
have to be identified. In this way, specific protein hydrolysates can be designed to ameliorate, delay,
or prevent the onset of a wide variety of Western immune-related conditions.
Author Contributions: Writing-Original Draft Preparation, M.B.G.K.; Writing-Review & Editing, M.M.F.
and P.d.V.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Sánchez, A.; Vázquez, A. Bioactive peptides: A review. Food Qual. Saf. 2017, 1, 29–46. [CrossRef]
2. Li-Chan, E.C.Y. Bioactive peptides and protein hydrolysates: Research trends and challenges for application
as nutraceuticals and functional food ingredients. Curr. Opin. Food Sci. 2015, 1, 28–37. [CrossRef]
3. Dhaval, A.; Yadav, N.; Purwar, S. Potential Applications of Food Derived Bioactive Peptides in Management
of Health. Int. J. Pept. Res. Ther. 2016, 22, 377–398. [CrossRef]
4. Bouglé, D.; Bouhallab, S. Dietary bioactive peptides: Human studies. Crit. Rev. Food Sci. Nutr. 2015,
57, 335–343. [CrossRef] [PubMed]
5. Kiewiet, M.B.G.; Gros, M.; van Neerven, R.J.J.; Faas, M.M.; de Vos, P. Immunomodulating properties of
protein hydrolysates for application in cow’s milk allergy. Pediatr. Allergy Immunol. 2015, 26, 206–217.
[CrossRef] [PubMed]
6. Parker, F.; Migliore-Samour, D.; Floch, F.; Zerial, A.; Werner, G.H.; Jollès, J.; Casaretto, M.; Zahn, H.; Jollès, P.
Immunostimulating hexapeptide from human casein: Amino acid sequence, synthesis and biological
properties. Eur. J. Biochem. 1984, 145, 677–682. [CrossRef] [PubMed]
7. Ashaolu, T.J.; Yanyiam, N.; Yupanqui, C.T. Immunomodulatory effects of pepsin-educed soy protein
hydrolysate in rats and murine cells. Funct. Foods Health Dis. 2017, 7, 889–900.
8. Caron, S.; Samanez, C.H.; Dehondt, H.; Ploton, M.; Briand, O.; Lien, F.; Dorchies, E.; Dumont, J.; Postic, C.;
Cariou, B.; et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element
binding protein in human hepatocytes. Mol. Cell. Biol. 2013, 33, 2202–2211. [CrossRef] [PubMed]
9. Kong, X.; Guo, M.; Hua, Y.; Cao, D.; Zhang, C. Enzymatic preparation of immunomodulating hydrolysates
from soy proteins. Bioresour. Technol. 2008, 99, 8873–8879. [CrossRef] [PubMed]
10. Mao, X.Y.; Yang, H.Y.; Song, J.P.; Li, Y.H.; Ren, F.Z. Effect of yak milk casein hydrolysate on Th1/Th2
cytokines production by murine spleen lymphocytes in vitro. J. Agric. Food Chem. 2007, 55, 638–642.
[CrossRef] [PubMed]
11. Rodríguez-Carrio, J.; Fernández, A.; Riera, F.A.; Suárez, A. Immunomodulatory activities of whey
β-lactoglobulin tryptic-digested fractions. Int. Dairy J. 2014, 34, 65–73. [CrossRef]
12. Wu, W.; Zhang, M.; Sun, C.; Brennan, M.; Li, H.; Wang, G.; Lai, F.; Wu, H. Enzymatic preparation of
immunomodulatory hydrolysates from defatted wheat germ (Triticum Vulgare) globulin. Int. J. Food
Sci. Technol. 2016, 51, 2556–2566. [CrossRef]
13. He, X.Q.; Cao, W.H.; Pan, G.K.; Yang, L.; Zhang, C.H. Enzymatic hydrolysis optimization of Paphia undulata
and lymphocyte proliferation activity of the isolated peptide fractions. J. Sci. Food Agric. 2015, 95, 1544–1553.
[CrossRef] [PubMed]
14. Lozano-Ojalvo, D.; Molina, E.; López-Fandiño, R. Hydrolysates of egg white proteins modulate T- and B-cell
responses in mitogen-stimulated murine cells. Food Funct. 2016, 7, 1048–1056. [CrossRef] [PubMed]
278
Nutrients 2018, 10, 904
15. Sutas, Y.; Soppi, E.; Korhonen, H.; Syvaoja, E.L.; Saxelin, M.; Rokka, T.; Isolauri, E. Suppression of lymphocyte
proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG-derived enzymes. J. Allergy
Clin. Immunol. 1996, 98, 216–224. [CrossRef]
16. Meram, C.; Wu, J. Anti-inflammatory effects of egg yolk livetins (α, β, and γ-livetin) fraction and its
enzymatic hydrolysates in lipopolysaccharide-induced RAW 264.7 macrophages. Food Res. Int. 2017,
100, 449–459. [CrossRef] [PubMed]
17. Kazlauskaite, J.; Biziulevicius, G.A.; Zukaite, V.; Biziuleviciene, G.; Miliukiene, V.; Siaurys, A. Oral tryptic
casein hydrolysate enhances phagocytosis by mouse peritoneal and blood phagocytic cells but fails to
prevent induced inflammation. Int. Immunopharmacol. 2005, 5, 1936–1944. [CrossRef] [PubMed]
18. Wen, L.; Chen, Y.; Zhang, L.; Yu, H.; Xu, Z.; You, H.; Cheng, Y. Rice protein hydrolysates (RPHs) inhibit
the LPS-stimulated inflammatory response and phagocytosis in RAW264.7 macrophages by regulating the
NF-κB signaling pathway. RSC Adv. 2016, 6, 71295–71304. [CrossRef]
19. Visser, J.; Lammers, K.; Hoogendijk, A.; Boer, M.; Brugman, S.; Beijer-Liefers, S.; Zandvoort, A.; Harmsen, H.;
Welling, G.; Stellaard, F.; et al. Restoration of impaired intestinal barrier function by the hydrolysed casein
diet contributes to the prevention of type 1 diabetes in the diabetes-prone BioBreeding rat. Diabetologia 2010,
53, 2621–2628. [CrossRef] [PubMed]
20. Visser, J.; Bos, N.; Harthoorn, L.; Stellaard, F.; Beijer-Liefers, S.; Rozing, J.; van Tol, E.A.F. Potential mechanisms
explaining why hydrolyzed casein-based diets outclass single amino acid-based diets in the prevention
of autoimmune diabetes in diabetes-prone BB rats. Diabete Metab. Res. Rev. 2012, 28, 505–513. [CrossRef]
[PubMed]
21. Plaisancié, P.; Claustre, J.; Estienne, M.; Henry, G.; Boutrou, R.; Paquet, A.; Léonil, J. A novel bioactive peptide
from yoghurts modulates expression of the gel-forming MUC2 mucin as well as population of goblet cells
and Paneth cells along the small intestine. J. Nutr. Biochem. 2013, 24, 213–221. [CrossRef] [PubMed]
22. Thoreux, K.; Balas, D.; Bouley, C.; Senegas-Balas, F. Diet Supplemented with Yoghurt or Milk Fermented by
Lactobacillus casei DN-114 001 Stimulates Growth and Brush-Border Enzyme Activities in Mouse Small
Intestine. Digestion 1998, 59, 349–359. [CrossRef] [PubMed]
23. Vinderola, G.; Matar, C.; Perdigón, G. Milk fermentation products of L. helveticus R389 activate calcineurin
as a signal to promote gut mucosal immunity. BMC Immunol. 2007, 8, 19. [CrossRef] [PubMed]
24. Nelson, R.; Katayama, S.; Mine, Y.; Duarte, J.; Matar, C. Immunomodulating effects of egg yolk low lipid
peptic digests in a murine model. Food Agric. Immunol. 2007, 18, 1–15. [CrossRef]
25. Chalamaiah, M.; Hemalatha, R.; Jyothirmayi, T.; Diwan, P.V.; Bhaskarachary, K.; Vajreswari, A.;
Ramesh Kumar, R.; Dinesh Kumar, B. Chemical composition and immunomodulatory effects of enzymatic
protein hydrolysates from common carp (Cyprinus carpio) egg. Nutrition 2015, 31, 388–398. [CrossRef]
[PubMed]
26. Ndiaye, F.; Vuong, T.; Duarte, J.; Aluko, R.E.; Matar, C. Anti-oxidant, anti-inflammatory and
immunomodulating properties of an enzymatic protein hydrolysate from yellow field pea seeds. Eur. J. Nutr.
2012, 51, 29–37. [CrossRef] [PubMed]
27. Duarte, J.; Vinderola, G.; Ritz, B.; Perdigón, G.; Matar, C. Immunomodulating capacity of commercial fish
protein hydrolysate for diet supplementation. Immunobiology 2006, 211, 341–350. [CrossRef] [PubMed]
28. Mallet, J.F.; Duarte, J.; Vinderola, G.; Anguenot, R.; Beaulieu, M.; Matar, C. The immunopotentiating effects
of shark-derived protein hydrolysate. Nutrition 2014, 30, 706–712. [CrossRef] [PubMed]
29. LeBlanc, J.; Fliss, I.; Matar, C. Induction of a Humoral Immune Response following an Escherichia
coli O157:H7 Infection with an Immunomodulatory Peptidic Fraction Derived from Lactobacillus
helveticus-Fermented Milk. Clin. Diagn. Lab. Immunol. 2004, 11, 1171–1181. [CrossRef] [PubMed]
30. Daddaoua, A.; Puerta, V.; Zarzuelo, A.; Suárez, M.D.; Sánchez de Medina, F.; Martínez-Augustin, O.
Bovine Glycomacropeptide Is Anti-Inflammatory in Rats with Hapten-Induced Colitis. J. Nutr. 2005,
135, 1164–1170. [CrossRef] [PubMed]
31. Espeche Turbay, M.B.; De Leblanc, A.D.M.; Perdigón, G.; Savoy de Giori, G.; Hebert, E.M.
β-Casein hydrolysate generated by the cell envelope-associated proteinase of Lactobacillus delbrueckii
ssp. lactis CRL 581 protects against trinitrobenzene sulfonic acid-induced colitis in mice. J. Dairy Sci. 2012,
95, 1108–1118. [CrossRef] [PubMed]
279
Nutrients 2018, 10, 904
32. Ortega-Gonzalez, M.; Capitan-Canadas, F.; Requena, P.; Ocon, B.; Romero-Calvo, I.; Aranda, C.; Suarez, M.D.;
Zarzuelo, A.; de Medina, F.S.; Martinez-Augustin, O. Validation of bovine glycomacropeptide as an intestinal
anti-inflammatory nutraceutical in the lymphocyte-transfer model of colitis. Br. J. Nutr. 2014, 111, 1202–1212.
[CrossRef] [PubMed]
33. Requena, P.; Daddaoua, A.; Martínez-Plata, E.; González, M.; Zarzuelo, A.; Suárez, M.D.; Sánchez de Medina, F.;
Martínez-Augustin, O. Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving
downregulation of interleukin 17. Br. J. Pharmacol. 2009, 154, 825–832. [CrossRef] [PubMed]
34. Lee, M.; Kovacs-Nolan, J.; Archbold, T.; Fan, M.Z.; Juneja, L.R.; Okubo, T.; Mine, Y. Therapeutic potential
of hen egg white peptides for the treatment of intestinal inflammation. J. Funct. Foods 2009, 1, 161–169.
[CrossRef]
35. Egusa, S.; Otani, H. Soybean protein fraction digested with neutral protease preparation, “Peptidase R”,
produced by Rhizopus oryzae, stimulates innate cellular immune system in mouse. Int. Immunopharmacol.
2009, 9, 931–936. [CrossRef] [PubMed]
36. Kiewiet, M.; van Esch, B.; Garssen, J.; Faas, M.; de Vos, P. Partially hydrolyzed whey proteins prevent clinical
symptoms in a cow’s milk allergy mouse model and enhance regulatory T and B cell frequencies. Mol. Nutr.
Food Res. 2017, 61. [CrossRef] [PubMed]
37. Meulenbroek, L.A.P.M.; van Esch, B.C.A.M.; Hofman, G.A.; den Hartog Jager, C.F.; Nauta, A.J.;
Willemsen, L.E.M.; Bruijnzeel-Koomen, C.A.F.M.; Garssen, J.; van Hoffen, E.; Knippels, L.M.J. Oral treatment
with beta-lactoglobulin peptides prevents clinical symptoms in a mouse model for cow’s milk allergy.
Pediatr. Allergy Immunol. 2013, 24, 656–664. [CrossRef] [PubMed]
38. Van Esch, B.C.A.M.; Schouten, B.; de Kivit, S.; Hofman, G.A.; Knippels, L.M.J.; Willemsen, L.E.M.; Garssen, J.
Oral tolerance induction by partially hydrolyzed whey protein in mice is associated with enhanced numbers
of Foxp3(+) regulatory T-cells in the mesenteric lymph nodes. Pediatr. Allergy Immunol. 2011, 22, 820–826.
[CrossRef] [PubMed]
39. Cai, B.; Pan, J.; Wu, Y.; Wan, P.; Sun, H. Immune functional impacts of oyster peptide-based enteral nutrition
formula (OPENF) on mice: A pilot study. Chin. J. Oceanol. Limnol. 2013, 31, 813–820. [CrossRef]
40. Pan, D.D.; Wu, Z.; Liu, J.; Cao, X.Y.; Zeng, X.Q. Immunomodulatory and hypoallergenic properties of milk
protein hydrolysates in ICR mice. J. Dairy Sci. 2013, 96, 4958–4964. [CrossRef] [PubMed]
41. Yang, R.; Zhang, Z.; Pei, X.; Han, X.; Wang, J.; Wang, L.; Long, Z.; Shen, X.; Li, Y. Immunomodulatory effects
of marine oligopeptide preparation from Chum Salmon (Oncorhynchus keta) in mice. Food Chem. 2009,
113, 464–470. [CrossRef]
42. Kim, M.J.; Kim, K.B.W.R.; Sung, N.Y.; Byun, E.H.; Nam, H.S.; Ahn, D.H. Immune-enhancement effects of
tuna cooking drip and its enzymatic hydrolysate in Balb/c mice. Food Sci. Biotechnol. 2018, 27, 131–137.
[CrossRef]
43. Yimit, D.; Hoxur, P.; Amat, N.; Uchikawa, K.; Yamaguchi, N. Effects of soybean peptide on immune function,
brain function, and neurochemistry in healthy volunteers. Nutrition 2012, 28, 154–159. [CrossRef] [PubMed]
44. Horiguchi, N.; Horiguchi, H.; Suzuki, Y. Effect of wheat gluten hydrolysate on the immune system in healthy
human subjects. Biosci. Biotechnol. Biochem. 2005, 69, 2445–2449. [CrossRef] [PubMed]
45. Nesse, K.O.; Nagalakshmi, A.P.; Marimuthu, P.; Singh, M. Efficacy of a Fish Protein Hydrolysate in
Malnourished Children. Indian J. Clin. Biochem. 2011, 26, 360–365. [CrossRef] [PubMed]
46. Farhadi, A.; Banan, A.; Fields, J.; Keshavarzian, A. Intestinal barrier: An interface between health and disease.
J. Gastroenterol. Hepatol. 2003, 18, 479–497. [CrossRef] [PubMed]
47. Peterson, L.W.; Artis, D. Intestinal epithelial cells: Regulators of barrier function and immune homeostasis.
Nat. Rev. Immunol. 2014, 14, 141–153. [CrossRef] [PubMed]
48. Liu, F.; Poursine-Laurent, J.; Wu, H.; Link, D.C. Interleukin-6 and the granulocyte colony-stimulating
factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage
commitment or terminal differentiation. Blood 1997, 90, 2583–2590. [PubMed]
49. Smith, K.A.; Maizels, R.M. IL-6 controls susceptibility to helminth infection by impeding Th2 responsiveness
and altering the Treg phenotype in vivo. Eur. J. Immunol. 2014, 44, 150–161. [CrossRef] [PubMed]
50. Hunter, C.A.; Jones, S.A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 2015, 16, 448–457.
[CrossRef] [PubMed]
51. Pabst, O. New concepts in the generation and functions of IgA. Nat. Rev. Immunol. 2012, 12, 821–832.
[CrossRef] [PubMed]
280
Nutrients 2018, 10, 904
52. Ligtenberg, A.; Veerman, E.; Nieuw Amerongen, A.; Mollenhauer, J. Salivary agglutinin/glycoprotein-340/
DMBT1: A single molecule with variable composition and with different functions in infection, inflammation
and cancer. Biol. Chem. 2007, 388, 1275–1289. [CrossRef] [PubMed]
53. Fernie-King, B.; Seilly, D.; Binks, M.; Sriprakash, K.; Lachmann, P. Streptococcal DRS (distantly related to
SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: A comparison of their
activities. Microbes Infect. 2007, 9, 300–307. [CrossRef] [PubMed]
54. Samuel, C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14, 778–809. [CrossRef] [PubMed]
55. Macpherson, A.J.; Smith, K. Mesenteric lymph nodes at the center of immune anatomy. J. Exp. Med. 2006,
203, 497–500. [CrossRef] [PubMed]
56. Santiago, A.F.; Fernandes, R.M.; Santos, B.P.; Assis, F.A.; Oliveira, R.P.; Carvalho, C.R.; Faria, A.M.C. Role of
mesenteric lymph nodes and aging in secretory IgA production in mice. Cell. Immunol. 2008, 253, 5–10.
[CrossRef] [PubMed]
57. Chabance, B.; Marteau, P.; Rambaud, J.C.; Migliore-Samour, D.; Boynard, M.; Perrotin, P.; Guillet, R.; Jolles, P.;
Fiat, A.M. Casein peptide release and passage to the blood in humans during digestion of milk or yogurt.
Biochimie 1998, 80, 155–165. [CrossRef]
58. Dia, V.P.; Torres, S.; De Lumen, B.O.; Erdman, J.W.; Gonzalez De Mejia, E. Presence of lunasin in plasma of
men after soy protein consumption. J. Agric. Food Chem. 2009, 57, 1260–1266. [CrossRef] [PubMed]
59. Rosser, E.C.; Mauri, C. Regulatory B Cells: Origin, Phenotype, and Function. Immunity 2015, 42, 607–612.
[CrossRef] [PubMed]
60. Kim, A.R.; Kim, H.S.W.H.S.; Kim, D.K.; Nam, S.T.; Kim, H.S.W.H.S.; Park, Y.H.; Lee, D.; Lee, M.B.; Lee, J.H.;
Kim, B.; et al. Mesenteric IL-10-producing CD5(+) regulatory B cells suppress cow’s milk casein-induced
allergic responses in mice. Sci. Rep. 2016, 6, 19685. [CrossRef] [PubMed]
61. Agyei, D.; Ongkudon, C.M.; Wei, C.Y.; Chan, A.S.; Danquah, M.K. Bioprocess challenges to the isolation and
purification of bioactive peptides. Food Bioprod. Process. 2016, 98, 244–256. [CrossRef]
62. Rutherfurd, S.M. Methodology for determining degree of hydrolysis of proteins in Hydrolysates: A review.
J. AOAC Int. 2010, 93, 1515–1522. [PubMed]
63. Silvestre, M.P.C. Review of methods for the analysis of protein hydrolysates. Food Chem. 1997, 60, 263–271.
[CrossRef]
64. Lemieux, L.; Piot, J.-M.; Guillochon, D.; Amiot, J. Study of the efficiency of a mobile phase used
in size-exclusion HPLC for the separation of peptides from a casein hydrolysate according to their
hydrodynamic volume. Chromatographia 1991, 32, 499–504. [CrossRef]
65. Chen, H.-M.; Muramoto, K.; Yamauchi, F. Structural Analysis of Antioxidative Peptides from Soybean
.beta.-Conglycinin. J. Agric. Food Chem. 1995, 43, 574–578. [CrossRef]
66. Kiewiet, M.B.G.; Dekkers, R.; Ulfman, L.H.; Groeneveld, A.; de Vos, P.; Faas, M.M. Immunomodulating
protein aggregates in soy and whey hydrolysates and their resistance to digestion in an in vitro infant
gastrointestinal model: New insights in the mechanism of immunomodulatory hydrolysates. Food Funct.
2018, 9, 604–613. [CrossRef] [PubMed]
67. Mukhopadhya, A.; Noronha, N.; Bahar, B.; Ryan, M.T.; Murray, B.A.; Kelly, P.M.; O’Loughlin, I.B.;
O’Doherty, J.V.; Sweeney, T. The anti-inflammatory potential of a moderately hydrolysed casein and its 5 kDa
fraction in in vitro and ex vivo models of the gastrointestinal tract. Food Funct. 2015, 6, 612–621. [CrossRef]
[PubMed]
68. Lafarga, T.; Hayes, M. Bioactive protein hydrolysates in the functional food ingredient industry: Overcoming
current challenges. Food Rev. Int. 2017, 33, 217–246. [CrossRef]
69. Chalamaiah, M.; Yu, W.; Wu, J. Immunomodulatory and anticancer protein hydrolysates (peptides) from
food proteins: A review. Food Chem. 2018, 245, 205–222. [CrossRef] [PubMed]
70. Monahan, F.J.; German, J.B.; Kinsella, J.E. Effect of Ph and Temperature on Protein Unfolding and
Thiol-Disulfide Interchange Reactions during Heat-Induced Gelation of Whey Proteins. J. Agric. Food Chem.
1995, 43, 46–52. [CrossRef]
71. Gordon, S. Pattern recognition receptors: Doubling up for the innate immune response. Cell 2002,
111, 927–930. [CrossRef]
72. Michallet, M.-C.; Rota, G.; Maslowski, K.; Guarda, G. Innate receptors for adaptive immunity.
Curr. Opin. Microbiol. 2013, 16, 296–302. [CrossRef] [PubMed]
281
Nutrients 2018, 10, 904
73. Abreu, M.T. Toll-like receptor signalling in the intestinal epithelium: How bacterial recognition shapes
intestinal function. Nat. Rev. Immunol. 2010, 10, 131–143. [CrossRef] [PubMed]
74. Kiewiet, M.B.G.; Dekkers, R.; Gros, M.; van Neerven, R.J.J.; Groeneveld, A.; de Vos, P.; Faas, M.M.
Toll-like receptor mediated activation is possibly involved in immunoregulating properties of cow’s milk
hydrolysates. PLoS ONE 2017, 12, e0178191. [CrossRef] [PubMed]
75. Tobita, K.; Kawahara, T.; Otani, H. Bovine beta-casein (1-28), a casein phosphopeptide, enhances proliferation
and IL-6 expression of mouse CD19(+) cells via toll-like receptor 4. J. Agric. Food Chem. 2006, 54, 8013–8017.
[CrossRef] [PubMed]
76. Iskandar, M.M.; Lands, L.C.; Sabally, K.; Azadi, B.; Meehan, B.; Mawji, N.; Skinner, C.D.; Kubow, S.
High Hydrostatic Pressure Pretreatment of Whey Protein Isolates Improves Their Digestibility and
Antioxidant Capacity. Foods 2015, 4, 184–207. [CrossRef] [PubMed]
77. Tsuruki, T.; Kishi, K.; Takahashi, M.; Tanaka, M.; Matsukawa, T.; Yoshikawa, M. Soymetide,
an immunostimulating peptide derived from soybean beta-conglycinin, is an fMLP agonist. FEBS Lett. 2003,
540, 206–210. [CrossRef]
78. Stefanucci, A.; Mollica, A.; Macedonio, G.; Zengin, G.; Ahmed, A.A.; Novellino, E. Exogenous opioid
peptides derived from food proteins and their possible uses as dietary supplements: A critical review.
Food Rev. Int. 2018, 34, 70–86. [CrossRef]
79. Liang, X.; Liu, R.; Chen, C.; Ji, F.; Li, T. Opioid System Modulates the Immune Function: A Review.
Transl. Perioper. Pain Med. 2016, 1, 5–13. [CrossRef] [PubMed]
80. Börner, C.; Lanciotti, S.; Koch, T.; Höllt, V.; Kraus, J. μ opioid receptor agonist-selective regulation of
interleukin-4 in T lymphocytes. J. Neuroimmunol. 2013, 263, 35–42. [CrossRef] [PubMed]
81. Cheido, M.A.; Gevorgyan, M.M.; Zhukova, E.N. Comparative Evaluation of Opioid-Induced Changes in
Immune Reactivity of CBA Mice. Bull. Exp. Biol. Med. 2014, 156, 363–365. [CrossRef] [PubMed]
82. Tomassini, N.; Renaud, F.; Roy, S.; Loh, H.H. Morphine inhibits Fc-mediated phagocytosis through mu and
delta opioid receptors. J. Neuroimmunol. 2004, 147, 131–133. [CrossRef] [PubMed]
83. Dalmasso, G.; Charrier-Hisamuddin, L.; Thu Nguyen, H.T.; Yan, Y.; Sitaraman, S.; Merlin, D. PepT1-Mediated
Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology 2008, 134, 166–178. [CrossRef]
[PubMed]
84. Kovacs-Nolan, J.; Zhang, H.; Ibuki, M.; Nakamori, T.; Yoshiura, K.; Turner, P.V.; Matsui, T.; Mine, Y.
The PepT1-transportable soy tripeptide VPY reduces intestinal inflammation. Biochim. Biophys. Acta
Gen. Subj. 2012, 1820, 1753–1763. [CrossRef] [PubMed]
85. Oyama, M.; Van Hung, T.; Yoda, K.; He, F.; Suzuki, T. A novel whey tetrapeptide IPAV reduces interleukin-8
production induced by TNF-α in human intestinal Caco-2 cells. J. Funct. Foods 2017, 35, 376–383. [CrossRef]
86. Adibi, S.A. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease.
Am. J. Physiol. Liver Physiol. 2003, 285, G779–G788. [CrossRef] [PubMed]
87. Bermudez-Brito, M.; Sahasrabudhe, N.M.; Rösch, C.; Schols, H.A.; Faas, M.M.; de Vos, P. The impact of
dietary fibers on dendritic cell responses in vitro is dependent on the differential effects of the fibers on
intestinal epithelial cells. Mol. Nutr. Food Res. 2015, 59, 698–710. [CrossRef] [PubMed]
88. Charrier, L.; Driss, A.; Yan, Y.; Nduati, V.; Klapproth, J.-M.; Sitaraman, S.V.; Merlin, D. hPepT1 mediates
bacterial tripeptide fMLP uptake in human monocytes. Lab. Investig. 2006, 86, 490–503. [CrossRef] [PubMed]
89. Knipp, G.T.; Vander Velde, D.G.; Siahaan, T.J.; Borchardt, R.T. The effect of beta-turn structure on the passive
diffusion of peptides across Caco-2 cell monolayers. Pharm. Res. 1997, 14, 1332–1340. [CrossRef] [PubMed]
90. Regazzo, D.; Molle, D.; Gabai, G.; Tome, D.; Dupont, D.; Leonil, J.; Boutrou, R. The (193-209) 17-residues
peptide of bovine beta-casein is transported through Caco-2 monolayer. Mol. Nutr. Food Res. 2010,
54, 1428–1435. [CrossRef] [PubMed]
91. Cam, A.; Sivaguru, M.; Gonzalez de Mejia, E. Endocytic Mechanism of Internalization of Dietary Peptide
Lunasin into Macrophages in Inflammatory Condition Associated with Cardiovascular Disease. PLoS ONE
2013, 8, e72115. [CrossRef] [PubMed]
92. Kneepkens, C.M.F.; Meijer, Y. Clinical practice. Diagnosis and treatment of cow’s milk allergy. Eur. J. Pediatr.
2009, 168, 891–896. [CrossRef] [PubMed]
93. Turcanu, V.; Brough, H.A.; Du Toit, G.; Foong, R.-X.; Marrs, T.; Santos, A.F.; Lack, G. Immune mechanisms
of food allergy and its prevention by early intervention. Curr. Opin. Immunol. 2017, 48, 92–98. [CrossRef]
[PubMed]
282
Nutrients 2018, 10, 904
94. Berin, M.C.; Sampson, H.A. Review Mucosal Immunology of Food Allergy. Curr. Biol. 2013, 23, R389–R400.
[CrossRef] [PubMed]
95. Curotto de Lafaille, M.A.; Kutchukhidze, N.; Shen, S.; Ding, Y.; Yee, H.; Lafaille, J.J. Adaptive Foxp3+
Regulatory T Cell-Dependent and -Independent Control of Allergic Inflammation. Immunity 2008,
29, 114–126. [CrossRef] [PubMed]
96. Morgan, M.E.; Koelink, P.J.; Zheng, B.; den Brok, M.H.M.G.M.; van de Kant, H.J.; Verspaget, H.W.; Folkerts, G.;
Adema, G.J.; Kraneveld, A.D. Toll-like receptor 6 stimulation promotes T-helper 1 and 17 responses in
gastrointestinal-associated lymphoid tissue and modulates murine experimental colitis. Mucosal Immunol.
2014, 7, 1266–1277. [CrossRef] [PubMed]
97. Dolina, J.S.; Schoenberger, S.P. Toll-like receptor 9 is required for the maintenance of CD25+FoxP3+CD4+
Treg cells during Listeria monocytogenes infection. J. Immunol. 2017, 198 (Suppl. 1), 151.9.
98. Deutz, N.E.; Matheson, E.M.; Matarese, L.E.; Luo, M.; Baggs, G.E.; Nelson, J.L.; Hegazi, R.A.;
Tappenden, K.A.; Ziegler, T.R.; Grp, N.S. Readmission and mortality in malnourished, older, hospitalized
adults treated with a specialized oral nutritional supplement: A randomized clinical trial. Clin. Nutr. 2016,
35, 18–26. [CrossRef] [PubMed]
99. Elting, L.S.; Cooksley, C.; Chambers, M.; Cantor, S.B. The burdens of cancer therapy—Clinical and economic
outcomes of chemotherapy-induced mucositis. Cancer 2003, 98, 1531–1539. [CrossRef] [PubMed]
100. Kaczmarek, A.; Brinkman, B.M.; Heyndrickx, L.; Vandenabeele, P.; Krysko, D.V. Severity of
doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. J. Pathol.
2012, 226, 598–608. [CrossRef] [PubMed]
101. De Koning, B.A.E.; van Dieren, J.M.; Lindenbergh-Kortleve, D.J.; van der Sluis, M.; Matsumoto, T.;
Yamaguchi, K.; Einerhand, A.W.; Samsom, J.N.; Pieters, R.; Nieuwenhuis, E.E.S. Contributions of mucosal
immune cells to methotrexate-induced mucositis. Int. Immunol. 2006, 18, 941–949. [CrossRef] [PubMed]
102. Cario, E. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity. Curr. Opin.
Support. Palliat. Care 2016, 10, 157–164. [CrossRef] [PubMed]
103. Villa, A.; Sonis, S.T. Mucositis: Pathobiology and management. Curr. Opin. Oncol. 2015, 27, 159–164.
[CrossRef] [PubMed]
104. Sahasrabudhe, N.M.; Beukema, M.; Tian, L.; Troost, B.; Scholte, J.; Bruininx, E.; Bruggeman, G.;
van den Berg, M.; Scheurink, A.; Schols, H.A.; et al. Dietary Fiber Pectin Directly Blocks Toll-Like Receptor
2–1 and Prevents Doxorubicin-Induced Ileitis. Front. Immunol. 2018, 9, 383. [CrossRef] [PubMed]
105. Crittenden, R.; Buckley, J.; Cameron-Smith, D.; Brown, A.; Thomas, K.; Davey, S.; Hobman, P. Functional
dairy protein supplements for elite athletes. Aust. J. Dairy Technol. 2009, 64, 133–138.
106. Foltz, M.; Ansems, P.; Schwarz, J.; Tasker, M.C.; Lourbakos, A.; Gerhardt, C.C. Protein hydrolysates induce
CCK release from enteroendocrine cells and act as partial agonists of the CCK1receptor. J. Agric. Food Chem.
2008, 56, 837–843. [CrossRef] [PubMed]
107. Kuehl, K.S.; Perrier, E.T.; Elliot, D.L.; Chesnutt, J.C. Efficacy of tart cherry juice in reducing muscle pain
during running: A randomized controlled trial. J. Int. Soc. Sports Nutr. 2010, 7, 1–6. [CrossRef] [PubMed]
108. Howatson, G.; McHugh, M.P.; Hill, J.A.; Brouner, J.; Jewell, A.P.; Van Someren, K.A.; Shave, R.E.;
Howatson, S.A. Influence of tart cherry juice on indices of recovery following marathon running. Scand. J.
Med. Sci. Sport. 2010, 20, 843–852. [CrossRef] [PubMed]
109. Koikawa, N.; Nakamura, A.; Ngaoka, I.; Aoki, K.; Sawaki, K.; Suzuki, Y. Delayed-onset muscle injury and its
modification by wheat gluten hydrolysate. Nutrition 2009, 25, 493–498. [CrossRef] [PubMed]
110. Hansen, M.; Bangsbo, J.; Bibby, B.M.; Madsen, K. Effect of whey protein hydrolysate on performance and
recovery of top-clas orienteering runners. Int. J. Sport Nutr. Exerc. Metab. 2014, 25, 97–109. [CrossRef]
[PubMed]
111. Buckley, J.D.; Thomson, R.L.; Coates, A.M.; Howe, P.R.C.; DeNichilo, M.O.; Rowney, M.K. Supplementation
with a whey protein hydrolysate enhances recovery of muscle force-generating capacity following eccentric
exercise. J. Sci. Med. Sport 2010, 13, 178–181. [CrossRef] [PubMed]
112. Cruzat, V.F.; Krause, M.; Newsholme, P. Amino acid supplementation and impact on immune function in
the context of exercise. J. Int. Soc. Sports Nutr. 2014, 11, 1–13. [CrossRef] [PubMed]
113. Okada, H.; Kuhn, C.; Feillet, H.; Bach, J.-F. The “hygiene hypothesis” for autoimmune and allergic diseases:
An update. Clin. Exp. Immunol. 2010, 160, 1–9. [CrossRef] [PubMed]
283
Nutrients 2018, 10, 904
114. Dabelea, D.; Mayer-Davis, E.J.; Saydah, S.; Imperatore, G.; Linder, B.; Divers, J.; Bell, R.; Badaru, A.;
Talton, J.W.; Crume, T.; et al. Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents
From 2001 to 2009. JAMA 2014, 311, 1778. [CrossRef] [PubMed]
115. Aw, D.; Silva, A.B.; Palmer, D.B. Immunosenescence: Emerging challenges for an ageing population.
Immunology 2007, 120, 435–446. [CrossRef] [PubMed]
116. Plowden, J.; Renshaw-Hoelscher, M.; Engleman, C.; Katz, J.; Sambhara, S. Innate immunity in aging: Impact
on macrophage function. Aging Cell 2004, 3, 161–167. [CrossRef] [PubMed]
117. Lloberas, J.; Celada, A. Effect of aging on macrophage function. Exp. Gerontol. 2002, 37, 1325–1331. [CrossRef]
118. Morey, J.N.; Boggero, I.A.; Scott, A.B.; Segerstrom, S.C. Current directions in stress and human immune
function. Curr. Opin. Psychol. 2015, 5, 13–17. [CrossRef] [PubMed]
119. Organization, W.H. Mental health: Facing the challenges, building solutions. In Proceedings of the First
WHO European Ministerial Conference on Mental Health, Helsinki, Finland, 12–15 January 2005.
120. Corazon, S.; Nyed, P.; Sidenius, U.; Poulsen, D.; Stigsdotter, U. A Long-Term Follow-Up of the Efficacy
of Nature-Based Therapy for Adults Suffering from Stress-Related Illnesses on Levels of Healthcare
Consumption and Sick-Leave Absence: A Randomized Controlled Trial. Int. J. Environ. Res. Public Health
2018, 15, 137. [CrossRef] [PubMed]
121. Dhabhar, F.S. Effects of stress on immune function: The good, the bad, and the beautiful. Immunol. Res. 2014,
58, 193–210. [CrossRef] [PubMed]
122. Godbout, J.P.; Glaser, R. Stress-induced immune dysregulation: Implications for wound healing, infectious
disease and cancer. J. Neuroimmune Pharmacol. 2006, 1, 421–427. [CrossRef] [PubMed]
123. Steptoe, A.; Hamer, M.; Chida, Y. The effects of acute psychological stress on circulating inflammatory factors
in humans: A review and meta-analysis. Brain Behav. Immun. 2007, 21, 901–912. [CrossRef] [PubMed]
124. Glaser, R.; MacCallum, R.C.; Laskowski, B.F.; Malarkey, W.B.; Sheridan, J.F.; Kiecolt-Glaser, J.K. Evidence for
a shift in the Th-1 to Th-2 cytokine response associated with chronic stress and aging. J. Gerontol. A. Biol. Sci.
Med. Sci. 2001, 56, M477–M482. [CrossRef] [PubMed]
125. Veru, F.; Dancause, K.; Laplante, D.P.; King, S.; Luheshi, G. Prenatal maternal stress predicts reductions in
CD4+ lymphocytes, increases in innate-derived cytokines, and a Th2 shift in adolescents: Project Ice Storm.
Physiol. Behav. 2015, 144, 137–145. [CrossRef] [PubMed]
126. Dhabhar, F.S.; Malarkey, W.B.; Neri, E.; McEwen, B.S. Stress-induced redistribution of immune
cells—From barracks to boulevards to battlefields: A tale of three hormones—Curt Richter Award Winner.
Psychoneuroendocrinology 2012, 37, 1345–1368. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Obesity, Inflammation, Toll-Like Receptor 4 and
Fatty Acids
Marcelo Macedo Rogero 1,2,* and Philip C. Calder 3,4
1 Nutritional Genomics and Inflammation Laboratory, Department of Nutrition, School of Public Health,
University of São Paulo, 01246-904 São Paulo, Brazil
2 Food Research Center (FoRC), CEPID-FAPESP, Research Innovation and Dissemination Centers São Paulo
Research Foundation, São Paulo 05468-140, Brazil
3 Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton,
Southampton SO16 6YD, UK; P.C.Calder@soton.ac.uk
4 National Institute for Health Research Southampton Biomedical Research Centre, University Hospital
Southampton National Health Service Foundation Trust and University of Southampton, Southampton
SO16 6YD, UK
* Correspondence: mmrogero@usp.br; Tel.: +55-11-3061-7850
Received: 28 February 2018; Accepted: 28 March 2018; Published: 30 March 2018
Abstract: Obesity leads to an inflammatory condition that is directly involved in the etiology of
cardiovascular diseases, type 2 diabetes mellitus, and certain types of cancer. The classic inflammatory
response is an acute reaction to infections or to tissue injuries, and it tends to move towards
resolution and homeostasis. However, the inflammatory process that was observed in individuals
affected by obesity and metabolic syndrome differs from the classical inflammatory response in
certain respects. This inflammatory process manifests itself systemically and it is characterized by a
chronic low-intensity reaction. The toll-like receptor 4 (TLR4) signaling pathway is acknowledged as
one of the main triggers of the obesity-induced inflammatory response. The aim of the present review
is to describe the role that is played by the TLR4 signaling pathway in the inflammatory response
and its modulation by saturated and omega-3 polyunsaturated fatty acids. Studies indicate that
saturated fatty acids can induce inflammation by activating the TLR4 signaling pathway. Conversely,
omega-3 polyunsaturated fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid,
exert anti-inflammatory actions through the attenuation of the activation of the TLR4 signaling
pathway by either lipopolysaccharides or saturated fatty acids.
Keywords: inflammation; toll-like receptor 4; obesity; fatty acids
1. Obesity
Obesity is a multifactorial and polygenic condition that has become a very concerning public
health issue that is affecting both developed and developing countries [1–3]. Overweight individuals
(defined as body mass index (BMI) ≥ 25 kg/m2) account for approximately 30% of the global
population, i.e., 2.1 billion people, of whom more than 600,000 are classified as obese (defined as
BMI ≥ 30 kg/m2) [4]. The analysis conducted by the Global Burden of Disease Study 2013 showed
that the overweight prevalence increased to 27.5% of adults and 47.1% of children in the past three
decades [5]. The prevalence of obesity is currently higher in developed countries; nevertheless,
approximately two-thirds of the obese population lives in developing countries [6]. Based on the
current scenario, it is estimated that up to 50% of the global population will be classified as overweight
or obese by 2030 [7]. Approximately 35% of adult individuals and 17% of children and adolescents
(2 to 19 years old) are considered to be obese (defined by values above the 95th percentile of the BMI
curve of these age groups) in the United States. It is estimated that approximately 300,000 people die
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due to obesity in the United States (U.S.) every year, which is the second highest cause of preventable
death [8].
Cardiovascular diseases, type 2 diabetes (DM2), non-alcoholic fatty liver disease, and cancer
stand out among the main health issues that are responsible for morbidity related to the obesity [9].
Obesity treatment and the treatment of its associated complications in developing countries has led
to significant cost increases in healthcare. Costs that are linked to DM2, in particular, stand out,
since 20–30% of overweight people present with a DM2 diagnosis, while 85% of diabetic patients are
overweight or obese [10]. Calle et al. [11] conducted a prospective study of more than one million
men and women and found that the lowest mortality rates, for all causes, in both men and women,
occur in individuals with BMIs that are between 23.5 and 24.9 and 22.00 and 23.4 kg/m2, respectively.
Another study including 900,000 adult individuals found that BMIs that were above 25 kg/m2 were
associated with a 30% increase in general mortality rate per each 5 kg/m2 increase [12].
Obesity results from the interactions of different factors, including genetic, metabolic, behavioral,
and environmental ones. Accordingly, the dramatic increase in obesity prevalence rates suggests
that behavioral and environmental components are the main factors that are responsible for obesity,
with an emphasis on eating habits and exercise. With regard to eating, modern societies converge to an
eating pattern called the Western diet, which is characterized by the intake of foods with high energy
densities. Such densities derive from the high contents of fat and carbohydrate, especially sugars, that
are found in these food types, a fact that contributes to obesity development [13,14].
The profile of fatty acids that are present in a diet may also be relevant to obesity. It is
worth highlighting that, according to anthropological and epidemiological studies, humans from
the Paleolithic Era—40,000 years ago—consumed a ratio of omega-6 (ω-6) to omega-3 (ω-3)
polyunsaturated fatty acids of approximately 1, mainly due to a high intake of marine and vegetable
sources of ω-3 polyunsaturated fatty acids (PUFAs). However, there was a significant increase in
the intake of lipids, trans fatty acids, and ω-6 PUFAs after the Industrial Revolution, as well as a
small increase in the intake of ω-3 fatty acids; meanwhile, intakes of vitamins C and E decreased.
Such changes are particularly relevant if one takes into account the participation of these nutrients
in the inflammatory response, which is linked to the physiopathology of different non-transmissible
chronic diseases, such as obesity, DM2, cardiovascular diseases, hypertension, and cancer [15–17].
2. Inflammation, Adipose Tissue and Obesity
Inflammation is a central component of innate immunity, and microorganism destruction is the
prime function of the inflammatory response, which is a process that involves the participation of
effector cells in contact with pathogens that are living in the infected tissue. Microbial components,
such as lipopolysaccharides (LPS) that are found in the cell wall of Gram negative bacteria, can trigger
an inflammatory response through their interactions with cell-surface receptors found, for instance,
in cells from the immune system, such as macrophages and neutrophils. Inflammation in response to
microorganisms involves the increased synthesis and secretion of a number of mediators, including
chemokines and cytokines. The latter include tumor necrosis factor (TNF)-α and interleukin (IL)-1,
which act on endothelial cells and leukocytes to promote the recruitment and activation of leukocytes
in the inflammatory area [18,19].
Inflammation can be classified as acute or chronic. Acute inflammation presents via three
principal components: (i) changes in the vascular caliber, which result in increased blood flow
in the inflammatory focus; (ii) structural changes in the microcirculation, which favor the exit of
plasma proteins and leukocytes from the blood to the tissue; and, (iii) adhesion and transmigration of
leukocytes from the microcirculation to the tissue, as well as their further activation, which allows the
elimination of harmful agents. As soon as the infection is eliminated, or at least controlled, mechanisms
are activated that act to limit any type of aggression against the host and to initiate the tissue repair
process. Such a process aims to reduce the inflammation and it is termed resolution. Resolution is
now known to be an active process involving the activation of negative feedback mechanisms, such as
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anti-inflammatory cytokine secretion, a reduction in receptor expression, activation of regulatory cells,
and the production of pro-resolving lipid mediators [20–22].
Histamine, bradykinin, neuropeptides, prostaglandins, thromboxanes, leukotrienes, and
platelet-activating factor stand out among the non-cytokine/chemokine mediators that are involved
in the inflammatory response. The generation of eicosanoids initially occurs due to activation of
phospholipase A2, which hydrolyzes membrane phospholipids to yield a free fatty acid. Arachidonic
acid, an ω-6 PUFA, is predominant among the fatty acids released by phospholipase A2. The released
fatty acids are used as a substrate by the cyclooxygenase enzymes (COX), which catalyze the synthesis
of prostaglandins and thromboxanes, as well as by lipoxygenase (LOX) enzymes, which catalyzes
the synthesis of leukotrienes. Such mediators are responsible for many aspects of the inflammatory
response, such as vasodilation (prostaglandin E2) and leukocyte migration (leukotriene B4) [23–25].
Chronic inflammation involves the progressive changes in inflammatory cells as well as in tissue
destruction and repair due to the on-going inflammatory process. Accordingly, inflammation can
become pathologic because of the loss of tolerance or regulatory processes. As a result, there is an
increase the plasma concentrations of many inflammatory biomarkers and in the number of activated
inflammatory cells in the bloodstream as well as in the primary lesion area. Such changes can be
easily observed, for instance, in patients with frank chronic conditions, like rheumatoid arthritis and
inflammatory bowel diseases [26,27].
Chronic inflammation can also be present at lower intensities than has been seen in the classic
inflammatory diseases. Evidence that obesity results in inflammation started emerging in the 1990s.
This inflammation is directly involved in the etiology of cardiovascular diseases, DM2, and certain
cancer types [28]. Hotamisligil et al. [29] found that genetically obese rodents, such as db/db and ob/ob
mice and fa/fa rats, had increased expression of the TNF-α gene in white adipose tissue. They identified
that the neutralization of TNF by anti-TNF-α antibodies mitigated the resistance of these animals
to insulin action, establishing a link between inflammation, insulin resistance, and hyperglycemia.
Macrophages from the stromal vascular fraction of adipose tissue appear to be the main cell type that
is responsible for TNF-α and IL-6 release from the adipose tissue. The increased concentration of
cytokines in this tissue is mostly derived from the infiltration of M1 macrophages, which are activated
in the classical way and are characterized by the high expression of pro-inflammatory cytokines,
like TNF-α, IL-1β and IL-6 [30–32] (Figure 1). It should be noted that macrophages correspond
to about 40% of total white adipose tissue cells in obese mice and humans, as compared to only
18% in lean controls [33]. In the white adipose tissue, the expression of monocyte chemoattractant
protein (MCP)-1 correlates positively with adiposity, and it is also higher in visceral adipose tissue
when compared to subcutaneous adipose tissue [34,35]. The receptor for MCP-1, C-C chemokine
receptor type 2 (CCR2), is expressed on monocytes present in peripheral blood and on adipose tissue
macrophages. This implies that obesity favors the process of migration of blood monocytes into the
visceral adipose tissue of obese individuals, which then differentiate into macrophages. This process
is regulated by colony stimulating factors, such as macrophage-specific growth factor, called colony
stimulating factor 1 (CSF-1) or macrophage colony-stimulating factor (M-CSF) [36].
In mammals, there are two types of adipose tissue: white and brown adipose tissue (BAT).
BAT is specialized in the production of heat (thermogenesis) and, therefore, actively participates
in the regulation of body temperature. BAT deposits are found in fetuses and newborns. In adult
humans, there is a small volume of BAT in the cervical supra-clavicular, supra-adrenal, and para-spinal
regions [37,38]. Brown and white adipocytes appear to have different physiology and opposing
functions [39] Beiging/browning of white adipose tissue promotes energy expenditure by triggering
thermogenesis, which suppresses diet-induced weight gain, as well as enhancing the efficiency of
BAT activity [40]. In this context, individuals with low amounts of BAT would be prone to the
development of obesity. Studies in animals lacking BAT or uncoupling protein 1 (UCP1) have clearly
demonstrated the involvement of BAT thermogenesis in the protection against diet-induced obesity
(DIO) [41]. Decreasing BAT activity or the removal of BAT in mice provokes increased glycemia and
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plasma triglyceride concentration and promotes insulin resistance [42]. Also, in humans, BAT activity
was found to be inversely related to BMI and fat mass [43]. Furthermore, visceral adipose tissue
inflammation may also be linked to the lower BAT volume, since TNF-α has been shown to induce
brown adipocyte apoptosis and to hamper BAT differentiation [44].
Obesity is a relevant causal factor in the etiology of insulin-action resistance. Thus,
obese patients present with reduced insulin action in the skeletal muscle due to lower
phosphorylation of the tyrosine residues of the insulin receptor substrate (IRS)-1 and the reduced
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) activity in this tissue. Such an outcome can
cause a further reduction in insulin-induced glucose transport into the muscle tissue [45].
Figure 1. Interaction between M1 and M2 macrophages and adipocytes. Abbreviations: IL, interleukin;
MCP, monocyte chemotactic protein; NEFAs, non-esterified fatty acids; TNF, tumor necrosis factor.
An increased inflammatory response is an important factor in the etiology of insulin-action
resistance in obese patients. Such a response triggers the activation of protein kinases related to Toll
signaling pathways and TNF-α receptors, such as the inhibitor of kappa B kinase (IKK) and c-jun
N-terminal kinase (JNK)-1, which are capable of phosphorylating IRS-1 at the serine 307 residue.
This reduces IRS-1 interaction with the insulin receptor beta subunit, and, consequently, causes
decreased insulin signal transduction [46,47]. JNK knockout mice show lower adiposity, enhanced
sensitivity to insulin and an increased capacity for insulin receptor signaling even when they are fed a
lipid-rich feed. These findings suggest that activation through JNK is an important mechanism linked
to insulin resistance in obese patients [48].
Among the inflammatory biomarkers that are related to obesity, IL-6 favors insulin-action
resistance in obese individuals due to the induction of the cytokine signaling suppressor protein
3 (SOCS3), which physically associates itself with tyrosine phosphorylated proteins, such as the
insulin receptor. In addition, SOCS3 decreases the phosphorylation of IRS-1 tyrosine, which weakens
the IRS-1 coupling to the insulin receptor and the subsequent association between IRS-1 and
phosphatidylinositol-3 kinase (PI3K). These findings suggest that SOCS3 is a relevant inhibitor of
the insulin signaling pathway, as well as allowing a better understanding of the IL-6 effect on the
insulin-action resistance that is induced by obesity [49].
Understanding that the immune system and different metabolic pathways are closely related
to each other, as well as that they are functionally dependent, is essential for studies that are
focused on obesity and on its possible metabolic repercussions. Thus, signaling pathways that
are responsive to nutrient intake and the presence of pathogens are evolutionarily conserved and
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greatly integrated [50]. The excessive intake of obesity-associated nutrients can be detected by innate
recognition receptors, and this results in the activation of pro-inflammatory signaling pathways as
well as in stress responses in many parts of the body. This causes low-intensity chronic inflammation,
defined by Hotamisligil et al. [30] as metabolic inflammation or as meta-inflammation, which is
different from the classic inflammatory response. Moreover, the genesis of this inflammation is closely
related to lifestyle and mainly to the quality of diet and exercise [51].
Meta-inflammation development is associated with a wide and integrated network of intracellular
signal pathways, among which inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β) and
c-Jun N-terminal kinase 1 (JNK-1) stand out. These proteins induce the synthesis of inflammatory
mediators in different cell types. IKK-β and JNK-1 activation results in activating the transcription
factors nuclear factor kappa B (NF-κB) and the activating protein (AP)-1, which translocate to the
cell nucleus and activate the transcription of many genes encoding the proteins that are involved
in inflammation, including TNF-α and COX-2. This process allows for the continuity of the
inflammatory reaction, which is associated with conditions, such as atherogenesis and insulin-action
resistance [52,53].
This systemic inflammatory response mainly originates from adipose tissue, which produces
a wide variety of pro-inflammatory cytokines and chemokines, called adipokines [23]. However,
currently, it is known that there are other tissues involved in meta-inflammation, such as the liver [54],
pancreas [55], hypothalamus [56,57], and skeletal muscle [58]. It seems likely that the chronic low-grade
inflammation that develops in adipose tissue with obesity is “transferred” to these other tissues through
the appearance of active inflammatory mediators in the bloodstream.
In the context of inflammation and obesity, the role of gut microbiota in the development of
metabolic disease should be noted. Studies have shown that certain bacteria populations produce
enzymes that increase the efficiency of nutrient digestion, leading to an improved nutrient supply to
the host, therefore, contributing to increased energy storage in the adipose tissue. The resulting increase
in body adiposity can trigger the development of insulin resistance. There is also evidence that the gut
microbiome can modulate that genes that are involved in energy storage and expenditure [59–62].
In 2004, Backhed et al. [61] reported that conventionally reared mice had a 42% increase in body fat
and a 47% increases in periepididymal adipose tissue when compared to germ-free mice. Furthermore,
transfer of the microbiota from the bowel of the conventional mouse to the gut of the germ-free
mouse resulted in a 57% increase in body fat in two weeks, although feed consumption decreased.
This result highlights the important role that the intestinal microbiota plays in energy homeostasis
and its potential involvement in the etiology of obesity. Germ-free mice are resistant to diet -induced
adiposity, which is associated with increased activity of AMP-activated protein kinase (AMPK) in liver
and muscle and increased expression of adipose factor that is induced by fasting (Fiaf) in the small
intestine [62]. On the other hand, the inoculation of the microbiota of conventional mice fed with this
diet into germ-free animals results in an increase in adiposity [59].
It should also be noted that the dysbiosis that is associated with consuming a high-fat diet has
been shown to increase intestinal permeability, which results in a greater translocation of LPS from
the intestinal lumen to the blood circulation. This metabolic endotoxemia is associated with increased
body fat, glucose intolerance, and increased expression of proinflammatory mediators and macrophage
infiltration in white adipose tissue [60].
3. Toll-Like Receptor 4 and Inflammatory Response
The innate immune systems of mammals—which encompasses cells such as neutrophils and
macrophages—use different strategies to recognize microorganisms. One of these strategies is based on
recognizing general aspects of molecules associated with pathogens (pathogen-associated molecular
patterns, or PAMPs) that result from microbial metabolism that is conserved throughout the evolution
of the species. These molecules are widely distributed among pathogens; for instance, the LPS molecule
is common in all Gram-negative bacteria, although it is not produced by the host [63–65].
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Innate immune system receptors that are capable of recognizing PAMPs are called pattern
recognition receptors, and these induce the expression of pro-inflammatory cytokines—for example,
TNF-α and IL-1β—as well as activating the host’s antimicrobial defense mechanisms, such as the
synthesis of reactive oxygen and nitrogen species, including hydrogen peroxide and nitric oxide (NO),
respectively [66,67]. PAMP recognition can induce cluster of differentiation 80 (CD80) and cluster of
differentiation 86 (CD86) costimulatory molecules on the surface of cells, presenting antigens, as well
as inducing small antigenic peptides that are linked to major histocompatibility complex (MHC) class
II molecules in cell membranes that present antigens to CD4+ T lymphocytes so activating adaptive
immune responses [68].
The innate immune system recognizes PAMPs through toll-like receptors (TLRs) that are a family
of transmembrane proteins that are responsible for playing an essential role in the innate immune
system [69]. The main function of the TLR protein lies in controlling inflammatory and immunological
responses. TLRs can recognize a whole variety of microbial PAMPs. Eleven different TLRs have been
identified in humans and thirteen among all mammals [70]. TLRs belong to the IL-1 receptor (IL-1R)
superfamily, which have a significant homology in their cytoplasmic regions, such as in the Toll/IL-1R
(TIR) domain. The TIR domain is needed for the interaction and recruiting of many adaptive molecules
that are involved in the activation of signaling pathways [67].
TLRs are expressed in different cell compartments and are recognized by many PAMPs deriving
from viruses, pathogenic bacteria, fungi, and protozoa. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11
are expressed in the cellular membrane, whereas TLR3, TLR7, TLR8 and TLR9 are expressed in
intracellular compartments, such as the endosome and the endoplasmic reticulum. Based on the amino
acid sequence and on the genomic structure, TLRs can be divided into five subfamilies: TLR2, TLR3,
TLR4, TLR5, and TLR9. The subfamily TLR2 comprises TLR1, TLR2, TLR6, and TLR10, whereas the
subfamily TLR9 encompasses TLR7, TLR8, and TLR9 [71–73].
TLR4 was the first TLR reported in humans; it is expressed in innate immune cells, including
monocytes, macrophages, and dendritic cells, as well as in other cell types, like adipocytes, enterocytes,
and muscle cells. As indicated above, LPS is the primary agonist for TLR4 [74]. LPS is an integral
structural component that is found in the external membrane of Gram-negative bacteria as well as
representing one of the most powerful microbial inflammation indicators. It is a complex glycolipid
composed of one hydrophilic polysaccharide and one hydrophobic domain called lipid A [75].
There is some evidence that saturated fatty acids can also bind to TLR4 and activate TLR4-mediated
signaling pathways [76,77]. Also, there are other endogens ligands for TLR4, like heat shock protein
(Hsp) 60, Hsp 70, type III repeat extra domain A of fibronectin, oligosaccharides of hyaluronic acid,
polysaccharide fragments of heparan sulfate, and fibrinogen [78]. In the context of obesity, the increase
in the plasma fibrinogen levels, which represents a positive acute phase protein, acts as a factor that
is involved in the activation of the TLR4 pathway, and, consequently, in the amplification of the
inflammatory response [79].
The interaction between LPS and TLR4 induces the synthesis of pro-inflammatory cytokines, such
as TNF-α, IL-1β, IL-6, IL-8, and IL-12, which, in turn, work as endogenous inflammatory mediators
by interacting with receptors found in different target cells. In addition to cytokines, macrophages
release a whole variety of biological mediators in response to LPS, including platelet activation factor,
prostaglandins, enzymes, and reactive oxygen and nitrogen species, such as superoxide anion and
nitric oxide (NO). The synthesis of these pro-inflammatory mediators by monocytes and macrophages
is designed to inhibit the growth and the dissemination of pathogens and to eliminate them either
directly or through induction of adaptive immune responses [63,80].
LPS initially binds to the LPS-binding protein (LBP), which is found in the blood or in extracellular
spaces. This protein promotes LPS binding to the CD14 molecule, which, in turn, is moored to the
lipid bilayer by means of a glycophosphatidylinositol group that is found in most cells, except for
endothelial ones. CD14 can also exist as a soluble protein, and, in this case, can lead LPS to the
cell surface. The CD14 molecule is not found in transmembrane and intracellular domains; thus,
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it cannot trigger signal transduction processes on its own. When LPS binds to CD14, LBP dissociates
itself and the LPS-CD14 complex physically associates with TLR4. Such a receptor needs an additional
molecule, the so-called extracellular accessory protein (MD2), which binds to the TLR4 extracellular
complex in order to recognize LPS [71].
Following ligand binding, TLRs dimerize and undergo conformational changes that are required
for the subsequent recruitment of cytosolic TIR domain-containing adaptor molecules, including the
cytoplasmic adapter protein MyD88. The association between TLR4 and MyD88 gathers proteins
from the IL-1 receptor associated kinase (IRAK) family. Two members (IRAK4 and IRAK1) are
phosphorylated in sequence, and this disrupts them from the receptor complex and promotes their
association with TNF receptor associated factor 6 (TRAF6). TRAF6 then activates mitogen activated
protein kinase (MAPK) proteins. These kinases can activate the AP-1 transcription factor [81].
The transcription factor NF-κB, which is found in a dimeric form in the cytoplasm of
non-stimulated cells, is inactive when it is associated with κB inhibitors (IκB) (Figure 2). The family of
IκB proteins includes IκBα, IκBβ, IκBε, and Bcl-3, as well as the carboxy-terminal regions of NF-κB1
(p105) and NF-κB2 (p100). The IκB proteins bind to different NF-κB dimers, although they have
different affinities and specificities; therefore, besides the different NF-κB dimers that are found in a
specific cell type, there are a large number of combinations of the IκB and the NF-κB dimers [82,83].
Figure 2. Toll-like receptor 4 (TLR4) induced signaling activates the transcription factor NFκB.
LBP: LPS-binding protein; LPS: lipopolysaccharides; IRAK: IL-1 receptor associated kinase; TRAF6:
TNF receptor associated factor 6; MAPK: mitogen activated protein kinase; IKK: inhibitor of nuclear
factor kappa-B kinase; iNOs: inducible nitric oxide synthase.
Via MAPK, TRAF6 activates the IκB kinase complex (IKK), which is composed of two catalytic
subunits (IKKα and IKKβ) and one regulatory subunit (IKKγ), and has the capacity to induce
IκB phosphorylation. This phosphorylation results in IκB dissociation from the NF-κB complex
and its subsequent polyubiquitination, which, in turn, leads to IkB degradation (mediated by the
26S proteasome) [73,81]. This process allows for the NF-κB dimer to translocate into the nucleus and
to activate the transcription of many κB-dependent genes, such as the genes of pro-inflammatory
cytokines, including TNF-α, IL-1β, IL-6, COX-2, and inducible nitric oxide synthase (iNOS) (Figure 2).
NF-κB also stimulates the synthesis of IκB. Accordingly, the newly synthesized IκB binds to NF-κB
and suppresses its activity, providing a feedback inhibition mechanism [74,81]. There are five members
of the family of NF-κB transcription factors in mammals: NF-κB1 (p105/p50), NF-κB2 (p100/p52),
RelA (p65), RelB, and c-Rel, which can dimerize to form homodimers and heterodimers that, in turn,
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are associated with specific transcriptional responses to different stimuli. NF-κB1and NF-κB2 do
not contain transcriptional activation domains and their homodimers work as repressors. On the
other hand, Rel-A, Rel-B, and c-Rel drive the transcriptional activation domain, and, except for Rel-B,
are capable of forming homodimers and heterodimers along with other members of this family
of proteins. Consequently, the balance between different NF-κB homodimers and heterodimers
regulates the transcriptional activity level. It is worth highlighting that these proteins are expressed
in a specific cell and tissue pattern, which leads to an additional level of regulation. NF-κB1 (p50)
and RelA, for example, are broadly expressed, and, therefore, the p50/RelA heterodimer is the most
common NF-κB-binding activity inducer [82,83].
Human monocytes express TLR1, TLR2, TLR4, TLR5, TLR6, TLR8, and TLR9; but TLR2 and TLR4
are the receptors that are most commonly expressed in these cells. The expression of TLR2 and TLR4 in
the plasma membrane of monocytes has been confirmed by flow cytometry; TLR2 and TLR4-binding
(by peptidoglycan and LPS, respectively) generates pro-inflammatory cytokine secretion in these cells.
Moreover, TLR2 and TLR4 activation recruits monocytes and forms foam cells in murine models of
atherosclerosis [30,84].
Studies that were conducted in vitro with cell cultures showed the negative effects of
pro-inflammatory cytokines deriving from TLR4 signal pathway activation on glucose uptake and
on the metabolism of fatty acids [33,85,86]. TLR4 gene deletion in mice has a protective effect against
adipose tissue inflammation and against the resistance to insulin action that is induced by the intake of
a high fat diet, a fact that points towards the causal role played by TLR4 in metabolic changes driven
by over-eating and obesity [87,88].
Humans with type I diabetes exhibit a greater expression of TLR2 and TLR4 in the cellular
membrane in monocytes, as well as greater MyD88 protein content and IRAK phosphorylation in
monocytes in the peripheral blood than in control groups [89]. Individuals with DM2 show increased
cellular membrane levels of TLR2 and TLR4 in blood monocytes, as well as a higher concentration of
IL-1β, IL-6, IL-8, and TNF-α in serum than in controls [90]. Similarly, TLR2, TLR4, and MyD88 are
more highly expressed in blood mononuclear cells and in the abdominal subcutaneous white adipose
tissue in obese and diabetic individuals than in patients with normal weight [63,80]. Also, overweight
and obese people showed increased expression of TLR2 and TLR4 on peripheral blood mononuclear
cells and in adipose tissue in comparison with lean people; the expression levels of TLR2 and TLR4
increased significantly with increasing body mass index [91].
Furthermore, insulin-action resistance in obese individuals can increase the expression of TLR4,
which depends on the designated PU.1 transcription factor, which, in turn, regulates the gene
expression that is related to the activation and the differentiation of myeloid cells, including the
TLR2, TLR4, and TLR9 receptors [92,93]. Insulin has a suppressive effect on the expression of TLR4 and
on the activity of the PU.1 transcription factor; however, the suppressive effect of the hormone would
be expected to be reduced due to the insulin-action resistance related to obesity. Such a reduction
would increase the expression of TLR4 in peripheral blood monocytes [94]. In view of this, it seems
that the increase of the inflammatory response favors the occurrence of resistance to the action of the
insulin, through the activation of the IKK-β and JNK kinases that reduce the activation of IRS-1 in
the insulin signaling pathway. Conversely, the presence of insulin resistance favors the expression of
TLR4, suggesting that insulin resistance promotes inflammation.
As described earlier, the TLR4 pathway increases the expression of pro-inflammatory cytokines,
such as TNF-α, IL-1, and IL-6, by activating the transcription factors NF-κB and AP-1. These cytokines,
in turn, increase the hepatic synthesis of CRP, which is the classic positive acute phase reactant and
the most studied and accepted inflammatory biomarker. CRP is often used in clinical practice due to
its high stability (mean half-life of 19 hours) and its rapid production in response to inflammatory
stimuli [95,96]. It is important to note that other inflammatory biomarkers, such as IL-6, TNF-α,
the intercellular adhesion molecule (ICAM)-1, P-selectin, E-selectin, the monocyte chemotactic protein
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(MCP)-1, fibrinogen, and soluble CD40, have been characterized as predictors of cardiovascular disease,
regardless of other cardiovascular risk factors [19,26].
Dietary lipids can cause changes in the expression patterns of TLRs [97]. Ingestion of a high
calorie (910 kcal), high lipid (51 g), and high carbohydrate (88 g) meal by normal weight individuals
caused significant changes in TLR in the post-prandial period, with TLR2 and TLR4 increasing in blood
mononuclear cells. This reinforces the potential importance of postprandial inflammation for obesity,
DM2, and cardiovascular disease physiopathology [98,99]. A high-fat meal also leads to increased
NF-κB activation in the post-prandial period, as well as increased leucocyte activation, as assessed by
the surface expression of CD11a, CD11b, and CD62L [100], and metabolic endotoxemia (i.e., increased
plasma LPS levels) [101].
4. Fatty Acids, Toll-Like Receptors and Inflammation
4.1. Saturated Fatty Acids
Saturated fatty acids, particularly lauric acid and palmitic acid, are capable of stimulating an
inflammatory response through the TLR4 signaling pathway [102]. Lee et al. [103] published the first
study that demonstrated the effect of different fatty acids on the TLR4 signaling pathway. In this
study, it was verified that lauric, palmitic, and stearic acids could induce COX-2 expression through an
NFκB-dependent mechanism in a macrophage cell line. Among the saturated fatty acids that were
tested, lauric acid (C12:0) had the greatest activation capacity through TLR4. Different from saturated
fatty acids, monounsaturated and polyunsaturated acids did not lead to TLR4 signal activation.
Moreover, cell pretreatment in vitro for three hours with different polyunsaturated fatty acids,
particularly the ω-3 fatty acid docosahexaeanoic acid (DHA: 22: 6 ω-3), or oleic acid (ω-9) significantly
reduced the subsequent pro-inflammatory effect induced by lauric acid [103].
Saturated fatty acids represent an essential component of bacterial endotoxins. The lipid A
portion of LPS has six saturated fatty acids coupled to this structure through ester or amide bonds.
The carbon chain length of these fatty acids in lipid A varies from 12 to 16 carbons. Interestingly,
the replacement of these saturated fatty acids by monounsaturated or polyunsaturated fatty acids
stops the pro-inflammatory activity of the LPS [104].
Saturated fatty acids can also induce an inflammatory response through the activation
of TLR2, which forms heterodimers in the plasma membrane, along with TLR1 or TLR6.
Diacylated and triacylated lipoproteins, peptidoglycans, and lipoteichoic acid are among this receptor’s
agonists [76,105,106]. Lee et al. [107] reported that lauric acid induced activation through NF-κB when
TLR2 was cotransfected with TLR1 or TLR6; however, this did not occur when TLR1, 2, 3, 5, 6, or 9 were
individually transfected. On the other hand, the omega-3 polyunsaturated fatty DHA suppresses
activation through the NF-κB signaling pathway, whether this is induced by LPS or by lauric acid [108].
Furthermore, the inhibition of TLR2 expression enhances the sensitivity to insulin action in the skeletal
muscle and in the white adipose tissue of mice that were fed on a high fat diet as well as inhibiting the
expression of this receptor. This process results in the partial reversal of palmitic acid-induced insulin
resistance [23,109].
Erridge and Samani [110] suggested that saturated fatty acids would not directly stimulate TRL2
and TLR4, but that this effect could result from the contamination of the bovine serum albumin that was
used to solubilize the saturated fatty acids in the studies conducted in vitro. However, Huang et al. [76]
demonstrated that saturated fatty acids activate the inflammatory response in vitro through TLR2
and TLR4. Lauric acid—which was not solubilized in bovine serum albumin—induced the activation
of the NF-κB signaling pathway through TLR2—which was dimerized with TLR1 or TLR6—and TLR4.
In addition, there are current propositions addressing TLR4 activation by saturated fatty acids that
depend on fetuin A, which is produced in the liver and works through endogenous TLR4-binding [77].
Palmitate acid that is bound to TLR4 activates the kinase proteins JNK and IKK-β, and
increases the expression and secretion of pro-inflammatory cytokines [86]. Palmitic acid also impairs
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insulin signaling pathways by inducing IRS-1 phosphorylation at serine residue position 307 [111].
This process reduces its interactions with the insulin receptor, and, consequently, diminishes the
insulin-induced signal transduction. Moreover, saturated fatty acids induce insulin-action resistance
due to the antagonistic action of the peroxisome proliferator-activated receptor-gamma coactivator
(PGC)-1 alpha. Such a process induces the expression of mitochondrial genes that are involved with
oxidative phosphorylation and with glucose capture, which is mediated by insulin [112,113].
4.2. Polyunsaturated Fatty Acids
Polyunsaturated fatty acids consist of two families (ω-3 and ω-6) that are characterized by the
double bond locations defined by the first double bond in relation to the methyl terminal group
in the fatty acid molecule. α-Linolenic and linoleic acids are examples of polyunsaturated fatty
acids belonging to the ω-3 and ω-6 families, respectively. These two fatty acids are not synthesized in
humans, and the lack of ω-3 and ω-6 intake causes signaling and symptom deficits, indicating that such
nutrients are essential to humans; therefore, they must be consumed through the diet [24,25,114,115].
However, studies have shown that the ratio of ω-6 to ω-3 fatty acids in the diet has implications for
health since increased ratios are associated with an increased risk of chronic disease incidence and
progression [116,117].
α-Linolenic acid is the precursor of the ω-3 polyunsaturated fatty acids with a longer chain and
a high degree of unsaturation, such as eicosapentaenoic acid (EPA: 20: 5 ω-3) and DHA, which are
found in seafood, especially fatty fish, and in fish oil supplements. It is important to note that the
α-linolenic concentration in the blood, cells, and tissues is significantly lower than that of the EPA and
DHA. This suggests that the primary biological function of α-linolenic is as a substrate in EPA and
DHA synthesis [118]. However, evidence shows that α-linolenic conversion into EPA and DHA in
humans is relatively low: conversion into EPA is estimated to only be around 8–12%, and conversion
into DHA is lower than 1% [119,120].
The beneficial effects resulting from an increased intake of ω-3 fatty acids were originally
associated with the suppression of thrombosis. However, epidemiologic evidence suggests that
the intake of ω-3 fatty acids reduces the morbidity and mortality rates due to cardiovascular diseases,
as well as reducing systemic blood pressure, triacylglycerol concentrations, and the risk of endothelial
dysfunction [27,121–126]. The capacity to lower triacylglycerol concentrations, which is related to
diminished hepatic VLDL secretion, stands out among the aforementioned possible metabolic effects
resulting from the intake of ω-3 fatty acids. This effect is partially dependent on mechanisms that are
related to nuclear receptors, particularly the peroxisome proliferator activated receptor (PPAR)-α [127].
An increased intake of ω-3 fatty acids results in the corresponding accumulation of these fatty
acids in cell membranes and circulating lipids. They replace ω-6 fatty acids (such as linoleic and
arachidonic acids) in blood lipids and in cell membranes, and also modulate/activate different
signaling pathways [128].
The ω-3 and ω-6 polyunsaturated fatty acids generate relevant modulations in the inflammatory
response because they are precursors to different series of eicosanoids, which have different effects
on the intensity of the inflammatory response. Accordingly, ω-6 arachidonic acid generates
even-series eicosanoids, such as prostaglandin E2 and leukotriene B4. These eicosanoids induce
pro-inflammatory effects, such as increased vascular permeability, vasodilation, fever, and chemotaxis.
It is important to note that prostaglandin E2 also has anti-inflammatory effects, such as reduced IL-1
and TNF-α production. EPA is the precursor for odd-series eicosanoids, such as prostaglandin E3,
thromboxane A3 and leukotriene B5, which induce lower-intensity inflammatory responses.
Leukotriene B5, for example, is 10 to 100 times less potent as a chemotactic agent in neutrophils
than leukotriene B4 [23,27,129]. EPA also competes with arachidonic acid for COX-2 and 5-LOX;
therefore, EPA reduces the synthesis of even-series eicosanoids [130]. In addition, higher EPA and
DHA concentrations in the plasma membrane favor the production of mediators, such as resolvins,
maresins, and protectins, which are involved in the resolution of inflammation and healing [21,25,131].
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The ingestion of alpha-linolenic acid can also modulate the inflammatory response in humans.
For example, Caughey et al. [132] observed a significant reduction of TNF-α, IL-1β, TXB2, and PGE2
production by LPS-stimulated mononuclear cell cultures that were obtained from healthy subjects who
consumed approximately 14 g/day alpha-linolenic acid for four weeks as compared to baseline and to
a control group. The effect of α-linolenic acid may have been mediated through its conversion to EPA.
With regard to the molecular effects of EPA and DHA on inflammatory-response modulation,
studies have shown that these fatty acids inhibit the expression of inflammatory genes, such as COX-2,
iNOS, and IL-1 in macrophages [103,108]. In contrast to the stimulating effect of saturated fatty acids
on TLR2 and TLR4 activation, EPA and DHA are capable of mitigating the activation of the NF-κB
transcription factor pathway that is induced by various agonists [103,133,134]. Thus, DHA reduces
NF-κB pathway activation and the expression of cytokines and COX-2 induced by TLR agonists,
such as lipopeptides (TLR2) and LPS (TLR4) in macrophages [89]. In addition, there is reduced gene
expression of COX-2 that is induced by LPS in monocytes from the peripheral blood of individuals
who use fish oil supplements [103,108]. The synthesis of the cytokines IL-1, IL-2, and TNF-α was also
mitigated after stimulation with LPS in vitro by mononuclear cells from the peripheral blood from
individuals that were supplemented with 18 g of fish oil per day for six weeks [135].
In addition, EPA and DHA present another mechanism to modulate the inflammatory response
by binding to G-protein coupled receptor 120 (GPR120), which is also known as free fatty acid
receptor 4 (FFA4). GPR120 activation induced by EPA or DHA leads to β-arrestin 2 recruitment to
the plasma membrane, where this protein binds to GPR120. Subsequently, the GPR120/β-arrestin
2 complex is internalized into the cytoplasmic compartment, where this complex binds to the
TAK1-binding protein (TAB1). This process impairs the association between TAB1 and the kinase
activated by the growth factor beta (TAK1), and, consequently, results in reduced TAK1 activation
and in reduced activity of the IKK-β/NF-κB and JNK/AP-1 signaling pathways. Accordingly,
the TAB1/TAK1 binding is a convergence point of stimuli that are induced by the TLR4 signaling
pathway and of the TNF receptor (TNFR). The mitigation of TAK-1 activation by DHA leads to the
reduced expression of genes with pro-inflammatory actions, such as TNF-α and IL-6 [136,137].
Other mechanisms that are related to the EPA and DHA effects concern their capacities to
bind to peroxisome proliferator activated receptors (PPARs), including the isoforms PPAR-alpha,
PPAR-gamma, and PPAR-beta/delta. PPARs are a group of nuclear receptors that are coded for by
different genes. PPAR isoforms form heterodimers with the retinoid X receptor (RXR) and bind to
peroxisome proliferator response elements (PPRE) in the region that is responsible for promoting the
target genes that are involved in lipid metabolism and in the inflammatory response; subsequently,
they modulate the expression of these genes [138]. PPAR-alpha and PPAR-gamma activations reduce
the expression of genes that code for proteins presenting pro-inflammatory actions through inhibition
of NF-κB activation. It is worth emphasizing that EPA and DHA directly interact with PPARs, and,
therefore, modulate the expression of genes that are involved in lipid metabolism and the inflammatory
response [139]. Furthermore, the anti-inflammatory effects of EPA and DHA on this signaling pathway
can occur due to diminished nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity,
which leads to lower TLR4 recruitment for lipid rafts and TLR4 dimerization [102]. Moreover, the
lower NADPH oxidase activity also decreases the production of reactive oxygen species, which, in turn,
are necessary to activate the TLR4 signaling pathway. Another possible mechanism of action of the
ω-3 fatty acids concerns the capacity of incorporating DHA into the plasma membrane, which can
lead to reduced TLR4 translocation for lipid rafts formation. This decreases TLR4 pathway activation,
and, consequently, decreases NF-κB activation [102,140,141].
Figure 3 shows the main molecular mechanisms related to the effects of saturated and omega-3
fatty acids on the TLR4 pathway.
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Figure 3. Molecular mechanism of the effects of saturated (16:0) and omega-3 polyunsaturated fatty
acids (EPA, DHA) on the TLR4 and NFkB pathways. The arrows → indicate activation and the
arrows indicate inhibition. Abbreviations: TNFα, Tumor necrosis factor; TNFR1, Tumor necrosis
factor receptor 1; LPS, Lipopolysaccharides; 16:0, palmitic acid; TLR4, Toll-like receptor 4; GPR120,
G-protein coupled receptor 120; EPA, eicosapentaenoic acid; DHA, Docosahexaenoic acid; IRS-1, Insulin
receptor substrate 1; Ser-P, phosphorylated serine residues; PPARγ, Peroxisome proliferator-activated
receptor gamma; JNK, c-Jun N-terminal kinases; IKK β, inhibitor of nuclear factor kappa-B kinase
subunit beta; IkB, NFKB Inhibitor; P, phosphate; AP-1, Activator protein 1.
5. Conclusions
The inflammatory process that occurs in obese people differs from the classical inflammatory
response in certain respects. This inflammatory process manifests itself systemically and is
characterized by a chronic low-intensity reaction. In this context, the TLR4 signaling pathway has
been recognized as one of the main triggers in increasing the obesity-induced inflammatory response.
This pathway responds to the increased exposure to saturated fatty acids and to LPS. Both of these
are relevant in the context of obesity, with saturated fatty acids arising from within the adipose
tissue triglyceride stores and the LPS arising from increased intestinal permeability perhaps due
to an altered gut microbiota. Adipose tissue driven inflammation increases insulin resistance, both
locally and systemically, so contributing to the co-morbidities of obesity, like DM2. Studies indicate
that omega-3 fatty acids, namely EPA and DHA, have an anti-inflammatory effect, which involves
attenuating the activation of the TLR4 signaling pathway. This has relevant implications for
reducing meta-inflammation, and, consequently, resistance to insulin action and the risk of DM2
and cardiovascular disease in obese individuals. The omega-3 fatty acids can oppose the action of both
classic TLR agonists (e.g., LPS) and saturated fatty acids in this regard.
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